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Prion diseases are a group of fatal neurodegenerative protein-misfolding diseases.  
Microglia, the resident myeloid cells found within the brain, have been shown to 
demonstrate a reactive morphology during the disease process with conflicting 
evidence for both a neurotoxic and neuroprotective role.  The studies presented here 
aimed to investigate the role of microglia activation using transcriptomic and 
morphological analysis of prion disease in mice. 
 
Initially, the host immune response to prion disease was explored using a publically 
available mouse prion disease dataset.  Re-analysis of this dataset was performed 
using BioLayout Express3D; a novel software tool that supports the visualisation and 
clustering of correlation networks.  Disease-associated genes up-regulated during the 
later stages of infection were present in two main clusters.  The cellular origin of these 
genes was explored by examining their expression in a dataset comprised of pure 
populations of cells.  This demonstrated that the primary cluster of up-regulated 
transcripts encompassed genes expressed mainly by microglia and to a lesser extent 
astrocytes and neurons.  The secondary cluster comprised almost exclusively of 
interferon response genes.  The conclusions of these analyses were different from 
those of the original study that suggested disease-associated genes were primarily 
neuronal in origin. 
 
Mouse models of prion disease were established by infecting a novel line of BALB/cJ 
inbred mice, expressing EGFP under control of a myeloid specific Csf1r promoter, with 
the 79A prion strain.  Quantification of the morphological changes of EGFP expressing 
microglia suggested the cells accumulated in the medulla at sites of early misfolded 
protein deposition with minimal change in their overall appearance.  An activated 
microglia morphology was not observed until protein deposition was extensive.  
Isolation of EGFP expressing microglia was performed for transcriptome analysis.  The 
vast majority of disease associated genes demonstrated increased expression at the 
onset of clinical symptoms.  The gene list was found to be highly enriched for genes 
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associated with an innate immune response regulated by the NFκB signalling cascade.  
Also highly enriched were processes associated with protein translation, energy 
production and stress response.  These data suggest a high metabolic load is 
burdened by proliferating microglia; and as part of a response which is strikingly more 
pro-inflammatory in nature than has previously been attributed to the microglia 
phenotype within prion disease.  
 
As an active contributor to normal homeostasis, microglia are more than just innate 
immune surveillance and are now considered an integral component in both the 
healthy and diseased brain.  The ramifications of activation toward the microglia 
phenotype shown here will have direct and potentially cytotoxic influence on 
neighbouring microglia and other brain cell types implying microglia as major 
contributors to the neurotoxic environment found within the CNS during prion 
disease.  Furthermore the identification of genes associated with metabolism offer 
many intriguing possibilities for manipulating the activity of microglia in pre-clinical 
therapeutic intervention.  
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1.1 Prion Disease 
1.1.1 Protein-Misfolding Diseases 
A neurodegenerative disease, as the name implies, demonstrates a loss of neuronal 
cells and eventual loss of brain function.  Neuronal loss can prove fatal; presumably 
as the capacity for maintaining normal bodily homeostasis crosses a threshold which 
cannot be reversed.  Other important hallmarks of a number of neurodegenerative 
diseases include accumulation of misfolded protein as intracellular tangles and 
extracellular plaques.  Such is the degree of protein accumulation that the illnesses 
are often classed as protein-misfolding diseases.  Prion diseases are a group of 
invariably fatal protein-misfolding neurodegenerative diseases which, uniquely, are 
transmissible between hosts (Pattison et al., 1959, Zlotnik and Rennie, 1962, Zlotnik 
and Rennie, 1965, Brotherston et al., 1968).  The diseases can be found in numerous 
mammalian species including Creutzfeldt-Jakob Disease in humans, Bovine 
Spongiform Encephalopathy in cattle, Chronic Wasting Disease in deer and Scrapie in 
sheep and goats (Table 1-1). 
 
1.1.2 Natural and Experimental Hosts 
The earliest recording of a prion disease in the United kingdom under the name 
‘Scrapie’, a name that continues to this day, was attributed to a flock of cross-bred 
Cheviot and Leicester sheep in a  farm near Yetholm within the Scottish Borders in 
1853 (Stockman, 1913).  The disease had been known, albeit often incorrectly 
categorised, under different names for many centuries (Appendix 8-1).  The more 
recent widespread epidemic of Bovine Spongiform Encephalopathy in cattle was first 
detected in 1987 by Wells et al. (1987).  Infected animals presented with abnormal 
behaviour, exhibited hypersensitive anxiety, progressive ataxia and resulted in the 
death of over 100,000 cattle.  Bovine Spongiform Encephalopathy was confirmed to 
have infected humans, presenting as New-Variant Creutzfeldt-Jakob Disease using 
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experimental mouse models where both human and cattle forms presented with the 
same pathology in mice (Bruce et al., 1994, Bruce et al., 1997).    Interestingly the first 
identified bovine case was in a zoological Nyala (Trugeluphus ungasi), an African 
ruminant belonging to the sub-family bovinae of the family Bovidae in a wildlife park 
(Jeffrey and Wells, 1988).  This case was followed a year later by the infection, in the 
same wildlife park, of a Gemsbok antelope (Oryx guzellu), again a member of the 
Bovidae family, and crucially there was no contact between the two animals.  The 
origin of the disease was presumed to be ingestion of ‘meat and bone meal’ animal 
feed produced from infected animals (Wilesmith et al., 1988, Wilesmith et al., 1991).  
Widespread ban of this type of feed coincided with the reduction in new cases. 
 
Other prion diseases have been shown to be directly infectious, including Chronic 
Wasting Disease and Scrapie, with little evidence to determine the source of 
infection.  Scrapie was shown to be infectious between sheep following carefully 
controlled trials in the 1940s  (Gordon et al., 1940, Greig, 1940).  Under experimental 
conditions Scrapie was revealed to be transmissible from sheep to goats (Chelle, 
1942, Pattison et al., 1959, Pattison and Millson, 1961, Brotherston et al., 1968).  
There has never been a case of human infection by Scrapie although there is some 
tentative evidence that non-human primates are susceptible following oral ingestion 
of Scrapie infected hamster or mouse brain (Gibbs and Gajdusek, 1972, Gibbs et al., 
1980).  Chronic Wasting Disease is highly contagious within cervid populations (Miller 
et al., 2004).  The disease was identified as a prion disease in 1980 (Williams and 
Young, 1980) and is widespread in both free-ranging and captive cervid populations 
in North America.  The contact between humans and both wild and captive cervid 
populations is frequent, particularly within the hunting fraternity, yet the natural host 
of Chronic Wasting Disease has remained within cervids with no reported natural 
transmission to other mammals.  The inability of prion diseases to easily adapt to 
another species is termed the species barrier.  The barrier presents as both the failure 
to infect another species by a natural (oral) route, (Figure 1-1) or if infection does 
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transmit there is evidence of adaptation through the shorter incubation periods of 
subsequent passages (Bruce et al., 1994). 
 
Table 1-1: Prion diseases found in mammalian species and the causes currently agreed upon by general 
consensus. 
 
Disease Species Cause 
Scrapie Sheep, Goats 





Ingestion of infected ‘meat and bone 
meal’ in animal feed 
Chronic Wasting Disease (CWD) Deer, Elk, Moose 





Unknown.  Suspected to be ingestion of 







Ingestion of (Bovine Spongiform 




Unknown.  Suspected de-novo generation 
of misfolded protein 
Familial Creutzfeldt-Jacob 
Disease (fCJD) 




Exposure to (Creutzfeldt-Jacob Disease) 
contaminated surgical equipment and 
tissue grafts. 
Variant Creutzfeldt-Jacob Disease 
(vCJD) 
Human 
Ingestion of (Bovine Spongiform 
encephalopathy) infected meat 
Kuru Human Ritual cannibalism of infected meat 
Gerstmann-Straussler-Scheinker 
Syndrome 
Human Germline mutation within the PRNP gene 
Fatal Familial Insomnia Human Germline mutation within the PRNP gene 
Atypical Scrapie Sheep 
Unknown.  Suspected to be genotypes 
associated with resistance to classical 
Scrapie 
Bovine “Amyloidotic” Spongiform 
Encephalopathy (BASE or Atypical 
BSE) 
Cattle 
Unknown.  Suspected de-novo generation 
of misfolded protein. 




Ingestion of infected ‘meat and bone 



















































Figure 1-1: Species barriers to natural (oral) routes of infection.  Bovine spongiform encephalopathy 
is orally transmissible to humans and presents as Variant Creutzfeldt-Jakob Disease.  Despite the long 
term presence of sheep Scrapie in commercial flocks, and the prevalence of human contact with cervids 
suffering from Chronic Wasting Disease, there has been no evidence for transmission of these diseases 
to humans. 
   
 *: Under laboratory conditions, using an artificial intracerebral route, transmission is possible 
(Raymond et al., 2000, Hamir et al., 2004, Concepcion et al., 2005, Hamir et al., 2005, Kong et al., 
2005, Hamir et al., 2006, Hamir et al., 2007, Dagleish et al., 2008, Greenlee et al., 2011, Greenlee et 
al., 2012, Konold et al., 2013). 
23 
 
1.1.3 The Infectious Agent 
The infectious agent for prion disease was initially proposed to be a ‘slow virus’ (Cho 
and Greig, 1975, Cho, 1976), a term first utilised in describing Maedi-visna infection 
of sheep by the Icelandic physician Dr Bjorn Sigurdsson (Sigurdsson et al., 1957, 
Sigurdsson and Palsson, 1958).  The considerably long incubation period and, 
following evidence gained from serial passage in both sheep and mice, the clearly 
replicating nature of the agent lent the disease well to the slow virus concept.  
Attempts to isolate the infectious agent, and more importantly associated nucleic 
acids, proved difficult (Alper et al., 1967).  Attempts to isolate nucleic acids using 
caesium chloride resulted in considerable loss of infectivity in the nucleic acid fraction 
(Mould et al., 1965, Adams et al., 1969).  However investigations into the size of the 
infectious agent revealed that at only 150 Kilo Daltons (KDa) the agent was in the 
realm of a viroid (Alper et al., 1966).  Considering the complex nature of the disease 
(it would require more than a few nucleobases) and that the agent was resistant to 
nucleic acid-damaging levels of ultraviolet radiation (Alper et al., 1967), the presence 
of nucleic acids in the agent was questioned.  Ultimately it was evidence that the 
application of ultraviolet light revealed a transparency to nucleic acid blocking 
wavelengths (Latarjet et al., 1970) that seriously challenged a viral origin for the 
agent.  Further experiments revealed tentative evidence to suggest a link between 
the agent and plasma membrane (Hunter et al., 1971, Millson et al., 1971).  The 
removal of nucleic acids from infected plasma membrane preparations did not result 
in loss of infectivity (Kimberlin et al., 1971a).  
 
As part of efforts to separate the infectious agent from membrane preparations it 
was noted that treatment of preparations with proteases, denaturing detergents and 
lowered pH dramatically reduced infectivity (Hunter and Millson, 1967, Hunter et al., 
1969, Kimberlin et al., 1971a).  This lead to suggestions that the coding and 
replication nature of the agent might  be contained within basic (Pattison and Jones, 
1967) or glycoproteins (Gibbons and Hunter, 1967, Lewin, 1972) with strong 
arguments for an endogenous and erroneously folded protein put forward that 
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would explain both the spontaneous and transmissible nature of the agent (Griffith, 
1967).  In the early 1980s it was noted in the lab of Stanley Pruisner (NIH San 
Francisco) that infectivity titre correlated with a partially protease resistant protein 
of 27-30 KDa in size when migrated on a sodium dodecyl sulphate polyacrylamide gel 
(Bolton et al., 1982).  This work was immortalised in 1982 when published as the 
Proteinaceous Infectious agent, abbreviated to Prion (Prusiner, 1982).  The structural 
protein component of the infectious fraction was later designated as the Prion 
Protein or PrP (McKinley et al., 1983).  The hypothesis proposed by Griffith (1967) 
was for a host origin for the replicative agent.  A cellular gene was found to encode 
the PrP 27-30 kDa protein (Oesch et al., 1985) with the complete PrP gene (Prnp) 
identified shortly after (Basler et al., 1986, Sparkes et al., 1986).  Further evidence 
implicating PrP as the replicative agent was that Prnp knockout mice were shown to 
be resistant to infection (Büeler et al., 1993).   
 
Stanley Prusiner was later awarded the 1997 Nobel Prize in Physiology, or Medicine, 
for coining the prion hypothesis which states that endogenous host PrPC 
sialoglycoprotein refolds from the normal and predominantly α-helical form (Baldwin 
et al., 1994) to a β-pleated sheet containing form (PrPSc) which is also the disease 
causing agent.  The conversion is mediated by the presence of PrPSc acting as a 
template (Nguyen et al., 1995b).  Gradually more of the cellular PrPC is requisitioned 
and changed into the abnormal isoform which accumulates within the brain as 
deposits.  Evidence for the template mediated conversion was shown within cell-free 
in-vitro conversion assays (Kocisko et al., 1994, Saborio et al., 2001).  To encompass 
the many different strains of disease, considered to be a confounding factor for a 
protein-only agent, it was proposed that although the primary sequence of PrPSc was 
identical the protein could exhibit many different biologically active conformations 
(Stahl et al., 1993, Prusiner, 1998, Tremblay et al., 2004).  A comparable system of 
prion protein-only mediation of phenotypic properties was also shown to exist within 
both experimental and wild yeast strains within the laboratory of Susan Lindquist 
(Patino et al., 1996, True and Lindquist, 2000, Halfmann et al., 2012).  The generation 
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of purified recombinant mis-folded prion protein provided further evidence for the 
strain encoding properties of a self-replicating infectious protein that could induce a 
strain-specific disease within mice (Legname et al., 2004, Legname et al., 2005, Wang 
et al., 2010).  The specificity of template refolding was demonstrated used purified 
synthetic protease sensitive PrPSc at the first passage and then harvested prions for 
the second passage (Colby et al., 2010).  Both passages induced neurodegeneration 
and yielded solely protease sensitive PrPSc.  The absolute requirement for a template 
‘seed’ of PrPSc to initiate misfolding of a batch of PrPC further supported the specificity 
of template misfolding (Cosseddu et al., 2011). 
 
Opponents to the non-Mendelian theory of inheritance that the prion only 
hypothesis would imply proposed the Virino hypothesis.   Whereby a small quantity 
of nucleic acid or additional cellular co-factors were contained within and protected 
by the prion protein isomer (Dickinson and Outram, 1988).  Attempts to counter the 
Virino hypothesis, and confirm a protein-only agent, led to experiments generating 
recombinant PrPSc with a complete absence of cellular co-factors, even going so far 
as to ensure the procedures were carried out in a laboratory that had seen no prior 
use of prion protein.   The subsequent passaging in mice revealed the lack of 
obligatory requirement for any additional co-factors to generate a robust, albeit 
lengthy, prion disease (Kim et al., 2010, Makarava et al., 2010, Wang et al., 2012).  
The requirement for co-factors has not been fully laid to rest with in-vivo experiments 
demonstrating the enhanced re-folding and accelerated disease properties in the 






















The connection of the Prnp gene with the prion protein was not the first time the 
gene had been associated with prion disease.  The gene was first identified in mice as 
important for controlling the incubation length of experimental Scrapie and was 
named the Scrapie Incubation (Sinc) gene (Dickinson and Mackay, 1964, Dickinson et 
al., 1968). Two alleles; Sincs7 and Sincp7 were identified in mice which depending upon 
the encoded genotype resulted in a short or long incubation period respectively. Such 
was the control of the alleles that a combined infection of two very different Scrapie 
strains into groups of mice with different alleles would result in a reversal of which 
prion strain dominated the disease pathogenesis (Dickinson and Meikle, 1971).     
Later work confirmed Sinc and PrnP were the same gene (Moore et al., 1998) but with 
PrnP already prevalent in the literature the original work by Dickinson has 
unfortunately been overshadowed and Sincs7 and Sincp7 remain known as PrnPa and 
Prnpb. 
 
The genotype of Prnp forms part of the species barrier affect with evidence for 
homophilic preference between the PrPSc containing inoculum and the host PrPC 
(Scott et al., Race et al., 1995).  In addition to inhibiting infection across species, the 







Figure 1-2: The prion hypothesis postulates the template folding of PrPC into the misfolded, partially 
protease resistant, and disease-information (coding) containing PrPSc isoform. 
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is exemplified by the impact of sheep genotype on the susceptibility to Scrapie 
(Hunter et al., 1997a, Hunter et al., 1997b, Dawson et al., 1998).  Such was the impact 
that attempts to control Scrapie through selective breeding of resistant genotypes 
were conducted in 2001 through the National Scrapie Plan of Great Britain 
implemented by the Department for Environment, Food & Rural Affairs.  
 
Other than a strong association with plasma membrane though a glycosyl 
phosphatidylinositol anchor (Naslavsky et al., 1997, Agostini et al., 2013), the actual 
role of Prnp and the encoded protein PrPC remains unknown with normal neonatal 
development and no apparent anatomical alteration occurring if the gene is knocked 
out (Büeler et al., 1993, Manson et al., 1994a).  At the cellular level the number of 
mitochondria is reduced (Miele et al., 2002) linking the association of the protein with 
the cellular response to oxidative stress (Brown et al., 1999a).  Neuronal circuits are 
altered (Collinge et al., 1994, Colling et al., 1997) and behavioural changes are also 
apparent with impairment to circadian sleep patterns (Tobler et al., 1996). 
 
1.1.4 Prion Strains 
It is known that interaction between the strain and host Prnp genotype (Bruce et al., 
1991, Carlson et al., 1994) glycosylation status (Kascsak et al., 1985, DeArmond et al., 
1994, DeArmond et al., 1997, Somerville et al., 1997, Cancellotti et al., 2010), 
availability of host PrP (Manson et al., 1994b) and protease sensitivity of the 
misfolded isomer (Safar et al., 1998) all influence disease pathology and 
susceptibility.  Disease phenotype can be further compounded by the ability to have 
an infection by more than one prion strain, first shown with competition between 
the 22C and 22A strains (Dickinson et al., 1972).   
 
An infectious isolate is only considered a pure strain when the outcome is a stable 
and unique disease.  The stability of prion strains is such that even when a species 
barrier is crossed, the adapted form of the disease will present with a potentially new 
but nonetheless unique and consistent pathology (Pattison, 1966, Sisó et al., 2012).  
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This is only possible once a strain is highly purified following successive mouse 
infections using low titre (cloned).  That said, it is still possible for some strains to be 
separated further using a highly selective host environment (Mahal et al., 2010).  This 
implies these strains remain a heterogeneous conglomerate of multiple prion agents 
and is a topic classed under the ‘quazi-species’ affect, a term first conceived by the 
German biophysicist and Nobel Prize in Chemistry winner Manfred Eigen (Eigen and 
Schuster, 1977) and associated with prion strains by Weissmann et al. (2011). 
 
Natural Scrapie is readily transmissible into laboratory mice and isolation of Scrapie 
infected material from serially passaged mice of different genetic backgrounds has 
yielded a number of murine-adapted experimental Scrapie isolates.  These isolates 
demonstrate variation in the magnitude and localisation of vacuolation, mis-folded 
protein deposition and marked differences in the length of the incubation period 
(Bruce, 2003).   
 
1.1.5 Effect of Host Age 
Infected neonatal mice were shown to either survive or demonstrate a significantly 
longer incubation period than the equivalent titre in postnatal mouse pups (Outram 
et al., 1973).  Prion disease infection was shown to first replicate in lymphoid tissue 
(Eklund et al., 1967) and the incomplete development of this tissue in neonatal mice 
hindered successful infection.  Replication within lymph tissue was later shown to 
specifically require the scavenging uptake and replication of infectious material by 
mesenchymal follicular dendritic cells (Fraser et al., 1996, Brown et al., 1999b).  When 
mice reach over 400 days old at the point of injection there is once again a noticeable 
impact on disease infection.  As part of the healthy aging process the loss of the 
splenic margin zones and the corresponding reduction in follicular dendritic cell  
uptake has a marked influence on whether the disease reaches clinical stage or 




1.1.6 Effect of Route of Infection 
The speed of infectious uptake into the central nervous system is determined in the 
main by the concentration of available infectious material.  Following injection, and 
regardless of route, dissemination of infectious material rapidly occurs to tissues 
throughout the body (Millson et al., 1979) with a higher rate of loss in titre observed 
with an intraperitoneal route than an intracerebral route (Kimberlin and Walker, 
1978).  Accordingly the infectivity titre of an inoculum is lower when using a 
peripheral route.  This is further compounded by the complexity of the peripheral 
mechanisms of replication in the lymphoid tissues (Kimberlin and Walker, 1979, 
Brown et al., 2009, Brown et al., 2011).  Thus use of an intracerebral route, effectively 
flooding the brain with a considerable quantity of infectious material, produces a 
much shorter overall disease incubation period. 
 
However the increase in incubation period in a peripheral route is not simply due to 
a lower titre of available infectious material.  The neural phases of replication, classed 
as the time from first detection of protein deposition in the central nervous system 
to clinical onset, is actually quicker in a peripheral route (Kimberlin and Walker, 1986, 
Langevin et al., 2011); conclusions born from the examination of many thousands of 
infected mice.  This almost counterintuitive situation is rationalised when it is 
considered that prion disease pathogenesis in the brain is restricted to certain 
neuroanatomical pathways (Fraser and Dickinson, 1968, Kimberlin and Walker, 1980, 
Kimberlin et al., 1983, Scott et al., 1992).  This can be observed in detail following an 
intraspinal route of infection where the requirements for extra-neuronal replication 
are bypassed, yet still requiring entry into the brain along nerve pathways.  The neural 
phase of replication is initiated from the outset, thereby reducing the time required 
for replication phase in the brain, resulting in the shortest incubation period of all the 
possible routes of infection (Kimberlin et al., 1987).   
 
The restriction of disease pathogenesis to neuroanatomical pathways means the 
regional distribution of lesions and PrP deposition specific to a strain/host 
30 
 
combination is typically conserved regardless of route of inoculation (Kimberlin et al., 
1971b, Kimberlin and Walker, 1980).  This is fortuitous as the disruption of the blood 
brain barrier in an intracerebral injection (Millson et al., 1979) initiates both an 
intracerebral and an systemic infection simultaneously.  The latter, due to the time 
required for movement into the central nervous system, lags significantly behind the 
pathogenesis already taking place in the brain yet both end up with the same, 
overlapping, pattern of misfolded protein deposition. 
 
1.1.7 Effect of Host Gender 
The impact of gender on experimental mouse-adapted prion disease pathogenesis is 
restricted to differences in incubation period.  Very large collections of data 
performed in a wide variety of mouse strains from inoculations spanning decades 
show that there is a small increase in the incubation period in male mice  (Kimberlin, 
1976, Kimberlin and Walker, 1978, McLean and Bostock, 2000).  The differences were 
not always statistically significant and in most cases the difference was only a few 
days.  No gender differences have been observed with regional targeting and severity 
of lesions, misfolded protein deposition, neuronal loss and levels of endogenous PrPC 
expression (Akhtar et al., 2011).  Interestingly the gender difference in incubation 
period is most pronounced following a peripheral route.  The increase in body size of 
male mice, and resulting reduction in the infectious titre already exaggerated by 
further loss with a peripheral route, is therefore a possible explanation.  There has 
also been tentative evidence to suggest that androgens influence incubation period 
in male mice following experiments in castrated mice (Loeuillet et al., 2010).  Within 
the healthy mouse brain the number of microglia are observed to be approximately 
20% less in male mice than females (Mouton et al., 2002), with female sex steroids 
shown to be marked inhibitors of microglia activation (Drew and Chavis, 2000, Saravia 
et al., 2007).  Castration is also known to affect the peripheral immune function of 
male mice by inducing a reduction in mature peripheral T cells and alterations to basal 
splenic B cell activation (Viselli et al., 1995).  The gender differences in incubation 
period seen by Loeuillet et al. (2010) were confined to a peripheral route;  
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Therefore requiring a fully functioning peripheral immune system.  The impact on 
lymphoid tissue function, and more specifically the uptake of infectious Scrapie 
agent, following castration has yet to be investigated. 
 
1.1.8 Defining the events in protein misfolding diseases  
The highly reproducible characteristics of mouse-adapted Scrapie strains make them 
an ideal model for studying neurodegenerative disease.  The neuronal loss, build-up 
of a misfolded host protein and, most importantly, the invariably fatal outcome 
match that observed in human neurodegenerative diseases.  
 
The association with a misfolded protein is similar in many respects to other 
neurodegenerative diseases including Alzheimer’s Disease (DeArmond, 1993) and 
there has been considerable effort in recent years to further investigate the amyloidal 
properties of the misfolded proteins found in other neurodegenerative diseases.  The 
overriding consensus is that initiation of misfolding from very small initial quantities; 
termed ‘seeding’, and the spread of misfolded protein from cell to cell within the host 
demonstrate overlapping properties to prion protein propagation (Bolmont et al., 
2007, Desplats et al., 2009, Stohr et al., 2012, Duran-Aniotz et al., 2013, Guo and Lee, 
2013, Dujardin et al., 2014).  There is no evidence to suggest the other non-prion 
protein diseases are transmissible from host to host but there has been work to 
suggest isolates of amyloid from other protein misfolding diseases demonstrate 
distinct pathogenic properties that could be described as prion-like strains (Kayed et 
al., 2010, Guo et al., 2013, Gath et al., 2014, Pinotsi et al., 2014, Stohr et al., 2014, 
Watts et al., 2014). 
 
Of particular relevance to this project is that many of the human neurodegenerative 
diseases including Alzheimer’s Disease, Parkinson’s Disease and Creutzfeldt-Jakob 
Disease demonstrate activation of microglia (McGeer et al., 1993, Guiroy et al., 1994, 
Eitzen et al., 1998, McGeer and McGeer, 1999, McGeer and McGeer, 2008, Abutbul 
et al., 2012), a pathological feature also replicated in experimental mouse-adapted 
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prion disease (Williams et al., 1994).  The injection of infectious prion material into a 
wild type mouse ensures the exact starting point of the disease is identified.  
Considering the proteinaceous seeding potential of many neurodegenerative 
misfolded host proteins, the exact determination of the start, of what would 
otherwise be a de-novo occurrence, is an advantage unique to prion disease (Jucker 
and Walker, 2013).   The middle and end stages are then clearly defined allowing for 
the time course of events during disease pathogenesis to be documented in 
chronological order.  Uninfected mice, kept separate from prion infected mice, do 
not develop disease and provide healthy control animals in which there is only one 
experimental variable to consider.  Conversely the use of complex transgenic 
manipulation required to develop other neurodegeneration diseases in mice, 








Whilst the neuron has been subject to the majority of research into protein 
misfolding diseases, other cells such as microglia have also been suggested as 
important players by demonstrating microgliosis throughout the infectious process 
(Williams et al., 1994).  Microglia are distributed fairly evenly, with a slight bias of 
location in the grey matter, and at an estimated 3.5 x106 cells comprise 
approximately 10% of all cells found in the adult mouse brain (Lawson et al., 1990).  
Unique to the central nervous system, microglia are of haematopoietic stem cell 
origin and, as will be discussed in this chapter, form an intrinsic part of the 
multicellular central nervous system far beyond merely operating as the principal 
resident innate immune cell. 
 
1.2.1 Origin of Microglia 
Microglia were recognised as a visually distinct type of neuroglia with rod-shaped 
nuclei almost simultaneously by Robertson (1900) and Nissl (1899) using platinum 
deposition and basic dyes respectively.  Prior to this, the blanket term ‘neuroglia’ was 
given to all non-nerve interstitial cells within the brain (Virchow, 1846, Virchow, 
1858).  In particular it was noted by Dr Fraz Nissl that his newly discovered 
“Stäbchenzellen” or ‘Rod-cells’ had the ability to scavenge dying neurons during 
trauma.  The action of phagocytosis by rod-cells, and their acknowledgement as a 
separate type of neuroglia, was not widely accepted with many leading neurologists 
of the time attributing the observations to an unfamiliarity with the nervous system 
(Cerletti, 1902, Cerletti, 1903, Cerletti, 1905, Noda, 1921).  It was not until the studies 
by Penfield (1925)  on diseased brains, inflicted with glioma, was the phagocytic 
activity found to be restricted to the rod shaped cells, arresting all doubt that this 
cellular activity took place within the brain.  The debate on how neuroglia were to be 
characterised was finally concluded in the 1930’s following the pioneering work by 
Pio del Río-Hortaga in which the three glia cell types were identified; and continue to 
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be known as microglia, astrocytes and oligodendrocytes  (Río-Hortega, 1920, Río-
Hortega, 1921, Rio-Hortega, 1932). 
 
Microglia progenitors were initially proposed to be present in both the embryonic 
and adult mouse brain following identification of a highly prolific cell type that rapidly 
differentiated under culture  into cells specific for myeloid markers (Alliot et al., 
1991).  The progenitors were later suggested to originate in the yolk-sac from day 8 
of mouse embryo development and continue to proliferate and differentiate into the 
adult microglia population by late gestation (Alliot et al., 1999, Kierdorf et al., 2013).  
In Csf-1r-deficient mice, microglia fail to develop correctly and this state of affairs was 
found to be maintained throughout the life of the animal despite uninterrupted 
numbers of circulating monocytes (Ginhoux et al., 2010).  Fate mapping with 
sophisticated fluorescent reporter mice also demonstrated how microglia 
progenitors present in the yolk-sac entered the embryo proper via the newly 
circulating blood system on embryonic day 9 (E9) and specifically contributed to 
microglia and not to other circulating myeloid cells (Ginhoux et al., 2010).  Further 
work using complex transgenic mice then traced the progenitors as leaving the yolk-
sac on E9 as an intermediate stage expressing Cd45 but not Cc3cr1, F4/80 or Cd115 
before entering the structures, that later develop into the brain on E10.5, as 
immature macrophages expressing Cd45+, Cc3cr1+ F4/80+ and Cd115+ (Neumann and 
Wekerle, 2013).  Immediately after birth microglia proliferate rapidly generating the 
numbers and distribution that will then persist for life (Alliot et al., 1999).  It is still 
not known if the rapid replication is entirely sourced from the resident microglia 
population or in part from influx of circulating myeloid cells but evidence would 
suggest that by E13.5 the mouse blood brain barrier is fully developed prior to the 
blood-borne circulation of monocytes (Daneman et al., 2010). 
 
1.2.2 Origin and Maturation of Monocytes 
The embryonic entry into the brain of specific hematopoietic progenitors is unique to 
microglia and very different to the formation of other tissue myeloid populations.  It 
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is prudent to next describe the processes of peripheral tissue macrophage formation 
as the necessity of inflammation and the actions of epithelium drive this process, and 
both have an impact on the turnover of the resident microglia population.   
 
Macrophages are represented in nearly every tissue type and display considerable, 
yet highly conserved, heterogeneity in resting phenotype dependent upon the 
microenvironment in which the cell resides (Figure 1-3).  Differing levels of burden of 
immune surveillance in any given tissue require resting macrophage function and 
appearance to be adapted to suit.  Few cells in as complex an environment as an adult 
body can be considered to be stand-alone and the macrophage is no exception with 
homeostatic function in a multi-cell type microenvironment equally as important as 
immune surveillance. 
 
The macrophage, meaning ‘big eater’ was largely identified following on from the 
work of Nobel prize winner Ilya Metchinkov in describing the uptake and subsequent 
destruction of microorganisms by mono-nucleated cells circulating within blood 
(Mechnikov, 1908).  The process of macrophage formation initially starts with a series 
of precursor cells derived from haematopoietic stem cell lineage in the bone marrow.  
The result of this process (leukopoiesis) is the monocyte cell population found in the 
blood stream, and now known to be those identified with use of aniline dyes by 
Metchinkov.  Monocytes are themselves divided into sub-populations, by expression 
levels, of lymphocyte antigen 6 complex (Ly6C) (Jutila et al., 1988, Kennedy and 
Abkowitz, 1998) and the associated retention of CC-chemokine receptors (CCR) 7, 




Figure 1-3:  Tissue macrophage variants and phenotypic surface marker expression.   Highly dependent 
upon the tissue type in which a monocyte takes up residence; resident macrophages display a remarkable 





















All newly formed monocytes express high levels of LY6C and are chemotactically 
attracted to sites of inflammation where they mature into inflammatory 
macrophages in an effort to return the tissue to normal homeostasis (Geissmann et 
al., 2003). It is now known that the blood-borne cells Metchinkov observed were in 
fact LY6CHi inflammatory monocytes; cells able to respond to inflammatory signals 
and thus demonstrate a weak phagocytic ability.  Monocytes that remain in general 
circulation gradually lose Ly6C expression along with the retention of CCR7, CCR8 and 
CCR2 (Geissmann et al., 2003) and would appear to gain the glycoprotein Cluster of 
Differentiation 16 (CD16) (Passlick et al., 1989) and the fractalkine receptor CX3CR1 
(Ancuta et al., 2003). The resulting LY6CLo/CD16Hi/CX3CR1Hi monocyte populations 
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are presumed to be lost from the blood through fractalkine mediated migration into 
vascular endothelium (Ancuta et al., 2003, Auffray et al., 2007, Nahrendorf et al., 
2007) and form the resident and wound-healing macrophage populations 
represented in nearly every tissue type. 
 
Resident non-inflamed tissue macrophages suddenly finding themselves in an acute 
site of inflammation, and those derived from LY6CHi inflammatory monocytes in 
response to inflammatory signals, react to their local microenvironment at an innate 
level when activated by both interferon gamma (INFg), a cytokine released by natural 
killer cells in response to exogenous molecules, and tumour necrosis factor (TNF) 
released by macrophages in response to Toll-like receptor (TLR) ligation with 
exogenous molecules.  The result is an increase in the production of reactive oxygen 
species and the ability to degrade exogenous intracellular material (Hibbs, 2002).  
This is in addition to production of further TNF and interleukins that stimulate natural 
killers to express more INF-g and recruit neutrophils and T-helper cells to the site of 
inflammation (Annunziato et al., 2012). 
 
1.2.3 Resident Ramified Population Turnover 
The resident microglia population is highly stable and efforts to determine if such 
stability is the result of a resident or a peripheral contribution have led to 
experiments performed in both healthy and diseased brain scenarios.  The questions 
posed of the resident population can be broken down into two areas of research, the 
maintenance of the healthy ramified pool and the circumstances surrounding the 
apparent increase in numbers during microgliosis.   
 
The immunoactive nature of the blood brain barrier in regulating monocyte 
transmigration into the parenchymal perivascular spaces (Piccio et al., 2002, Kovac et 
al., 2011) would suggest that from E13.5 onwards resident microglia in the healthy 
brain comprise a self-sufficient population.  Healthy microglia turnover has been 
shown, using [3H]thymidine incorporation and autoradiography, to be 20 fold slower 
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than all other tissue macrophage populations with only 0.05% of the microglia 
population at any given time undergoing mitosis (Lawson et al., 1992).    
 
There is limited evidence to determine the exact contribution of monocyte crossover 
to the healthy resident microglia population although the mechanisms certainly exist 
for monocytes to enter the healthy adult brain.  Without disruption of the blood brain 
barrier a very slow crossover has been shown with detection in the parenchyma of < 
10 cells per 1 x106 fluorescently labelled monocytes injected into the blood stream 
after a period of 24 hours (Wu et al., 2006).  The influx is most likely to be mature 
LY6CLo/CX3CR1+ monocytes for which inflammation mediated crossover is not 
necessarily required.  The specific detection of LY6CLo CX3CR1+ monocytes using 
transgenic mice expressing red fluorescent protein tagged CCR2 (CCR2-RFP), 
combined with green fluorescent protein tagged CX3CR1, has allowed this population 
of cells to be distinguished from the resident microglia population (Saederup et al., 
2010).  This type of experiment has shown that infiltration by CCR2-RFP expressing, 
and therefore LY6CHi, monocytes in the healthy brain is negligible.   
 
Far greater numbers of monocytes have been shown to rapidly enter the brain and 
replace missing microglia following the use of transgenic thymidine kinase expression 
under the control of the Cd11b allele (Cd11b-HSVTK) to specifically elicit widespread 
microglia ‘suicide’ (Varvel et al., 2012). Importantly the study by Varvel et al. (2012) 
reported the surviving resident microglia remained ramified and did not exhibit any 
sign of activation although the same was not true of the astrocytes population.  The 
exclusion of LY6Clo/CX3CR1+ from the inflamed brain would suggest that in situations 
of mass depletion, microglia are replaced by LY6CHi inflammatory monocytes 
(Mildner et al., 2007, Saederup et al., 2010).   
 
An alternative explanation has been offered that missing microglia are replenished 
through resident mitotic potential. This has been elegantly shown, and in the absence 
of inflammation, by the work of Parkhurst et al. (2013) using mice expressing 
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tamoxifen-inducible Cre recombinase under the control of the CX3CR1 promoter and 
a red fluorescent combination reporter.  Following administration of tamoxifen, the 
resident microglia population remained exclusively recombined long after tamoxifen 
had dissipated and with no evidence for the non-recombined cell influx observed in 
peripheral tissues.  The use of elegant parabiotic experiments in which the circulatory 
systems of two healthy mice were co-joined, one of which expressed myeloid 
transgenic reporters, also demonstrated extremely low contribution from circulating 
progenitors and that upon entry the cells maintained a strict line of lineage 
differentiation into microglia only (Massengale et al., 2005).  Recent work has also 
uncovered evidence that following microglia depletion the rapidly proliferating cells 
which replenish the population express nestin, a marker of stem lineage, and were 
devoid of the microglia specific marker allograft inflammatory factor 1 (AIF1) 
suggesting a microglia progenitor resides in the adult brain (Elmore et al., 2014).   
Widespread depletion of microglia has therefore been instrumental in determining 
the ability of monocytes to enter the brain.  Overall it would therefore seem that 
while monocyte influx can contribute to turnover of the resident microglia when 
inflammation is present, the population in the healthy brain is largely self-sufficient.   
 
1.2.4 Perivascular Microglia 
Occupying the parenchymal perivascular regions, the perivascular microglia present 
with a higher turn-over rate with a steady contribution from influx of circulating 
myeloid precursors (Hickey and Kimura, 1988).  Both perivascular and intermediately 
located juxtavascular (Lassmann et al., 1991) populations demonstrate rapid 
activation and expression of myeloid inflammatory surface receptors (Vass and 
Lassmann, 1990) indicating that similar to the resident parenchymal microglia, the 
contributing circulating myeloid precursors are indistinguishable in their function 
once matured.  Also as per parenchymal microglia; perivascular microglia intrinsically 
communicate with other cells and respond with a localised and highly specific 
activation state (Serrats et al., 2010).  Indeed the maturation of myeloid precursors 
into a perivascular microglia phenotype is not possible out with the multicellular 
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brain microenvironment (Tanaka et al., 1993).  Although perivascular populations can 
be identified by expression of specific markers (Galea et al., 2005) it is accepted 
terminology that the perivascular populations are considered microglia subtypes 
separated only by location and not appearance (Gehrmann et al., 1995).  
 
1.2.5 Population Dynamics during Microgliosis 
Microgliosis is the term used to describe both the visual change in appearance and 
the increase in population size observable when microglia become activated.  Much 
debate surrounds whether the apparent increase in microglial numbers observed 
during microgliosis is due to influx of circulating monocytes or though the mitotic 





















Figure 1-4: Microglial morphological response. A: resting microglia in the healthy brain display a 
small central soma with delicate processes extending out into the parenchyma.  B: Conversely activated 
microglia have enlarged somas with shorter thicker processes.  The cell density also increases through 
recruitment and/or division.  Scale bars equate to 50 µm. Murine microglia in the thalamus stained with 
anti-Allograft inflammatory factor 1. 
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The minimal contribution of circulating LY6Clo/CX3CR1+ monocytes to the resident 
microglia pool during normal turnover is the result of limited expression of 
chemoattractants in the healthy brain (Section 1.2.3).  By contrast the brain in 
situations of acute and chronic trauma is, as evidenced by activated microglia and 
astrocytes, a source of inflammatory cytokines and chemokines.   The conditions are 
therefore favourable for the influx of LY6CHi inflammatory monocytes (Section 1.2.2) 
and studies utilising re-constitution with transgenic reporters in situations of chronic 
neurodegeneration reported a high level of contribution from reconstituted cells to 
the resident population  Two notable studies that have adopted transgenic reporters 
are those by Williams et al. (1995) and Priller et al. (2006).  The former utilised XX-XY 
chimeric reporter mice in which irradiated C57BL/6J female mice were reconstituted 
with bone marrow derived from C57BL/6J male mice.  A combination of 
immunohistochemistry and detection of the Y-chromosome by in-situ hybridisation 
revealed that prion infected mice chimeric mice demonstrated recruitment of 
peripheral Y-probe positive myeloid derived cells.  Furthermore no difference in 
visible morphology could be attributed between host microglia and those containing 
a Y-chromosome.  The use of XX-XY chimerism elegantly allowed host and 
reconstituted microglia to be distinguished and the study concluded that the overall 
low-level recruitment of monocytes was independent of both lesion severity and 
incubation length.  The maximum level of chimerism gained within the experiment 
was 33% and by ensuing that a considerable proportion of the original host microglia 
were intact the study were able to conclude that the recruitment of peripheral 
myeloid cells was not a critical part of the disease process. 
 
By contrast a significantly higher proportion of peripheral bone marrow-derived 
derived microglia were observed in the study by Priller et al. (2006).  This study 
utilised a green fluorescent protein tagged bone morrow reconstitution reporter 
system and found that, although the total number of microglia in prion infected brain 
remained constant, the number of reporter cells comprised just over half of the 
population.  Furthermore bone marrow derived cells were recruited early on in the 
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disease process suggesting a constant turnover throughout the incubation period.  
Although the use of lethal irradiation has been defended by the studies that utilised 
the method, typically by control measurements including checking the stability of the 
host microglia population as part pf the aging process and blood brain barrier 
integrity through detection of Immunoglobulin G extravasation (Priller et al., 2006) 
there remains the generation of a non-physiological condition. 
Parabiotic experiments co-joining the circulatory systems of two mice during both 
acute and chronic neuroinflammation following irradiation that, crucially, left 
microglia and the blood brain barrier intact, established that in a physiologically 
correct situation no circulating monocytes cross over into the brain (Ajami et al., 
2007).  Importantly, further experiments by Ajami et al. (2007) revealed that 
significant monocyte influx took place if a healthy mouse subjected to lethal 
peripheral irradiation with a head shield was rescued with bone marrow 
reconstitution.  The act of lethally irradiating mice to deplete myeloid cells followed 
by reconstitution with a bone-marrow donation induces a non-physiological state 
with possible persistence of hematopoietic cells and progenitors normally found in 
bone marrow remaining in circulation (Mildner et al., 2007).  Others have also shown 
how the significant monocyte influx associated with cranial irradiation contributes 
directly to the resident microglial population in efforts to mediate irradiation induced 
inflammation (Burrell et al., 2012)   Consequently it would seem that lethal irradiation 
and/or bone marrow reconstitution are actually necessary for crossover of circulating 
monocytes bringing the interpretation of previous experiments using these 
techniques to quantify circulating progenitor contribution to resident microglia into 
question (Ransohoff, 2007).  Most studies since this seminal work now take the 
precaution to shield the head during irradiation to allow for the spontaneous 
infiltration of monocytes to be reported in a more normal pathological state. 
 
The exception to most neurodegenerative diseases would appear to be artificially 
induced experimental autoimmune encephalomyelitis in which monocytes can cross 
a physiologically intact blood brain barrier (Ransohoff, 2011).  Using transgenic CCR2 
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and CX3CR1 knockout mice, expressing red and green fluorescent tags respectively, 
demonstrated that inflammatory LY6CHi/CCR2+ monocytes increase the 
morphological activation of all resident microglia during experimental autoimmune 
encephalomyelitis (Saederup et al., 2010).  Indeed the progression of experimental 
autoimmune encephalomyelitis can actually be halted by using CCR2 knockout mice 
to inhibit recruitment of LY6CHi/CCR2+ monocytes into the brain implying these cells 
are crucial to the ongoing pathology, even if, after resolution of the acute phase, all 
undergo apoptosis leaving only resident cells to persist (Ajami et al., 2011).   
 
The contribution in acute injury is more complex with conflicting reports existing for 
the contribution of LY6CHi inflammatory monocytes to the increase in microglia 
observed during acute microgliosis.  Efforts to reconstitute circulating monocytes 
following depletion of circulating progenitors with injected clodronate-encapsulated 
liposomes, a method that results in minimal lasting inflammation, found the bulk of 
replicating microglia to be resident in origin (Ladeby et al., 2005).  Conversely, 
reconstitution following lethal irradiation revealed considerably more LY6CHi 
monocytes contributed to the resident pool (Getts et al., 2008).  The difference 
between the levels of LY6CHi monocyte influx might be attributed to changes in the 
immunoactive state of both the brain parenchyma and vascular epithelium.  
 
There is some data to support the crossover of infiltrating cells back into the blood 
circulation as antigen presentation cells following active phagocytosis of debris in 
localised acute lesions (Joly et al., 2009) and that interleukin 10 expressing anti-
inflammatory macrophages, derived from infiltrating cells, are necessary for acute 
lesion recovery and are recruited by involvement of the adaptive immune system 
(Shechter et al., 2009).  The involvement of the adaptive immune system in 
neurodegenerative diseases is still little understood although the recruitment  of T-
cells into the brain parenchyma is known (Lewicki et al., 2003) with further evidence 
to suggest partial protection is afforded by their presence (Klein et al., 2005, Iken et 




1.2.6 Acute Inflammatory Activation  
Resident resting microglia continuously sample the surrounding microenvironment 
with highly mobile actin rich protrusions for which motility is regulated by purinergic 
receptors (Capani et al., 2001, Boucsein et al., 2003, Davalos et al., 2005, Haynes et 
al., 2006, Franke et al., 2007).  Even in the resting state microglia demonstrate broad 
regional differences in morphology (Lawson et al., 1990) through adaptations to local 
architecture (section 1.2.4).  Microglia are incredibly sensitive to any perturbations 
within their immediate environment and respond rapidly to any insult with increased 
process motility and physical migration to the affected area (Davalos et al., 2005, 
Nimmerjahn et al., 2005, Kozai et al., 2012).  Such is the sensitivity of microglia that 
Nimmerjahn et al. (2005) found the heat generated from scraping a scalpel blade 
across mouse skull to thin down the bone for in-vivo multi-photon imaging was, if not 
performed gently enough, sufficient to aggravate underlying microglia in the cortex 
(Hughes, 2012). 
 
Microglia express a wide variety of scavenging, Toll-like, Nod-like receptors and 
receptors for advanced glycation end products (RAGE) to detect the presence of 
damage-associated molecular patterns (DAMPS) including ATP, nucleotides, oxidised 
lipids, and DNA histones released by dead and dying cells (reviewed extensively in 
Bianchi, 2007).  Also included within the spectrum of acute detection, primarily by 
toll-like receptors, is the detection of pathogen-associated molecular patterns 
(PAMPS).  PAMPS, as the name implies, initiate the response to pathogens and 
foreign bodies.  The detection of PAMPs and DAMPs by microglia initiates the MAP 
kinase, p21ras and the NF-KB pathways leading to amplification of microglia activation 
(Lander et al., 1997, Basta et al., 2002). 
 
The full activation of microglia in acute damage is kept at bay though the action of 
constitutively expressed inhibitory membrane bound neuronal ligands including the 
chemokine CX3CL1 (Boehme et al., 2000, Hughes et al., 2002, Cardona et al., 2006b, 
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Liang et al., 2009) and the glycoproteins CD200 and CD47 (Hoek et al., 2000, Jenmalm 
et al., 2006, Gitik et al., 2011).  Where neurons are functioning correctly these 
inhibitory ligands bind to corresponding receptors on microglia and keep the full 
activation of microglia under tight feedback control.  The release of inflammatory 
cytokines and oxidative products is quickly suppressed to limit the collateral damage 
to surrounding neurons (Nahrendorf et al., 2007, Clausen et al., 2008, Hines et al., 
2009, Shechter et al., 2009).  Even when phagocytising damaged and apoptotic 
neurons in the otherwise healthy brain, microglia demonstrate a remarkably down-
regulated phenotype (Takahashi et al., 2005, Sierra et al., 2010)  in a process that has 
been termed ‘phagoptosis’ (Brown and Neher, 2012).  The phagocytosis of dying cells 
and debris is a well-known function of microglia during the resolution of 
inflammation (Neumann et al., 2008, Neumann et al., 2009).  The relatively silent 
removal of otherwise viable neurons by phagoptosis is also seen as a core component 
of neurodegeneration (Fricker et al., 2012).   
  
Traditionally, macrophage differentiation in response to INF-g and corresponding 
antagonists Interleukin (IL) 4 and IL-13, released by T-helper-1 and T-helper-2 cells, 
(Mosmann and Coffman, 1989, Sallusto and Lanzavecchia, 2009) is thought to result 
in two distinct phenotypes: classical M1 and alternative M2 (Mantovani et al., 2007, 
Martinez et al., 2009, Varin and Gordon, 2009). There is also some controversy over 
a third macrophage subtype splitting categorisation into classical, regulatory and 
wound-healing phenotypes (Mosser, 2003, Mosser and Edwards, 2008).  As the 
resident myeloid immune cell in the central nervous system the classifications of 
classical and alternative activation have been applied to microglia, particularly as 
microglia are able to express a wide variety of macrophage associated cytokines 
(Table 1-2).  Experiments performed in situations of acute central nervous system 
damage revealed the presence of classically activated M1 microglia, immediately 
following an acute lesion, resulted in significant neuronal loss (Boutin et al., 2001, 
Kigerl et al., 2009).  Alternatively activated microglia, associated with neuro-
regeneration are present in the minority. This situation rapidly resolves as the ratio 
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reverses and normal homeostasis is restored.  Those cells that could be described as 
demonstrating a classically activated phenotype, associated with neuronal loss, 
outnumber those displaying an alternatively activated phenotype associated with 
neuro-regeneration (Kigerl et al., 2009, Varin and Gordon, 2009).  Gradually this 
situation resolves as the ratio reverses and normal homeostasis is restored. 
 
 
Table 1-2: The main macrophage-like cytokine and chemokine repertoire expressed by microglia 










IL-18./IGIF interleukin-18/interferon-γ inducing factor 
M-CSF macrophage-colony stimulating factor 
TGFB transforming growth factor β 
TGFA transforming growth factor α 
GROA growth regulated oncogene α 
MCP-1 monocyte chemoattractant protein-1 
MIP-1a/Mip-1b macrophage inflammatory protein-1α/1β 
MIP-2 macrophage inflammatory protein-2 
RANTES regulated on activation, normal T cell expressed and secreted 
 
 
1.2.7 Chronic Activation in Neurodegenerative Diseases 
Neurodegenerative diseases typically involve chronic microglial activation that lasts 
throughout the disease process.  The protracted timescale of the diseases introduces 
the potential for changes in inflammatory triggers to occur in the central nervous 
system as the disease progresses.  The activation of microglia during chronic 
inflammations is therefore considerably more complex.  Indeed it is now considered 
likely that microglia in chronic diseases do not conform to the M1 and M2 profiles 
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Figure 1-5: Microglial activation plasticity.  Any perturbations to the immediate microenvironment 
surrounding microglia initiates an immediate but unique response governed by many factors including 
the type of insult, host age, and overall host (systemic) inflammatory state.  The latter has the capacity 
to influence microglial activation phenotype from outside of the central nervous system.  It is therefore 
important to consider the differences in host condition, and the corresponding downstream effect on 
microglia activation phenotype, when comparing an experimental host population with a heterogeneous 
human population.  Image courtesy of Perry et al. (2010). 
and instead demonstrate a considerable degree of plasticity (Figure 1-5) with unique 
phenotypes at any given point in time determined by changes in the immediate 






Chronic protein misfolding neurodegenerative diseases affect large areas of the brain 
and microglial activation is seen on a wider scale.  The recruitment of microglia has 
been associated with the deposition of amyloid precursor protein (APP) plaques in 
APP transgenic mice where numbers of microglia are proportional to amyloid plaque 
size (Stalder et al., 1999, Bolmont et al., 2008).  Involvement of microglia with plaques 
is thought not to be direct engulfment of amyloid but an intricate, and little 
understood, interaction with surrounding cells and filaments on the outer edges of 
the plaque (Stalder et al., 2001, Hughes et al., 2010, Cramer et al., 2012). 
 
Activated microglia impart a cytotoxic environment through expression of soluble 
pro-inflammatory products including IL-1β, IL-6, tumour-necrosis factor-α (TNF-a), 
and multiple reactive oxygen species (Boje and Arora, 1992, Benzing et al., 1999, Cox 
et al., 2013).  The long term effects of chronic activation and the role a cytotoxic pro-
inflammatory saturated environment are not well known.  Prion disease models are 
one of the few models that successfully replicate both misfolded protein deposition 
and neuronal loss and in this group of diseases neurons appear not to die though 
toxin or damage mediated necrosis but through caspase-mediated apoptosis (Giese 
et al., 1995, Lucassen et al., 1995, Jamieson et al., 2001, Siso et al., 2002).  The 
presence of progressive autophagy has also been suggested as part of this process 
(Boellaard et al., 1991, Xue et al., 1999, Sikorska et al., 2004, Xu et al., 2012).  The 
clearance of apoptotic cells by myeloid cells involves the ligation of thrombospondin-
1 on the apoptotic cell surface with CD36 and αVβ3 receptors on the phagocyte as 
part of the self-recognition process (Brown et al., 2002).  Binding with 
thrombospondin-1 induces a reduction in pro-inflammatory TNF-a, and a marked 
increase in expression of anti-inflammatory transforming growth factor-β1 (TGF-b1) 
and IL10 (Voll et al., 1997, Freire-de-Lima et al., 2000).  Murine models of prion 
disease have been described as being dominated by an increase in expression of TGF-
β1 (Cunningham et al., 2002, Boche et al., 2006).   The resulting downstream anti-
inflammatory profile induced by increasing levels of TGF-b1, has led to the 
widespread adoption of the term ‘atypical inflammation’ when describing microglia 
49 
 
phenotype in neurodegenerative diseases (Fadok et al., 1998, Baker et al., 1999, 
Walsh et al., 2001, Cunningham et al., 2002, Perry et al., 2002, Baker and Manuelidis, 
2003). 
 
The multifunctional cytokine TGF-β1 is evident throughout the disease process 
where, although it has no impact on the deposition of misfolded protein, it is involved 
in supressing microglia activation through inhibiting translation (Lodge and Sriram, 
1996, Abutbul et al., 2012).  The cytokine is also heavily involved in maintenance of 
endothelium basement membrane and the blood brain barrier (Cunningham et al., 
2002, Garcia et al., 2004).  TGF-β1 is known to act in concert with Glial Cell Line-
Derived Neurotrophic Factors (GDNF), further members of the transforming growth 
factor superfamily, to impart a neurotrophic potential on neurons (Krieglstein et al., 
1998, Schober et al., 1999, Peterziel et al., 2002).  GDNFs are now recognised as 
beneficial to the survival of dopaminergic neurons in Parkinson’s Disease (Grathwohl 
et al., 2009, Ramaswamy et al., 2009, Patel et al., 2013, Tereshchenko et al., 2014).  
Care however needs to be applied in describing the neurotrophic function of 
transforming growth factors within the context of microglia in neurodegenerative 
diseases.  Microglia express and bind with a wide variety of neurotrophic factors 
(Elkabes et al., 1996).  Although the presence of these factors are known to increase 
in murine prion models of neurodegenerative disease (Lee et al., 2006), the 
modulatory effect on microglia activation following ligation of neurotrophic factors 
to microglia-bound receptors is not universal throughout the brain (Elkabes et al., 
1996, Boscia et al., 2009).  There is also some in-vitro data hinting at an increase in 
nitric oxide, T-a and the phagocytic response in the presence of transforming growth 
factors (Wang et al., 2013, Zlotnik and Spittau, 2014). 
 
Microglia have the mechanism in place to elicit a cytotoxic action on other cells and 
this has been comprehensively demonstrated using in-vitro co-cultures through 
detection of reactive oxygen species following activation of microglia by 
lipopolysaccharide (LPS), Interferon-gamma (INF-g), amyloid-β or the prion protein 
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amino acid 106-126 peptide sequence (Colton and Gilbert, 1987, Boje and Arora, 
1992, Meda et al., 1995, Peyrin et al., 1999).  To date there is no evidence for actual 
neuronal toxic activity in-vivo where the added complications of a multicellular 
environment and multi-functional immunomodulators restrict the ability to form 
definite conclusions (Jeong et al., 2010). 
 
Pioneering work investigating the response of microglia in the regenerative 
environment, induced by sub lethal motor neuron axotomy, revealed microglia to 
express a wide range of immunomodulators including the adhesive and migration 
associated protein thrombospondin (Moller et al., 1996, Schiefer et al., 1999).  
Crucially thrombospondin is also associated with immature microglia during CNS 
development and is an aid to axon growth (Chamak et al., 1994, Chamak et al., 1995).  
Also observed were major histocompatibility complex (MHC) Class I antigens (Streit 
et al., 1989b) which upon further investigation into the proximal location of microglia 
to sites of neuronal repair led to the conclusion that activated microglia expression 
might also have a role in both initial synaptic loss and subsequent neuron 
regeneration (Kreutzberg et al., 1989, Streit et al., 1989c). 
 
Within in-vivo mouse models of neurodegenerative disease the earliest indications of 
neuronal stress are the loss of synapses, termed ‘synaptic stripping’ (Gray et al., 2009, 
Hilton et al., 2013, Siskova et al., 2013).  The accumulation of misfolded protein is not 
thought to directly interfere with synaptic vesicle transport (Asuni et al., 2008) but 
by interfering with lipid raft located transmembrane proteins (Jeffrey et al., 1997, 
Siso et al., 2002, Bouzamondo-Bernstein et al., 2004, Ishikura et al., 2005, Inoue et 
al., 2009, Godsave et al., 2013, Vargas et al., 2014).  Co-cultures of neurons and 
microglia in the presence of a PrP 106-126 peptide sequence has shown microglia will 
engulf damaged neurons (Brown et al., 1996, Bate et al., 2001) and that this is 
dependent upon for CD14 mediated contact (Bate et al., 2005).  Gene expression 
studies have also revealed interruptions to the otherwise neurotrophic actions of N-
methyl-D-aspartic acid receptor signalling (Liu et al., 2007, Majer et al., 2012). 
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With a clearer understanding of the vital roles microglia perform in the brain as part 
of a tightly regulated multi-cellular system, combined with a better understanding of 
the non-physiological conditions that can impact on the microglia population (see 
section 1.2.5), it is perhaps not surprising that recent investigations have observed 
minimal contribution from circulating monocytes during neurodegenerative mouse-
adapted prion disease (Gomez-Nicola et al., 2014).  The resident population is, for the 
most part, self-maintained.  It is interesting to note that past evidence for removal of 
anti-inflammatory IL-10 and the corresponding acceleration in disease progression 
and severity (Thackray et al., 2004) was previously dismissed in the literature with 
the aforementioned consensus for an ‘atypical’ anti-inflammatory phenotype.  What 
the data indicated was that pro-inflammatory modulators were a key driving force 
and recent work has once again shown how microglia activation is regulated by the 
Spi1 transcription factor initiating a strong IL34-driven differentiation into a pro-
inflammatory phenotype (Gomez-Nicola et al., 2013), and that ablation of microglia 
proliferation and pro-inflammatory activity considerably slows down neuronal 
damage (Gomez-Nicola et al., 2013, Sakai et al., 2013, Song et al., 2013).  Microglia 
activation by the JAK-STAT signalling pathway, and resulting expression of pro-
inflammatory products, has been shown to be regulated by non-coding MicroRNA 
146a (Saba et al., 2012) and overall activation requires perturbation of neuronal 
inhibitory signalling (Riemer et al., 2008, Fuhrmann et al., 2010, Xie et al., 2013) 
providing evidence that the complex and tight control over inflammation seen in the 
healthy brain is maintained during chronic disease.  
 
The large numbers of activated microglia all releasing inflammatory modulators has 
the potential to induce a self-perpetuating cycle maintaining high levels of microglial 
activation; termed reactive-microgliosis.  This can be elegantly observed within the 
1-Methyl-4- Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) toxin model of selective 
dopaminergic neuron loss (Langston et al., 1983).   The strong link between MPTP 
toxin and microglial activation is well known (Wu et al., 2003) and, importantly, 
neuro-inflammation continues to take place long after any remaining MPTP toxin has 
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been cleared from the system (Langston et al., 1999, McGeer et al., 2003).   Reactive-
microgliosis is also observable under conditions of Wallerian degeneration, where 
the separation of the axon from the cell soma has been initiated.  Microglial activation 
is rapid following separation (Lawson et al., 1994) yet following resolution the 
microglia remain activated with an anti-inflammatory phenotype that can persist for 
years (Palin et al., 2008). 
 
Tachyphylaxis, the increasing tolerance to a stimulant, is not an uncommon response 
displayed by in-vitro macrophage cultures.  While in-vitro does not always match the 
in-vivo environment, tachyphylaxis is a factor to be considered in the conditions of 
long term chronic activation, particularly if that tolerance is toward anti-
inflammatory signalling.  Microglia cultured in-vitro have been shown to express 
numerous pro-inflammatory cytokines in response to 24 hour exposure to the 
cytotoxic prion protein amino acid 106-126 peptide sequence (Peyrin et al., 1999).  
Interestingly there is a marked reduction in tumour necrosis factor-α following 
prolonged exposure (Zhou et al., 2008) suggesting a level of tolerance has been 
reached.  The persistence of microglia activation during reactive microgliosis has 
been suggested to be a form of “innate immune memory” (Perry et al., 2010) 
although it is not known if this is an advantageous adaption.  A more subtle form of 
chronic activation can however be studied in situations of ‘priming’ both from 
systemic signalling and the effects of senescence. 
 
1.2.8 Microglia Priming and Senescence 
The sensitivity of microglia to even the smallest perturbation within their immediate 
microenvironment mean microglia also responded to local signals with an origin from 
outside of the central nervous system.  At the broadest level, microglia are a key part 
of ‘cytokine-induced sickness behaviour’ whereby the host will demonstrate fever, 
malaise, anorexia and seek solitude during the acute phase reaction to pathogenic 
infection.  The evolutionary significance of this well-defined set of physiological and 
behavioural actions is to make the host inhospitable for pathogen survival, enhance 
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the normal immune response and, through seeking solitude, minimise further spread 
of the disease (Miller, 1964, Kluger, 1979, Hart, 1988, Dantzer, 2001).  The release of 
pro-inflammatory cytokines in the brain parenchyma during sickness behaviour 
including IL1β, TNF-a and nitric oxide synthase have been extensively documented 
with specific contributions made towards sickness behaviour upon recombinant 
inoculation and/or infection by LPS determined for each (Ban et al., 1992, Kent et al., 
1992, Gatti and Bartfai, 1993, Laye et al., 1994, Buttini and Boddeke, 1995, Quan et 
al., 1999, Thomson et al., 2014).  Importantly morphology can be observed to be 
independent of cytokine expression for the release of pro-inflammatory cytokines 
during the acute phase reaction to pathogenic infection is by ramified microglia and 
indicating activation toward a more amoeboid appearance is kept at bay (van Dam et 
al., 1992, Van Dam et al., 1995). 
 
The sensitivity of microglia to peripheral inflammation can result in excessive 
production of pro-inflammatory cytokines if microglia are pre ‘primed’ from an 
underlying chronic neurodegenerative condition afflicting the brain.  Such a 
secondary peripheral insult has the potential to ‘switch’ the current predominant 
down-regulated anti-inflammatory microglia phenotype, found in most 
neurodegenerative diseases, to a more neurotoxic pro-inflammatory phenotype 
(Palin et al., 2008, Murray et al., 2011).  This has been demonstrated in experimental 
mouse-adapted prion disease in which the combined sources of inflammation 
pertaining from both the periphery and the brain yielded a considerable increase in 
expression of cytokines and accelerated disease pathogenesis (Combrinck et al., 
2002, Cunningham et al., 2005b, Cunningham et al., 2009, Field et al., 2010, Murray 
et al., 2012).  Studies in transgenic mouse models of Alzheimer’s Disease and 
Parkinson’s Disease also show an increase in pro-inflammatory response upon acute 
systemic insult with LPS (Sly et al., 2001, Kitazawa et al., 2005, Pott Godoy et al., 
2008).  The importance of combined brain and peripheral insult is particularly 
relevant in lengthy chronic neurodegenerative diseases where the presence of 
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multiple co-morbidities are a real possibility, particularly in human diseases where 
the incubation period can be many years (Drake et al., 2011, Thaler et al., 2012).   
 
The impact of systemic inflammation in the aged brain also results in exaggerated 
innate inflammation initiated and maintained by microglia.   Microglia residing in this 
aged environment adopt a phenotype with increased expression of pro-inflammatory 
MHC Class II antigen, TNF-a, IL1b and IL-6 (Perry et al., 1993, Sierra et al., 2007, 
Kohman et al., 2013).  Shorter less complex processes are also visible presumably 
indicative of a state of permanent ‘priming’  (Streit et al., 2004, Sierra et al., 2007).  
There is also a marked increase in inflammation induced by gradual neuronal and glial 
cell loss by apoptosis and associated microglia activation (Lee et al., 2000, 
Schuitemaker et al., 2012, Gao et al., 2013).  Isolated cultured microglia demonstrate 
a similar aged phenotype indicating microglia are subject to, and respond to, their 
own age related changes and not just to the condition of surrounding cells (Sierra et 
al., 2007, Caldeira et al., 2014).  There is also a marked reduction in surface expression 
of the CX3CR1 fractalkine receptor signifying loss of inhibitory support from neurons 
(see section 1.2.6) as a possible cause of priming (Wynne et al., 2010).  Impact on 
mitotic potential through analysis of telomeres revealed a progressive reduction in 
telomere length both in-vivo and in-vitro by senescent microglia (Flanary et al., 2007).  
Despite this, actively replicating and pre-primed aged microglia in-vivo show 
increased basal telomerase activity partly mitigating telomere length (Flanary and 
Streit, 2005, Conde and Streit, 2006).  The rate of proliferation of aged microglia in 
response to injury is also greater (Conde and Streit, 2006) as is the basal expression 
of certain anti-inflammatory cytokines including TGFβ1 and IL-10 suggesting a certain 
level of inherent counteraction to the rising levels of inflammation within the 
parenchyma (Sierra et al., 2007).   
 
Senescent microglia respond to systemic inflammation with a phenotype strikingly 
similar to that seen in neurodegenerative diseases (Godbout et al., 2005, Dilger and 
Johnson, 2008, Murray et al., 2012) .    Indeed the increased basal levels of pro-
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inflammatory cytokines released by senescent microglia have been suggested as a 
cause of age-related neurodegeneration (Benzing et al., 1999, Riemer et al., 2004).   
  
1.2.9 Involvement in Neurodevelopment, Neurogenesis and Repair 
The brain is not a one cell-type centric environment and shows evidence of 
multicellular interactions and regulation.  Regulation of microglia immune response 
by neuronal inhibitory signals has been discussed (1.2.6); however microglia extend 
their interaction with neurons and other glial cells in activities that are not necessarily 
associated with immune function.   
 
Microglia progenitors enter the embryonic region that will later develop into the 
brain as a distinct group of cells with a hematopoietic origin (see section 1.2.1).  Why 
these cells should enter this region so early in development, prior to other resident 
tissue myeloid populations, led to investigations into determining if the cells have a 
role in correct neurodevelopment.  Evidence from in-vivo knockout studies in which 
microglia were ablated using spleen proviral integration oncogene (Spi1) and colony 
stimulating factor-1 (Csf-1), both recruitment factors, strongly supported the 
requirement of primitive yolk-sac derived microglia as critical for correct 
neurovascular development.  The developing brain does not have an intrinsic vascular 
system and relies entirely on angiogenesis (Vasudevan et al., 2008).  Hematopoietic 
cell lineages failed to develop correctly without angiogenesis stimulating factors 
(Scott et al., 1994, Kubota et al., 2009).  Furthermore microglia knockout resulted in 
a significant reduction in brain vascular structure complexity, thereby indicating a 
strong role for these cells in angiogenesis (McKercher et al., 1996, Kubota et al., 
2009).  Microglia have also been implemented in the regulation of post-natal 
angiogenesis by governing the suppression of branching (Stefater et al., 2011) and 
the absence of microglia in-vivo and in-vitro from neuronal precursors negatively 
impacts neurogenesis, proliferation and the bias of stem cell differentiation into 





Interfering with microglia function after vascular development has shown microglia 
to be critical for correct motor function.  The use of Tgfb1 knockout mice to gradually 
ablate microglia in in the embryo from E14.5, until the almost complete ablation by 
postnatal day 160, resulted in severe motor coordination abnormalities and weight 
loss (Butovsky et al., 2014).  Crucially it was noted by Butovsky et al. (2014) that there 
was a steady influx of LY6Chi/CD11b+ circulating progenitors that replaced the 
postnatal resident population of microglia.  These were immunologically active but 
did not correct lost motor function or display the same gene expression profile as the 
original microglia. Indeed infiltrating inflammatory monocytes would appear to be 
detrimental to homeostatic vascularisation (Li et al., 2012).   
 
The development of postnatal synaptic connections requires microglia for initiation 
of dendritic spine formation and synapse formation through IL-10 mediated 
stimulation (Lim et al., 2013).  The modulation of synapses in the postnatal 
developing brain also requires continual pruning by microglia for correct neuronal 
circuit maturation, and ablation of microglia to limit pruning has been shown to yield 
persistent electrophysiological hallmarks of immature brain circuitry (Paolicelli et al., 
2011, Rogers et al., 2011) and even perturbations to sexual differentiation (Levi et al., 
1998, Minghetti and Levi, 1998, Lenz et al., 2013).    
 
The mass caspase-mediated programmed cell death of immature neurons is critical 
for the correct formation of neuronal architecture, leaving behind the bulk of neurons 
and connections that will be retained for life.   The apoptotic process is driven 
competitively by starvation of nerve growth factors (Martin et al., 1988, Cattaneo and 
McKay, 1990) and microglia engulf the dead and dying cells and processes.  Critically, 
microglia are not just reacting to the presence of apoptotic cells but are drivers of the 
process with selective killing of immature neurons through targeted respiratory burst 




The capacity for the adult brain to renew neurons is limited and the primary reason 
for the tight regulation of inflammation to minimise damage.  A secondary side effect 
of Inflammation is inhibition of neurogenesis (Ekdahl et al., 2003, Goshen et al., 2007, 
Perez-Asensio et al., 2013).  Inflammation inhibited neurogenesis is therefore a 
contributing factor to the overall neuronal loss seen in neurodegenerative diseases 
(Kiyota et al., 2010) and efforts to block pro-inflammatory, or enhance anti-
inflammatory inflammation, at least partially restored adult neurogenesis (Monje et 
al., 2003, Kiyota et al., 2012, Mouihate, 2014).  Microglia, as considerable 
contributors to soluble inflammatory immunomodulators, are therefore involved in 
regulating neurogenesis and can enhance cell renewal and repair when the activation 
phenotype is biased toward the resolution of inflammation (London et al., 2011, 
Zhang et al., 2014).   
 
Resident ramified microglia also have a direct influence on both the maintenance and 
differentiation of neural stem cell populations (Zhu et al., 2008, Bachstetter et al., 
2011, Vinet et al., 2012).  It is important to note that these resting microglia display 
no visible morphological indication of activation.  There has recently been 
considerable research in investigating the interaction between ramified microglia and 
other cells in the adult healthy brain and the role microglia play in normal neuronal 
function and the most striking evidence to date for microglia involvement with 
neuronal function in the healthy brain is work performed by Tremblay et al. (2010) 
and Chen et al. (2014).  This seminal in-vivo work by Tremblay et al. (2010) witnessed 
microglia dynamically altering their interaction with newly formed and transient 
synapses in response to visual sensory stimuli and directly influenced dendritic spine 
plasticity.  Ablation of microglia has since revealed the vital role microglia play in 
modulating the increase in hippocampal neurogenesis in response to exercise 
(Vukovic et al., 2012), the lack of which is known to correlate with the decline in 
activity of neuronal precursor cells (Blackmore et al., 2009, Blackmore et al., 2012).  
Highly detailed 3D ultrastructure analysis of microglia using 3D electron microscopy 
was used by Chen et al. (2014) to determine that microglia are intrinsically involved 
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in regulating the neuroprotective and anti-apoptotic response of neurons in the adult 
brain by actively displacing inhibitory synapses.  Microglia interaction with synapses 
is made by actin cytoskeletal rich processes of which even the finest are highly mobile 
(Tasker et al., 2012) and the length of time contact is made is directly related to 
synapse excitatory levels (Wake et al., 2009).      
 
Not all synapses are shared with microglia during homeostasis and at any one time 
approximately 6% of synapses have microglia interaction and then by only 30% of the 
available processes on an individual microglia (Tremblay et al., 2010).  Although the 
term ‘quad-partite’ synapse has been coined in describing such interaction (Schafer 
et al., 2013) it is not perhaps as prevalent as the ‘tri-partite’ complex between 
astrocytes and neuronal synapses found ubiquitously throughout the brain and 
necessary for neurotransmitter recycling and correct synapse function (Araque et al., 




1.3 The Transcriptomic Revolution 
The ability to capture the entire profile of genetic mechanisms in a tissue sample at 
once offers many advantages in determining expression levels and sequencing, not 
least cost and time, over previous gene-by-gene methods including quantitative real 
time polymerase chain reaction and gene knockout studies.  The ability to investigate 
the entire gene expression profile was made possible by the whole genome 
sequencing of target organisms.  Microarrays were developed as a surface chip upon 
which are attached DNA probe sequences corresponding to multiple genes in the 
target organism (Fodor et al., 1991).  Target RNA is reverse transcribed into tagged 
complimentary DNA (cDNA) sequences and washed over the chip surface to hybridise 
with the corresponding probe sequences on the chip surface, whereby annealing is 
quantified using the tagged  cDNA (Nguyen et al., 1995a, Schena et al., 1995, Lashkari 
et al., 1997).  Initially used as an aid to sequencing, the application of microarrays for 
determining differential gene expression on a large scale was rapidly adopted 
(Schena et al., 1996, Duggan et al., 1999).  The main issues of reproducibility, 
sensitivity and specificity have been addressed, and much data has been made freely 
available, to the point that confidence in the accuracy of the technology for 
expression studies is high within the scientific community (Brazma et al., 2001, 
Barrett and Edgar, 2006, Shi et al., 2006, Barrett et al., 2007, Parkinson et al., 2007, 
Shi et al., 2008, Shi et al., 2010).  
 
1.3.1 Cluster Based Analysis 
Cluster analysis is a multivariate technique that is frequently adopted when there is 
little knowledge of the overall dynamics taking place within the sample.  The 
technique investigates the similarity between all the samples, termed n-dimensional 
vectors, within a population to yield an answer based upon the grouping together of 
similar entities.  Within the context of gene expression differential this is 
accomplished through calculation of the correlation distance by determining whether 
any two n-dimensional vectors increase or decrease in the same way (Butte and 
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Kohane, 2000).  False significance is a hazard of this type of multiple-testing 
architecture whereby outliers can have a pronounced effect on measured distances 
throughout the sample.  Normalisation of the data is therefore key prior to starting 
analysis although multiple resampling to adjust the p-value or confidence of the 
clustering is typically applied (Westfall, 1993) and includes techniques such as 
‘bootstrapping’ (Felsenstein, 1985, Zharkikh and Li, 1995) and ‘permutation’ 
(Edgington, 1964) to ensure some ‘goodness-of-fit’ measurement.    To gain a better 
understanding of the biological significance within a cluster network the weighting of 
similarities between samples is typically applied whereby the weight of the link 
signifies the strength of the connection (Zhang and Horvath, 2005). 
 
BioLayout Express3D (The Roslin Institute & R(D)SVS, Easter Bush, UK) network 
analysis software provides a cluster based approach to systems biology analysis of 
gene expression by generating a three dimensional network graph where nodes, 
representing individual genes, are connected to each other based upon their co-
expression with other genes throughout the entire sample (Freeman et al., 2007, 
Theocharidis et al., 2009).  The software has the ability to accommodate very large 
datasets and automatically calculates the Pearson correlation matrix, edge weighing 
and p-value confidence.  The threshold matrix cut-off above which relationships are 
plotted is user defined thus allowing the number of calculations for similarities 
between samples, and the resulting clustering complexity, to be controlled.  Graphs 
are produced in a three dimensional environment that efficiently removes the 
requirement to manipulate the layout as a compromise between logic and aesthetics 
in an effort to fit the data with the confines of a given space.  BioLayout Express3D 
negates the necessity of identification of gene origin to explain potential contribution 
within the network.  A gene is clustered in a three dimensional neighbourhood with 
other genes sharing a similar expression both in intensity and, if part of a serial 
analysis, time of expression.    BioLayout Express3D therefore provides a visual and 
unbiased instrument for identification of a gene both in terms of shared origin with 
other genes and expression differentiation. 
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1.4 Thesis Aims 
The aim of this thesis was to use mouse-adapted Scrapie prion disease as an in-vivo 
model of neurodegeneration to determine the role of microglia during 
neurodegenerative disease development.  Microglia are crucial for healthy 
homeostatic function and recent research has uncovered the intricate nature of 
microglia interaction with other cells in the central nervous system and the impact 
this has on neurodegenerative diseases.  Furthermore microglia are not the only 
source of immunomodulators and other cells found in the brain can also impart a 
marked influence on the surrounding environment (Sheng et al., 1997, Schultz et al., 
2004, Norden et al., 2014).  The current literature portrays microglia in 
neurodegenerative diseases as down-regulated or ‘atypical’ in their overall response.  
Separating the specific microglial contribution towards the overall immune signature 
seen in neurodegenerative diseases has not yet been performed.   
 
The first part of this thesis explored the inflammatory response found within mouse-
adapted prion disease using previously published total brain transcriptome data.  This 
was analysed using the novel cluster-based analysis tool BioLayout Express3D which 
confirmed the majority of differential expression was microglial in origin.  A 
consistent microglial signal occurred regardless of the length of disease incubation 
period, disease severity or mouse background and increased in strength as the 
disease progressed.  A considerable number of genes could not be attributed to any 
one cell type and it was not possible to further separate the signal indicative of an 
extremely high degree of co-expression by microglia and the other cell types found 
in the brain.  A mouse model of prion disease was then characterised using a novel 
strain of mice in which microglia were tagged with a ubiquitously-expressed green 
fluorescent protein transgene.  Following confirmation that the transgene and 
fluorescent protein made no impact to disease the specific areas of microglial activity 




The second half of the thesis covers time course mouse experiments in which 
morphological changes made by microglia in response to prion disease were 
quantified using the green fluorescent protein and image analysis software.  The aim 
was to determine if microglia are significant contributors towards a neurotoxic 
environment resulting from disruptions to normal homeostasis.  Using the same time 
points as the preceding experiments the final results chapter reports on the 
successful isolation of adult microglia from infected mice and the analysis of their 
transcriptome using BioLayout Express3D.  This allowed for determination of the 




2 Re-analysis of the Brain Transcriptome of Multiple Mouse Strains Infected with 
Multiple Strains of Prion Disease. 
2.1 Introduction 
This chapter describes the re-analysis of a previously published microarray dataset 
using the novel biological network analysis tool BioLayout Express3D (Freeman et al., 
2007).  In 2009 a large scale prion disease study made by Hwang et al. (2009) argued 
to have identified a core set of disease associated markers shared by many different 
prion disease pathologies.  The data was freely available 
(http://prion.systemsbiology.net) to download thereby facilitating re-analysis and 
reinterpretation.  By choosing to reanalyse a previously published dataset this 
chapter was able to determine the disease associated signature associated with 
murine-adapted prion disease in both wild type and Prnp transgenic mice and 
determine the overall contribution of microglia within the signal.  
 
The original study identified a glial cell response as part of the developing pathology 
but the proportion of genes associated with an immunological response was felt not 
to be in accordance with other studies in which neuroinflammation was noted 
(Brown et al., 2003, Riemer et al., 2004, Brown et al., 2005).  The study by Hwang et 
al. (2009) focused on the contribution of toxic prion replication within neuronal lipid 
rafts.  Furthermore the explanation for the presence of lysosome markers and 
cytoskeletal processing was attributed to neuronal prion protein processing.  In part, 
this prompted this re-analysis using BioLayout Express3D to better determine gene 
origin as it was felt that many of those genes attributed to be neuronal in origin could 
equally be associated with the innate immune system. 
 
The study of Hwang et al. (2009) described how pathological differences of prion 
disease are not due to inherent properties of any given strain and that differences in 
incubation time and severity are due to specific interactions between the individual 
host and prion strain.  Accordingly two prion inoculates were utilised; Rocky 
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Mountain Laboratory (RML) derived from a mixture of mouse adapted Drowsy goat 
Scrapie strains (Dickinson, 1976), and 301V derived as a pure strain from Bovine 
Spongiform Encephalopathy (BSE) adapted to mice (Bruce et al., 2002), were chosen 
for their marked differences in incubation time and pathological hallmarks within a 
single inbred mouse strain.  These were inoculated into C57Bl/6 strains homozygous 
for either a and b alleles of Prnp and FVB/NCr (FVB) homozygous for the ‘a’ allele.  
The generation of a heterozygous strain for Prnp, by crossing FVB.1290Prnptm1Zrch 
with FVB mice, expressed a reduced PrPC level and accordingly demonstrated a 
dramatic increase in the incubation period but not intensity of the disease (Manson 
et al., 1994b).  By direct contrast the study adopted (FVB-Tg(PrP-A)4053 indicator 
mice (Tg4053) over-expressing the Prnp a allele >30 times over normal levels (Carlson 
et al., 1994) in which incubation times are considerably shorter. 
 
It becomes increasingly difficult to distinguish general disease damage from prion-
specific response at the later stages of the incubation period and in particular just 
prior to terminal disease (Booth et al., 2004).  The importance of time points early on 
in disease pathogenesis is paramount and unfortunately few studies have this broad 
number of time points taken during the earlier events of prion disease.  It was in this 
area of contention in which the study by Hwang et al., had significant power over all 
other RNA analysis studies courtesy of the sheer number of serial investigative points 
throughout disease progression in multiple mouse and prion strain combinations. 
 
Finally, the data were freely available (http://prion.systemsbiology.net) to download 
thereby facilitating re-analysis and reinterpretation.  By choosing to reanalyse a 
previously published dataset this chapter was able to determine the disease-
associated signature associated with murine-adapted prion disease in both wild type 
and Prnp transgenic mice and determine the overall contribution of microglia within 





2.2.1 Origins of Data: Mouse Inoculations by Hwang et al., (2009) 
Using a systems biology approach, Hwang et al., (2009) adopted a multiple 
host/strain combination study to generate eight prion/mouse strain combinations 
(summarised in Table 2-1).  Their aim was to ascertain the differentially expressed 
genes (DEGs) involved in prion disease pathogenesis regardless of individual host and 
prion strain combinations. Mice were inoculated by an intracerebral (i.c) route at 5 
weeks with either 10 µl of 10% RML or 301V infected mouse brain material.  Mice 
inoculated with normal brain homogenate acted as age and genotype matched 
controls to eliminate perturbations resulting from both inoculation and the effects of 
ageing.  Three mice from each group were harvested at 1, 2 or 4 week intervals 
depending upon the length of incubation period to provide 8 - 10 samples across the 
entire incubation range.  
 
The group felt that pathological differences of TSE disease are not due to inherent 
properties of any given strain and reflected that differences in incubation time and 
severity are due to specific interactions between the individual host and TSE strain.  
Accordingly two TSE strains; RML derived from mouse adapted Drowsy goat Scrapie 
strains (Dickinson, 1976), and 301V derived from mouse adapted BSE (Bruce et al., 
2002), were chosen for their marked differences in incubation time and pathological 
hallmarks within a single inbred mouse strain.  These were inoculated (summarised 
in Table 2-1) into C57Bl/6 strains homozygous for either a and b alleles of Prnp, 
FVB/NCr (FVB) homozygous for the ‘a’ allele.  The generation of a heterozygous strain 
for Prnp, by crossing FVB.1290Prnptm1Zrch with FVB mice, expressing a reduced PrPC 
level and accordingly demonstrate a dramatic increase in the incubation period but 
not intensity of the disease(Manson et al., 1994b).  By direct contrast the study 
adopted (FVB-Tg(PrP-A)4053 indicator mice (Tg4053) over-expressing the Prnp a 
allele >30 times over normal wild type levels (Carlson et al., 1994) in which incubation 




Table 2-1: Number of microarrays arranged by murine and prion strains as utilised in the original study 
by Hwang et al., (2009).  The aim was to generate murine disease encompassing multiple differing 





Table 2-2: Number of microarrays arranged by murine and prion strains incorporated in this re-analysis 
following global background quality control. A total of 32 arrays failed this process and were not 















Mean N° of 
Arrays per 
Group 
C57BL/6J RML 23 12 27 38 2.50 ± 0.27 SE 
C57BL/6J 301V 41 10 25  2.29 ± 0.19 SE 
C57BL/6.I-1 RML 52 11 25 34 2.36 ± 0.20 SE 
C57BL/6.I-1 301V 18 9 27  2.50 ± 0.22 SE 
FVB/NCr RML 22 11 29 34 3.00 ± 0.00 SE 
FVB-Tg(PrP-A) 4053 RML 8 8 22 20 2.41 ± 0.23 SE 
(FVBxFVB.129Prnptm1Zrch) F1 RML 56 14 31 31 2.68 ± 0.22 SE 

















C57BL/6J a/a RML 23 12 31 
45 
C57BL/6J a/a 301V 41 10 25 
C57BL/6.I-1 b/b RML 52 11 27 
39 
C57BL/6.I-1 b/b 301V 18 9 27 
FVB/NCr a/a RML 22 11 33 34 
FVB-Tg(PrP-A) 4053 > 30a RML 8 8 24 22 
(FVBxFVB.129Prnptm1Zrch) F1 a/0 RML 56 14 32 33 
FVB x FVB.129Prnptm1Zrch 0/0 RML 51 7 22 24 
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Dataset downloaded from Prion Disease Database  
Quality control and Normalisation  
(Fios Genomics Ltd) 
Probe sets annotated (Bioconductor) 
Sample-to-sample Pearson correlation 
at 0.99 calculated within BioLayout 
Express
3D 
Mouse/Prion stain nodes identified 
and analysed 
Group-to-group Pearson correlation at 
0.70 calculated within BioLayout 
Express
3D 
Clustering performed on graph with 
user defined threshold correlation of 
0.70.  Clusters demonstrating disease 
associated signal isolated 
1-by-1 probeset checks performed to 
arrive at final list of disease associated 
genes 
Gene ontology applied using Ensembl 
BioMart.  Cellular maps constructed 
within yEd. 
Normalised within RMA Express to 
GNFv3, Brain TRAP and 
Macrophage/LPS external datasets 
Cell origin determined 
Figure 2-1: Analysis workflow pipeline. 
2.2.2 Data Handling for Re-analysis 
Formatting and analysis of the datasets used in this study were processed as per the 








Quality Control and Normalisation  
The Affymetrix microarray data assembled from the time course inoculations of 
mouse strains C57BL/6J, C57BL/6I, FVB/NCr, FVB-Tg(PrP-A)4053, (FVB x FVB.129-
Prnptm1Zrch) F1 and FVB.129-Prnptm1Zrch with RML and 301V were downloaded as 418 
.CEL files from the Prion Disease Database (Gehlenborg et al., 2009).   
 
Quality control on downloaded raw .CEL data was performed independently by Fios 
Genomics Ltd (Edinburgh, Scotland) using the ArrayQualityMetrics package available 
from Bioconductor (http://www.bioconductor.org).  To identify outlier arrays, those 
which demonstrate significant variations generated during labelling, hybridization 
and scanning; a system scoring was performed on each chip based upon evaluation 
of MA-plot, boxplot, heatmap, relative log expression (RLE) and spatial distribution 
of log-intensity (Kauffmann et al., 2009) metrics.  A chip was considered an outlier 
and removed from the dataset if it failed on one or more metrics.  Quality control 
removed 32 microarrays leaving 386 as the final data set for re-analysis (Table 2-2). 
The loss of arrays yielding an overall mean average of 2.5 ± 0.08 SE arrays per time 
point and thus did not affect the overall balance of the dataset.  Following global 
background quality control, normalisation of individual data sets generated from .CEL 
files was undertaken using the Robust Multiarray Average (RMA) expression measure 
(Irizarry et al., 2003). The RMA Express program (http://rmaexpress.bmbolstad.com) 
is a stand-alone graphic user interface that operates as a quintile normalization 
technique to reduced gene-to-gene variation. The aim is to set the distribution of 
probe intensities the same for each array in the dataset (Bolstad et al., 2003).  The 
remaining perturbation between arrays is of biological significance and not an 
artefact of intensity variation. 
 
Normalised data was saved as an ‘.expression’ file and Affymetrix chip probe set 
identifications were annotated using the latest Affymetrix Mouse Genome 430 2.0 
Array annotation available from Bioconductor (http://www.bioconductor.org) 
including global gene name, function, pathway if known and a unique identifier 
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comprising probeset ID concatenated to gene symbol.  Samples were ordered in 
terms of the strain of mouse/prion agent and the relative incubation period from 
which the brain sample was derived.   
 
2.2.2.1 Sample-to-Sample Data Analysis 
Normalised data was loaded into BioLayout Express3D with the matrix threshold cut-
off set at 0.99; set at this high value to visualise the differences in correlation that 
were not present at < 0.98.  Here nodes were assigned to classes corresponding to 
animal background, uninfected control group (regardless of strain) and prion infected 
groups subdivided into a gradient representation of the serial time points across the 
disease pathology.  
 
2.2.2.2 Group-to-Group Data Analysis:  Selection of Genes of Interest 
With a Pearson correlation matrix cut-off threshold set to r = 0.7 within the user 
interface of BioLayout Express3D, the annotated .expression files were loaded into 
BioLayout Express3D and pairwise correlations were calculated for each probeset on 
the array against all other probesets (P2/2 pairwise calculations, where P is the 
number of probesets) and values of r ≥ 0.7 were saved as a binary ‘.pearson’ file for 
future analysis.   
 
BioLayout Express3D correlation threshold was set at 0.75 to limit the number of 
edges to a manageable number and allow for visualisation of biological relationships 
that demonstrate a statistically significant perturbation in correlation.  This formed a 
highly structured graph consisting of nodes (probesets) connected by edges of 
expression correlation. 
 
To identify groups of co-expressed genes, clustering of the graph was performed 
using the graph based Markov clustering (MCL) algorithm (Dongen, 2000) which has 
been designed to function with weighted or non-weighed graphs.  The algorithm 
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operates on the principle of generating artificial paths through the data from which 
Markov stochastic matrices apply the mathematical results of the random walks 
directly to the graph. Using the expression viewer it is possible to observe the 
expression of probe sets in each cluster and identify those demonstrating biological 
interest. 
 
2.2.2.3 Expression Analysis 
The expression profile of each cluster was viewed, as a mean, in the class viewer 
function within BioLayout Express3D.  9 clusters (here on termed ‘clusters of interest’) 
were identified as differentially expressed during disease.  Annotations for each of 
these clusters was isolated into a new expression file generating a new graph of 671 
probesets demonstrating differential expression in response to prion disease. 
 
Disease association was viewed within BioLayout Express3D.   Probesets with a poor 
profile in which the expression profile was not sharp or had a considerable amount 
of signal noise were removed.  Probeset duplicates were removed by keeping only 
the expression profile with the highest difference in expression.  This left a dataset 
comprising 492 genes in which there was high degree of user confidence. 
 
2.2.3 Ontological Analysis  
2.2.3.1 Ensembl Biomart Derived Functional Ontology 
Functional ontology was determined by uploading the Affymetrix chip ID of the 
disease associated genes to the online Ensembl Biomart data mining tool 
(ensembl.org/biomart) using the Mus musculus genes dataset (Ensembl Genes 66).  
Filters were applied restricting results to the Affymetrix 430 2.0 chip probe sets.  To 
increase accuracy for correct selection of function, filters for gene ontology evidence 




2.2.3.2 Known and Predicted Protein-Protein Interactions 
The 492 disease associated genes were uploaded as a multiple sequence to the online 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) (http://string-
db.org)(Jensen et al., 2009) and predicted associations attributed to Mus musculus.  
Within the network view, edges were restricted to evidence based prediction for co-
expression, experimental and database determined interactions.  Clustering was 
performed dynamically by initiating the relaxation feature to force nodes to adopt a 
distance proportional to the STRING global score.  Grouping based on shared co-
interaction was performed using the inbuilt MCL function with an inflation value of 
2.0. 
 
2.2.3.3 Cell Origin: Normalisation with the Cultured Macrophage, Mouse Brain 
RNA Trap and GNFv3 Mouse Tissue Datasets 
Cell origin was determined with reference to external datasets derived from purified 
central nervous system cells found in the GNFv3  (Su et al., 2002, Wu et al., 2009) and 
mouse brain RNA TRAP datasets (Doyle et al., 2008, Heiman et al., 2008).  Also 
Included were datasets derived from serial macrophage cultures subjected to 
lipopolysaccharide (LPS) bacterial endotoxin (Lattin et al., 2008). The LPS datasets 
were included to allow for labelling of those genes associated with activation of the 
innate immune system.  The strong inflammatory reaction by macrophages to LPS is 
well characterised and involves the majority of cellular inflammatory mechanisms 
(Ulevitch and Tobias, 1995). 
 
Mouse brain cell type data from the external datasets were loaded into the 
‘.expression’ file for the genes demonstrating differential expression in response to 
prion disease.  Overlaps between Affymetrix chip probeset identifications were 
filtered to both confirm the validity of using the external datasets and identify the 




The chosen .CEL files data for both the external datasets and the Prion Disease 
Database derived genes datasets were then loaded into the RMA Express 
(http://rmaexpress.bmbolstad.com) GUI program and the former normalised to 
match the previously normalised Prion Disease Database derived genes of interest.  
Following normalisation the genes demonstrating differential expression in response 
to prion disease were then identified from the normalised GNFv3 mouse tissue 
dataset through chipset annotation.  These genes were then incorporated into the 
‘.expression’ file to allow for a direct comparison to be made on the origin of 






2.3 Results   
2.3.1 Sample to Sample  
Sample-to-sample graph analysed in BioLayout Express3D with a matrix cut-off 
threshold set to 0.99 generating an organised graph with a divide based upon mouse 
background (Figure 2-2A).  The matrix threshold determines which nodes are 
incorporated into the graph.  This was based on whether they correlate to other data 
within the dataset above the set threshold.  Nodes would only be incorporated if they 
satisfied this user set level and at 0.99 the threshold matrix is sufficiently high for this 
to be independent of differential expression and produce a graph comprising nodes 
with only extremely high correlation with others.   No divide was observable at a 
threshold of 0.98 in which all nodes were found to be correlating with each other.  
 
Each mouse/prion combination was assigned a different colour incorporating both 
infected and normal brain controls.  The number of nodes dropped to 378 joined by 
17853 edges, a result of the matrix filter set to display only the high correlation 
relationships between chipsets.  The lower divide contained solely the C57BL strains 
inoculated with both RML and 301V whilst the upper encompassed the remaining 
strains inoculated with RML alone hinting at a slight variation in the host immune 
response specific to C57BL mice.   
 
The lack of a significant change in differential expression when all infected and 
uninfected source nodes were highlighted in one colour prompted a need to 
determine if there was a difference when the infected nodes were coloured 
corresponding to their time of capture within the disease incubation periods. To 
achieve this each infected serial time point was given a scaled colour ranging from 
white at disease initiation then changing through increasing darkening shades of 
yellow, orange and finally ending with red at terminal disease (Figure 2-2B).  An 
outward pattern in the infected datasets could be observed as signifying a reduction 
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in correlation, and consequently an increase in difference, between earlier and later 
stages of disease progression. 
 
The nodes for both infected and uninfected samples were then assessed according 
to animal background and each given a new colour; red for infected and white for 
controls (Figure 2-2C).  The distribution of nodes analysed according to mouse 
background can be visualised as forming loose clusters with a degree of overlap in 
the centre of each divide.  The difference in correlation between infected and control 
nodes was not immediately obvious.  Interestingly, the lack of discernible pattern 
between nodes derived from infected brains and those from control animals 
suggested that the perturbation to gene expression in the developing pathology in 
prion disease is not particularly strong.  The exception was the B4053 PrPC 
overexpressing mice in which disease is very rapid.  In the B4053 strain a clear 
difference could be determined between nodes from infected and those from an 














B Mouse Strain 
● : B6i1 
● : B6j 
● : B4053 
● : Fvbncr 
● : Fvbprnp00 
● : Fvbprnp01 
Incubation Period 
○ : ~10% 
● : ~25% 
● : ~40% 
● : ~55% 
● : ~70% 
● : ~85% 
● : Terminal 
Fvbprnp00 B6i1 B6j 
fvbprnp01 B4053 Fvbncr 
Inoculation 
○ : Uninfected 
● : Infected 
Figure 2-2: Global array sample-to-sample graphs revealed differences between prion infected and 
uninfected controls to be subtle.  A: A threshold matrix cut-off set at >0.98 was required to visualise any 
difference between strains.  Stains based on the BL/6 mouse background form a distinct cluster to the 
lower half of the graph.  B: As disease progressed the datasets dissociate from both neighbours and 
earlier disease time points and migrate toward the outer edges of the cluster (from white to red).  This 
reflected the slight reduction in correlation between nodes caused by a progressive increase in difference.  
C:  Subtlety of differences in arrays induced by disease also evident when comparing infected and 
uninfected arrays for each strain.  Note difference bought about potentially by the rapid and severe 
pathology in the PrP
C




2.3.2 Group-to-Group: Genes of Interest 
Transcript level prion infected microarray data within BioLayout Express3D at a 
correlation threshold of 0.70 produced a highly organised graph comprising 21,550 
nodes joined by 1,253,332 edges.  A threshold of 0.70 was adopted as the difference 
in correlation at group (probeset) level was greater than sample (array) level and at 
group level produced a highly organised graph which allowed for visualisation of 
biological relationships.  The graph was grouped by MCL into 416 clusters comprising 
14253 nodes with the remaining 7297 assigned as ‘no class’; the latter indicative of 
no correlation with other nodes in the graph at the designated correlation threshold.  
The clusters each represent probesets which have a high degree of correlation of 
expression and hence share a biological relationship.  The expression profile of each 
cluster was viewed, as a mean, in the class viewer function within BioLayout 
Express3D.  Seven clusters comprising 692 probesets in close proximity to each other 
demonstrated a disease associated change in expression (Figure 2-3A).  Out of the 
333 genes identified in the original study by Hwang et al., (2009), 321 were taken 
through to the group-to-group graph at a correlation threshold of 0.70.  These also 
predominantly resided in the same location.  There were more outlying nodes with 
little correlation to the rest (Figure 2-3B).  Note also that some of these were ‘no-









Figure 2-3: BioLayout Express3D generated transcript-to-transcript clustered graph of total brain data 
obtained from all serial mouse/prion combinations. A:  Comprising 142531 nodes (no-class nodes 
removed) and clustered by MCL revealed 416 highly organised clusters, each assigned a random colour, 
representing genes sharing a high degree of co-expression.  Enlarged nodes represent the 692 nodes 
with an expression pattern indicative of disease association and in close proximity to each other 
indicative of a high degree of correlation.  Note the purple nodes showing lower correlation towards the 
primary green cluster. B:  Red nodes are the disease associated genes identified by Hwang et al., (2009) 
of which 321 are incorporated into the graph at a correlation threshold of .70. 
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Following removal of probeset duplicates the final number of disease associated 
genes identified in this study was 492.   Visualising the 492 genes within BioLayout 
Express3D with a correlation threshold set at 0.75 revealed a tightly grouped graph 
organised into 2 main clusters by MCL (Figure 2-4A).  A threshold of 0.75 enabled the 
majority of the biologically significant data to be incorporated in the graph and allow 
for visualisation of biological relationships.   
 
Clustering the differentially expressed genes identified by Hwang et al., (2009), at the 
same correlation threshold of 0.75, produced a graph of 321 nodes.  This was also 
organised into 2 main clusters (Figure 2-4B).  21 nodes were not assigned to a class 
and correspond to the outliers seen in Figure 2-3B.  In total 205 of the genes identified 
by the original study were taken through with this re-analysis.  All genes followed a 
similar expression profile with an increase in expression starting at approximately 
50% of the incubation period (Figure 2-4C). There was an expression bias of the 










































































































































































































































































































































































































































































































































































































































































































































Serial Array Time Point
Primary (mainly myeloid) cluster Secondary (interferon response) cluster
  A B 
Figure 2-4: BioLayout Express3D generated graphs at a correlation threshold of 0.75 from genes 
demonstrating a disease associated signal.  A: The final list of 492 genes was organised into 2 main 
clusters by MCL with the primary cluster (green) comprising 410 nodes joined by 29339 edges 
indicating a high degree of co-expression between genes. The secondary cluster (purple) comprised 67 
nodes and 1453 edges.  B:  Clustering the genes found in the original analysis by Hwang et al., (2009) 
revealed 21 nodes (dark blue) that are not assigned to a cluster by MCL.  The majority of the others (of 
which 205 are included in this re-analysis) are also grouped within two main clusters.  C: Early up-
regulation of disease signature at approx. 50% of incubation period. As a mean expression profile for 
all genes in the primary cluster, there is a very similar disease signature for all genes in all mouse/prion 
combinations.  Expression for the secondary, mainly interferon response genes, is predominantly 




2.3.3 Group-to-Group: Exploring the Graph. 
Out of 416 clusters within the large group-to-group graph only 9 demonstrated a 
disease associated signal.  These were determined following individual cluster-by-
cluster checks of the expression signature within BioLayout Express3D for a profile 
that convincingly changed with disease pathogenesis.  Those clusters that contained 
profiles that were unconvincing collectively comprised fully 97% of the available 
infected brain data.  Ontological analysis within FuncAssociate was performed on the 
top 5 largest clusters to determine why these clusters were formed and what they 
comprised (Figure 2-5).  
 
The largest (yellow), cluster 1, was unique as it showed the least correlation with the 
main graph and resided as a singular, but highly correlated, cluster some distance 
away on the periphery.  The cluster comprised overwhelmingly of random metabolic 
genes although there was a small but highly enriched component for epithelium-
associated keratin filaments.  Considering the majority were not related to a specific 
function, the lack of correlation with the main graph was most likely influenced by 
differences in chip intensity or a batch effect.   
 
The remaining clusters had relatively low levels of expression and an invariable profile 
with no evidence of association with the disease process.  The formation of clusters 
by MCL within BioLayout Express3D is dependent upon a degree of shared co-
expression between multiple gene nodes.  Slight differences in what amounts to a 
majority of random metabolic genes in these clusters would suggest partial 
specialisation and enrichment statistics of 2, 4 and 5 indicate an association with 
organelle membrane, ribosome location and dendrite protection respectively.  Both 
clusters 2 and 5 also included enrichment for nitrogen metabolism. 
 
Cluster 57 was not one of the largest clusters but was included here to portray the 
effects of intermittent hybridisation. Cluster 57 was found to be highly enriched for 
hormone binding and contained probesets associated with the pituitary gland.  Due 
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to the location of the gland it is entirely feasible for the gland to be variably collected 
during the procedure of brain removal due to human error and this would explain the 
entire absence of pituitary gland probesets on some arrays but not others.  The 
variable inclusion is particularly striking in this dataset where, using RML infected 
BL/6 mice as an example, the genes are found only in 5, 7 and 9 weeks and absent 
from all other time points.  The cluster therefore appears as a separate component 
in the graph with no correlation to the main dataset and was excluded from the 
dataset at an early stage  
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Figure 2-5: Gene expression profiles and enrichment analysis for the top 5 clusters that were not 
associated with prion disease.  The presence of enrichment is directly associated with the generation of 
a cluster based on levels of co-expression and explains the formation of these clusters.  Cluster 57 
contained genes associated with the pituitary gland and was included to demonstrate the effects of 





This was performed within BioLayout Express3D with reference to the GNFv3 (Su et 
al., 2002, Wu et al., 2009), RNA TRAP (Doyle et al., 2008, Heiman et al., 2008) and 
finally serial cultured macrophages with lipopolysaccharide LPS endotoxin (Lattin et 
al., 2008) to external datasets.  A total of 377 genes out of 492 showed peaks in 
association with macrophages, microglia and osteoclasts confirming myeloid origin ( 
Figure 2-6).  The remaining 115 were distributed among other the main CNS cell types 
either individually or as groups (Appendix 8-4). 
 
Out of the 377 myeloid associated genes, 275 were associated with LPS activation of 
macrophages confirming the majority are also associated with innate immune system 
activation (Figure 2-7).  An absence of a peak over LPS activated macrophages but a 
peak over microglia and pure macrophages was indicative of a constitutively 
expressed myeloid gene that is expressed independently of activation. The remaining 
102 genes were classed as constitutively expressed myeloid genes.  Many of the 
genes showed overlap in CNS cell origin and some transcripts were assigned to more 
than one cell type (Figure 2-8).  BioLayout Express3D was also unable to further 
separate clusters (Appendix 8-3) providing additional support that many genes were 






Figure 2-6: Cross reference of the expression data for 492 disease associated genes with co-normalised 
GNFv3, Trap and M0/LPS data within the expression viewer of BioLayout Express3D.  Shown as a 
mean expression profile, peaks are largest over myeloid associated purified cell datasets confirming the 
majority of the disease associated genes are microglial in origin.  A considerable number are expressed 
by serially cultured macrophages activated with LPS confirming the genes are strongly associated with 
immune activation.  Error bars equate to standard error.     








































































































































































































































































































































































































































































































































































































































































































































Figure 2-7: Cross reference of the expression data for the 377 myeloid specific genes with co-
normalised GNFv3, Trap and M0/LPS data within the expression viewer of BioLayout Express3D.  
Individually compared with the external datasets and view here as mean expression for all, the myeloid 













































































































































































































































































































































































































































































































































































































































































































































Neuron Myeloid & Astrocyte
Myeloid & Neuron Astrocyte & Neuron
Myeloid, Neuron and Astrocyte Oligodendrocyte
Generic
Myeloid 
4632428N05Rik, A830007P12Rik, AA467197, Abi3, 
Adcy7, Adfp, AF251705, Aif1, Alox5ap, Anxa2, Anxa3, 
Anxa4, Arhgdib, Arpc1b, Aspg, Axl, B2m, Bcl2a1a, Bcl3, 
Brd4, C1qa, C1qb, C1qc, C3, C3ar1, C4b, Capg, Casp1, 
Casp8, Ccl12, Ccl2, Ccl3, Ccl5, Ccl6, Ccl8, Ccl9, Ccr5, 
Ccl6, Ccl8, Cd14, Cd37, Cd44, Cd48, Cd52, Cd53, Cd68, 
Cd72, Cd74, Cd84, Cd86, Cebpa, Cebpb, Ch25h, 
Clec4a3, Clec7a, Clic1, Cln3, Cmtm3, Cmtm6, Cmtm7, 
Cp, Crispld2, Csf1, Csf1r, Csf2rb, Csf3r, Cst7, Cstb, Ctsa, 
Ctsb, Ctsc, Ctsd, Ctsh, Ctsl, Ctss, Ctsz, Cxcl10, Cxcl13, 
Cxcl16, Cyba, Cybb, Ddx58, Ddx60, Dock2, Dtx3l, Ebi3, 
Edem1, EG667823 (Trim5), Emr1, Epsti1, Fas, Fcer1g, 
Fcgr1, Fcgr2b, Fcgr3, Fcgr4, Fcrls, Fermt3, Fgd2, Ftl1, 
Ftl2, Fuca1, Fxyd5, Fyb, Galnt6, Gbp2, Gbp3, Gbp3, 
Gbp6, Ggta1, Glipr1, Gmfg, Gngt2, Gns, Gpnmb, 
Gpr183, Gpr34, Gpr65, Gpr84, Gpsm3, Grn, Gusb, H2-
Aa, H2-Ab1, H2-DMb2, H2-K1, H2-M3, H2-Q7, Havcr2, 
Hck, Hcls1, Hexa, Hexb, Hfe, Hmox1, Hpgd, Hsd3b7, 
Hvcn1, Icam1, Ifi204, Ifi205, Ifi27l2a, Ifi30, Ifi35, Ifi44, 
Ifi47, Ifih1, Ifit1, Ifit2, Ifit3, Ifitm3, Igtp, Iigp1, Ikzf1, 
Il10rb, Il13ra1, Inpp5d, Irf5, Irf7, Irf8, Irf9, Irgm1, Irgm2, 
Itgam, Itgax, Itgb2, Itpripl2, Kcnk6, Lag3, Lair1, Lamp2, 
Laptm5, Lat2, Lcp1, Lcp2, Lgals3bp, Lgals9, Lgmn, Lilrb4, 
Lpcat2, Lpxn, Lrrc33, Lst1, Ltbr, Ly9, Lyn, Lyz1, Lyz2, 
Mafb, Man2b1, Man2b2, Mdfic, Mmp12, Mpa2l, 
Ms4a6b, Ms4a6d, Ms4a7, Msn, Myd88, Myo1f, Naglu, 
Naip2, Naip5, Ncf1, Ncf2, Ncf4, Nckap1l, Nek6, Nfe2l2, 
Nlrc5, Oas1g, Oasl2, OTTMUSG00000000971, P2ry13, 
P2ry6, Parp12, Parp14, Parp3, Parp9, Phf20l1, Pld4, 
Plec1, Plek, Plp2, Plxnb2, Pon3, Pros1, Psmb8, Psmb9, 
Psme1, Psme2, Ptgds2, Ptplad2, Ptpn18, Ptpn6, Ptprc, 
Pycard, Pyhin1, Rab32, Rab3il1, Renbp, Rnase4, 
Rnaset2a, Rnf213, Rrad, Rsad2, Rtp4, S100a11, S100a4, 
S100a6, S1pr3, Samd9l, Samsn1, Sash3, Scpep1, Selplg, 
Sema4d, Sepx1, Sfpi1, Sgpl1, Sh3bp2, Shisa5, Siglec5, 
Siglech, Skap2, Slamf9, Slc11a1, Slc15a3, Slc29a3, 
Slc39a14, Slc43a3, Slc5a3, Slc7a7, Slfn2, Slfn8, Socs3, 
Spp1, Sqrdl, Srgn, Stat1, Stat3, Sulf2, Syngr2, Tagln2, 
Tap2, Tapbp, Tbxas1, Tcn2, Tgfb1, Tgfbr1, Tgfbr2, Tgif1, 
Tgm2, Thbs2, Tifa, Timp1, Timp2, Tln1, Tlr1, Tlr13, Tlr2, 
Tm4sf1, Tmem119, Tmem173, Tmem86a, Tnfaip2, 
Tnfaip8l2, Tnfrsf1a, Tor3a, Trem2, Trim25, Trim30, 
Trim34, Trim47, Trpt1, Tspo, Tyrobp, Ube1l, Unc93b1, 
Usp18, Vwa5a, Xaf1 
Myeloid & Astrocyte 
CD9, Cd151, Clec5a, Cybrd1, Dhrs1, Efemp2, Eya4, 
Galnt4, Gfap, Gstm1, Klk8, Lpcat3, Ly86, Mtmr11, Npl, 
Nupr1, Pbxip1, Pdpn, Pnpla7, Prdx6, Retsat, S100a1, 
Sat1, Sh3pxd2b, Tlr3, Trf, Upp1, Vcam1, Zfp91 
Astrocyte 
Abhd4, Aldh1l1, Aqp4, Casp12, Chi3l1, Cyp4f14, Decr1, 
Fgfrl1, Gal3st4, Gm967, Id3, Naprt1, Plcd4, Plscr2, 
Prelp, Prrx2, Rbp1, Slc25a18, Sox9 
Neuron 
Aldh1l2, Hspb8, Sema3d, Serping1 
Myeloid & Neuron 
A2m, Cyb5r3, Glipr2, Gpx1, Lgals1, Lgals3, Olfml3 
Astrocyte & Neuron 
Ccdc122, Fxyd1, Kcne1l, Lgi4, Lmcd1, Mlc1, S100a16, 
Slc14a1, Thbs3, Tsc22d4, Vwa1 
Myeloid, Neuron and Astrocyte 
Cd81, Cotl1, Cyp4v3, Dbi, Ifi27l1, Igfbp2, Itgb5, Ltc4s, 
Mt1, Mt2, Necap2, Npc2, Oat, Pdlim4, Rab31, Rab7l1, 
Rhbdf1, Rhoc, S100a13, Sh3glb1, Tmbim1, Tmem176a, 
Tmem176b, Tspan4, Ucp2, Vamp8, Vim 
Generic 
1700112E06Rik, 5430427O19Rik, Afp, Aga, Ampd3, 
Angpt1, Atp6v0e, Avp, BC026585, Bdh2, Bmp2k, Capn3, 
Ccdc80, Cd9, Cebpd, Cklf, Clu, Cnn3, Col16a1, Cst3, 
Cyp7b1, Cyth4, D4Ertd22e, Dap, Ddr1, Dok1, 
E230029C05Rik, Ecm1, Emp1, Emp3, Entpd1, Ephx1, 
F13a1, Fam102a, Fam129b, Farp1, Fes, Fkbp7, Fzd9, 
Gba, Gbp6, Golm1, Gpr37l1, Hspb6, Idh2, Ifitm2, Igf1, 
Igsf6, Il33, Itpkb, Klhl6, Litaf, Lrrfip1, Mrps6, Nat2, 
Osmr, P2rx7, Palld, Phyhd1, Pik3ap1, Rgs10, Scamp2, 
Scrg1, Slco2b1, Spata13, Spsb1, Srebf1, Tax1bp3, Znrf2 
Oligodendrocyte 
Tppp3, Tmem98, Pdlim2, Klk6, Galntl2, Dbndd2, Apod, 
Adamtsl4 
Figure 2-8: The vast majority of the 492 genes are attributed to myeloid origin either as a single 
ontological association or mixed between cell types.  There is a strong signal for innate immunity with 
a considerable number (coloured red) associated with innate activation of macrophages.  
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Determination of intracellular location and function of the myeloid component was 
investigated using ontology data from Ensembl Biomart.  This facilitated construction 
of a cellular map of the myeloid genes found in the primary cluster which comprised 
the majority of the 492 genes (Figure 2-9) using yED graph editor software 
(http://www.yworks.com).   In keeping with the results of cellular origin, data mining 
on Ensembl Biomart found genes associated with phagocytosis, 
endosomes/lysosomes and late innate immune response.  Network edges formed 
from known protein-protein interactions gained from the STRING database revealed 
a compact self-contained system regulated by the cytokine ligating transcriptional 
regulator Stat1 (Figure 2-10).  It is important to highlight that this map comprising 
only those genes demonstrating differential expression.   The system spanned the 
entire cell ranging from extracellular lysozyme proteins to intercellular mediators of 
NADPH oxidase.  Stat 1 is a key component of the JAK-STAT signalling pathway heavily 
involved in innate immune activation (Mowen et al., 2001). 
 
A strong interferon response was detected with almost a third of the total gene set 
found to be associated with the interferon system following data mining on Ensembl 
Biomart.  The vast majority of these genes were found localised in the semi-separate 
secondary cluster (coloured purple in Figure 2-4).  The majority of the genes in this 
cluster were BLl6 mouse in origin.  The stronger interferon response characteristic of 
the C57BL/6 mice strains is well known (Schilling et al., 2009) and resulted in the 
reduction in correlation of this cluster with the majority in the graph within BioLayout 








Figure 2-9: Cellular ontology map of myeloid genes found in primary cluster.  The majority of genes 
found within the primary cluster were determined as myeloid in origin and are associated with innate 
immune activation of macrophages (red).  The remaining genes (grey) are considered constitutively 
expressed macrophage genes.  Collectively the signal is one of robust activation involving pro-





Figure 2-10: Myeloid associated interferon response genes.  A: Ontological map of the myeloid 
associated interferon response genes reveals a tightly regulated transmembrane signalling system with 
extracellular lysozyme proteins and mediators of NADPH oxidase.  B: The self-contained system is 







2.3.5 Cytoskeletal Restructuring 
Genes involved in actin and cytoskeletal restructuring were found associated with 
those genes identified as myeloid in origin.  These include Rhoc (Ras homolog gene 
family, member C) which belongs to the Rho family and it is involved in signal 
transduction for amoeboid cell motility/actin cytoskeletal restructuring (Ridley, 2006) 
and are essential for adhesion (Hakem et al., 2005).  Adhesion within myeloid cells is 
supported by in an increase in expression of genes related to integrin pathways 
including Icam1 ligation to alpha-M beta-2 (αMβ2) integrin formed from Itgb2 (Cd11b) 
and Itgb2 (Cd18) subunits (Hynes, 1992, Schenkel et al., 2004).  Integrin molecules 
including vcam1 are known to be used by myeloid cells to facilitate the entry across 
the endothelium to sites of nerve damage (Brown et al., 1997).  Also seen in support 
of myeloid adhesion was Emr1 (F4/80) (Baud et al., 1995).  These same genes are 
required for diapedesis and the recruitment of myeloid cells is further supported by 
the presence of Csf1 and Csf1r.   
 
Formalins act as specific effectors for GTPase proteins involved in actin restructuring 
(Kitzing et al., 2010) and in this dataset differential expression of Cyb5r3 (cytochrome 
b5 reductase 3) was noted; a formalin closely associated with the Rho family 
(Fernandez-Borja et al., 2005) and associated both with myeloid membrane 
restructuring for migration and phagocytic activity (Brandt et al., 2007) and neural 
axon extension (Arakawa et al., 2003).  An increase in expression of Dbi, a 
neuromodulatory steroid released by neurons and glia was observed.  It is expressed 
to induce a functional or structural alteration of the GABAergic system present in 
axon terminals, and is observed in both Parkinson’s and Alzheimer’s disease 
(Papadopoulos et al., 2006).  Interestingly, despite the increased stress and the need 
for energy neurons encounter during disease, the up regulation of both Rhoc and 
Lgals1 seen in this dataset reflect the down-regulation of neurogenesis and 





2.3.6 Oxidative Stress 
Also observed was an increase in Ucp2 which is linked with an increase in synaptic 
plasticity, mitochondrial number and dendritic spine synapses, indicative of an 
increase in both energy consumption and remodelling in response to stress (Paradis 
et al., 2003, Dietrich et al., 2008, Islam et al., 2012).  Disturbances in mitochondrial 
functions reduce ATP synthesis and this has varying effects on the cells depending on 
their metabolic requirements.  For neurons which have high metabolic requirements 
due to high overturn of activity at synapses this creates a more drastic effect than for 
other cell types.  Evidence of a response during disease to oxidative stress is seen in 
the form of Gpx1 (glutathione peroxidase 1) which plays an important regulatory role 
in the protection of neural cells in response to extreme oxidative stress during 
ischemia/reperfusion injury (Wong et al., 2011). 
 
Interestingly Cyb5r3 has also been implemented in mitochondrial distribution 
whereby overexpression in-vitro leads to a loss in mitochondrial motility and 
adhesion to actin (Minin et al., 2006).  Indeed genes expressed under conditions of 
stress were observed including S100a13 (S100 calcium binding protein A13).  These 
are induced in conditions of stress bought about by Cu2+ oxidation (Mouta Carreira 
et al., 1998, Landriscina et al., 2001).  Also noted was an increase in metabolism via 
amino acid consumption.  This was primarily noted by an increase in Oat expression. 
OAT is associated with amino acid processing (Ventura et al., 2010) and is required 
for conversion of the amino acid proline to L-ornithine and suggests an overall 
increase in metabolism akin to that seen under conditions of oxidative stress.  
Oxidative stress due to mitochondrial dysfunction is commonly described within 
neurodegenerative disease.  This dataset strongly supports a microglia origin for this 
signature following overwhelming association with myeloid cells.   
 
It was noted that there was a degree of contamination present in the purified cultures 
within the external data sets.  Astrocyte cytoskeletal gene Gfap, considered solely 
expressed by astrocytes (Sofroniew and Vinters, 2010) was found, to a small extent, 
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within the purified microglia sample of the GNFv3 dataset.  Consequently, 95 genes 
were accredited as full and partial astrocyte in origin for which the degree of overlap 
with other cell types, in particular myeloid, resulted in 20 of these as associated with 
strong (LPS) immune activation. Finally 57 genes as full or partial neuronal in origin 
were identified with 17 demonstrating immune activation. 
 
2.3.7 Protein-to-Protein interaction 
Evidence of protein to protein interaction was performed within STRING 
(http://string-db.org).   Out of the 492 disease associated genes, 488 genes were 
taken through by STRING and joined with 2999 edges comprised solely from co-
expression, experimental and database determined interactions.  Adoption of the 
inbuilt MCL function located in STRING produced clusters with striking similarity 
(Figure 2-11) to that produced by BioLayout Express3D in Figure 2-4 with the green 
cluster containing mainly interferon response markers and the main central cluster 
indicative of myeloid activation.  Representation of the gene co-expression network 
by BioLayout Express3D is therefore confirmed as concurrent with the current 
knowledge of protein behaviour in the literature.  
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Figure 2-11: STRING generated evidence based protein-protein interaction map base on the input of 
the 492 disease associated transcripts.  Connections between nodes are based on experimental evidence 
and clustering has been performed using MCL.  The overall arrangement of three main clusters matched 
that generated by BioLayout Express3D and included a dominant central myeloid cluster surrounded by 
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The disadvantage of observing the disease progression based on analysis of tissue 
samples or small scale gene analysis mean results are viewed as part of a subjective 
hypothesis and conclusions drawn only from the limited number of tested variables.  
A global analysis of gene expression from time points taken during the course of 
developing prion disease pathology, has the potential to provide, in the unprocessed 
form, unbiased data that encompasses all the potential causative and consequential 
factors relating to disease development.  The difficulty lies in trying to analyse the 
large amount of information generated in an impartial manner.   BioLayout Express3D 
was chosen for analysis of this dataset.  The software has the ability to accommodate 
very large gene datasets which are viewed in a three dimensional neighbourhood 
with other genes based on a user defined threshold of co-expression.  The capacity 
to handle very large datasets is integral to the software design in which the optimized 
graph layout and clustering algorithm are rendered within a hardware-accelerated 
OpenGL framework using the computer graphics processing unit and its inherent 
capability to handle very large numbers of calculations in a short period of time 
(Freeman et al., 2007).  This allowed rotational interaction with the graph; conferring 
a greater understanding of how cluster of genes are positioned in relation to one 
another and importantly in an environment in which there are no prior assumptions 
as to the data layout.   The biological explanation is then led from the clusters with 
an explanation attributed to groups of genes now known to be linked with a shared 
expression.  BioLayout Express3D therefore provides a visual and unbiased instrument 
for identification of a gene both in terms of shared expression with other genes and 
expression differentiation when serial data is entered.  By adopting parallel 
comparison with additional external datasets it was possible to convincingly attribute 
microglia as significant contributors in prion disease. 
 
There are however limitations to a correlation of expression approach that must be 
taken into account.  Correlation network software, including BioLayout Express3D rely 
upon a normalised background level of expression to allow pairwise comparison to 
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be conducted.  Therefore the inclusion of outliers can have a pronounced effect on 
measured distances throughout the sample (Westfall, 1993).  Where outliers exist 
and are not readily detectable; typically through a small sample population size, there 
exists the potential to form false conclusions.  It was for this reason that quality 
control checks were outsourced to Fios Genomics Ltd (Edinburgh, Scotland)/ 
 
At the global sample-to-sample level in BioLayout Express3D, with the threshold 
matrix cut-off to 0.75, the robust quality control and normalisation techniques 
adopted by this study revealed an extremely tight correlation between all the mouse 
prion combinations.  It was not until the threshold matrix cut-off was set to >0.98 
were any differences detected between the mouse/prion strain combinations.  The 
similarity of disease progression within the different strains in the study, despite 
demonstrating strikingly different disease pathologies, resulted in the generation of 
one highly organised graph of disease associated genes.  Had the mouse/prion strain 
combinations displayed differing disease signatures, the resulting graph would have 
been divided into multiple separate components with no correlation between them.  
This confirmed the suitability of the dataset for finding markers shared by the 
mouse/prion strain combinations.  In the B4053 strain a clear difference could be 
determined between nodes from infected and those from an uninfected source, yet 
it should be noted that this difference was still only detectable at a threshold matrix 
cut-off set to >0.98.  The fact the difference was greater indicated a strong diverge of 
the infected from the uninfected B4053 mice but the overall grouping of the group-
to-group dataset into one large graph does not make it possible to determine if cause 
of this difference is due to a more rapid and severe pathology. 
 
No genes were found in which expression decreased with disease progression.  The 
lack of down-regulation can be explained by the cluster based nature of analysis using 
BioLayout Express3D.  Due to the nature of microarray hybridisation there can be 
variation in gene hybridisation across different chips as part of a serial analysis.  A 
study performing a fold difference analysis might mistakenly declare such variations, 
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both up and down, as a biological perturbation.  BioLayout Express3D compares the 
entire dataset for patterns of shared co-expression and clusters of genes sharing a 
high degree of correlation.  It is however important to consider the limitations of 
whole brain RNA analysis.  It is feasible for a smaller population, possibly 
demonstrating a down-regulated signal, to be diluted by the rest of the dataset.  
 
Comparison with the external GNFv3, Brain TRAP and Macrophage/LPS datasets and 
in-depth search of the literature was used to assign cellular origin to each gene.  
Microglia dominated the signal with almost two thirds of the genes associated with 
myeloid origin.  The vast majority of these were associated with an activated innate 
immune response.  Mapping myeloid genes into ontological groups disclosed 
multiple pathways to be associated with each cluster.  Pathways for each ontological 
functional group were compiled using STRING (http://string-db.org/) and as such 
reflect the current literature.  Using the Pearson correlation function inbuilt into 
STRING generated a graph strikingly similar to that generated using the microarray 
data with BioLayout Express3D and confirming the clustering to be correctly 
orientated with current literature.   
 
The Microglial response in prion disease is usually associated with low levels of 
immune gene expression and has previously been reported within studies of the 
hippocampus of mice infected with ME7 (Brown et al., 2003, Brown et al., 2005).  In 
those studies, microglia were activated and present in large numbers in this area of 
the brain at or near clinical even if relative gene expression was not found to be in 
proportion to the visible change in morphology brought about by activation.  In this 
re-analysis dataset the activation signal was considerable stronger and the signal 
origin was at approximately 50% of total the incubation period.  Of particular note 
was that the signal remained consistent throughout the entire course of disease.  
Switching on of specific pathways at distinct intervals was not observed. Activation 
was a gradual process with expression of just one set of disease associated genes 
steadily increasing in signal strength until death.  This was concurrent across all the 
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prion/mouse strain combinations with little variation in the expression pattern 
between the different mouse/prion strains implying that all the models in this dataset 
shared a striking similarity in the disease associated expression.  Furthermore, the 
expression profile is near identical between clusters implying simultaneously 
expression by multiple cell types in the brain.  
 
Perhaps as a result of myeloid derived communication, the TGF-Β pathway is evident. 
Presence of the TGF-β1 protein in prion disease and influence on microglial activation 
are well documented (Lodge and Sriram, 1996, Cunningham et al., 2002). The TGF-β 
protein mediated inducement of differentiation/proliferation genes is seen 
throughout the analysis including Egf, which through Bmp2, interacts with the IL-
10/STAT pathway and drives cellular proliferation (Fukuda et al., 2007) with signal 
transduction mediated by secondary messenger’s cAMP, cGMP, diacylglycerol, 
arachidonic acid, InsP3, and Ca2+, and tertiary messengers through the 
phosphorylation of CREB and expression of C-FOS4.  Many of the pathways detected 
have downstream associations with different cellular lineage to the origin.  This 
provides a strong argument for a tightly controlled signal of intracellular, intra-
lineage communication. 
 
Also seen, and suggesting a strong glial interaction with neurons, were genes involved 
with neuronal cellular oxidative and metabolic stress as evidenced by Mt1, Mt2 and 
Nfe2l2.  The source of the differentiation/proliferation signals also appears to be both 
neuronal and glia in origin with differential expression of Rhbdf1 and Rab31, involved 
with trafficking of TGF-a/b and EGFR (Nakagawa et al., 2005, Liu et al., 2006, Ng et 
al., 2009).  In the brain, TGF-a triggers neuronal and glial proliferation (Burgess, 1989, 
Fallon et al., 2000).   
 
Particular evidence of oxidative stress is seen via the increase in expression of the G 
protein-coupled Melatonin receptors1 and 2 (Mt1 and Mt2).  Melatonin is a strong 
anti-oxidant, linked with TGF-β, calcium influx regulation and osteoclast 
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differentiation (Pandi-Perumal et al., 2006, Pandi-Perumal et al., 2008). The overall 
effect of an increase in melatonin is considered to be neuroprotective (Ohtsuji et al., 
2008, Radogna et al., 2009).  Production is typically associated with myeloid cells in 
the CNS where it is involved in up-regulation of the immune response including IL-2 
production (Carrillo-Vico et al., 2004).  Another gene for which expression increased 
in an effort to control oxidative levels in our dataset was Nuclear factor [erythroid-
derived 2]-like 2 (Nfe2l2). The protein form of NFE2l2 is closely associated with MT1 
and MT2 and forms part of the antioxidant response element (Ohtsuji et al., 2008). 
 
Astrocytes demonstrate a significant increase in metabolic genes involved in amino 
acid synthesis including Aldehyde dehydrogenase 1 family, member L1 (Aldh1l1).  
Actively involved in purine synthesis (Kutzbach and Stokstad, 1971) Aldh1l1 is 
implemented with cellular proliferation (Krupenko and Oleinik, 2002).  An increase in 
both astrocyte and microglia cell proliferation and differentiation is marked by 
numerous genes involved in the TGF-B1 pathway.  The expression of Tgf-B1 is already 
known to be strongly associated with prion disease where it is implicated in an effort 
to reduce microglial activation (Cunningham et al., 2002).  Seen here are genes 
involved primarily in differentiation and apoptosis including Rhomboid 5 Homolog 1 
(Rhbdf1), (Ras homolog family member C) Rhoc, Clusterin (Clu), stress-induced 
secreted protein 1 (Dies1), olfactomedin-like 3 (Olfml3), and BMP-2-inducible protein 
kinase (Bmp2k).  Downstream effectors of these genes are directly implemented with 
the TGF-B pathway (Pappano et al., 1998, Kearns et al., 2001, Nakagawa et al., 2005, 
Aloia et al., 2010) suggesting a signal in direct competition with that for proliferation. 
 
A strong interferon response was detected and comprised one third of the total gene 
set.  The vast majority are found localised in a semi-separate cluster, swayed no doubt 
by the stronger interferon response characteristic of the C57Bl/6 mice strains 
(Schilling et al., 2009).   Only a few previous studies have documented the activation 
of the interferon response system (Riemer et al., 2004) but none with such an early 
activation and as part of a tightly regulated system.  The Interleukin 10 receptor 2 (Il-
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10r2) is up-regulated; a receptor sharing considerable homology to members of class 
1 and class 2 cytokine receptors and intrinsically involved in the interferon system 
(Moore et al., 2001, Liu et al., 2012).  Activation of the IL-10 pathway results in a 
significant reduction of cytokine synthesis and inhibition of cytokine activity (Lodge 
and Sriram, 1996, Pestka et al., 2004).  In turn this would explain the increase in 
Suppressor of cytokine signalling 3 (Socs3) observed in our analysis: a potent inhibitor 
of Ifn-γ, Il-10 Il-2 and Il-4-induced signal transduction (Gil et al., 2001, Ding et al., 
2003).  Activation of the IL-10R2 complex results in phosphorylation of both STAT1 
and STAT3 and transcriptional initiation of Socs1 and Socs3 (Wehinger et al., 1996) 
explaining the strong presence of STAT mediated pathways in this dataset.  The role 
of STAT1 has been linked with PrPC biology (Spudich et al., 2005) and both STAT1 and 
STAT3 confer a neuroprotective function (Frigg et al., 2006).  This re-analysis 
suggested a dominant role of the STAT pathways within activated microglia and 
perhaps as a continuation of intracellular support by ramified microglia mediated by 
this pathway in the healthy brain (Zhu et al., 2008). 
 
2.4.1 Comparison with the Previously Published Conclusions in Hwang et al. 
(2009) 
By using a variety of mice and strain combinations, the aim of the study by (Hwang et 
al., 2009) was to identify a core set of regulatory genes involved in prion disease that 
are independent of variations in both mouse and prion strains and shared as a core 
by all mouse disease models.   The group used a subtractive process to eliminate 
genes considered artefacts of a given mouse and prion strain combination.  A 
particular prion strain can result in a short incubation period in one mouse strain but 
a significantly longer period in another mouse strain.  At the same time a particular 
mouse strain can have differing incubation periods when exposed to differing prion 
strains.  Therefore the study felt it important to understand that incubation time is 
not a property of any given prion strain or Prnp genotype, but was associated with 




Consequently Tg4053 and Prp0/+ mice were inoculated with RML and used as a filter 
to eliminate differentially expressed genes associated with differing (short and long) 
incubation times in a high PrP concentration environment.  This ensures only 
differentially expressed genes associated with strain phenotype were entered.  To 
eliminate differentially expressed genes associated with prion inoculation but not 
associated with prion infection, Prnp Null mice were inoculated with the RML prion 
strain (Appendix 8-2).  Aged and genotype matched mice were inoculated with 
normal brain as controls.   
 
Gene Ontology was applied to assign the identified differentially expressed genes into 
four main groups; PrPSc replication and accumulation, microglial and astrocyte 
activation, synaptic degeneration and neuronal cell death.  Although a strong 
activation signature was both identified and examined in detail the majority were 
considered more important only at the later stages of the disease process.  The lack 
of glial activation shown by a lack of up-regulation of Cd14, Cd68, Gfap and C1qb in 
long incubation period PrP0/+ mice until the first histoblot detection of PrP deposition 
at 16 weeks was reported to suggest glial activation is in response to prion 
accumulation and not neuronal damage.  Glial contribution was further played down 
by the suggestion that activation of endothelial cells through cytokine release would 
recruit cells from the periphery, shown by an increase in Csf1, and result in an 
increase in leukocyte numbers and hence leukocyte gene expression.  The over 
activation of microglia secondary to exposure of PrP was suggested as a possibility 
for increased neuronal death.  However the study concluded that severe neuronal 
stress resulting from perturbations within lipid raft mediated prion replication was 
the main and dominant signature within the disease. 
 
2.4.2 Conclusions 
Shown in this dataset and for the first time is a consistent and immune system 
dominated disease associated signal that remains consistent from around halfway 
through the incubation period.  Contained within the expression profile are genes 
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involved in metabolic and oxidative stress, ER/Golgi associated quality control 
mechanisms, proliferation/differentiation, immune activation and at the same time 
suppression of both proliferation and activation phenotypes.  The signals are 
strikingly intra-cellular in origin, which ties in with the formation of a one large 
inseparable cluster in BioLayout Express3D, and indicative of a tightly regulated 
mechanism between differing cell populations in the diseased brain.  Although 
microglia appear to dominate the overall signature, it indicates that increasingly 
stressful conditions are for some time successfully endured by all cell types long 
before the onset of the clinical phase of disease.  
 
The nature of the inseparable multi-cellular signal would require teasing apart one 
cell type at a time to overcome the limitations of both whole brain RNA and post 
origin allocations, that although addressed in a novel way in this study, were still 
subject to signal contamination and incomplete/incorrect expression by external 
immature primary cultures that fail to represent the mature in-vivo expression.  
Single cell type analysis would provide an insight into what a cell is not contributing, 
an aspect often overlooked but vital in determining the correct direction of cell-cell 
communication pathways.  The overall immune response described in this present 
study is both pro-inflammatory and anti-inflammatory and does not present with the 
hallmarks of either a classical or alternatively activated myeloid phenotype.  Due to 
the potential incorporation of other cell types within the signal it is not possible to 
state for certain that this mixed phenotype is unique to prion disease.  A single cell 
type analysis would therefore also facilitate in determining if the microglial response 
is specific to prion disease or a stereotypic LPS-type response by myeloid cells 




3 Characterisation of the Response of BALB/cJFms-EGFP/- Mice to Prion Infection 
3.1 Introduction 
The aim of this chapter is to characterise prion infection in BALB/cJFms-EGFP/- mice and 
their suitability for studying the role of microglia during the course of infection. 
BALB/cJFms-EGFP/- mice are a novel genetically modified mouse line which express 
Enhanced Green Fluorescent Protein (EGFP) under control of the C-fms operon.  C-
fms encodes for macrophage colony-stimulating factor-1 (CSF-1), a myeloid linage 
specific growth factor that binds to colony-stimulating factor receptors (CSF-1R) on 
cells of myeloid origin.  CSF-1 is directly involved in the survival, proliferation, and 
differentiation of mononuclear phagocytes (Stanley et al., 1997). The Fms-EGFP 
reporter gene was first used in C57BL/6 mice to generate the Macrophage-Green 
(MacGreen) mouse model (Sasmono et al., 2003).  The Fms-EGFP reporter gene has 
now also been inserted into the BALB/cJ background generating the BALB/cJFms-EGFP/- 
strain of transgenic mice.   
 
Mouse availability at the start of this project dictated the use of the BALB/cJFms-EGFP/- 
mice.  BALB/cJ are well characterised with prion models and are heavily utilised in 
other neurodegenerative disease models and immunological studies (Appendix 8-6).  
All cells of myeloid origin that express the lineage specific growth factor Csf-1 in the 
BALB/cJFms-EGFP/- mouse will yield EGFP.  This also includes cells of neutrophilic 
granulocyte lineage sharing the same progenitor as monocytes (Sasmono et al., 
2007).  For the purpose of studying microglia during neurodegenerative disease, the 
expression of EGFP by this group of cells allows for detailed analysis and easy 
isolation.  The Fms-EGFP reporter insertion into BALB/cJ was by random integration 
and the precise location of the reporter in the genome was therefore unknown.  
Homozygosity for the Fms-EGFP reporter is fatal in utero suggesting knock-out of a 
vital sequence required for correct development in utero.  Animals demonstrating 
heterozygosity appear to be unaffected and behave and interact normally with the 
wildtype animals suggesting the functional complimentary copy of the gene is 
103 
 
sufficient.  In addition BALB/cJFms-EGFP/- share a comparable lifespan to the wild type 
animals (~800 days).  The lack of apparent detrimental effects and the high availability 
of mice heterozygous for the Fms-EGFP reporter made the strain suitable for this 
project. 
 
This chapter will cover two aims using infection with two very different prion strains.  
The first aim was to confirm that the BALB/cJFms-EGFP/- mice are susceptible to prion 
disease infection by direct comparison with the BALB/cJ wild type.  The second aim 
was a serial investigation to document the sequence of events following infection.  
BALB/cJFms-EGFP/- and the wild-type background BALB/cJ mice were infected with 
either 79A or ME7 prion strains.  These two well characterised strains were chosen 
due to the differences in original origin (Appendix 8-7) and the recognisable and 
reproducible pathology in mice both sharing the Prnp-a allele (Fraser and Dickinson, 
1985).  Successful infection by two very different strains demonstrating very different 
pathologies would confirm BALB/cJFms-EGFP/- are fully susceptible to, and suitable for 
use in studying, murine prion disease.  Furthermore, previous unpublished work 
within the Neurobiology Division, The Roslin Institute & R(D)SVS, demonstrated prion 
strain dependant variability in persistence of infection of cultured microglia-like cells 
(Appendix 8-8). 
 
3.1.1 Choice of Prion Infection Route and Serial Investigation Time Points 
This experiment made use of an intraperitoneal route of infection.  This route was 
adopted to ensure microglial activation was the result of a response to initial infection 
entering into the CNS environment, at the start of the neural phase of replication, in 
what amounts to a more natural route.  By contrast the rapid dissemination of 
infectious material throughout both the CNS and periphery following an intracerebral 
injection does not allow for exact confirmation of the initial microglial response 




The regional targeting of disease pathology in the brain of intraperitoneal and 
intracerebral infection is identical once uptake into the CNS has been achieved as the 
spread of prion disease pathogenesis in the brain is restricted to neuroanatomical 
pathways (Kimberlin and Walker, 1980, Kimberlin et al., 1983, Scott et al., 1992).  
Following disease entry into the CNS, the reduced complexity of entry into the brain 
with a peripheral route via rapid replication along neuroanatomical pathways results 
in a surprisingly shorter neural phase of replication, classed as the time from first 
detection of protein deposition to clinical onset, following a peripheral route than an 
intracerebral injection (Kimberlin and Walker, 1986, Langevin et al., 2011).   This can 
be observed in detail when the requirements for extra-neuronal replication are 
bypassed and the neural phase of replication is initiated from the outset following an 
intraspinal route of infection (Kimberlin et al., 1987). 
 
Although the replication phase in the brain is reduced using a peripheral route of 
infection, the disease incubation period is considerably longer than an intracerebral 
route.  The speed of infectious uptake into the CNS is determined in the main by the 
concentration of available infectious material.   Following injection, dissemination to 
tissues rapidly occurs with a higher rate of loss in titre following an i.p. route than an 
i.c. route (Kimberlin and Walker, 1978, Millson et al., 1979).  Accordingly the 
infectivity titre of an inoculum is lower when using a peripheral route and the period 
required prior to successful initial entry into and replication within the CNS is 
increased.  This is further compounded by the complexity of the peripheral 
mechanisms of replication (Kimberlin and Walker, 1979, Brown et al., 1999b) all of 
which are considered important for this project as microglia are extremely sensitive 
to signals both pertaining and outwith of the parenchyma (Nimmerjahn et al., 2005). 
 
It was therefore important to capture these initial events of peripheral and CNS 
replication phases, time points were carefully chosen based on expected incubation 
periods of ME7 and 79A within Prnp-a allele containing BALB/cJFms-EGFP/- and BALB/cJ 
mice using an i.p route (Appendix 8-9) To offset for potential delays in entry into the 
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CNS from using a peripheral route, time points in this study were included at 45% and 
65% of the incubation period (Figure 3-1) to document pre-clinical disease uptake in 
the CNS.  
Studies focusing on the hippocampus, made due to the regular architecture and well 
characterised location of the pyramidal neuronal population found in this region, 
revealed the first immunostained PrP was detectable in the hippocampal CA1 pyramidal 
cell layer 70 dpi and proceeded vacuolation, synaptic loss and axon degeneration; all 
observed to steadily increase from 100 dpi (Johnston et al., 1998, Jeffrey et al., 2000, 
Brown et al., 2001, Jeffrey et al., 2001) with significant loss by terminal (Belichenko et al., 
2000).  These hippocampal studies utilised the ME7 Scrapie strain inoculated into the 
F1 cross produced from pairing of the Prnp-a allele containing C57BL mouse strain with 
the Prnp-b containing VM strain.  The resulting CVF1 mouse strain (CV) harbours both 
Prnp alleles (Prnp-a/b). The ME7/CV model following intracerebral inoculation, 
demonstrates an incubation period of 32 weeks (226 days) with extensive and 
widespread diffuse deposition of PrP throughout the brain by terminal (Jeffrey et al., 
2001).  The activation of astrocytes and microglia was also observed from 100 dpi with 
the former observed to actively internalise degenerating axons (Jeffrey et al., 2000, 
Jeffrey et al., 2001).  Crucially the ME7/CV model demonstrates the activation of 
microglia to be 30 days after the initial detection of PrP deposition and is therefore in 
disagreement with the aforementioned ME7 inoculations into Prnp-a allele C57BL6/J 
mice.  Whether microglia are the cause of developing pathology or merely responding to 
damage has still not been resolved highlighting the need, as per this analysis, to focus on 




Figure 3-1: Early events documented for ME7 infection in C57BL6/J mice (Prnp-a) following stereotaxic 
i.c. inoculation based on work performed by (Cunningham et al., 2003) and (Cunningham et al., 2005a).  
A: Early signs of microglia activation and PrP deposition were first observed at approximately 50% of the 
incubation period.  B: Expected points of pathological events following i.p. infection in BALB/cJFms-EGFP/- 
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3.2 Methodology  
3.2.1 Experimental Set up 
The breeding of BALB/cJFms-EGFP/- mice was performed with the pairing of a BALB/cJFms-
EGFP/- with a BALB/cJ bought from Charles River Laboratories (Elpinstone).  Pairs 
contained either a male or a female BALB/cJFms-EGFP/-.  The breeding pairs were mixed 
with regards to the gender of the BALB/cJFms-EGFP/- parent and no difference was noted 
in offspring number or quality between the two pairing alternatives for the gender of 
the BALB/cJFms-EGFP/- mouse.  Offspring were genotyped for presence of the Fms-EGFP 
reporter. Animals negative for the reporter gene were considered to be wild type 
BALB/cJ and selection for these animals was considered the same as choosing a 
BALB/cJ bought from Charles River Laboratories (Elpinstone).  All groups were gender 
matched.  Mice with an average age of 116 days ± 1.2 SE were given an 
intraperitoneal injection with 0.02 ml of 10-2 w/v of either 79A or ME7 infected brain 
homogenate suspended in PBS and with a 1 ml syringe (Table 3-1) sourced from 
C57BL/6J mice (Appendix 8-10).  Additional mice, run in parallel, were inoculated with 
0.02 ml of 10-2 w/v normal brain homogenate suspended in PBS to serve as controls 




Table 3-1: Mice used for BALB/cJFms-EGFP/- characterisation study infected with either 79A or ME7 
mouse-adapted Scrapie prion strains.  Control mice were inoculated with normal brain (NBr) 
homogenate.  Mice were split into two experiments with the NBr inoculated mice serving as controls 
for both.  
 







Age at Injection 





12 BALB/cJFms-EGFP/- 126 ± 1.9 79A i.p. 
12 BALB/cJ 129 ± 1.3 79A i.p. 
12 BALB/cJFms-EGFP/- 101 ± 1.5 ME7 i.p. 
12 BALB/cJ 101 ± 0.8 ME7 i.p. 
6 BALB/cJFms-EGFP/- 131 ± 0.7 NBr i.p. 
150 
9 BALB/cJFms-EGFP/- 127 ± 0.1 79A i.p. 
9 BALB/cJFms-EGFP/- 103 ± 3.6 ME7 i.p. 
6 BALB/cJFms-EGFP/- 127 ± 0.8 NBr i.p. 
100 
9 BALB/cJFms-EGFP/- 124 ± 1.3 79A i.p. 
9 BALB/cJFms-EGFP/- 104 ± 2.4 ME7 i.p. 
6 BALB/cJFms-EGFP/- 126 ± 0.7 NBr i.p. 
35 
9 BALB/cJFms-EGFP/- 121 ± 2.6 79A i.p. 
9 BALB/cJFms-EGFP/- 102 ± 3.1 ME7 i.p. 




3.2.2 Scoring of TSE Clinical Signs and Lesions 
All mice were monitored daily for general health.  Mice belonging to the groups to be 
taken to terminal disease were scored every 7 days for clinical signs from 65% of the 
incubation period (150 dpi) when first PrP protein accumulation was predicted to be 
present indicating the onset of the neural replication phase.  This was performed 
using a modified version of the coding system first introduced by Dickinson et al. 
(1968) and now universally adopted: 
 
1: The animal is healthy with no signs of abnormal behaviour. 
2:  Possibly prion disease affected: Abnormalities observed but necessarily due to 
prion disease, including lethargy, unkempt appearance and weight loss. 
+:  Prion disease affected: Animal has clinical signs of prion disease including 
hunching, unkempt appearance, weight loss, wet genitalia, semiperminant 
inactivation (freezing) and poor balance.  
g:  The animal portrays abnormalities in gait but not necessarily due to prion 
disease. 
G:  The animal has a clinical score of 2 with gait abnormality.  
 
Mice were culled following two consecutive recordings of a ‘+’ score.  If disease signs 
were considered very severe the animal was culled following just one instance of a 
‘+’ to reduce suffering.  To allow for standardization both within this project and with 
prion disease experiments in the literature, brains were cut to a template following a 
standard operating procedure, almost universally adopted, to produce 6 µm 
haematoxylin and eosin stained tissue sections (Fraser and Dickinson, 1967).  Lesion 
scoring was performed on 9 grey matter (of which mice have a correspondingly 
higher proportion than human brain) and three white matter regions (Figure 3-2).   
Lesions were scored on a scale of 1-5 within the grey matter and 1-3 within the white 
matter.  A score of 1 is indicative of the presence of minor vacuolation of which origin 
















Figure 3-2: Standardised lesion scoring regions. Lesion scoring was performed on 9 grey matter and 3 
white regions: 1: medulla, 2: cerebellum, 3: superior colliculus, 4: hypothalamus, 5: thalamus, 6: 
hippocampus, 7: septum, 8: retrosplenial cortex, 9: cingulate & motor cortex, WM 1: cerebellum, WM 




3.2.3 Genotyping of BALB/c and BALB/cJFms-EGFP/- Mice 
Genotyping for presence of the Fms-EGFP reporter gene was performed both as part 
of animal selection and following experimental cull to confirm original genotype 
designation.  Primers for the Fms-EGFP reporter gene and the fatty acid binding 
protein 500 (Fabpi500) positive control gene were obtained from Eurofins MWG 
Operon.  The Fabpi500 gene (Green et al., 1992, Chmurzyńska, 2006), multiplexed 
into the reactions, was utilised for quality control by ensuring the lack of an EGFP 
band is due to the absence of the transgene and not due to failure of the PCR.   
 
3.2.3.1 Preparation of Primers 
Primers for Fms-EGFP reporter gene and Fabpi500 positive control gene were 
obtained from Eurofins MWG Operon (Ebersberg, Germany) as a lyophilised powder 
in 2 ml screw top tubes synthesised in the following sequences: 
 
EGFP Forward:  5'-GCA CGA CTT CTT CAA GTC CGC CAT GCC-3'  
EGFP Reverse:   5'-GCG GAT CTT GAA GTT CAC CTT GAT GCC-3' 
Fabpi500 Forward: 5'-CCT CCG GAG AGC AGC GAT TAA AAG TGT CAG-3' 
Fabpi500 Reverse: 5'-TAG AGC TTT GCC ACA TCA CAG GTC ATT CAG-3' 
 
Each primer pair was rehydrated in the required volume of distilled H2O (Gibco, 
15230) specified by the manufacturer for each individual tube to make 100 µM 
primer stock solution.  Aliquots of 60 µl were made and stored at -20°C in 0.5 ml 
tubes. 
 
3.2.3.2 DNA Extraction from Ear Punch Biopsy of Mice Obtained from Breeding 
Colony  
An ear biopsy, performed as part of routine ear mark, was taken using an ear punch 
and placed in a labelled 2 ml screw top microcentrifuge tube. To each tube, 180 µl 
Buffer ATL (QIAGEN DNeasy™ 69506) was added followed by 20 µl Proteinase K 
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(QIAGEN DNeasy™ Kit, 69506).  These tubes were then incubated overnight at 55°C 
with oscillation at 150 rpm.   
 
Following incubation a premix of 200 µl Buffer AL (QIAGEN DNeasy™ 69506) and 200 
µl ethanol was added to each tissue lysate and vortexed for 15 sec to mix.   Each 
lysate was transferred to a new DNeasy™ spin column contained within a new 2 ml 
collection tube and centrifuged at 6000 x g (8000 rpm on Eppendorf Centrifuge 
5415D)  for 1 min.  Flow through and collection tube were subsequently discarded 
and the spin column placed in a new collection tube. 
 
To each spin column 500 µl Buffer AW1 (QIAGEN DNeasy™ 69506) was applied prior 
to centrifuge at 6000 x g.  Flow through and collection tube were subsequently 
discarded and the spin column placed in a new collection tube.  To each spin column 
500µl buffer AW2 (QIAGEN DNeasy™ 69506, UK) was applied prior to centrifuge at 
6000 x g (8000 rpm on Eppendorf Centrifuge 5415D) for 3 min to fully dry the column 
membrane. Flow through and collection tubes were discarded and spin columns 
carefully transferred to clean labelled 1.5 ml microcentrifuge tubes. 
  
To each column, 200 µl Buffer AE (QIAGEN DNeasy™ 69506, UK) was applied directly 
to the membrane and incubated under cover at room temperature (25°C) for 1 min.  
To elute DNA, all spin columns were subjected to a final centrifuge at 6000 x g.  All 
1.5 ml tubes contained DNA were transferred to 4°C storage. 
 
3.2.3.3 DNA Extraction from Prion Infected Tail Biopsy following Experimental Cull 
A 1 cm tail tip was cut from each mouse when culled and stored at -20°C.  From each 
frozen tail tip, a 2 mm section was removed using a clean disposable scalpel and 
placed into a labelled 2 ml screw top tube.  A fresh disposable scalpel was utilised for 
each tail to avoid contamination.   To each tube 800 µl Tissue Lysis Buffer was added 




Following incubation, 600 µl Phenol/Chloroform 1:1 was added to each tube and 
mixed thoroughly by vortex.  All tubes were then centrifuged at 10000 x g (13000 rpm 
on Eppendorf Centrifuge 5415R) for 5 min.  The top 600 µl aqueous phase was 
transferred to a new 1.5 ml microcentrifuge tube and 20 µl of 3 M sodium acetate 
followed by 600 µl isopropanol added and inverted 15 times to mix.  Sealed tubes 
were then left to stand for 10 min at room temperature (25°C). 
 
The DNA was precipitated at 10000 x g for 2 min then washed in 200 µl 70% ethanol 
at 10000 x g for 1 min and left to air dry at room temperature (25°C) for 10 min.  The 
DNA pellet was resuspended in 200 µl Buffer AE (QIAGEN, 19077) and transferred to 
4°C storage until required. 
 
3.2.3.4 Polymerase Chain Reaction using QIAGEN Type-it™ Mutation Detection Kit 
or Microzone MegaMix-Blue. 
Primer stock solution aliquots were removed from -20°C storage and thawed at room 
temperature.  An Fms-EGFP primer pair 10 µM working solution prepared by mixing 
60 µl of Fms-EGFP F stock solution and 60 µl of Fms-EGFP R stock solution with 480 
µl distilled H2O.  The Fabpi500 primer pair 10 µM working solution was prepared by 
mixing 60 µl of Fabpi500 F stock solution and 60 µl of Fabpi500 R stock solution with 
480 µl distilled H2O.  The primer pair mix was then prepared by combining 20 µl Fms-
EGFP Primer pair 10 µM working solution with 20 µl Fabpi500 Primer pair 10 µM 
working solution made up to 500 µl with Tris EDTA buffer.   
 
Stock PCR solution was prepared on ice by mixing 6.5 µl double distilled H2O (ddH2O), 
12.5 µl 2x MasterMix (QIAGEN Type-it™ Kit, 206343), 2.5 µl Primer Pair Mix and 2.5 
µl CoralLoad Dye (QIAGEN Type-it™ Kit, 206343).   Alternatively a stock PCR solution 
was prepared on ice by mixing 48 µl MegaMix-Blue (Microzone 2MMB-100), 0.5 µl 





The Stock PCR solution was then mixed by vortex and 24 µl aliquots transferred by 
pipette into labelled 0.10 ml tubes with one for each PCR genotype reaction.  Also 
included were three extra tubes for negative, positive and ddH2O controls.  To each 
tube; 1 µl target DNA from a mouse to be genotyped was added and vortexed to mix.  
DNA from a mouse known to be Fms-EGFP positive was added as a positive control, 
and DNA from a mouse known to be Fms-EGFP negative was used as a negative 
control.  To the tube marked ddH2O, a 1 µl aliquot of the same volume of ddH2O used 
in preparing the master mix was included.  The PCR cycle run was performed in in a 
thermocycler (Geneamp PCR System 9700) with 35 cycles of denaturation at 94 °C for 
30 sec, annealing at 65 °C for 30 sec and elongation at 72 °C for 3 min.   
 
3.2.3.5 Gel Electrophoresis Visualisation of PCR Amplified DNA 
PCR products were removed from 4°C storage and, if required, supplemented with 
loading dye.   For each tube, 5 µl was loaded into a 2% agarose gel prepared using 
TAE buffer and ethidium bromide. Visualisation and image capture was performed 
under ultra violet light. 
 
3.2.4 Tissue Processing 
3.2.4.1 Paraffin Wax Embedded Tissues 
Mice were culled by cervical dislocation at 35, 100, 150 days post inoculation (dpi) 
and at terminal stage.  Tissues were fixed in formal saline then placed in > 99% formic 
acid for 1 hour to reduce titre infectivity by ≥ 1.0 and ≥ 5.0 log titres when mice were 
challenged with 0.02ml of 10-2 w/v infected brain material (Taylor et al., 1997).  Brain 
tissue was sectioned as per the standard method first developed by Fraser and 
Dickinson (1967), and outlined in SOP-PSG-008 used by the Pathology Department at 
The Roslin Institute (Figure 3-1), prior to embedding in paraffin wax.  Sections were 




3.2.4.2 Frozen Tissue Fixation and Cryostat Sectioning 
Brain tissue was taken directly from BALB/cJFms-EGFP/- mice and placed into 5 ml pre 
chilled 4% paraformaldehyde solution for 2 hours at 4°C.  Following fixation tissues 
were transferred to pre chilled 18% sucrose solution overnight at 4°C.  
 
Following incubation brain tissue was dissected and arranged on a thin layer of 
optimum cutting temperature (OCT) freezing compound (Cellpath, KMA-0100-00A) 
in a tissue mould (Surgipath, 03065) following the procedure outlined in SOP-PSG-
008 used by the Pathology Department at The Roslin Institute (Figure 3-1).  Once 
aligned correctly the brain sections were covered completely in additional freezing 
compound. 
 
The moulds were then lowered into a beaker of isopentane (BDH, 103641T) clamped 
over a Dewar of liquid nitrogen in which 1 cm of the beaker was submerged below 
the nitrogen surface.  Moulds were removed by forceps after 1 min and left to dry for 
10 sec before the frozen OCT embedded tissue blocks were prised out of the moulds.  
All blocks were stored at -40°C on dry ice until completion of procedure and then 
transferred to permanent storage at -70°C.  
 
Frozen OCT embedded tissue blocks to be sectioned were removed from -70°C 
storage and placed within the -20°C working area of the cryostat (LEICA CM 1900) for 
10 min to reduce the block temperature to within working limits.  Tissue blocks were 
mounted onto the cryostat chucks using several drops of OCT freezing compound and 
correctly aligned with aid of the cryostat mounting tool.  The chuck and tissue block 
combination were then mounted onto the microtome and the temperature of both 
the environment and microtome adjusted to -20°C.  Sections were cut at 6 µm using 
a new microtome blade and immediately placed onto microscope slides.  Slides were 




Figure 3-3: Trimming and embedding levels for mouse brain sectioning detailed in SOP-PSG-008 








3.2.5.1 Labelling of PrP Deposition with 6H4 anti-mouse PrP Primary Antibody 
Prionics (Switzerland) 6H4 is a mono-clonal mouse antibody that detects amino acids 
144 – 152 in the human protein.  It also has a high affinity for the mouse protein, 
indicating the replacement of tyrosine with a tryptophan at position 145 in murine 
PrP has no impact on binding affinity.   
 
All paraffin wax embedded 6 µm thick brain tissue sections were taken through 
xylene to remove paraffin wax and finally successively diminishing concentrations of 
ethanol ending in dH2O to both remove the xylene and rehydrate the tissue.   
Following rehydration, antigen retrieval was performed in an autoclave at 121°C for 
15 min in dH2O and then incubated in formic acid for 10 min at room temperature to 
aid antigen retrieval.  The slides were washed thoroughly in running tap water prior 
to blocking of endogenous peroxidase with 1% H2O2 (Sigma-Aldrich, H1009) in 100% 
methanol for 10 min.  The slides were again rinsed in running tap water then placed 
into phosphate buffered saline supplemented with 0.2% bovine serum albumin in 
PBS (PBS/BSA) wash buffer for 5 min at room temperature. 
 
All sections were blocked with serum-free mouse protein block (Dako, X0909) or 
normal goat serum diluted to 1 µg ml-1 with antibody diluent (phosphate buffered 
saline supplemented with 1% bovine serum albumin) for 20 min at room 
temperature.  Following blocking, the serum was tapped off each slide and 
monoclonal mouse 6H4 (Prionics, 01-011, Switzerland) primary antibody applied at 
0.5 µg ml-1 to the experimental slides and left to incubate overnight at room 
temperature. Negative control slides were treated overnight with mouse mixed 




3.2.5.2 Labelling of Microglia Cells with Allograft inflammatory factor 1 (AIF1) 
Antigen retrieval was performed in the microwave (600 Watt) in 0.1 M citrate buffer 
at pH 6.0.  Endogenous peroxidase was blocked with 1% H2O2 (Sigma-Aldrich, H1009) 
in 100% methanol for 10 min, then rinsed in running tap water and placed into 
phosphate buffered saline supplemented with 0.2% bovine serum albumin (PBS/BSA) 
wash buffer for 5 min at room temperature. 
 
All sections were blocked with 20% normal goat serum diluted with antibody diluent 
for 20 min at room temperature.  Following blocking the serum was tapped off each 
slide and polyclonal rabbit anti-allograft inflammatory factor 1 (Abcam, ab108539) 
primary antibody diluted to 0.5 µg ml-1 was applied to the experimental slides and 
left to incubate overnight at room temperature.  Control slides were treated with 
serum. 
 
3.2.5.3 Application of Secondary Antibody & Enzymatic Location of 
Antibody/Enzyme Complexes 
Following overnight incubation the primary antibody and serum was tapped off and 
slides were washed three times for 5 min in PBS/BSA wash buffer keeping controls 
separate.   Addition of an intermediate enzymatic reacting incorporating the 
deposition of biotinylated phenolic compound increases the available biotin 
molecules onto which streptavidin-biotin-peroxidase is catalysed.  These regents are 
commercially incorporated into the Catalysed Signal Amplification (CSA) System 
(Dako, K1500).  The CSA amplification kit (Dako, K1500, Cambridgeshire UK), if used, 
was applied following the manufactures instructions, otherwise secondary 
biotinylated antibody at a concentration of 1 µg ml-1 was applied to all slides for 1 
hour at room temperature followed by three 5 min washes in PBS/BSA wash buffer.  
All slides were then incubated in Vectastain avidin/biotinylated enzyme complex 
(Vector, PK-6100) for 30 min at room temperature followed by three 5 min washes in 
PBS/BSA wash buffer.  Slides were then incubated for 5 minutes in 3,3′-
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Diaminobenzidine tetrahydrochloride solution acting as a substrate for added H2O2 
to enzymatically locate the avidin/biotinylated enzyme complex by generating a dark 
brown oxide. 
 
Slides were then placed into PBS/BSA wash buffer for 5 min at room temperature and 
rinsed in running tap water before immersion for 1 min in haematoxylin followed by 
a 1min immersion in Scott’s tap water to blue nuclei.  Finally the slides were rinsed in 
running tap water and taken to xylene through successively increasing concentrations 
of ethanol to dehydrate the tissues.  Hydrophobic mounting of coverslips was 
performed using Pertex mounting medium (Cellpath, SEA-0104-004) and all sections 
were then left to dry overnight.  Sections were viewed on a Nikon E800 bright field 
microscope and images captured using Image Pro software. 
 
3.2.6 Statistics 
Comparison between two populations was performed using a two-tailed t-Test 
assuming a variance depending upon the outcome of an f-Test for variance.  Such a 
system is optimised for a smaller number of populations in utilising a wider 
distribution curve to ensure a higher value is required for the t-critical to become 
significant.  The f-test ensured that variance was correctly identified as equal or un-
equal and provided additional insurance against making a Type I/II error.  Comparison 
of Kaplan-Meier plots was performed using the survdiff Log Rank Test function 
(Harrington and Fleming, 1982) located within the survival package of R (Version x64 
3.1.2): 
 
Log Rank Test: 
 
Ot = Total Number of Events (Sum of O1 and O2) 
Et = Expected Number of Events (Et = Nt*(Ot/Nt)  
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3.3 Results:  Suitability of BALB/cJFms-EGFP/- for use in Prion Disease Infection 
3.3.1 Clinical Signs and Incubation Period  
Mice infected with 79A or ME7 prion strains and belonging to the groups taken out 
to terminal disease were scored every 7 days for clinical signs from 150 dpi.  Signs 
recorded were lethargy, hair unkempt/loss, and hunching with no discernible 
indication of a difference in clinical signs between either genotype.  Only one mouse 
was observed to have gait problems and none were discerned to suffer from wetness 
around the genitalia.  Results were initially noted as a ‘2’ on the scoring sheet and a 
‘+’ if noted at the next consecutive evaluation.  The onset of clinical signs was 
determined as a mean average of the dpi for each mouse from the BALB/cJFms-EGFP/- 
and BALB/cJ groups infected with either prion strain.  The BALB/cJFms-EGFP/- and 
BALB/cJ groups infected with 79A first demonstrated clinical signs at 201 ± 6.0 days 
standard error (SE) and 209 ± 4.2 days SE respectively.  For the BALB/cJFms-EGFP/- and 
BALB/cJ groups infected with ME7 the onset of clinical signs was 295 ± 8.9 days SE 
and 306 ± 9.1 days SE.  No statistical difference (p > 0.05) was noted between the 
onset of clinical signs for either mouse genotype inoculated with either prion strain 
(Figure 3-4A).  Control BALB/cJFms-EGFP/- inoculated with normal brain homogenate 
were culled at 250 days after showing no signs of clinical disease.  The total disease 
incubation periods were also determined as a mean average with BALB/cJFms-EGFP/- and 
BALB/cJ mice infected with either 79A culled at 225 ± 6.3 days SE and 227 ± 6.5 days 
SE respectively and BALB/cJFms-EGFP/- and BALB/cJ mice infected with either ME7 culled 
at 310 ± 8.6 days SE and 317 ± 9.5 days SE respectively.  Statistical significance (P > 
0.05) between disease incubation periods was not noted between BALB/cJFms-EGFP/- 
and BALB/cJ mice infected with either 79A or ME7 (Figure 3-4B).  Individual values 
were used to construct Kaplan-Meier survival curves for each group (Figure 3-5).  
Both BALB/cJFms-EGFP/- and BALB/cJ showed very similar patterns in the overall spread 
of cull dates indicating no marked differences in either disease pathogenesis or 
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Survival (days post injection)
ME7/BALB/cJFms-EGFP/- (n = 12)
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Figure 3-4: Kaplan-Meier survival curves for BALB/cJFms-EGFP/- or BALB/cJ following intraperitoneal 
challenge with either 79A or ME7 prion strains. A: BALB/cJFms-EGFP/- and BALB/cJ infected with 79A or 
B:  ME7 prion stains both have curves with a high degree of overlap indicating no notable difference 
between BALB/cJFms-EGFP/- and BALB/cJ infected with either prion strain (statistical analysis performed 
using performed using the survdiff function (Log Rank test) located within the survival package of R).  
Figure 3-5: Incubation period and onset of clinical signs for BALB/cJFms-EGFP/- or BALB/cJ following 
intraperitoneal challenge with either 79A or ME7 prion strains. A: Onset of clinical signs for BALB/cJFms-
EGFP/- and BALB/cJ mice.  A slight increase in sample distribution determined by f-Test assumed unequal 
variance, however no statistically significant difference was found for onset of clinical signs (t-Test two-
sample assuming unequal variances) between BALB/cJFms-EGFP/- and BALB/cJ mice infected with either 
prion stain.  B: Mean incubation periods for BALB/cJFms-EGFP/- and BALB/cJ.  No statistically significant 
difference found (f-Test for variance then t-Test two-sample assuming equal variances) between 




3.3.2 Grey Matter Lesion Scoring 
All brain tissues embedded in paraffin wax were investigated for the presence of 
prion disease associated lesions.  In addition to confirming infection, a vacuolation 
score profile provides a semi-quantitative and highly reproducible pattern allowing 
for correct strain identification (Bruce et al., 1991). Strain typing in this manner also 
serves as a powerful tool for comparing the disease pathogenesis of two different 
mouse genotypes infected with the same prion strain.  Any impact upon infection of 
prion disease by the Fms-EGFP transgene in BALB/cJFms-EGFP/- mice would be revealed 
upon comparison with wild type BALB/cJ mice. 
 
All mice culled at 35, 100 and 150 dpi were clinically negative at the time of death 
and all scored pathologically negative with scores of 0 in all regions.  All mice that 
scored as pathologically positive for prion disease demonstrated brain regions with 
lesions associated with prion infection (Figure 3-6).  The severity of lesions was more 
severe with ME7 infection with the majority of tested regions containing a higher 
proportion of scores at 2 or above.  Lesion profiles for both BALB/cJFms-EGFP/- and 
BALB/cJ groups infected with ME7 show a comparable trend in grey matter regional 
targeting indicating no significant difference between infection in BALB/cJ regardless 
of the presence of the Fms-EGFP reporter.   
 
By contrast 79A infection demonstrated far fewer regions containing vacuolation 
indicating a more targeted pathology.  It should be noted that scoring of several 
regions, particularly the superior colliculus area and septum area were scored with 
slight differences for BALB/cJFms-EGFP/- and BALB/cJ infected with 79A.  A minimum of 
6 animals is required for correct lesion profiling and although 8 BALB/cJ and 9 
BALB/cJFms-EGFP/- animals incorporated, not all regions were captured successfully in 
paraffin wax resulting in a minimum of 6 sections for some scored regions.    
 
Although the 79A scoring met the minimum requirements, the difference in curves 
between the BALB/cJ and BALB/cJFms-EGFP/- mice may be the product of a reduced 
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scoring population and/or poor quality paraffin wax sections.   By contrast, a 
minimum of 9 BALB/cJ and 10 BALB/cJFms-EGFP/- sections from 10 and 12 animals 
respectfully was obtained from ME7 infected mice.  It is also important to consider 
when strain typing, the final incubation period and the pattern of PrP deposition. The 
latter do not show any significant differences (Section 3.3.3) and as such the use of 




















3.3.3 Terminal Stage PrP Staining using 6H4 Anti-PrP Antibody 
The conversion of the host prion protein (PrPC) into the misfolded insoluble PrPSc is 
one of the defining principles of prion infection.  The accumulation of PrP can be 
visualised as deposits in the brain using immunohistochemistry. The pattern of 










79A/BALB/cJ: n = 6 - 8










ME7/BALB/cJ: n = 9 - 10
ME7/BALB/cJFms-EGFP/-: n = 10 - 12
A B 
Figure 3-6: Scrapie lesion density profiles in BALB/cJ and BALB/cJFms-EGFP/- mice following 
intraperitoneal challenge of A: 79A or B: ME7 Scrapie prion strains.  Both prion strains show a similar 
pattern of targeting in BALB/cJ mice regardless of Fms-EGFP reporter presence although there are some 
differences in the superior colliculus and septum between the two mouse genotypes infected with 79A. NB: 
lesion curves should not be visualised as a continuous data line chart. 
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Immunohistochemical analysis of PrP deposition forms an important component in 
the identification of host infection and strain identification. 
 
Tissues obtained from BALB/cJFms-EGFP/- mice were subjected to 1 hour immersion in 
formic acid.  Immersion in formic acid reduces the infectivity of mouse-adapted 
Scrapie by ≥ 1.0 and ≥ 5.0 log titres respectfully when mice are challenged with 0.02ml 
of 10-2 w/v infected brain material (Taylor et al., 1997).  To ascertain if the 6H4 
antibody was suitable for use with formic acid treated tissues immunohistochemistry 
was carried out on formic acid treated control sections taken from the institute 
archives and incorporated a titration of 6H4 to determine the optimum 
concentration.  PrP deposition was detectable at all tested concentrations of 1.25 µg 
ml-1, 0.80 µg ml-1, 0.60 µg ml-1, 0.50 µg ml-1, 0.25 µg ml-1, 0.10 µg ml-1 and 0.05 µg ml-
1 confirming the suitability of 6H4 on formic acid treated sections.  Experimental 79A 
infected BALB/cJFms-EGFP/- and BALB/cJ sections were then incubated with 6H4 at 0.50 
µg ml-1; the concentration found to be optimum for 6H4.  However only weak PrP 
staining was detected in the thalamus of all experimental sections (Figure 3-7 A-C).   
 
To improve 6H4 staining intensity the procedure was incorporated with the Dako CSA 
signal amplification kit.  Use of 6H4 with the Dako CSA kit on a small sample of 79A 
terminal BALB/cJFms-EGFP/- and BALB/cJ sections resulted in stronger staining than the 
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Figure 3-7:  Optimising 6H4 anti-PrP antibody for use with experimental sections. A: 6H4 alone at 0.5 µg 
ml-1 on 87V/VM positive control B: 6H4 alone at 0.5 µg ml-1 on terminal 79A/ BALB/cJFms-EGFP/-.  C: 
Negative control using 0.5 µg ml-1 mouse isotype control.  D: 6H4 at 0.5 µg ml-1 in combination with Dako 
CSA amplification on 87V/VM positive control.  E: 6H4 at 0.5 µg ml-1 in combination with Dako CSA 
amplification on terminal 79A/ BALB/cJFms-EGFP/-.  F: Negative control using 0.5 µg ml-1 mouse isotype 
control in combination with Dako CSA amplification.  In all instances sections from the same animal were 
utilised for comparison.  Deposition visualisation of PrP using 6H4 on experimental BALB/cJFms-EGFP/- 




BALB/cJFms-EGFP/- and BALB/cJ brain sections from mice challenged i.p. with 79A or 
ME7 were stained for PrP deposition using 6H4 at 0.5 µg ml-1 in combination with the 
Dako CSA amplification kit (Figure 3-8). Included in the same immunohistochemical 
assays were brain sections from BALB/cJFms-EGFP/- mice inoculated with normal brain 
homogenate.  These mice served as controls to confirm that the act of i.p. injection 
had no impact on mouse health or disease pathogenesis.  Background staining was 
minimal on all sections.  No PrP deposition was present on brain sections inoculated 
with normal brain homogenate although some non-specific staining, residing only on 
the surface of the section, was observed in the corpus callosum and the fimbria 
hippocampus; both white matter regions surrounding the hippocampus.   BALB/cJFms-
EGFP/- and BALB/cJ mice infected with 79A at terminal stage of disease demonstrated 
diffuse deposition of PrP as fine punctate particles throughout most of the brain.  
Accumulation of the misfolded protein was strongest in the thalamus extending back 
to the medulla and was indicative of successful 79A infection (Bruce, 1993, Cancellotti 
et al., 2010).  To a lesser extent, deposition in the hippocampus was found in all 
animals, while deposition in the cortex was found in some but not all animals.  
Despite cross reference with records of litter mates and gender no explanation for 
the latter observation was found.       
 
In the ME7 infection deposition of PrP at terminal stage of disease was found in the 
thalamus as a heavy accumulation of fine punctate plaques (Figure 3-9).  Larger 
plaque aggregates were found in the oriens and CA3 regions of the hippocampus.  
Similar to 79A, fine diffuse deposition was found extending back from the 





Figure 3-8: Staining for PrP deposition using 6H4 with Dako CSA signal amplification on terminal 
BALB/cJFms-EGFP/- mice challenged i.p. with 79A.    A:  Deposition of PrP in BALB/cJFms-EGFP/- mice is 
heaviest in the thalamus, cortex and to a lesser extent in the hippocampus.  Deposition can be traced 
from the thalamus back through B:  the midbrain, neo-cortex and finally C:  the medulla.  D:  400 x 
magnification reveals thalamic deposition to comprise of diffuse punctate aggregates.  E:  
79A/BALB/cJFms-EGFP/- IgG control.   The deposition pattern of 79A PrP in BALB/cJ mice F-I:  is as per 
BALB/cJFms-EGFP/- mice with the same regional targeting.  J:  79A/BALB/cJ IgG control.  K-N:  Included 
in the same assay were BALB/cJFms-EGFP/- inoculated with normal brain homogenate.  O:  
NBr/BALB/cJFms-EGFP/- IgG control   No pathology or deposition was observed in these mice.  All images 
representative. Scale bars equate to 500 µm except D, I and N where scale bars equate to 50 µm. 

















Figure 3-9: Staining for PrP deposition using 6H4 with Dako CSA signal amplification on terminal 
BALB/cJFms-EGFP/- mice challenged i.p. with ME7.  A:  Deposition of PrP in BALB/cJFms-EGFP/- mice is 
heaviest in thalamus and hippocampus.  Similar to 79A, deposition can be traced back through B:  the 
midbrain, neo-cortex and finally C:  the medulla.  D:   400x magnification of the C3 region of the 
hippocampus revealed formations of plaques amongst punctate aggregates.  E:  ME7/BALB/cJFms-EGFP/- 
IgG control.   The deposition pattern of ME7 PrP in BALB/cJ mice F-I:  is as per BALB/cJFms-EGFP/- 
mice with the same regional targeting.  J:    ME7/BALB/cJ IgG control.   No pathology or deposition 
was observed in these mice.  All images representative. Scale bars equate to 500 µm except D & I 













3.3.4 Terminal Stage Microglia Staining using AIF1 Antibody 
Microglia were stained with microglia specific anti-allograft inflammatory factor 1 
(AIF1) (Abcam, ab108539). Resting microglia stained with AIF1 display a ramified 
morphology with a small central body and long delicate processes.  Conversely 
activated microglia exhibit a large central body and shorter thicker processes (Streit, 
2002).  Microglia in BALB/cJFms-EGFP/- and BALB/cJ mice challenged i.p. with 79A and 
examined at the terminal stage of disease displayed activated morphology in areas 
containing PrP deposition including the thalamus, medulla and hippocampus (Figure 
3-10 A-B).  In addition to morphological activation microglia were typically spaced 
closer together at ~25 µm.  In areas without deposition microglia did not show 
morphological activation and were typically distributed at the normal resting spread 
in these mice of 50 – 100 µm apart.  No difference was observed in microglia 
activation or regional accumulation between BALB/cJFms-EGFP/- and BALB/cJ mice. 
 
BALB/cJFms-EGFP/- and BALB/cJ mice challenged with ME7 and taken to terminal stage 
of disease also displayed activated microglia in regions of PrP deposition.  In areas of 
larger plaque deposits dispersed amidst diffuse aggregates (Figure 3-10 C-D), 




Figure 3-10: Terminal stage microglia activation is associated with PrP deposition in terminal 
BALB/cJFms-EGFP/- and BALB/cJ mice.  A:  Terminal Stage 79A PrP deposition is found as diffuse 
aggregates in the thalamus within which B: activated microglia demonstrating enlarged central body 
and shortened processes accumulate.  C: Terminal stage ME7 PrP (6H4 staining) deposition is found as 
diffuse aggregates in the thalamus with larger plaques dispersed at ~ 100 µm in the hippocampus 
(dentate gyrus shown).  D:  Microglia (AIF1 staining) can be found tightly spaced at ~25 µm in areas 
of diffuse PrP deposition but do not appear to be cluster around the location of plaques.  All images 































Figure 3-11: Gender differences in mean incubation period and survival of grouped BALB/cJFms-EGFP/- 
and BALB/cJ challenged i.p. with either 79A or ME7.  A: Mice infected with 79A showed no 
significant difference in incubation period but mice infected with ME7 did demonstrate a small but 
significant difference between the genders (f-Test for variance then t-Test: Two-Sample Assuming 
Unequal Variances).  B:  This is reflected in the tight survival curves for both genders infected with 
79A. A small but significant difference was also noted between the survival curves between male and 
female mice infected with ME7 (statistical analysis performed using performed using the survdiff 





















Survival (days post injection)
79A/BALB/cJ ♀ 79A/BALB/cJ ♂
ME7/BALB/cJ ♀ ME7/BALB/cJ ♂
NS (P= 0.70)
* P = 0.047 
3.3.5 Influence of Gender on Disease Pathogenesis 
It was noted that there was no gender dependant difference on incubation period in 
animals infected by 79A, but a small but statistically significant difference was noted 
in mice infected with ME7. This was also reflected in a difference in survival spread 







3.3.6 EGFP Preservation in BALB/cJFms-EGFP/- mice 
To utilise the EGFP expression required that tissues taken were into 4% 
paraformaldehyde, thereby fixing the tissues prior to sucrose immersion, freezing in 
freezing media (OCT) and sectioning on a Cryostat.  Tissues from three culled 
BALB/cJFms-EGFP/- 79A terminal stage animals were taken though to cryostat sectioning 
at 6 µm.  Despite confirmation of the correct BALB/cJFms-EGFP/- genotype, EGFP 
fluorescence was extremely faint due to significant levels of overpowering 
background auto-fluorescence from blood related artefacts that could not be 
removed (Appendix 8-11).   
 
Further experiments were undertaken utilising uninfected healthy BALB/cJFms-EGFP/- in 
an effort to preserve EGFP to investigate two options available in fixing fresh tissues 
using paraformaldehyde; Perfusion with saline and post-fixation by soaking in 
paraformaldehyde or perfusion directly with paraformaldehyde following saline.    
Perfusion with saline in both cases removed all blood related artefacts.  The contrast 
between the vibrancy of EGFP expression between perfused-fixed and post-fixed was 
considerable (Figure 3-12) with finely branched microglial processes visualised 
following perfusion fixation. 
  
A B 
Figure 3-12:  Compiled Z-stack Confocal images (Zeiss LSM 5 Pascal) of 25 µm BALB/cJFms-EGFG/- 
brain sections from healthy mice (thalamus shown).  A: Perfusion-fixed microglia express vibrant EGFP 
with finely detailed ramified processes.  Cells are typically spaced 50 µm apart in an even distribution.  
B:  By contrast EGFP expression is much reduced in post-fixed samples and ramified processes are not 
as well defined.  All images representative.  Scale bars equate to 50 µm. 
133 
 
3.4 Results: Serial Investigation of BALB/cJFms-EGFP/- and BALB/cJ Mice Challenged 
with 79A or ME7 Prion Strains 
3.4.1 Time Course Microglia and PrP Deposition Staining  
The earliest accumulation of PrP deposition following 79A i.p. challenge was found in 
the medulla at 150 dpi or 65% of the total incubation period (Figure 3-13).  Microglia 
were seen accumulating in the medulla in the same region as protein deposition yet 
did not show a strong morphological appearance of activation.  In areas lacking PrP 
deposition, microglia demonstrated a normal ramified appearance and distribution.  
No evidence of microglia accumulation, activation or PrP deposition could be found 
within any of the ME7 injected brain sections taken from pre-clinical serial 
investigation time points of 35, 100 or 150 dpi. 
 
It was important to ensure injection of foreign material did not elicit a lasting cycle of 
inflammation that could lead to misinterpretation of microglial response (Betmouni 
and Perry, 1999).  This is particularly important as microglia are sufficiently sensitive 
to respond to peripheral stimuli (Nimmerjahn et al., 2005).  Animals culled at 35 dpi 
presented with no signs of pathology and scored clinically negative.  There was also 
no evidence of microglia activation at this time confirming that any perturbation, if 







Figure 3-13: Time Course of microglia activation in BALB/cJFms-EGFP/- and BALB/cJ mice challenged 
i.p. with 79A. A/B:  Earliest accumulation of PrP (6H4) is at 150 dpi in the Medulla.  Microglia can be 
seen C/D: as accumulating in the same areas of deposition.  E/F:  Normal Microglia in the thalamus and 
medulla respectively of mice challenged with normal brain demonstrate a ramified appearance and 









3.5.1 Suitability of BALB/cJFms-EGFP/- mice for use in Prion Disease Infection 
The use of EGFP expression by microglia allows for novel and detailed investigations 
into the role of these cells in protein mis-folding diseases.  BALB/cJFms-EGFP/- mice 
containing the fms-EGFP reporter gene and wild type BALB/cJ mice were challenged 
i.p. with 79A or ME7 mouse adapted Scrapie. The aim of this experiment was twofold; 
the first objective was to confirm that BALB/cJFms-EGFP/- are suitable for use as an in-
vivo model for prion disease and behave as per BALB/cJ mice.  The second aim was 
to address when and where microglia activations occurs in response to initial 
infection entering into the CNS environment. A peripheral route of infection was 
therefore adopted as it is the only route in which this is accurately encapsulated and 
it lacks the direct perturbation of the central nervous system that occurs with an 
intracerebral inoculation. 
 
Both BALB/cJFms-EGFP/- and BALB/cJ genotypes presented with specific regional 
targeting hallmarked by the accumulation of PrP deposition and vacuolation.  At 
terminal disease stage, and common to both prion 79A and ME7, the thalamus was 
the main target with extensive diffuse aggregates of PrP matching that seen in the 
literature for infection for these strains (Bruce et al., 1991, Cancellotti et al., 2010).  
Animals challenged with ME7 also presented with larger plaque deposits dispersed 
amongst diffuse deposits in the thalamus along with the dentate gyrus, CA3 and 
oriens layers of the hippocampus.  Deposition was also detected in the brain through 
to the medulla. 
 
The initial batch of mice chosen for the terminal group of 79A injections were aged 
116 days ± 1.2 SE at the point of inoculation.  All subsequent animals were therefore 
aged to match at inoculation to maintain consistency.  The impact of age beyond 600 
days on prion disease infection in mice is well documented with the requirement for 
clinical disease of a fully functioning lymphoid system (Brown et al., 1999b, Brown et 
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al., 2009).  Loss associated with normal aging of splenic margin zone, and associated 
Follicular Dendritic Cell mediated uptake and replication of infectious material also 
has a marked effect on whether the disease reaches clinical or remains sub-clinical 
without entering the CNS (Brown et al., 2011).  Disruption of the lymphoid system 
does not produce noticeable affects until > 400 days old at the point of injection.  
Consequently, and as all mice inoculated presented with clinical signs indicative of an 
advanced disease stage, it does not seem likely that the starting age of 116 day old 
BALB/cJFms-EGFP/- and BALB/cJ mice would have any impact on disease pathogenesis.  
Indeed past experiments documented in the divisional archives for BALB/cJ mice 
challenged i.p. with 0.02ml of 10-2 w/v 79A infected brain material (Appendix 8-12) 
revealed a starting age of ~ 100 days would not have a discernible impact on disease 
progression.  Limited information on starting age for i.p. infection of BALB/cJ with 
ME7 could be found however the data was considered sufficient based upon 79A 
alone.  It would therefore seem unlikely that this starting age would have an influence 
on the longer than expected incubation periods associated this batch of ME7.  The 
incubation period should have been approximately 250 days and not the yielded time 
of approximately 300 days.   
 
The only tentative explanation for the longer incubation period for i.p. ME7 infection 
of both BALB/cJFms-EGFP/- and BALB/cJ genotypes was attributed to the source material 
used to generate the infected inoculum.  This comprised C57Bl/6J mice infected, by 
an intracerebral route, with ME7 infected mouse brain which almost invariably yields 
an incubation period of 160 days.  The animals chosen to generate the source ME7 
material () succumbed at a slightly longer incubation period of 166 and 171 days.  
Factoring in the 5.3% difference in expected outcome once averaged may explain the 
20% difference in expected outcome for the longer than expected incubation period 
following i.p. infection of BALB/cJFms-EGFP/- and BALB/cJ mice; the difference between 
the two percentages a result of a lower starting titre and higher titre loss from the 
aforementioned increase in material dissemination following a peripheral route 




The similarities between lesion profiling, incubation period and deposition pattern of 
BALB/cJFms-EGFP/- and BALB/cJ mice following both 79A and ME7 infection suggests no 
discernible impact on disease susceptibility or pathogenesis in the presence of the 
Fms-EGFP transgene.  Knowledge of the targeted regions in the brain as part of a time 
course, combined with the lack of any noticeable difference between genders, 
strongly supported the continued use of the 79A prion strain for future 
experimentation with BALB/cJFms-EGFP/- mice.  The difference between the origins of 
79A and ME7 prevented any future predictions on the pathogenesis of ME7 to be 
drawn from the results of 79A infection.  Combined with the slight but statistically 
significant difference between genders, and a lack of successful characterisation of 
the earlier events surrounding ME7 disease pathogenesis, the continued use of ME7 
for further study in this project was severely limited.  The ME7 time course was not 
an informative experiment although the terminal stage results did contribute 
towards confirming the suitability of the BALB/cJFms-EGFP/- strain for use in further 
prion infection research. 
 
 
3.5.2 Use of EGFP Fluorescence 
Following the culling of three BALB/cJFms-EGFP/- mice terminally challenged with 79A it 
was realised that the procedural methods for visualising EGFP by cryostat sectioning 
were not compatible with analysis of prion disease related lesions.  Lesion scoring is 
an integral part of prion strain verification and necessary for confirmation of infection 
by a specific prion strain.  Sectioning on a cryostat introduced distortion of the tissue 
causing uncertainty in the origin of lesions.  The protocols were modified for all 
subsequent tissues to be taken into formal saline for embedment in paraffin wax 
after which no EGFP was detectable.  Later efforts with uninfected BALB/cJFms-EGFP/- 
mice overcame difficulties with preserving EGFP and would allow future experiments 
to be carefully designed to exploit this novel feature allowing for imaging software 
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quantification of microglia number and morphology to be performed on fluorescent 
images. 
 
3.5.3 79A Infection Time Course Analysis of Microglia Activation and PrP 
deposition 
The role of microglial interaction with mis-folded protein in prion disease has not 
been fully explored with only limited evidence for focal distribution of activated 
microglia with PrP deposition (Williams et al., 1994, Williams et al., 1997, Rezaie and 
Lantos, 2001).  Coinciding with initial observation of mis-folded protein in the medulla 
at 150 dpi in BALB/cJFms-EGFP/- and BALV/cJ mice challenged i.p. with 79A, this in-vivo 
model presents an accumulation of microglia in the same vicinity as PrP deposition.  
In areas lacking PrP deposition no accumulation or morphological change of microglia 
was observed. By the terminal stage of disease microglia are densely accumulated in 
areas of PrP deposition and present with an amoeboid morphology comprising 
enlarged central bodies with considerably shortened processes.   
 
The use of AIF1, a constitutively expressed microglia marker widely used to 
determine activation based on morphology alone, is limited by not reflecting the 
more subtle stages of initial microglia activation.  These data reveal a difference 
between the initial microglia recruitment response to prion invasion of the CNS and 
a more visible morphological activation once the disease has become widespread.  
This suggests a disparity between morphological activation and the changes, 
presumably protein translational in nature (Streit et al., 1989a), required to instigate 
recruitment of surrounding microglia.   To address this shortfall attempts were made 
to stain microglia with CD68 (Cambridge Bioscience, 137002) and I-A/I-E (Cambridge 
Bioscience 107602) markers of migration and phagocytic function respectfully.  A lack 
of time prevented optimisation of these assays and staining with CD68 and I-A/I-E 
was unsuccessful.  Also unsuccessful were assays to co-localise microglia and PrP 
deposition to investigate interaction using immunofluorescence.  With additional 
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time alternative antibody clones and antigen retrieval methods could have been 
explored.     
 
The previous chapter revealed a strong microglia and astrocyte response to infection 
regardless of prion strain.  This signal was impossible to separate between the two 
types of cells.  The observation of microglia accumulation at deposits of PrP without 
showing significant visible morphological activation would suggest that analysis of 
the microglia transcriptome alone following an i.p. 79A challenge would provide 
insight into the initial microglia response to prion disease.  To date this has not been 
performed on isolated microglia as part of a serial investigation and certainly not as 
part of a peripheral route capturing the early events of microglia response as 
infection enters their domain. 
 
3.5.4 ME7 Infection Time Course Analysis of Microglia Activation and PrP 
deposition 
The lack of accumulation of PrP deposition or microglial response in the pre-clinical 
time points of brains of ME7 infected mice is attributed to the longer than expected 
incubation period. It is likely that the selected time points were too early to document 
infection of the CNS.   Limited information could be found in the archives for 
peripheral inoculation of BALB/cJ mice with ME7 however data published by Outram 
(1976) revealed an expected incubation period of 261 days when using a peripheral 
route of infection (). The same serial investigation time points mice infected with 79A 
were therefore decided upon to encompass the same expected pathological events.  
Unforeseeable was the considerably longer incubation time of 310 and 317 days in 
BALB/cJFms-EGFP/- and BALB/cJ respectfully despite utilising the same inoculum 





These data demonstrate the suitability of the BALB/cJFms-EGFP/- mouse prion disease 
model with no significant differences between animals heterozygous for the Fms-
EGFP transgene and the wild type BALB/cJ background.  Of the two prion strains 
tested, the 79A prion strain was shown to have a more targeted pathology 
commending this strain for further use with BALB/cJFms-EGFP/- mice.  The ME7 
experiments would need repeating with later time points or alternatively an entirely 
new inoculum batch to document the early events of microglia activation.   
 
The peripheral route model described in this present study portrays the initial 
microglial response to coincide with first PrP detection, matching that of 
intracerebral inoculated 79A (Giese et al., 1998), but not other prion strains shown in 
the literature to significantly proceed or follow PrP accumulation (Williams et al., 
1994, Manuelidis et al., 1997, Williams et al., 1997, Baker et al., 1999).  The data 
presented here therefore suggests a disparity between initial recruitment and later 
morphological activation.  By utilising the novel BALB/cJFms-EGFP/- mouse line, and 
information gained on the targeted regions in which microglia respond, further 
experiments would utilise EGFP expressing microglia by fluorescence microscopy or 
ex-vivo analysis and image quantification to fully document the specific timing the 






4 Serial Investigation of Microglia Response to Developing Prion Disease  
4.1 Introduction 
The aim of this chapter is to assess the response of microglia to developing prion 
infection by utilising the EGFP expression in BALB/cJFms-EGFP/- mice.  Microglia 
expressing EGFP facilitated the quantification of the multi-stage transition made by 
microglia from a resting state to a state of full morphological activation.  The time 
course in chapter 3 used infection of BALB/cJFms-EGFP/- mice with the 79A prion stain 
and showed how PrP deposition first occurred within the medulla.  Chapter 2, 
describing a re-analysis of microarray first published by Hwang et al. (2009), revealed 
a strong signal of myeloid activation and cellular stress that steadily increased in 
strength as prion disease progressed.  It is hypothesised that microglia first 
accumulate at sites of replication before demonstrating a significant and recognisable 
activation morphology.  
 
The BALB/cJFms-EGFP/- mice strain was shown to behave as per the BALB/cJ wild type 
previously in Chapter 3. The strain is eminently suitable for further study using the 
79A prion disease strain.  Briefly, paraffin wax embedded brain sections from 
BALB/cJFms-EGFP/- and BALB/cJ mice challenged i.p. with 79A and stained with AIF-1 
(Abcam) revealed microglia respond in sites of PrP deposition.  The initial reaction 
was shown as an accumulation of microglia in the medulla at 150 dpi followed by a 
marked morphological activation in the thalamus at terminal disease.  The necessity 
in those experiments of using paraffin wax sections to ascertain the clinical and 
pathological features of BALB/cJFms-EGFP/- mice in response to prion infection inhibited 
the full exploitation of the novel Fms-EGFP transgene marker.  By taking mice at serial 
points post 79A infection from BALB/cJFms-EGFP/- and harvesting brain tissue with a 
method fully compatible with visualisation of EGFP, this chapter describes the use of 





In BALB/cJFms-EGFP/- mice, microglia activation appeared to coincide with initial 
deposition of PrP, raising the importance, if a correct interpretation of the initial 
cause of activation is to be determined, of ensuring activation coincides with initial 
entry of infection into the brain.  A peripheral route of infection is the only route in 
which this is accurately encapsulated (Millson et al., 1979) and was again adopted to 
ensure microglia can be determined as responding to infection travelling from the 
periphery into the brain.  
 
Previous experiments in this study had the last time point taken at 65% of the 
incubation period (150 dpi).  The experiments did not therefore document the spread 
of pre-clinical infection from the medulla to other areas of the brain between this 
time point and terminal disease.  Onset of clinical signs was found to be at ~ 200 days 
thereby including an additional cull point at this time should document this critical 
stage of disease.  The onset of clinical disease has been shown to coincide with a 
significant reduction in synaptic density and behavour changes (Cunningham et al., 
2003).  Focus was made on specific regions; the medulla as the predicted ingress 
point, the thalamus as a region specifically targeted by replication of PrP once 
infection spread forwards into the brain.  Finally the hippocampus and cerebellum 
were chosen as regions demonstrating  less concentrated PrP depostion. 
 
binding of an antibody specific to microglia or the mutagenic incorporation of a 
fluorescent marker continue to be the standard methods employed in 
immunohistochemistry or immunofluorescence assays to visualise microglial 
morphology.  The transgenic incorporation of markers are favourable as the method 
effectively removes any concern over incomplete ligation of antibody conjugated 
markers (Sasmono et al., 2007).   Microglial activation is described as a marked 
increase in diameter of the central body and a distinct reduction in the length and 
number of processes with engorgement of those remaining (McGeer et al., 1993).  
Full activation reveals a cell countenance almost circular in appearance and, 




Determination of visual microglia activation is typically accomplished by incarnating 
morphological activation as a scoring system based on appearance (Lemstra et al., 
2007), percentage of activated cells per defined area (Kauppinen et al., 2008) or 
quantifying intensity of  bound antibody (Gallaher et al., 2012).  Analysis of digital 
images using imaging software to quantify specific cellular features has been shown, 
by direct comparison with methods requiring user interpretation, to give results with 
less variability between sample populations (Donnelly et al., 2009, Yamada and Jinno, 
2013).  This study utilised software mediated quantification of microglia number and 






4.2.1 Experimental Design  
Groups of BALB/cJFms-EGFP/- mice were challenged by an intraperitoneal (i.p.) injection 
with 0.02 ml of 10-2 w/v 79A or Normal brain homogenate (NBr) and culled with serial 
investigative time points of 35, 100, 150, 200 dpi and terminal stage disease (Table 
4-1).  The infected material used to produce the new 79A inoculum was sourced from 
the same batch of animals as previous experiments. The initial age of animals at 
challenge was 113 days ± 1.4 SE to ensure that disease progression would be 
comparable to previous chapters.   
 
Table 4-1: Mice used for BALB/cJFms-EGFP/- microglia quantification study challenged i.p. with 79A 
mouse-adapted Scrapie prion strain.  Control mice were inoculated with normal brain (NBr) 
homogenate.  All mice were culled by saline perfusion followed immediately by 4% paraformaldehyde 
perfusion.  * Used for pathological analysis of strain verification only. † Used to confirm resolution of 


















Age at Infection 
(Days ± SE) 
Inoculum Route 
Terminal  8 * BALB/cJFms-EGFP/- 124 ± 6.0 79A i.p. 
200 
4 BALB/cJFms-EGFP/- 115 ± 1.1 79A i.p. 
4 BALB/cJFms-EGFP/- 116 ± 4.4 NBr i.p. 
150 
4 BALB/cJFms-EGFP/- 98 ± 5.0 79A i.p. 
4 BALB/cJFms-EGFP/- 123 ± 6.9 NBr i.p. 
100 
4 BALB/cJFms-EGFP/- 106 ± 4.6 79A i.p. 
4 BALB/cJFms-EGFP/- 100 ± 2.0 NBr i.p. 
35 
4 † BALB/cJFms-EGFP/- 138 ± 2.7 79A i.p. 
4 † BALB/cJFms-EGFP/- 134 ± 2.6 NBr i.p. 
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4.2.2 Tissue collection 
Mice were anaesthetised using isoflurane (Merial Animal Health Ltd, Vm08327/4131) 
with additional oxygen to maintain a steady condition of anaesthesia.  Mice were 
culled by cardiac puncture perfusion using a Watson Marlow 205U multichannel 
cartridge pump supplying 20 ml ice cold diethylpyrocarbonate (DEPC) treated Hank’s 
Balanced Salts Solution (HBSS) through a 26G x 0.45 mm microlance (BD 300300).  
The flow rate was held constant at 5.0 ml min-1 before switching to 20 ml 4% 
paraformaldehyde at pH 7.4 on ice.  Brains were removed and placed in 4% 
paraformaldehyde at 4°C for 24 hours.  Those removed from animals culled at 35, 
100, 150 and 200 dpi were then rinsed in HBSS and incubated for a further 24 hours 
in 20% Sucrose solution at 4°C.  Sucrose penetration was confirmed by a lack of 
buoyancy whereupon tissues were rinsed in HBSS, snap frozen in isopentane 
precooled at –40°C, wrapped in foil and then stored at –20°C in an absence of light. 
 
4.2.3 Tissue Sectioning 
Thicker sections were required for Z-section confocal microscopy.  Frozen brain tissue 
was therefore sectioned at 25 µm on a freezing block microtome and taken into 
ethylene glycol/glycerol based cryoprotectant solution in 12 well plates in sequence.  
Each well then contained sequential sections, distanced apart by 300 µm.  The plates 
were stored at –20°C in an absence of light.  When required, sections were floated 
onto glycerol treated microscope slides using HBSS.  Sections were air dried at room 
temperature in an absence of light for 24 hours before overlaid with coverslips 
adhered with hard-set mounting medium (Vector Laboratories, H1400).  Brain tissue 
taken from animals culled at terminal stage were processed directly from 4% 
paraformaldehyde and sectioned as per the standard method first developed by 
Fraser and Dickinson (1967), and outlined in SOP-PSG-008 used by the Pathology 
Department at The Roslin Institute, prior to embedding in paraffin wax.  Sections 





BALB/cJFms-EGFP/- sections were imaged using a Zeiss LSM-5 Confocal module attached 
to a Zeiss Axioskop 2 FS-MOT upright microscope operating LSM Pascal image capture 
software (AIM).  EGFP excitation was initiated with an argon 488 nm laser with 
emission capture though a secondary dichroic beam splitter NFT 545 diverting all light 
below 545 nm to a single channel operating a BP505-600 nm band pass filter plate. 
 
Images for cell number quantification were captured as a 50 optical slice (each 1 airy 
unit) Z-stack at x10 magnification (Zeiss Plan-Neofluar x10 / 0.30 objective) and 
compiled into a single composite image using ImageJ software 1.48a (Schneider et 
al., 2012).  Images were converted to a threshold-adjusted binary 8 bit image and 
quantification of EGFP expressing microglia cell number was performed using particle 
analysis within ImageJ. 
 
From a series of 9 coronal sections, spaced 300 µm apart and encompassing the 
thalamus and medulla, 3 sections were chosen at random.  Within each chosen 
section, 3 images for morphological quantification were captured as a 20 optical slice 
(each 1 airy unit) Z-stack taken at x40 magnification (Zeiss Plan-Neofluar x40 / 1.30 
objective) in combination with immersion oil (Immersol, Zeiss 518F).  Additional 
images were recorded on adjacent sections if the total number of EGFP expressing 
microglia was below 50 cells.   
 
Microglia total radius, measured from the longest visible projection, was measured 
directly within ImageJ on AIM software scaled Z-stack compilations.  Euclidean 
distance mapping was performed on an 8-bit processed binary image to generate a 
32-bit distance map.  Using the region of interest function within ImageJ a histogram 
was compiled for each individual cell showing the shortest measured distances, 
recorded as a grey value, between a foreground pixel and the nearest background 
(zero value) pixel (Leymarie and Levine, 1992).  The lower the mean grey bin value, 
the lower the number of longer recorded distances. This was interpreted as a finer 
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structured cell indicative of a more ramified morphology.  By virtue of the 
methodology adopted, cell number was also attained. 
 
4.2.5 Statistics 
Comparison between two populations was performed using a two- tailed t-Test 
assuming a variance depending upon the outcome of an f-Test for variance.  Such a 
system is optimised for a smaller number of populations in utilising a wider 
distribution curve to ensure a higher value is required for the t-critical to become 
significant.  The f-test ensured that variance was correctly identified as equal or un-






4.3.1 Clinical Signs and Incubation Period 
Infected mice were scored every 7 days for clinical signs from 150 dpi.  Prion disease 
signs recorded included lethargy, hair unkempt, hair loss and hunching.  Problems 
with gait or wet genitalia were very rarely seen and only 1 mouse was culled with 
these.  The onset of clinical signs was determined, as an average, to be 198.5 ± 1.0 
days SE (Figure 4-1A).  Mice were culled at terminal disease stage following an 
incubation period of 229.4 ± 3.6 days SE with a tight survival spread (Figure 4-1B).    
All BALB/cJFms-EGFP/- mice challenged with 79A and culled at 35, 100, and 150 dpi did 
not present with clinical signs.  Mice culled at 200 dpi were starting to show clinical 
signs.  BALB/cJFms-EGFP/- inoculated with normal brain homogenate showed no signs of 
clinical disease or ill health in general. 
 
Lesion scoring was performed using the method first described by Bruce et al. (1991) 
on paraffin wax embedded brain sections taken from mice showing confirmed clinical 
disease .  These produced lesion profiles very similar to 79A peripheral challenges of 
BALB/cJFms-EGFP/- and BALB/cJ previously covered in chapter 3 (Figure 4-1C).  
Deposition of PrP, stained for with the 6H4 antibody (Prionics, Switzerland), revealed 
widespread and strong punctate aggregation in the thalamus with less, but still 























































Figure 4-1: Strain typing confirmed the BALB/cJFms-EGFP/- mice were successfully infected i.p. with 79A.  
A-B: The onset of clinical signs, the interval at which terminal stage is achieved and the spread of terminal 
acquisition are very similar to previous experiments. C:  Deposition of PrP at terminal (stained with 6H4) 
presents with previously documented targeting by fine punctate aggregates.  D: Lesion profile scoring is 
very similar to that found in BALB/cJ mice challenged i.p. with 79A documented in previous chapters. The 




































Successful infection was confirmed with attainment of near identical disease 
incubation period, onset of clinical signs, terminal lesion profile and PrP deposition 
to that seen in chapter 3 and previously published data (Bruce, 1993, Cancellotti et 
al., 2010).  The final pattern of PrP deposition was identical to that observed with an 
intracerebral route (Giese et al., 1998, Cancellotti et al., 2010) indicative of 
achievement of the same final pathology, regardless of route, once infection has 
infiltrated the CNS (Kimberlin and Walker, 1978).  A lack of time prevented optimising 
the immunohistochemical staining of pre-clinical PrP on the paraformaldehyde 
perfusion-fixed sections.   
 
4.3.2 Time Course Investigation 
Sections were analysed on a confocal miroscope.  Microglia, observable by EGFP 
expression on paraformaldehyde perfuse-fixed sections, were vibrant and clearly 
observable in all infected and uninfected BALB/cJFms-EGFP/- mice.  Microglial processes 
expressed EGFP and permitted highly detailed and accurate analysis.  
Paraformaldehyde is known to excite at 488 nm on a long-pass filter if present in 
sufficient quantity to allow for an unacceptable quantity of formaldehyde to form. 
Formaldehyde is able to bind to amines within the sample including amine-containing 
endogenous flavins inciting auto fluorescence across a wide spectrum (Andersson et 
al., 1998, Billinton and Knight, 2001).  Some sections obtained from this experiment 
contained fine punctate deposits of autofluorescence indicative of flavins when 
exited at 488 nm.  Compilations from multiple Z stack images neutralised this affect 
and prevented incorporation into the data. 
 
4.3.2.1 EGFP Visualisation by Confocal Microscopy 
At 35 and 100 dpi microglia in the medulla presented with a resting ramified 
phenotype with long thin processes extending into the brain parenchyma.  The cells 
were evenly distribution with a typical separation of 50 – 100 µm and with processes 
of up to 75 µm in length.  At these early time points there was no difference between 
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infected and uninfected animals.  By 150 dpi, 65% of the total incubation period, 
microglia in the medulla of prion infected mice were spaced closer at ~ 25 µm apart; 
the result of a higher concentration of microglia than that of the resting state seen in 
the parallel normal brain inoculated control mice (Figure 4-2). The number of 
microglia was maintained at 200 dpi in the medulla.  It was at this later time point 
that microglia in all infected mice demonstrated both shortened processes and a 
considerably enlarged central body indicative of reactive microglia.  By contrast the 
microglia in uninfected animals at the same time point remained ramified in 
appearance with no change in cell number. 
 
Microglia in the thalamus at 100 and 150 dpi had a ramified appearance in both 
infected and uninfected animals with no apparent difference between the two 
groups.  As per the medulla the cells were evenly distributed at these pre-clinical time 
points.  At 200 dpi a considerable increase in cell number was observed in all infected 
animals (Figure 4-3). Such a concentration meant a degree of contact or overlap was 
evident between the processes of neighbouring cells.  A grossly enlarged central body 
with short and thickened processes were evident on the vast majority of cells within 
this region.  The microglia in uninfected control animals at 200 dpi continued to 
present with a ramified appearance as per pre-clinical and uninfected animals. 
 
Within the dentate gyrus (Figure 4-4) and cerebellum EGFP expressing microglia were 
typically observed as spaced 50 to 100 µm apart up to and including 200 dpi.  The 
appearance of microglia in these regions remained ramified at all tested time points 
and there was no notable difference between infected and uninfected mice.    
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Figure 4-2: EGFP expressing microglia in the medulla of BALB/cJFms-EGFP/- mice following i.p. 
challenge with 79A at 100, 150 and 200 dpi.  EGFP expressing microglia were seen to first increase in 
number in the medulla at 150 dpi.  The accumulation of microglia separated at 25 µm was maintained 
through to 200 dpi.  Before 150 dpi, and in NBr inoculated mice, microglia were seen to adopt a normal 




Figure 4-3: EGFP expressing microglia in the thalamus of BALB/cJFms-EGFP/- mice following i.p. 
challenge with 79A at 100, 150 and 200 dpi.  No difference in the number of EGFP expressing cells was 
observed in the thalamus until 200 dpi when a concentration of reactive microglia spaced less than 25 
µm was observed.  Before 200 dpi, and in the NBr inoculated mice, microglia were observed as spaced 
at 50 - 100 µm and adopt a normal ramified morphology.  Scale bars equate to 200 µm. Inset scale bars 











Figure 4-4: EGFP expressing microglia in the dentate gyrus region of the hippocampus of BALB/cJFms-
EGFP/- mice following i.p. challenge with 79A at 100, 150 and 200 dpi.  During normal resting state, 
observable in the NBr inoculated animals, microglia in the hippocampus are regularly spaced at 50 µm.  
This same resting state distribution was observed in the 79A challenged animals at all intervals indicating 









































4.3.2.2 Quantification of EGFP expressing Microglia 
Particle analysis, on threshold adjusted binary images of low magnification images 
encapsulating an entire brain region, was performed to capture all EGFP expressing 
cells.  A statistically significant increase of ~ 50% in microglia cell number in the 
medulla was confirmed at 150 dpi (Figure 4-5) matching the onset of first observed 
PrP deposition (Chapter 3).  This accumulation of microglia was retained as disease 
developed.  At 200 dpi a statistically significant increase in microglia number in the 


























Figure 4-5: Broad area quantification of regional microglia cell number in BALB/cJFms-EGFP/- mice. 
Following i.p. challenge with 79A at 100, 150 and 200 dpi.  EGFP expressing cells were counting using 
ImageJ particle analysis function on x10 magnification 25µm Z-stack compiled images each comprising 
50 optical slices.  The thalamus and medulla are shown previously to be areas heavily targeted by PrP 
deposition.  The dentate gyrus and the cerebellum are areas with less concentrated PrP deposition.  
Microglial density increases in the medulla by ~ 50% at 150 dpi whereupon numbers remain constant 
in this region as PrP deposition spreads anteriorly.   By 200 dpi microglia density in the thalamus had 




Quantification of EGFP expressing microglia radius and process complexity was 
performed on Z-stack compiled images.  Microglia in the thalamus at 200 dpi 
presented with a reduction in process length and an engorged central body 
consistent with morphological activation (Figure 4-6A). Complexity of protrusion 
branching and central body area was encapsulated by 32-bit Euclidean distance 
mapping on threshold adjusted 8-bit binary images.  Microglia increased by a mean 
Euclidean distance of ~ 1 µm (Figure 4-6B).  Such a change indicated a considerable 
mean increase in Euclidean distance required to travel from any given pixel in the cell 
to the next nearest white, or non-data pixel and reflects the larger and less complex 
area the cell occupies.  The number of cells per 0.05 mm² doubled to ~ 14 cells (Figure 
4-6C).  By contrast microglia in the thalamus prior to 200 dpi in both infected and 
infected mice were fewer in number and shared a mean Euclidean of 2 µm reflecting 
a more complex ramified morphology comprising long fine processes and a small 
central body area. 
 
The radius and mean Euclidean distance of microglia in the medulla of infected mice 
remain unchanged at 100 dpi (Figure 4-7) with no difference observable when 
compared to control mice.  By contrast, at 200 dpi, microglia in the medulla presented 
with all the hallmarks of morphological activation as evidenced by the reduction in 
radius from an average of 30 µm down to 20 µm.  The reduction in radius was 
matched by an increase in Euclidean distance by 1 µm similar to that seen in the 
microglia in the thalamus, and indicative of shorter thicker processes and a larger 
central body.    
 
A difference was noticed in the mean Euclidean distance of microglia in the thalamus 
between normal brain inoculated animals and that of 79A infected mice at 100 and 
150 dpi and prior to any detectable pathology (Figure 4-6C).  No statistical difference 
was detected between any possible combinations of normal brain groups (Appendix 
8-13). 
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Figure 4-6: Software determined quantification of EGFP expressing microglia in the thalamus and 
medulla of BALB/cJFms-EGFP/- mice challenged i.p. with 79A or NBr at 100, 150 and 200 dpi.  A-B: At 
200 dpi, microglia present with an engorged central body and shortened processes conferring a 
significant reduction in radius.  Euclidean distance mapping affords a highly sensitive quantification of 
cell complexity encompassing both cell body size and process branching.  The reduction in cell radius 
at 200 dpi is reflected in a mean Euclidean distance increase of 1 µm.  Distance mapping also detailed 
a slightly less complex cell type in the NBr animals.  C:  Microglia density in the thalamus at 200 dpi 
has increased by ~ 100%.  † Comprises mean for all NBr inoculated BALB/cJFms-EGFP/- mice at all serial 
investigation time points.  ‡ Mean statistical value. NS = Not Significant 
Figure 4-7: Medullic microglia react in much the same way as the Thalamus at 200 dpi.  Statistical 
significance determined using T-test assuming variances determined by F-test.  † Comprises mean for 
all NBr inoculated BALB/cJFms-EGFP/- mice at all serial investigation time intervals.  ‡ Mean statistical 
value. NS = Not Significant 




The injection by an intraperitoneal route of 0.02 ml of 10-2 w/v 79A infected mouse 
brain in the BALB/cJFms-EGFP/- mouse model was shown in chapter 3, and now in this 
chapter, to induce a robust prion disease with a predictable incubation period and 
clearly defined stages of progression.  Described in chapter 3 was the use of anti-PrP 
antibody staining to reveal strong deposition of diffuse punctate PrP aggregates.  
These were first observable as small patches in the medulla at 65% of the incubation 
period.  Deposition could then be traced forwards through the midbrain before 
heavily targeting the thalamus with the onset of clinical signs at 90% of the total 
incubation period measured from the point of injection until cull.   
 
The spread of diffuse PrP deposition within a 79A infection is a gradual increase in 
the intensity of deposition throughout the brain as the disease progresses (Giese et 
al., 1998).  The experiments in this study also portray a gradual spread from the site 
of entry at the rear of the brain, presumably induced by the choice of route and 
transmission along the spinal cord and CNS nerve fibres (Kimberlin et al., 1983).  This 
is matched by the widespread but nominal presence of vacuolation when mice were 
scored at terminal disease. Vacuolation supports the targeting of pathology to the 
areas of strongest deposition at terminal with the highest scores present in the 
thalamus then targeting traced back through to the midbrain following scoring of the 
septum nuclei. 
Using the microglia-specific marker anti-AIF1 it was noticed that the first reaction by 
microglia in the medulla was an accumulation of cells in same areas of punctate PrP 
deposition at 65% of the incubation period.  No further serial time points were taken 
between this point and 200 dpi by which time microglia had adopted an activated 
morphological appearance with short stubby processes and a grossly enlarged central 
body.  These data suggested that microglia appeared to first react with an increase in 
numbers at the targeted sites of PrP deposition and changed morphology as a 
secondary response.  Although microglial morphological response to induced 
parenchyma injury can be sudden in the healthy brain (Nimmerjahn et al., 2005), 
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studies suggest that the translational response is more a more gradual affair  (Streit 
et al., 1989a).  Furthermore  misinterpretation of microglial contribution can ensue 
as the initial response, morphological changes, voltage potentials and production of 
immune related receptors are not necessarily linked (Yamada and Jinno, 2013) raising 
the importance of a detailed and full quantitative analysis of the microglia 
morphological response to infection when investigating the role these cells play in 
the disease.  Described in Chapter 3 was the appearance of PrP deposition in the 
dentate gyrus and cerebellum.  The results in this chapter would suggest that 
microglia are not responding to the deposition of misfolded protein.  It could be 
conluded therefore that either a threshold level of deposition is required before 
microglia react, or alternatively microglia are responding to a different purtubation 
in their enviroment. To experimentally test this would require additional time points 
to record the gradual increase of deposition in an area that demonstrates a high load 
of misfold protein.  Using the 79A and BALB/cJ model the thalamus would be the ideal 
region to futher invesigate the relationship between the accumulation of misfolded 
protein and the early stages of microglial activation between the 150 and 200 dpi 
time points taken in this present analysis. 
 
Quantification of images to determine microglia morphology inherently requires the 
assumption that the entire cell including all fine protrusions has been captured at the 
point of exposure.  The use of antibody conjugated markers in immune-assays are 
reliant on antibody penetration of the tissue and successful binding throughout the 
cell.  An alternative is the use of a constitutively expressed fluorescence markers in 
which the signal is known to be uniform throughout the cell.  Providing the tissues 
are harvested and processed correctly the use of a transgenic marker effectively 
removes all concerns regarding incomplete capture of cell features.   The BALB/cJFms-
EGFP/- mouse model has strong constitutive EGFP expression within all cells of myeloid 
origin (Sasmono et al., 2003) and made the strain eminently suitable for quantifying 




Euclidean distance mapping affords a highly sensitive determination of distance 
change (Schneider et al., 2012) and was applied to images of EGFP expressing cells to 
quantify cell complexity.  By the onset of clinical disease, microglia demonstrated a 
clear change towards a less complex Euclidean distance; the result of a more 
amoeboid morphology.  The main areas of microglia activation and accumulation 
were restricted to the medulla and thalamus indicating the microglia response was 
strongest in regions known to be targeted by PrP deposition.   
 
Interestingly the sensitivity of Euclidean distance mapping was sufficiently high to 
detect a small but statistically significant difference, within the thalamus, between 
the mean Euclidian distance of the control microglia and infected animals in the 
absence of any detectable pathology.  The data acquired in this experiment was not 
sufficient to explain the difference but does serve to highlight the importance of 
always ensuring differences between controls and tested populations are made on a 
two-tailed assumption. 
 
A lack of time prevented full morphological quantification of medullic microglia at the 
initial site of response.  The x40 quantification of the thalamus supported the increase 
in cell number determined from the x10 magnification regional cell count.  
Consequently it was reasonable to assume that x10 quantification of the medulla was 
sufficient alone as confirmation that, from 150 dpi, microglia accumulated in this 
region without the need to count cells at a higher magnification.   In addition the self-
explanatory images for EGFP expression in the medulla provide clear visual evidence.   
 
All cells of myeloid origin express EGFP in BALB/cJFms-EGFP/- mice.  Consequently it is 
not possible to distinguish between the resident microglia population and the 
possible influx of monocytes.  There is strong evidence by multiple groups that reveal 
the negligible degree of monocyte influx into the brain during neural inflammation 
(Ajami et al., 2007, Mildner et al., 2007) with evidence for the requirement of non-
physiological disruption to the blood brain barrier for any influx to occur (Mildner et 
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al., 2007).  The resident microglia pool is reported to be highly self-sufficient and 
microglia are rapidly produced when additional or replacement cells are required 
(Ajami et al., 2007, Ajami et al., 2011, Varvel et al., 2012).  There is also some recent 
evidence to suggest a resident AIF1-ve and nestin+ve microglia progenitor resides in 
the CNS and can differentiate rapidly into new microglia within a matter of days (Kim 
et al., 2014).   
 
Microglia have been observed as activated prior to any detectable PrP deposition yet 
in a transmissibly infectious environment (Betmouni et al., 1996, Manuelidis et al., 
1997) implementing microglia as either responding to PrP below the threshold of 
detection, an additional trigger or actively involved as a causative agent.  Other 
studies report the accumulation of PrP deposition as the initiation of microglia 
response (Williams et al., 1994, Williams et al., 1997).  There are no detectable clinical 
signs associated with this early immune response with initial detection of 
abnormalities in behaviour coinciding with neuronal synaptic stripping (Cunningham 
et al., 2003, Siskova et al., 2013).   Microglia appear not to be implemented in 
stripping during prion disease (Siskova et al., 2009), despite conflicting observations 
of active stripping by microglia as an important component of normal homeostasis 
(Schafer et al., 2012, Ji et al., 2013), in response to injury (Wake et al., 2009) and in 
other neurodegenerative diseases (Trapp et al., 2007, Kettenmann et al., 2013).  
Although readily apparent when these sections were viewed using a confocal 
microscope, the lack of cell radius and Euclidean distance quantification mean that 
these data are not sufficient to state categorically if the morphological response is 
indeed secondary to the apparent increase in cell number.  The data in this 
experiment therefore suggests, but cannot state for certain, that there is a separation 
of microglia activation into two components; accumulation at the site of perturbation 
as the first and initial response, and the morphological activation as the second. 
 
The next chapter will further investigate the microglial response to developing 
pathology by analysing the transcriptome of microglia isolated from BALB/cJFms-EGFP/- 
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mice infected with 79A at the same time points as the preceding chapters.  The aim 
was to determine the function of the morphologically activated cells at stages of 
disease when misfolded protein was both still minimal and, later on in the process, 
much more evident.  Crucially, by isolating microglia their specific contribution could 
be determined in the absence of immunomodulators released by the other cell types 
found in the brain; in particular astrocytes, which were shown in Chapter 2 to respond 




5 The Microglia Transcriptome during Prion Disease Progression 
5.1 Introduction 
In chapter 3 and 4 it was shown than microglia responded to prion disease infection 
in the medulla by accumulating in areas of initial PrP deposition and did so with 
minimal change in overall morphology.  Towards the latter stages of the disease, 
EGFP expressing microglia presented with a phenotype consistent with an activated 
inflammatory phenotype.  Processes were shortened, the central soma was engorged 
and activated cells were widespread throughout the brain.  This data suggested a 
disparity between initial response and morphological activation.  In the healthy brain 
microglia comprise only 10% of the cells in the adult mouse brain, yet chapter 2 
revealed the dominate source of differential gene expression in mouse-adapted prion 
disease to be microglial in origin.    This is supported in the literature where an 
immunological signal has been observed as part of prion disease expression anyslsis 
(Brown et al., 2003, Booth et al., 2004, Riemer et al., 2004, Xiang et al., 2004, Brown 
et al., 2005, Skinner et al., 2006, Xiang et al., 2007, Moody et al., 2009), implicating 
microglia as an important cell in the neurodegenerative process.   
 
The inflammatory phenotype typically associated with prion disease has been shown 
to be remarkably anti-inflammatory (Walsh et al., 2001, Baker and Manuelidis, 2003).  
Transforming growth factor, TGF-β1, a down regulator of cytokine release has been 
shown to be the dominant, differentially expressed anti-inflammatory cytokine 
present in murine prion disease models (Cunningham et al., 2002).  Via the TGF-β1 
signalling pathway, the cytokine plays a key role in limiting microglia activation (Lodge 
and Sriram, 1996) and is evident throughout the disease process (Boche et al., 2006, 
Abutbul et al., 2012).  The growth factor also provides microglia with a phenotype 
akin to the resolution of apoptotic cells and wound healing (Fadok et al., 1998).  Little 
is known on the impact of such a phenotype in neurodegenerative diseases with 
considerable debate on the neurotoxic or neuroprotective function of microglia.   
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The evidence for the negative impact of inflammatory cytokines on 
neurodegenerative diseases is aimed at testing what has been termed the 
inflammatory (or cytokine) hypothesis (Cerejeira et al., 2010).  Central to the 
hypothesis is the enzyme indoleamine 2, 3 dioxygenase, the rate-limiting enzyme in 
the kynurenine pathway that converts the essential amino acid tryptophan to 
kynurenine (Rafice et al., 2009).  The downstream production by the kynurenine 
pathway of neurotoxin quinolinic acid (QUIN), a potent neurotoxic N-methyl-D-
aspartate receptor agonist, is most relevant to neurodegenerative diseases (Stone 
and Perkins, 1981, Stone, 2001, Fernandes et al., 2008).  The pathway is initiated by 
inflammatory cytokines including TNF-α, INF-γ (O'Connor et al., 2009), which in turn 
mediate NF-κB translocated activation of the kynurenine pathway (Robinson et al., 
2006).   Microglia contain the complete pathway and express neurotoxic QUIN (Heyes 
et al., 1996, Espey et al., 1997, Guillemin et al., 2005) and as such have been 
implemented as the main effector for the inflammatory hypothesis in 
neurodegenerative diseases (Henry et al., 2009, Yamada et al., 2009).   
 
The activation signature of macrophages, and indeed microglia, has traditionally be 
classed into M1 (Classical) or M2 (alternative).  A resting (M0) macrophage in the 
presence of certain epitopes able to bind to membrane bound pattern recognition 
receptors is activated as part of a stereotypic signalling cascade mediated by 
transcription factor nuclear factor kappa B (NFkB) (Pahl, 1999, Boldrick et al., 2002).  
This leads to increased expression and extracellular release of pro-inflammatory 
cytokines TNF-a, IL-1 and IL-6 in addition to proteases, superoxide anions, nitric oxide 
and reactive oxygen-nitrogen species including N2O3, NO2 and an overall 
transmembrane epitope profile considered as an M1 phenotype. (reviewed in 
Martinez et al., 2008).  Other resident macrophages within the vicinity, and LY6CHi 
monocytes chemotactically attracted into the site of insult, are in turn also activated 
leading to the macrophage population at the site of inflammation to be dominated 




A balance has to be struck in the triggering of inflammation; too little a response and 
the risk is further injury, too much and the ensuing damage caused by inflammation 
can result in consequences worse than the original infection; extracellular proteases 
and free radicals are highly damaging to surrounding tissue (Wells et al., 2005).  It is 
important therefore for resolution of inflammation to take place to prevent further 
damage and begin the healing process.  The macrophage is a principle component in 
maintaining this balance.  This is particularly the case in the periphery where the 
dominant cell found at a site of innate inflammation is the polymorphonuclear 
neutrophil.  Neutrophils express generous quantities of superoxide creating a highly 
oxidizing environment, which combined with a short half-life and mass apoptosis 
leads to the rapid buildup of potentially toxic cellular matter that must be recognised 
and removed by macrophages (Savill et al., 1989, Babior et al., 2002).  These 
macrophages are in turn are stimulated to express TGF-b1 inducing a change from a 
pro-inflammatory toward an alternatively activated or anti-inflammatory wound-
healing phenotype (Fadok et al., 1998, Huynh et al., 2002, Kim et al., 2004).   
 
The alternatively activated or M2 macrophage is a blanket term collectively used to 
class macrophages that are involved in the resolution of inflammation.  There are 
several subtypes of M2 and includes those derived for the aforementioned 
accumulation of TGF-b1 (M2c) or by a reduction in the available epitope able to bind 
to pattern recognition receptors in combination with a gradual excess of IL-4 (M2a).  
The source of IL-4 is from both the now dominate M1 type macrophage and recruited 
CD4+ T-helper cells (Stein et al., 1992, Shimoda et al., 1996). The presence of IL-4 
stimulates newly recruited LY6CHi monocytes, and residing M1 macrophages, to 
adopt an M2 activation profile.  Both M2a and M2c macrophage phenotypes do not 
release high levels of pro-inflammatory cytokines, reactive oxygen species or MHC 
class II and are potent inhibitors of macrophage and CD4+ t helper cell proliferation 
(Schebesch et al., 1997).  Despite a limited role in MHC mediated antigen 
presentation, M2a and M2c macrophages are highly efficient phagocytes b are able 
to clear dead and dying cells without triggering further inflammation (Fadok et al., 
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1998).  The final subtype, M2b, is induced in the presence of gradually increasing 
levels of IL-10 released from both nearly all immune cell types.  M2b macrophages 
release high levels of IL-10 that exert a powerful anti-inflammatory influence within 
their environment (Gerber and Mosser, 2001) but are otherwise very similar to 
classically activated M1 macrophages and are therefore considered as 
immunoregulatory (Anderson and Mosser, 2002b, Sironi et al., 2006).  The M2b 
macrophage phenotype is also actively involved in CD4+ T-helper cell differentiation 
(Anderson and Mosser, 2002a). 
 
Within the central nervous system, the general premise of a shift from a prevailing 
neurotoxic M1 signature towards a neurotrophic M2 dominance has been well 
characterised within rodent models of both acute injury of the spinal cord and 
traumatic brain injury using cortical impact (Kigerl et al., 2009, Hsieh et al., 2013, 
Turtzo et al., 2014).  Within chronic neurodegenerative the activation profile is not 
so easy to distinguish as there are many variables to consider.  These include the type 
of disease, the point in time that microglia are investigated during the disease 
development, the age (Flanary et al., 2007, Sierra et al., 2007, Hart et al., 2012, Lai et 
al., 2013), gender (Loeuillet et al., 2010, Akhtar et al., 2011), microglial population 
dynamics (see Chapter 1) and finally the impact of secondary insults, particularly 
those pertaining from the periphery, shown to impart a functional shift in microglia 
activation profile (see Chapter 1).  There is also recent research indicating a marked 
regional heterogeneity of microglial demonstrated both by resident microglia 
residing in different areas of the brain (de Haas et al., 2008, Lai et al., 2011, Hart et 
al., 2012) and a difference in function between resident and potential recruited 
blood-derived monocytes; the latter thought to be considerably more 
neuroprotective (Shechter et al., 2009, London et al., 2011, Butovsky et al., 2012).  
Therefore the activation profile of microglia during chronic neurodegeneration 
should be considered much more diverse with analysis focusing more on determining 
microglial function within a specific environment. 
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An immune response however is not cell-centric and is maintained and regulated by 
the actions of numerous communicating cell groups and not just those cells 
considered to be a part of the immune system.  A complete serial analysis of the 
whole microglia transcriptome in response to developing prion disease has not been 
performed.  Furthermore, isolation of microglia from a diseased brain will provide a 
unique microglia orientated angle of this multi-cellular response to developing 
pathology.  Furthermore ramified microglia are known to dynamically interact with 
surrounding cells including neurons and continually express neurotrophic factors 
(Wake et al., 2009, Tremblay et al., 2010).  It is not therefore possible for microglia to 
first respond in a support capacity without resulting to an inflammatory response; a 
situation seen both in aging and acute insult to the brain (van Dam et al., 1992, Van 
Dam et al., 1995, Konsman et al., 1999). 
 
The aim of this chapter was to successfully isolate adult microglia from adult 
BALB/cJFms-EGFP/- mice infected, as a time course, with the 79A mouse-adapted Scrapie 
strain.  In light of the potential regional heterogeneity demonstrated by microglial 
populations the ideal experiment would have incorporated microdissection of 
different brain regions.  It was found that obtaining a working protocol of regional 
isolation of microglia, and sufficient RNA downstream, was not practical within the 
confines of this project.   This analysis therefore focused on the whole brain microglial 
population.  The time points chosen were the same as the previous chapter thereby 
allowing for determination of the specific contribution made by microglia at these 
interesting stages of the disease.  BioLayout Express3D software was used to select 
groups of genes considered to show a disease assoicated expression profile and 
determine the specific functional contribution to the host immune response made by 
microglia, and the potential impact this may have within the brain parenchyma.  In 
addition, microglia are not the only source of immunomodulators and equally 
importantant, and indicative of the greater power of single cell type isolations, will 




5.2.1 Experimental Design 
Groups of gender matched BALB/cJFms-EGFP/- mice were challenged i.p. with either 0.02 
ml of 10-2 w/v 79A infected or normal brain material sourced from C57BL/6J mice.  
The average initial age of animals at challenge was 116 days ± 2.1 SE to ensure that 
disease progression would be comparable to previous chapters.  For each inoculum;  
groups of four mice at 35, 100, 150 and 200 dpi were anaesthetised using isoflurane 
(Merial Animal Health Ltd, VM08327/4131) with additional oxygen to maintain a 
steady condition of anaesthesia.  Mice were culled by cardiac puncture perfusion 
using a Watson Marlow 205U multichannel cartridge pump supplying 20 ml ice cold 
0.1% diethylpyrocarbonate (DEPC) treated Hank’s Balanced Salts Solution (HBSS) 
through a 26G x 0.45 mm microlance (BD 300300) at a flow rate of 5.0 ml min-1. Brains 
were carefully isolated and taken into ice cold 0.1% DEPC treated HBSS. 
 
5.2.2 Isolation of Microglia from Experimental BALB/cJFms-EGFP/- Mice 
Brains were dissociated on a GentleMACS™ Dissociator (Miltenyi Biotec, 130-095-
235) using the Neural Tissue Dissociation Kit P (Miltenyi Biotec #130-092-628); 
adjusting the reagent volumes to match brain weight following measurement in 1 ml 
ice cold Hanks balanced Salt Solution without Ca2+ & Mg2+ (Invitrogen, 14175-053).  
Brain tissue was sectioned into six roughly equal sized pieces to aid disassociation 
prior to adding the tissue to the first enzyme solution.  Following dissociation, the 
tissue was passed through a 40 µm filter then rinsed twice with 10 ml HBSS with Ca2+ 
& Mg2+ at 300 x g for 10 min at 4°C. The final cell pellet was re-suspended in 16 ml 
35% Isotonic Percoll® (GE Healthcare, 17-0891-02), split between two 15 ml 
centrifuge tubes and overlaid at 150 µl sec-1 with 5 ml ice cold 0.1% DEPC treated 
HBSS.  The resulting Percoll® gradient was centrifuged at 400 x g for 45 min at 4°c 
using no brake.  The resulting pellets were then suspended and recombined into a 
final volume of 5 ml ice cold 0.1% DEPC treated HBSS.  Cells were then again pelleted 
at 400 x g for 5 min at 4°c using no brake, re-suspended in 90 µl ice cold MACs buffer 
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(Miltenyi Biotec), 10 µl CD11b (microglia) microbeads (Miltenyi Biotec, 130-093-634) 
and incubated at 4°C for 15 min with gentle shaking. 
 
Following incubation with CD11b microbeads, the cell suspension was washed in 1 
ml ice cold MACs buffer at 300 x g for 5 min at 4°C, then re-suspended in 500 µl ice 
cold MACs buffer.  Cells were passed through magnetised LS columns (Miltenyi 
Biotec, 130-042-401) using three x 3 ml washes of ice cold MACs buffer.  A depleted 
sample was kept for FACS confirmation of CD11b depletion.  Cells positive for CD11b 
were removed from demagnetised LS columns using the supplied plunger into 5ml 
ice cold MACS buffer, then pelleted at 400 x g for 5 min at 4 °C.  The pellet was then 
re-suspended in 1 ml ice cold MACs buffer before four x 50 µl samples were removed 
and three of the samples blocked with 1 µg ml-1 purified anti-mouse CD16/32 Fc 
receptor antibody (Cambridge Bioscience, 101302).  The remaining solution 
(approximately 0.25 ml) containing on average 3x105 CD11b+ve cells and was pelleted 
at 400 x g for 5 min at 4°C and stored at -70°C until required.  
 
Microglia identification markers were stained (Table 5-1) with phycoerythrin (PE) 
anti-mouse CD11b (Cambridge Bioscience, 101208) and allophycocyanin (APC) anti-
mouse CD45 (Cambridge Bioscience, 109814).  A further 50 µl was stained with PE 
Rat IgG2b (Cambridge Bioscience, 400608) and APC Rat IgG2a (Cambridge Bioscience, 
400512) isotope controls and a final 50 µl was left unstained to serve both as negative 
control and verification of correct BALB/cJFms-EGFP/- genotype.  All samples were then 
incubated for 20 min at 4°C with gentle shaking prior to rinsing in 1ml MACs buffer at 
400 x g for 5 min at 4°c.  Determination of cell viability was achieved using 1 µl of 1 
mM SYTOX® Blue dead cell stain (Invitrogen, S34857) added to each tube 5 min prior 
to FACS analysis.  All cell samples were analysed on a BD FACS Aria IIIu 4-laser/11 
detector Cell Sorter running BD FACSDiva™ Software (BD Biosciences).  Subsequent 














5.2.3 Total RNA Extraction 
The protocol for isolating total RNA from microglia was first perfected using the BV2 
microglia like cell line.  This was in accordance with the three R’s (Replace, Reduce, 
and Refine) ensuring whenever possible live animals were not used when an 
alternative was available (Russell, 1959).  
 
At all stages, RNA isolation was performed in RNase-free Microcentrifuge Tubes 
(Applied Biosystems, AM12400). Homogenisation of isolated microglia cells was 
performed by adding 0.75 ml of TRIzol® Reagent (Life Technologies, 15596026), pre-
warmed to room temperature, to the 0.25 ml cell suspension (see section 5.2.2).  
Gentle mixing by pipette was used to facilitate cell lysis prior to incubation at room 
temperature for 5 min to ensure complete dissociation.  Separation of nucleic acids 
from organic molecules was performed with the addition of 0.2 ml 1-Bromo-3-
chloropropane per 1 ml TRIzol® reagent.  Each tube was capped securely and 
rigorously shaken by hand for 15 seconds prior to further incubation for 3 min at 
room temperature. 
 
Phase separation was performed using centrifugation at 12,000 x g for 15 min at 4°C.  
Each tube was then angled at 45 degrees and the upper clear acidic aqueous phase 
containing dissolved ribonucleic acids removed carefully by pipette. To mitigate any 
chance of DNA crossover, 15% of the aqueous phase, above the interphase, was left 
Fluorochrome Excitation Laser (nm) Emission (nm) 
CD11b-PE & IgG2b-PE 565 578 
CD45-APC & IgG2a-APC 633 660 
EGFP (For BALB/cJFms-EGFP/-) 488 507 
SYTOX® Blue 405 480 
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behind.  Precipitation of the RNA was initiated with the addition of 0.5 ml 100% 
absolute molecular grade isopropanol (Fisher Scientific, BP2618) per 1 ml of TRIzol® 
reagent used in initial homogenisation. Also added was 1 µg ml-1 neat linear 
acrylamide (Ambion, AM9520) to act as an inert co-precipitant carrier.  RNA was 
induced to pellet by centrifugation at 12,000 x g for 10 min at 4°C.  The pellet was 
invariably minuscule; to prevent loss the supernatant was carefully removed into a 
new sterile tube to capture the pellet if accidently removed. 
 
The resulting total RNA pellet was then washed in 100% absolute molecular grade 
ethanol (Fisher Scientific, BP2818) using a vortex.  Brief centrifugation at 7,500 x g for 
5 min at 4°C allowed the pellet to resettle, thereby facilitating removal of all the 
remaining ethanol.  The pellet was left in an extraction hood for 5 min to air dry while 
ensuring the pellet was not allowed to completely dry out.  The total RNA pellet was 
finally suspended in 20 µl of RNase-free water (Invitrogen, 10977035) and incubated 
at 55°C for 15 min.  Nanodrop analysis for 260:280 nm and 260:230 nm absorbance 
ratios was performed immediately on a NanoDrop® ND-1000 spectrophotometer 
(NanoDrop Technologies, Delaware USA).  The remaining sample was then stored at 
-70 °C until required. 
 
5.2.4 Analysing RNA Purity 
Total RNA quality was checked on an Agilent 2100 Bioanalyser.  For each sample, 1 µl 
of total RNA at a concentration of 1 ng µl-1 in RNase-free water (Invitrogen, 10977035) 
was loaded onto a Eukaryote Total RNA Pico Series II chip (Agilent Technologies, 
5067-1513) along with appropriate gel-dye matrixes and ladder following the 
manufacturer's instructions.  The chip was then placed on an IKA vortex with 
appropriate chip adapter (Agilent Technologies, 5065-9966) for 5 min at 2400 rpm 
then loaded into the Agilent 2100 Bioanalyser.  The 28S:18S rRNA ratio and quantity 
were analysed within Agilent 2100 expert software as an indication of the mRNA 
quality within the total RNA sample.  In addition, and by using the entire 
electrophoretic trace, the software also calculated RNA integrity values (RIN) to serve 
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as a further indicator of mRNA quality.  A RIN value of >7.0 was immediately passed 
as suitable for analysis.  Samples with a RIN value of lower than 7.0 where individually 
assessed for inclusion in the analysis.  
 
5.2.5 Microarray Hybridisation 
Microglial RNA processing was handled by ARK Genomics (The Roslin Institute & 
R(D)SVS).  The mRNA converted to double-stranded cDNA containing biotin, using a 
single round of amplification, from both the poly-A 3 ́ tail and randomly using the 
NuGen Ovation® picoSL WTA system (NuGen, 3310) followed by the NuGen Encore® 
Biotin module biotin labelling process (NuGen, 4200).  The cDNA samples were 
hybridised to Affymetrix Mouse Gene 1.1 arrays on an Affymetrix GeneTitan® Multi-
Channel instrument (Affymetrix, High Wycombe, UK) incorporating the hybridisation, 
washing, staining and scanning stages.  Annotation and quality control was 
performed with the Affymetrix Expression Console. Normalisation was undertaken 
using the robust multi-array average expression measure (Irizarry et al., 2003). 
 
5.2.6 Group-to-Group Data Analysis:  Selection of Genes of Interest  
With a Pearson correlation matrix cut-off threshold set to r = 0.7, annotated 
.expression files were loaded into BioLayout Express3D as a .Expression file and 
pairwise correlations were calculated for each probeset on the array against all other 
probesets (P2/2 pairwise calculations, where P is the number of probesets).  Values 
of r ≥ 0.7 were saved as a binary ‘.pearson’ file for future analysis.   
 
The user-defined correlation threshold within BioLayout Express3D was set at 0.90 for 
visualisation of biological relationships of interest in a highly structured graph 
consisting of nodes (probesets) connected by edges of expression correlation.  To 
identify groups of co-expressed genes, clustering of the graph was performed using 
the graph based Markov clustering (MCL) algorithm (Dongen, 2000) which has been 
designed to function with simple or weighted graphs.  The inflation value was set at 
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2.3.  The algorithm operates on the principle of generating artificial paths through 
the data from which Markov stochastic matrices apply the mathematical results of 
the random walks directly to the graph. Using the expression viewer it was possible 
to observe the expression of probe sets in each cluster and identify those 
demonstrating a convincing disease-associated signature.  Clusters with a high level 
of noise or an unconvincing expression profile were dropped from the analysis.  The 
chosen genes were entered into a new .Expression file.  
 
5.2.7 Sample-to-Sample Data Analysis 
The genes of interest were loaded into BioLayout Express3D and transposed to show 
sample-to-sample level.  The matrix threshold cut-off was maintained at 0.90.  Edges 
were set to colour by weight and nodes were searched for and coloured for clarity.    
 
5.2.8 Gene Ontology 
Gene ontology was determined by uploading the Affymetrix chip ID of the disease-
associated genes into the Ensembl Biomart data mining tool (ensembl.org/biomart) 
using the Mus musculus (GRCm38.p2) genes dataset (Ensembl Genes 74).  Filters 
were applied to restrict results to the Affymetric Microarray MoGene 1 0 stv1 probe 
sets.  To increase accuracy for correct selection of function, filters for external GO 
evidence code, domain and name were applied with a preference where possible for 
experimental evidence codes.   
 
5.2.9 Known and Predicted Protein-Protein Interactions 
Disease-associated genes were inputted into STRING (http://string-db.org) (Jensen et 
al., 2009) as a multiple sequence with predicted associations attributed to Mus 
musculus.  Within the network viewer, edges were restricted to evidence based 
prediction for co-expression, experimental and database determined interactions.  
The graph was organised dynamically by initiating the relaxation feature to force 




5.2.10 Biological Pathway Analysis 
Determination of the involvement of the identified disease-associated genes in 
biological pathways was performed using the Reactome peer reviewed pathways 
database (http://www.reactome.org) (Vastrik et al., 2007).  Genes were entered as a 
list into the data analysis section.  Comparison with Mus musculus pathways was 
performed using the species comparison section built into Reactome to ensure 
suggested pathways were fully applicable to mice. 
 
5.2.11 Statistics 
Fold-change difference was calculated on mean averages for the arrays at 150 and 
200 dpi.  The difference chosen was that generated between the equivalent normal 
brain control time point, plus or minus standard error.  BioLayout utilised Pearson 
correlation distance to determine the measure of similarity between a group of n-
dimensional probesets.   Probesets were therefore included in the graph based purely 
on whether they correlate with other probesets above a user defined threshold 
reducing the number of edges down from an impractical -1.0 ≥ P ≤ 1.0.   Within this 
analysis all probeset pairs with a Pearson correlation coefficient ≥ 0.7 were plotted. 
 
5.2.12 BV2 Microglia-like Cell Line Culture 
BV2 cells were kindly supplied by Dr Barry McColl (The Roslin Institute &R(D)SVS) as 
cells at a concentration of x106 cells ml-1 cryopreserved in freezing media (10% 
dimethyl sulfoxide and 90% foetal calf serum).  The cells were gently thawed to room 
temperature (21°C) then added to 9 ml  of pre-warmed (37°C) tissue culture media 
comprising L-glutamine Dulbecco's modified eagle medium (Gibco, 11965) containing 
10% foetal calve serum (Sigma, 12133C) , 100 U ml-1  penicillin, and 100 μg ml-1  
streptomycin (Gibco, 15140-148) in a sterile pre-treated T80 flask (Thermo-Scientific, 




Passage of BV2 cell culture was performed every 3 days.  The cells were washed twice 
in 6 ml phosphate buffered saline pH 7.4 without Ca2+ & Mg2+ (Gibco 10010-015).  
Following washing the cells were lifted from the flask surface with 2 ml 0.25% trypsin 
(Gibco, 25200) and incubated for 1 min at 37°C.  The flask was tapped sharply by hand 
to ensure all cells were dislodged prior to the addition of 8 ml fresh pre-warmed (37 
°C) tissue culture media.  The cell solution was removed into a sterile 15 ml centrifuge 
tube and gently pelleted at 200 x g for 5 min with no brake.  The pellet was suspended 
in 10 ml pre-warmed (37 °C) tissue culture media and transferred to a new a sterile 




5.3.1 Cell Isolation 
Initial attempts to isolate microglia from a total mouse brain single cell suspension 
utilised FACS cell sorting of EGFP expressing cells.  A variety of enzyme solutions were 
tested including the neural tissue dissociation kit P (Miltenyi Biotec) both with and 
without the automated Tissue Dissociator (Miltenyi Biotec), or various 
collagenase/dispase mixtures (adapted from Njie et al. (2012) and Cardona et al. 
(2006a)) with gentle shaking at 37°C followed by passing the tissue through a sieve.  
Regardless of the method attempted the yield of EGFP expressing cells was 
approximately 2x104 and insufficient for RNA extraction.  It was noted that there was 
an extremely high level of debris and myelin within the sample and attempts at 
myelin removal using magnetic beads was only partially successful.  Unfortunately 
the cells did not survive the sorting process despite attempts to optimise both the 
collection buffer solution and FACS nozzle pressure.  It was therefore decided that 
removal of the myelin was critical to the process and the protocol was adapted to 
incorporate a 35% / 75% interphase using a discontinuous Percoll™ gradient as 
described by Cardona et al. (2006a).  Samples were stained with CD11b-PE and CD45-
APC.  The collected interphase was found to be considerably cleaner with less debris 
(FIGURE).  EGFP cells isolated from BALB/cJFms-EGFP/- mice were directly correlated with 
the Cd11bhi and cd45mid population.  Perfusion was confirmed as successful with 
negligible cd11bhi and cd45hi monocyte contamination.  There was also negligible 
presence of CD45hi and CD11blo T and B cells.  Analysis revealed the pre-sort purity of 
microglia to be >95% yet it was not possible to FACS sort more than 2x104 microglia 
from the collected interphase and cells still did not survive the FACS sorting process.   
 
Allowing microglia to pellet by removing the 35% / 75% interphase had an immediate 
improvement with 3 x 105 cd11bhi cells sorted with a purity of > 95 % (Figure 5-1).  
Parallel trials of a variety of enzyme mixtures confirmed the mixture adapted from 
Cardona et al. (2006a) generated the highest yields of cd11bhi microglia.  Incubating 
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brain fragments in digestive enzymes both prior and following homogenisation was 
also compared with FACS analysis confirmed the cell suspension contained 
considerably less debris when tissue was incubated in enzyme prior to 
homogenisation.  Perfusion was also adopted to remove bone marrow derived 
monocyte contamination.   Viable microglia were successfully isolated following a 
switch from FACS sorting to CD11b magnetic microbeads.   
 
The population size of cells isolated by CD11b microbeads was determined by FACs 
analysis of a sample.  Yields isolated from whole brain were consistent at 3x105 cells.  
During protocol workup, additional confirmation by haemocytometer on a bright 
phase microscope confirmed both the population count and a rounded refractive 
appearance indicative of healthy viable cells.  The isolation procedure was highly 
reproducible and each brain yielded 3x105 viable microglia independent of time 
point. 
 
5.3.2 Microglia Purity 
Samples of isolated microglia were analysed by FACS to confirm population purity.  
To ensure consistency the same gated regions were maintained throughout when 
analysing the results within Dako Summit 4.3 software.  Purity of EGFP expressing 
cells stained with CD11b microglial and CD45 pan-macrophage fluorochrome 
conjugated antibodies was confirmed at 93% ± 0.52 SE (Figure 5-2).  The remaining 
7% were not tested but further gene expression analysis was performed on the 
isolated microglia confirming purity of isolated microglia was high (See section 5.3.3).  
Adult Microglia are typically CD11bHigh and CD45Mid (Ginhoux et al., 2010) and the 
slightly lower than expected CD11b forward and side scatter is attributed to 
competition for available antigen between the CD11b microbeads and CD11b-PE 
marker.  The number of CD45high cells, indicative of monocyte contamination, was 
negligible.  No non-specific binding or auto-fluorescence was seen with appropriate 
isotope controls or unstained samples.  Cell viability was confirmed at 97% ± 0.43 SE 










Figure 5-1:  Microglia Isolation using a discontinuous Percoll™ gradient.  A:  Following centrifugation 
microglia collect at the 35%/75% Percoll™ interphase as a faint white band and the majority of the 
myelin collects at the 75%/HBSS interphase.  Side and forward scatter FACS analysis revealed a 
considerable volume of debris and myelin that ranged in size and complexity throughout the scale.  Low 
granularity regions confirmed the presence of a population of CD11b and CD45 positive cells (Region 
Q2).  B: A significant reduction in debris and an increase by an order of magnitude in the number of 
CD11b and CD45 positive cells and was achieved following removal of the 35%/75% Percoll™ 












Figure 5-2: FACS sample analysis of CD11b microbead purified microglia.  A: Cells stained with and 
positive for CD11b-PE & CD45-APC demonstrate a high purity.  B: Isotope control and C: negative 
control show no non-specific binding or auto-fluorescence respectively.  D:  Cell viability was 
confirmed using SYTOX® live-dead stain.  Inset: Isolated cells are EGFP positive. 
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5.3.3 Quality Control 
Isolation of total RNA from microglia samples proved difficult to accomplish.  The 
260:280 nm and 260:230 nm absorbance ratios, determined on a NanoDrop® ND-
1000 spectrophotometer, yielded an average of 1.77 ± 0.07 SE and 0.37 ± 0.03 SE 
respectfully.  The average quantity of total RNA was found on the Nanodrop® to be 
low at 36.54 ng µl-1 ± 2.94 SE.  Total RNA integrity quality control, based on an Agilent 
2100 Bioanalyser electropherogram, revealed the majority of the samples to have 
weak peaks at 40 and 47 seconds indicative of digested 18S and 28S ribosomal 
subunit RNA (Figure 5-3).  There was also noise between 35 and 50 seconds indicative 
of partial sample digestion.  In all curves the peak for 28S ribosomal RNA was lower 
than the 16S peak indicative of borderline-acceptable levels of digestion within even 
the better samples.  The samples with the highest evidence for digestion also had 
high peaks between 20 and 25 seconds, overlapping the marker peak, and associated 
with fragments of < 100 base pairs.  In these poorer quality samples the 18S and 28S 
ribosomal peaks demonstrated a shift to the left.   No evidence of DNA contamination 
was noticed either interfering with the 28S peak or baseline of the electropherogram 
beyond 50 seconds.   Arbitrary RIN values were also correspondingly low.   
 
The two best samples from each group, independent of gender, were selected for 
microarray array hybridisation (Table 5-1) giving 16 samples with an average RNA 
quantity of 38.97 ng µl-1 ± 5.80 SE and an average RIN value of 6.01 ± 0.26 SE.    The 
remaining samples were considered unsuitable for further analysis.  
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Figure 5-3: Agilent Bioanalyser 2100 procured electropherograms of total RNA integrity.  A:  The 
better samples had more intense peaks at 40 and 47 seconds indicative of intact 18S and 28S ribosomal 
subunit RNA.  B:  The majority of the samples demonstrated weaker 18S and 28S ribosomal RNA 
peaks and noise indicative of partial sample digestion.  C: The poorest quality samples demonstrated 
significant digestion with strong peaks associated with small fragments < 100 base pairs and left shift.   


















































































































































































Figure 5-4: Box plots of log2 probe intensity for raw un-normalised arrays.  Array intensity is comparable 
both within groups and across the entire array population.    
Table 5-2: Microglia Total RNA samples chosen to take forward in the analysis following quality 
control checks for RNA integrity. 
dpi (Days) Inoculum Gender RNA Conc. (ng/µl) Agilent RIN Value 
200 79A ♀ 31.12 7.5 
200 79A ♂ 26.7 6.2 
150 79A ♀ 20.91 7 
150 79A ♂ 87.95 4 
100 79A ♀ 99.19 6.5 
100 79A ♂ 17.15 6 
35 79A ♀ 66.77 7.6 
35 79A ♀ 36.35 4.6 
200 NBr ♀ 24.43 6.8 
200 NBr ♂ 20.92 4.9 
150 NBr ♀ 32.62 7 
150 NBr ♀ 25.55 4.5 
100 NBr ♀ 27.37 6.7 
100 NBr ♀ 50.04 6.4 
35 NBr ♀ 24.18 5.8 
35 NBr ♀ 32.26 5.6 
 
Microarray quality control was performed on sample-independent probe intensity to 
highlight defects that typically arise from high background noise, low signal intensity 
and array sectional bias.  Mapping the log2 probe intensity for the raw data to a grey 
scale allowed for relative comparison of the medium values (Figure 5-2).  Some 
variation was to be expected using un-normalised data but the plot revealed all array 
intensity levels to be comparable both across the entire sample population and 
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Post-normalisation quality control analysis was performed within the reading plate 
on the Affymetrix GeneTitan® Multi-Channel instrument and included the generation 
of an array-array correlation matrix plot based upon log2-scaled Pearson correlation 
distance for RMA normalised sample signal intensity (Figure 5-5).  The plot revealed 
the 100 dpi array from the 79A infected group had less correlation to the rest of the 
array population.  The concentration of RNA for this sample was also appreciably 
lower than the other samples in the population (Table 5-2).  This array was 
subsequently dropped from the analysis.  The remaining arrays all demonstrated high 
levels of correlation indicating acceptable signal intensity homogeneity across the 














Following acquisition and normalisation of isolated microglia microarray data, a 
selection of genes, either well known in the literature or previously identified in 
chapter 2 as cell specific for microglia, astrocytes, neurons or oligodendrocytes were 
searched for within both the uninfected and infected datasets.  The relative 
expression for each was determined as an average and plotted in comparison.  This 
confirmed the purity of isolated microglia was high with minimal expression of genes 
associated with the other main brain cell types (Figure 5-6).  Importantly, astrocyte-
Figure 5-5:  Array-array correlation matrix plot of RMA normalised array signal intensity.  * One array, 
for the infected 100 dpi time point demonstrated less correlation of intensity with the rest of the arrays 

























































































































































































Gene & Cell Origin
Microlgia Astrocyte Neuron Oligodendrocyte
† P = 2.15 x10-4
NS
specific glial fibrillary acidic protein (Gfap) (Pekny et al., 1995) was expressed at 
negligible levels confirming the presence of Gfap found in the isolated microglia 
external datasets used in Chapter 2 were contaminated with astrocytes. 
 
 
Table 5-3:  The microarrays analysed in this study arranged by time point.  One array was dropped in 





















35 2 2 
100 1 2 
150 2 2 
200 2 2 
Figure 5-6: Isolated microglia are relatively pure.  For each cell type the relative expression of ten 
genes, which are well-known and/or previously identified in chapter 2 of this study as being cell-specific 
markers of the four main brain cell types, were plotted using the uninfected microarray data generated 
from purified microglia. † Mean statistical values determined using t-Test assuming variances 
determined by f-Test.  NS = Not Significant. Error bars equate to ± SE.   
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Group-to-Group Selection of Genes of Interest using BioLayout Express3D  
The data set was perceived as extremely linear requiring a high correlation threshold 
of 0.90 to allow for visualisation of nodes of biological interest, and ensure only nodes 
that portrayed a differential expression were incorporated in the graph.  This 
resulting in the dropping of a considerable proportion of transcripts that were not 
highly correlated with each other and not therefore considered biological interesting.  
The bulk of the biologically interesting nodes were displayed in a graph comprising 
2592 nodes, joined by 125,004 edges, grouped into two separate components and 
organised into 60 clusters by MCL (Figure 5-7).  The two components shared no edges 
and consequently the two components shared no correlation.  The top most 
component contained the clusters with a convincing disease signature.  It was from 
this component that the clusters considered relevant to the disease were chosen 
using the expression profile viewer built into BioLayout Express3D.  Clusters with a 
weak and/or noisy signal were considered unconvincing and dropped from the 
analysis.  In total 28 clusters were considered to demonstrate a convincing disease 
signature and analysed further.  The remaining 32 were dropped.    
 
The bottom most component comprised genes which, when shown as an average for 
the arrays for each group, appeared to demonstrate a decrease in expression.   
Predominantly the genes within this component were associated with olfactory 
pheromone receptors and odorant induced signal transduction.  None of the clusters 
containing these genes were found within, or joined by edges, to those with an 
increase in expression in the adjacent component.  Furthermore the average relative 
expression change for the genes with a decrease in expression was small with a fold 
difference between infected and controls at 200 dpi of 0.63 ± 0.01 SE.  It was 
therefore decided that the genes associated with a decrease in expression offered an 
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Figure 5-7: BioLayout Express3D generated group-to-group clustered graph of total array data obtained 
from all time points.  A: With  a Pearson correlation matrix threshold set at 0.90 a graph was produced 
comprising 2592 probesets joined by 125,004, organised into 123 clusters by MCL (inflation 2.3) and 
comprised two separate components that demonstrated no correlation with each other.  The upper 
component expression profile was for an increase in expression at the later stages of disease.  B: The 
lower component mean expression profile for all nodes portrayed a decrease in expression from 100 
dpi.  The expression changes are weak and unconvincing when compared to expression by control 
animals.  Error bars equate to standard error. 
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5.3.4 Parallel Pathology of 79A infected BALB/cJFms-EGFP/- Mice 
The determination of the pathogy of infection by the 79A prion strain, using an 
intraperitetonal route, in the BALB/cJFms-EGFP/- strain of mice has been the subject of 
other chapters within this study.  Briefly BALB/cJFms-EGFP/- mice infected 
intraperitetonally with 79A first displayed accumulation of fine punctate PrP 
deposition in the medulla at 150 dpi (65% of the incubation period).  This coincided 
with an increase in microglia numbers in the same region of the medulla.  The onset 
of clinical signs associated with prion disease was at 200 dpi and coincided with 
widespread accumulation of punctate PrP deposits and microglia activation 
throughout the brain. The concentration of both PrP protein and activated microglia 
was particularly heavy in the thalamus.  Within this analysis, infected mice used to 
confirm correct strain type, were culled with terminal disease at 225 days.  The 
experimental source of the inoculum and the origin of the mice used in this 
experiment was the same as that used throughout this project allowing for direct 
comparison between chapters. 
 
5.3.5 Disease-Associated Differentially Expressed Genes 
The vast majority of the identified disease-associated microglia genes demonstrated 
an increase in expression at 200 dpi.  This coincided with the widespread and 
significant deposition of punctate PrP and microglia activation (Chapters 3 and 4).  At 
150 dpi the average (mean) expression for these genes did not rise more than 1.5 fold 
above the basal levels of expression established by the normal brain inoculated 
control mice.  Any observable morphological response by microglia at this time is 
restricted to the medulla and the detection of any, and presumably weaker, signal 
produced by this small group of cells would be diluted by the use of total brain 
microglia.   
 
The chosen clusters of interest were loaded into BioLayout Express3D with a 
correlation threshold set at 0.90 to allow for visualisation of transcripts with 
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biological interest within the resulting structure.  A single graph was produced that 
comprised 741 nodes, joined by 29297 edges, and organised using the MCL algorithm 
into 2 large clusters and 13 smaller clusters.  All clusters shared a similar gene 
expression profile with a clear increase in expression at the 200 day time point.  The 
organisation into a single graph, with a similar expression profile for all nodes, 
demonstrated the homogeneity of the signal produced by whole brain microglia.  
Animals inoculated with normal brain material presented with normal background 
levels of variation expected of microarrays and showed no significant change in 
expression throughout the disease period.  There was no difference in expression 
between male and female mice. Consequently gender had no impact on the disease 
process within this analysis.   
 
Transposing the 741 genes of interest to display a sample-to-sample (array) level 
graph within BioLayout Express3D revealed the two arrays from the 79A infected 200 
dpi time point had less correlation with the rest of the nodes and a high degree of 
correlation with each other.  This was performed at the same correlation threshold 
of 0.90 as the group-to-group analysis.  Therefore the overall change in expression 
produced by microglia at 200 dpi was of sufficient magnitude to induce a clear 
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Figure 5-9:  Global microarray sample-to-sample transposed BioLayout Express3D graph.  Prion infected 
and uninfected pre-200 dpi arrays are highly correlated and organised into one component.  Displaying high 
inter-correlation but lower correlation with the rest of the population are the arrays for the 200 dpi infected 
group.  Note: nodes have been coloured only for clarity and are not indicative of MCL clustering 
Figure 5-8:  BioLayout Express3D group-to-group graph at a correlation threshold of 0.90 created from the 
transcripts demonstrating a disease-associated signal.  A:  The graph was highly organised and comprised 
two main clusters.  B:  The expression profile for the array averages within each group revealed a strong 





Gene ontology was performed for each gene using the data made available on the 
Ensembl Biomart database to allow for functional associations to be determined 
(Figure 5-10).  Just under two thirds of the 741 identified differentially expressed 
disease-associated genes were attributed to metabolism and the maintenance of 
homeostasis.  The correct determination of differentially expressed metabolic genes 
to a specific cell type is only possible through the type of single cell type analysis 
presented here.  Metabolic genes are typically expressed by all tissue cells types 
making identification of the cellular origin from a multicellular population impossible.   
 
Genes that were related to the immune response comprised just under a quarter of 
the total (Figure 5-10).  The 6% of genes associated with cytoskeletal changes and 
migration were classed into their own groups respectively.  Due to the multirole 
function of genes associated with cytoskeletal changes and migration these groups 
could have been incorporated as part of the immune response.  Indeed many of the 
pathways associated with membrane reshuffling were also found associated with 
migration and phagocytosis by myeloid cells on the Ensembl database.  However as 
microglia are known to be highly motile in the healthy brain environment 
(Nimmerjahn et al., 2005) a degree of caution was felt appropriate.  Genes associated 
with differentiation were directly incorporated into the immune system as it was felt 
that genes associated with differentiation that were isolated from a microglia only 
population could only be attributed to pathways associated with activation and the 
subsequent differentiation of recruited inflammatory monocytes.  The genes 
associated with mitosis were kept as a separate group for clarity as the increase in 
microglia numbers observed in prion disease could be considered as self-sufficient 
turnover by the resident microglia population (Parkhurst et al., 2013).  
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Figure 5-10: Regulated disease-associated genes allocated by function.  Using the Ensembl Biomart 
database the majority of the regulated genes were ascribed to metabolism and homeostasis.  Genes 
associated with immune system, for which differentiation has been included, comprise only a fifth.  This 
highlights the power of a signal cell isolation in correctly determining the association of metabolic genes 




































To investigate the protein-protein interactions the 741 genes of interest were loaded 
into STRING (http://string-db.org).  STRING produced a graph in which the vast 
majority of the nodes were separated into two loosely connected but highly 
correlated components (Figure 5-11).  The larger of the two components comprised 
the proteins associated with metabolism, ribosomal function and translation.  The 
second component was comprised of those proteins involved in immune system 
signalling and innate immune activation.  The immune system component displayed 
the potential for further separation into separate clusters if MCL could be applied.  
































Figure 5-11: STRING generated map of known protein-protein interactions.  The vast majority of the 
nodes are located into two loosely connected yet highly correlated components comprising nodes 
associated with homeostasis and metabolism in one and the immune system in the other. 
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5.3.6 Gene Enrichment Analysis 
Enrichment analysis of the 741 identified genes using the FuncAssociate database, 
confirmed the breakdown of the transcripts into groups by specific function; 
translation, energy production, immune response, interferon response and cell stress 
(Table 5-1).  All functional terms had a P-value of considerably greater than 1x10-3 
with an average of 2.90x10-06.  Immunological response comprised the single largest 
category in respect to total gene number.  The signature was one of proteolysis, with 
NF-KB mediated cytokine cascades and innate immunity.  The GO enrichment 
functional groups of mitochondria, ribosome, cell stress, apoptotic process and 
proliferation had the largest individual grouping of genes, thereby confirming the 
dominant metabolic processes present within the signature.  
 
Fold change analysis based on the difference between infected and control mean 
average for the arrays at 150 and 200 dpi revealed a spread of differential changes to 
the increase in expression that were subsequently organised into bins (Table 5-5).  A 
cut-off of >1.2 was chosen for the fold change difference at 150 dpi as the bulk of the 
genes at this time point did not portray a convincing increase in expression. For the 
genes that did demonstrate a noted increase in expression at 150 dpi, an increase in 
fold change from 150 to 200 dpi was noted for all but 9 genes; Baiap2, Fbxw4, Fus, 
Gosr2, Impad1, Rab1b, Slc6a6, Usp15 and Vac14.  Intriguingly Usp15 encodes for a 
receptor stabiliser for the TGFβ1 receptor (Inui et al., 2011).  Also of note, the genes 
Vac14, Slc6a6, Fus, Fbxw4 and Baiap2 have all been implemented as neuronal 
synaptic stabilisers, neurotransmitter transporters and regulators of neuronal 
differentiation (Heller-Stilb et al., 2002, Kim et al., 2009, Hoeck et al., 2010, Huang et 
al., 2010, Zhang et al., 2012).  The majority of the genes with a fold change of between 
1.0 and 2.0 are enriched for protein translation.   The fold change increases of greater 
than 2.0 were dominated by genes highly enriched for the innate immune response 
including, chemotaxis, antigen presentation and NFκB mediated cytokine signalling 
cascades.      
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Table 5-4:  GO enrichment terms determined from the identified 741 differentially expressed genes 
using FuncAssociate 2.0 revealed protein translation, respiration, cellular stress and components of the 








Protein Translation     
ribosome GO:0005840 6.37E-54 72 9.72 
translation GO:0006412 3.52E-26 67 9.04 
ribosome biogenesis GO:0042254 2.70E-12 27 3.64 
endoplasmic reticulum GO:0005783 1.11E-05 68 9.18 
     
Energy Production     
mitochondrion GO:0005739 1.10E-13 111 14.98 
generation of precursor 
metabolites and energy 
GO:0006091 1.94E-05 21 2.83 
respiratory chain GO:0070469 1.92E-13 19 2.56 
     
Immune Response     
lysosome GO:0005764 1.55E-12 42 5.67 
regulation of cytokine production GO:0001817 1.47E-09 38 5.13 
chemokine receptor binding GO:0042379 2.20E-09 13 1.75 
regulation of locomotion GO:0040012 1.03E-07 41 5.53 
endosome GO:0005768 6.35E-07 41 5.53 
cell proliferation GO:0008283 3.00E-06 78 10.53 
I-kappaB kinase/NF-kappaB 
cascade 
GO:0007249 8.03E-06 19 2.56 
innate immune response-
activating signal transduction 
GO:0002758 1.38E-05 12 1.62 
     
Interferon Response     
response to interferon-gamma GO:0034341 1.32E-07 12 1.62 
response to interferon-beta GO:0035456 1.60E-07 9 1.21 
response to type I interferon GO:0034340 8.99E-07 7 0.94 
     
Cell Stress     
response to stress GO:0006950 2.53E-13 138 18.62 
apoptotic process GO:0006915 5.05E-07 82 11.07 




Table 5-5: Differentially expressed genes of interest at arranged by time point and fold change. GO 
ontology data shown for genes lists that were enriched for function. 
 
 






Gene GO Enrichment 
150 dpi 
≥ 1.2 - 
≤ 1.49  
1700021F05Rik, 1810037I17Rik, 2700094K13Rik, Acot10, 
Anxa3, Atox1, Axl, Baiap2, Bst2, Capg, Ccdc23, Ccl4, Cd52, 
Cd83, Cd86, Cdc37, Ch25h, Chchd3, Chmp1b, Chst1, 
Churc1, Cmc1, Coro1c, Csnk2b, Cstb, Cxcl9, Dnajb14, 
E330009J07Rik, Etf1, Ezr, Fam92a, Fbxw4, Fdx1, Fgl2, Fgr, 
Fus, Gba, Gosr2, Grpel1, H2-D1, H2-gs10, H2-Q7, Hebp1, 
Impad1, Impdh2, Itgax, Kif3a, Klf10, Lox, Lrpap1, Naf1, 
Ndufa6, Nfkbia, Nfkbib, Nfkbie, Ngfrap1, Nmi, Pfkfb3, 
Ppap2a, Prdx4, Psmb2, Psmb3, Rab1b, Rasgef1b, rp9, 
Rpl14, S1pr1, Sass6, Scand1, Slc6a6, Snhg8, Sqstm1, Tceb2, 
Tmem160, Tnf, Tnfaip2, Tnfaip3, Tpd52, Tpi1, Uqcr10, 
Usp15, Utp11l, Vac14, Xdh, Yaf2, Zcchc17, Znrd1 
Negative regulation of cytokine 
production: P = 5.7 x10-6 
 
Positive regulation of immune 
system process: P = 1.52 x10-5 
 




≥ 1.5 – 
≤ 1.99 
Gem, Il1b, Niacr1 
Regulation of adiponectin secretion: 
P = 3.51 x10-8 
200 dpi 
≥ 1.0 - 
≤ 1.49 
1110007C09Rik, 1200014J11Rik, 2010011I20Rik, 
2700007P21Rik, 2810405K02Rik, Adh5, Aif1, Alcam, Apob, 
Arl2, Arrdc4, Asah1, Asph, Atl2, Atp2b1, Azin1, Baiap2, C4b, 
Caprin1, Casd1, Ccny, Cd300lf, Cenpc1, Cep135, Cfl1, 
Chmp7, Cic, Cln8, Creb3, Csf2rb2, Ctns, Ctsd, Cuedc2, 
Cyp4v3, Diap2, Dnlz, Dnmt3a, Drap1, Dtnbp1, Ebna1bp2, 
Ecd, Eif1a, Eif2s2, Erbb2ip, Erlec1, Evi2a, Exoc2, Extl3, 
Fam32a, Fbxw4, Fcf1, Flna, Fth1, Ftl1, Ftl2, Furin, Fus, 
Gabarapl1, Galnt6, Gcnt2, Gfpt1, Glrx5, Gm10653, 
Gm15772, Gm5805, Gns, Golim4, Gosr2, H2-T10, Iigp1, 
Ikbke, Il10rb, Il12b, Impad1, Irf9, Itgb1, Kctd2, Klhdc4, 
Lamp2, Ldhb, Mcm6, Mfap1a, Mina, Mirn692-2b, Mtmr2, 
Mxd4, Naca, Ncf1, Nd1, Ndufb2, Ndufv1, Nkap, Nono, Npat, 
Npm1, Nup98, Nus1, Pdcd5, Pde4dip, Pfkfb3, Pgam1, 
Pgap1, Pigl, Pigu, Plekhh2, Plin2, Plxnb2, Ppm1m, Ppp1cc, 
Ppp1r15b, Prdx5, Prpf6, Ptgfrn, Ptplad2, Rab1b, Rap2a, 
Rbm42, Rbx1, Rcc2, Rnaseh2b, Rnf13, Rpl21, Rpl3, Rps2, 
Rps27a, Rps29, Rps4x, Rps6, S100a1, Sart3, Scnm1, Sdcbp, 
Sec63, Slc6a6, Snf8, Sph21_3049, Srp72, Sssca1, St14, St5, 
Surf4, Syncrip, Synj2, Tacc3, Taf5l, Tatdn2, Tbc1d22a, Tlr1, 
Tmx3, Top2a, Tpt1, Trip12, Ubxn1, Uhrf1bp1l, Usp15, 
Vac14, Xrn2, Zfp868, Znhit1 
Protein targeting to ER: P = 6.07 
x10-7 
 








Gene GO Enrichment 
200 dpi 
≥ 1.5 – 
≤ 1.99 
1110059G10Rik, 1500032L24Rik, 1700021F05Rik, 
1700112E06Rik, 2010107E04Rik, 2310003F16Rik, 
2310039H08Rik, 4931406C07Rik, A430005L14Rik, Abca1, 
Acadl, Acbd6, Acot10, Adap1, Adar, Aggf1, Akr1a4, Alas1, 
Aldoa, Anapc13, Ankra2, Ap3s1, Apbb2, Apitd1, Aplp2, 
Apobec1, Apoe, App, Arhgap24, Arl6ip5, Arpc1b, Arpc5l, 
Atp1a3, Atp5h, Atp5l, Atp6ap2, Atp6v0e, Atp6v1g1, Atxn10, 
Bag1, BC003266, Bcas2, Bhlhb9, Bloc1s2, Bst2, C3ar1, 
Cadm1, Calu, Ccdc23, Ccdc90a, Ccl8, Ccl9, Cct2, Cd14, 
Cd180, Cd200r4, Cd83, Cd86, Cdc37, Cenpo, Cetn3, Cfdp1, 
Chchd3, Chst1, Chst2, Clec5a, Cndp2, Colec12, Commd1, 
Cops5, Cops6, Coq7, Cox4i1, Cox5b, Cox6a1, Cox6b1, 
Cox7a1, Cox8a, Csnk2b, Ctbs, Ctla2a, Ctnnb1, Ctsa, Ctsb, 
Ctse, Ctsh, Cul4b, Cux1, Cxcl14, Cxcl9, Cycs, D10Wsu52e, 
Dctn6, Ddx1, Dek, Derl1, Dna2, Dnajb14, Dpp7, Dpy19l4, 
Dram2, Dscc1, Dusp2, Eef1b2, Efcab2, Eid1, Eif2ak2, Eif3e, 
Eif3h, Eif3l, Eif4b, Ell2, Enpp1, Eprs, Etf1, Exosc9, Fam165b, 
Fam167b, Fam174a, Fam50a, Fau, Fdx1, Fnip2, Fuca1, 
Fundc2, Fxyd5, Gaa, Gadd45a, Galc, Galnt7, Gba, Gca, Gde1, 
Ghitm, Glb1, Glrx5, Gm10063, Gm10136, Gm12191, 
Gm2695, Gm6251, Gm6548, Gm9975, Gmds, Gnb2l1, Gng5, 
Gnl3, Gnpda2, Gnptab, Golph3, Got1, Gpr84, Gpx4, Grasp, 
Grinl1a, Grpel1, Gsto1, Gusb, Gyg, Hat1, Hcst, Hgf, Higd2a, 
Hint1, Hmgn3, Hprt, Hsd17b11, Hspe1, Idh1, Ifi30, Ifih1, 
Ifit1, Il2rg, Ipo5, Irf1, Irgm1, Isg15, Katna1, Kif3a, Klf10, 
Lamp1, Ldha, Lgals3, Lilrb4, Lrp12, Lrpap1, Lsm2, Ly6e, Lyst, 
Lyz2, Map3k7, Map3k8, Mapkapk2, Mbd2, Mcee, Mcm3, 
Mfsd1, Mmgt2, Mospd2, Mrpl22, Mrpl34, Mrpl39, Mrpl52, 
Mrps33, Mrps9, Mrrf, Ms4a4c, Ms4a6c, Mtap4, Myl6, 
Naa50, Naf1, Naip2, Ndufa3, Ndufa8, Ndufb11, Ndufc2, 
Ndufv3, Nedd8, Neu1, Nfkbib, Nfkbie, Nipsnap3b, Nme1, 
Nol7, Npc2, Npnt, Nptn, Nrp1, Nuak2, Nucb1, Nucb2, Oasl2, 
Ogfr, Ola1, Olfr110, Osbpl8, Oxct1, Parp14, Parp9, Pdcd6, 
Peci, Pfdn1, Pfkl, Pgk1, Plau, Plekha1, Plekha3, Postn, 
Ppap2a, Prkar1a, Psat1, Psma7, Psmb1, Psmb2, Psmb4, 
Psmd8, Psme1, Ptbp1, Ptgs2, Ptpra, Pus3, Rab12, Ranbp1, 
Rassf4, Rer1, Rlf, Rnf128, rp9, Rpl10a, Rpl11, Rpl12, Rpl13, 
Rpl13a, Rpl14, Rpl18a, Rpl19, Rpl22, Rpl26, Rpl27, Rpl27a, 
Rpl28, Rpl31, Rpl35, Rpl35a, Rpl36, Rpl36a, Rpl36al, Rpl37, 
Rpl37a, Rpl38, Rpl39, Rpl39l, Rpl4, Rpl41, Rpl5, Rpl6, Rpl7, 
Rpl8, Rplp0, Rps10, Rps14, Rps15a, Rps15a-ps6, Rps16, 
Rps17, Rps18, Rps19, Rps20, Rps23, Rps25, Rps27, Rps3, 
Rps3a, Rps5, Rps7, Rps8, Rragc, Sap30, Sass6, Scand1, Sdc3, 
Sdc4, Sdf4, Sec61b, Serp1, Setd3, Sgpl1, Shfm1, Slamf9, 
Slc11a2, Slc23a2, Slc25a4, Slc38a6, Slc7a11, Slfn5, Snap29, 
Snord38a, Snrpd3, Snrpf, Snx17, Snx24, Snx3, Spcs1, Spopl, 
Sqstm1, Srd5a3, St8sia6, Stk3, Sulf2, Surf1, Syngr1, Taf10, 
Tank, Tapbp, Tceb1, Tcp1, Tmem154, Tmem160, Tmem222, 
Tmem49, Tmsb10, Tnfaip2, Tomm7, Tpi1, Tpm4, Trim30a, 
Ttc1, Ttc30b, Tubb2a, Txndc5, Uba52, Uqcrb, Utp11l, 
Utp14a, Utp3, Vat1, Vim, Vps28, Vps29, Xdh, Zbp1, 
Zc3h12a, Zfp704, Znrd1 
Ribosome: P = 4.02 x10-48 
 




protein targeting to membrane P = 
2.08x10-53 
 
Protein localisation to membrane:  
P = 2.11x10-32 
 
Lysosome: P = 7.11 x10-7 
 
Antigen processing via MHC class 1: 
P = 8.68 x10-5 






Gene GO Enrichment 
200 dpi 
≥ 2.0 – 
≤ 2.49 
0610031J06Rik, 1500011K16Rik, 1500012F01Rik, 
1810027O10Rik, 1810037I17Rik, 2310028O11Rik, 
2700094K13Rik, 2900010M23Rik, 3830403N18Rik, 
5430435G22Rik, Anxa3, Anxa5, Atox1, Atp5k, Atp6v1a, 
Bcl2a1c, Bcl2a1d, Casp4, Ccdc122, Cd274, Cd48, Cd72, 
Chmp1b, Churc1, Cks1b, Cmc1, Coro1c, Cox17, Creg1, Ctsz, 
Cxcl11, Cxcr4, Cybb, D14Ertd668e, Eif3k, Eya4, Ezr, F2r, 
Fam92a, Fgl2, Fgr, Fmn1, Glipr1, Gltp, Gm2a, Gm5921, 
Gpr65, H28, H2-t9, Hebp1, Hif1a, Higd1a, Ifi204, Ifitm3, 
Igbp1, Irf7, Itga5, Krtcap2, Lsmd1, Ly9, Mif, Milr1, Mrpl36, 
Msr1, Myo5a, Naa20, Ndufa4, Ndufb5, Nfkbia, Ngfrap1, 
Ninj1, Nmi, Oas1g, Pcyt1a, Pfdn5, Pld3, Prdx1, Prdx4, Prim1, 
Psmb6, Ptger4, Rap2b, Rasgef1b, Rhoc, Romo1, Rpl22l1, 
Rpl32, Rpl37a, Rpp38, Rps12, Rps21, Rps26, Rsad2, S1pr1, 
Selm, Smpdl3a, Snhg8, Snrpe, Srp14, Stat1, Tbca, Timp2, 
Tlr2, Tmed3, Tmem9b, Tnfaip3, Tor3a, Tpd52, Txndc17, 
Ubl5, Uqcr10, Uqcrh, Usmg5, Vcam1, Vkorc1, Vti1b, Yaf2, 
Zcchc17 
Positive regulation of cytokine 
secretion: P = 1.50 x10-6 
 
I/NFκB cascade: P = 2.09 x10-5 
 
LPS-mediated signalling pathway:  P 
= 8.89x10-6 
200 dpi 
≥ 2.5 – 
≤ 2.99 
Anxa4, Atp5e, Bcl2a1a, Bcl2a1b, Bola2, Capg, Ccrl2, Cd84, 
Cd9, Chst11, Cox6a2, Ctsl, Fabp5, Gla, H2-gs10, H2-Q7, 
Hscb, Hspb11, Id2, Ifit2, Il1b, Lag3, Lgals1, Ly6a, Mir29a, 
Mmp12, Myeov2, Myo1e, Ndufa2, Ndufa6, Plaur, Psmb3, 
Robld3, Rps11, Serpine2, Sp100, Ssr4, Tceb2, Wbp5 
Regulation of glia cell 
differentiation: P =  1.06 x10-6 
200 dpi 
≥ 3.0 – 
≤ 3.99 
Axl, Ccl4, Ccl5, Ch25h, Cpd, Cstb, Cxcl16, E330009J07Rik, 
Gas2l3, Gem, H2-D1, H2-K1, I830012O16Rik, Ifi44, Impdh2, 
Ndufa1, Nexn, Niacr1, Rilpl2, Rps27l, Slfn2, Tnf 
Lymphocyte chemotaxis: P = 8.86 
x10-7 
 
Antigen processing and 
presentation of 
endogenous antigen: P = 2.70 x10-7 
 
Chemokine receptor binding: P = 
1.268 x10-5 
200 dpi 
≥ 4.0 – 
≤ 4.99 
Cd52, Csf1, Cst7, Fam20c, Fcgr4, Ifi202b, Lox, Rtp4 N/A 
200 dpi 
≥ 5.0 
Apoc1, Clec7a, Cxcl10, Cxcl13, Gadd45b, Ifi27l2a, Ifit3, 
Itgax, Lgals3bp, Lpl, Spp1 
 
Response to virus: P = 1.09 x10-6 
 
Leukocyte chemotaxis:  P = 2.26 
x10-5 
 
Protein-Lipid complex remodelling: 
P = 3.65 x10-5 
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5.3.7 Gene Ontology Analysis 
Determination of the sub-cellular component for each gene considered to be 
associated with metabolism/homeostasis was performed from data obtained from 
the Ensembl Biomart database.  This enabled the location of each gene to be plotted 
onto a cellular map and further organised by function (Figure 5-12).  The identified 
cellular components included a significant increase in expression of genes associated 
with ribosomes within the rough endoplasmic reticulum and cytoplasm.  Indeed the 
bulk of the metabolic genes were associated with the structurally distinct proteins 
that comprised the subunits of ribosomes and thereby implying an increase in 
ribosome numbers and/or ribosome turnover.  No doubt associated with the increase 
in translation are allocation of genes to protein processing including vesicular 
transport and prefoldin complexes.  Also present was a significant concentration of 
genes associated with proteolysis, including proteasome based ubiquitination.   
 
Consistent with the increase in metabolic load were a considerable number of genes 
associated with oxidative phosphorylation and energy production in mitochondria 
including subunits for cytochrome-c oxidase, NADH dehydrogenase and lactate 
dehydrogenases; the latter associated with breakdown of increased levels of lactate 
in situations of respiratory stress (Brooks et al., 1999).  Indications of oxidative stress 
are evidenced by the presence of DNA repair processes including expression of 
transcriptional regulator and DNA damage-dependant nuclear protein poly(ADP-
ribosyl)ation-14 (Parp14) (Ame et al., 2004, Mehrotra et al., 2011).  Furthermore, 
pathway analysis using the Reactome database revealed the increase in expression 
of Fam50a (family with sequence similarity 50, member A), and sources of ubiquitin 
through Uba52 (ubiquitin A-52 residue ribosomal protein fusion product) and Rps27 
(ribosomal protein S27), offer tentative evidence of involvement of the DNA damage-




2700094K13Rik, Acadl, Adap1, Atp5e, Atp5h, Atp5k, 
Atp5l, Cox5b, Cox6a1, Cox6a2, Cox6b1, Cox7a1, Cox8a, 
Cybb, Cycs, Cyp4v3, Fdx1, Glrx5, Gm10136, Grpel1, 
Higd1a, Higd2a, Hsd17b11, Idh1, Ldha, Ldhb, Ndufa1, 
Ndufa2, Ndufa3, Ndufa4, Ndufa6, Ndufb11, Ndufc2, 
Ndufv3, Prdx4, Romo1, Slc25a4, Surf1, Tmx3, Tomm7, 
Txndc5, Uqcr10, Uqcrb, Uqcrh, Usmg5, Vat1, Xdh 
Carbohydrate Metabolism 
Chst1, Chst11, Chst2, Galnt6, Galnt7, Gcnt2, Gfpt1, 
Gmds, Gnpda2, Gnptab, Gyg, Pfkfb3, Pfkl, Pgk1, Pigl, 
Pigu, Prkar1a, Tpi1, 
DNA Binding/Repair  
1200014J11Rik, Apitd1, Dek, Dmrtc1c, Dnmt3a, Dscc1, 
Eya4, Fam50a, Mir29a, Mirn692-2b, Nono, Rps27, 
Parp14, Pgap1, Rlf, Sap30, Trip12, Uba52, Utp3, Xrn2, 
Zbp1, Zcchc17 
Ion Binding/Transport (membrane) 
4931406C07Rik, Aif1, Anxa4 Anxa5, 
Asph, Atp13a5, Atp1a3, Atp2b1, 
Calu, Ccdc90a, Cmc1, Cox17, Dnlz, 
Fus, Fxyd5, Gca, Gnb2l1, Kctd2, 
Ndufv1, Nme1, Nucb1, Nucb2, rp9, 
Sdf4, Slc11a2, Ssr4, Tpd52, Vwce, 
Zfp704, Zfp868 
Lipid processing (membrane) 
Abca1, Acbd6, Acot10 , Anxa3, Aplp2, 
Apob, Apobec1, Apoc1, Apoe, Ch25h, 
Chchd3, Fam167b, Gde1, Gltp, 
Lrpap1, Msr1, Osbpl8, Pcyt1a, Peci, 
Pld3, Plin2, Ppap2a, Ptgfrn, Ptgs2, 
Ptplad2, Sgpl1, Srd5a3, Ttc1, 
Translation 
Eef1b2, Eif1a, Eif2s2, Eif3e, Eif3h, Eif3k, Eif3l, Eif4b, 
Etf1, Fau, Gm6251, Lsm2, Mrpl22, Mrpl34, Mrpl36, 
Mrrf, Naf1, Oas1g, Oasl2, Rpl10a, Rpl11, Rpl12, Rpl13, 
Rpl13a, Rpl14, Rpl18a, Rpl19, Rpl21, Rpl22, Rpl22l1, 
Rpl26, Rpl27, Rpl27a, Rpl28, Rpl3, Rpl31, Rpl32, Rpl35, 
Rpl35a, Rpl36, Rpl36a, Rpl36al, Rpl37, Rpl37a, Rpl38, 
Rpl39, Rpl39l, Rpl4, Rpl41, Rpl5, Rpl6, Rpl7, Rpl8, 
Rplp0, Rps10, Rps11, Rps12, Rps14, Rps15a, Rps15a-
ps6, Rps16, Rps17, Rps18, Rps19, Rps2, Rps20, Rps21, 
Rps23, Rps25, Rps26, , Rps27a, Rps27l, Rps29, Rps3, 
Rps3a, Rps4x, Rps5, Rps6, Rps7, Rps8, Sart3, Sec61b, 
Sec63,  
Transcription  
Bcas2, Churc1, Cic, Cops5, Creb3, Cux1, Ddx1, Drap1, 
Ebna1bp2, Eprs, Exosc9, Fcf1, Hmgn3, Ipo5, Mbd2, 
Mina, Mxd4, Naca, Npat, Phf11d, Prpf6, Ptbp1, Pus3, 
Rbm42, Rpp38, Rtcb, Scand1, Scnm1, Setd3, Snf8, 
Snord38a, Snrpd3, Snrpe, Snrpf, Syncrip, Synj2, Taf10, 
Taf5l, Tatdn2, Tceb2, Trim30a, Utp11l, Utp14a, Yaf2, 
Znhit1, Znrd1 
Protein Processing (Inc. Proteasome) 
Cndp2, Cpd, Cuedc2, Cul4b, Derl1, Dnajb14, Erlec1, 
Fbxw4, Isg15, Mmp12, Nedd8, Pfdn1, Pfdn5, Psma7, 
Psmb1, Psmb2, Psmb3, Psmb4, Psmb6, Psmd8, Psme1, 
Ptpra, Rbx1, Shfm1, Spcs1, St14, St8sia6, Tceb1, Tcp1, 
Ubl5, 
Protein Transport (Inc. Vesicular) 
Ap3s1, Arl6ip5, Bst2, Cct2, Chmp1b, Chmp7, Exoc2, 
Golim4, Golph3, Gosr2, Mfsd1, Mmgt2, Mtmr2, Myl6, 
Nipsnap3b, Nup98, Plekha3, Rab1b, Rap2a, Rap2b, 
Rasgef1b, Rer1, Rtp4, Slc23a2, Slc38a6, Slc6a6, 
Slc7a11, Snap29, Snx17, Snx24, Snx3, Srp14, Srp72, 
Tbc1d22a, Tmed3, Vps28, Vps29, Vti1b, 
General Metabolism 
1700021F05Rik, 1810037I17Rik, 2010107E04Rik, 
Akr1a4, Alas1, Atl2, Azin1, Bhlhb9, Casd1, Dpy19l4, 
Enpp1, Erbb2ip, Evi2a, Extl3, Fam165b, Fam174a, 
Fundc2, Gm10063, Impad1, Lsmd1, Ly6e, Mcee, 
Mrpl39, Mrpl52, Mrps33, Mrps9, Naa20, Naa50, Nd1, 
Ndufa8, Ndufb2, Ndufb5, Oxct1, Pde4dip, Pgam1, 
Ppm1m, Smpdl3a, Surf4, Tor3a, Vkorc1, Wbp5,  
Figure 5-12: Genes of interest associated with metabolism and homeostasis.  A considerable number of 
genes with an increase in expression are associated with protein translation and processing.  The increased 





The identified genes of interest association with a specific function out with 
metabolism/homeostasis were plotted onto a cellular map using ontology data 
obtained from the Ensembl Biomart database.  This enabled the location of each gene 
to be determined and further organised by function (Figure 5-13).   The overall 
expression profile from this set of genes is one of robust pro-inflammatory myeloid 
cell activation. The increased expression of lysosomal-associated membrane protein, 
ATPase proton pumps and numerous lysosomal enzymes including cathepsins, 
histocompatibility subunits and genes involved in membrane restructuring strongly 
support antigen presentation and a classic hallmark of classically activated innate 
immune cells.  Surface markers CD48 CD86, CCL8, CXCL9, CXCL13, and TLR2 are all 
typically associated with a pro-inflammatory classical activation phenotype 
(Mantovani et al., 2004, Martinez et al., 2008, Elishmereni and Levi-Schaffer, 2011, 
Samuel and Kroner, 2011). 
 
The expression of numerous pro-inflammatory cytokines and chemokines, including 
IL-1b and TNF-a, indicate active processing within the caspase-1 mediated 
inflammasome (Franchi et al., 2009).  Expression was also increased for caspase-4 
(Casp-4); implicated as an ‘inflammatory caspase’ in regulating inflammasome 
function (Martinon and Tschopp, 2007, Sollberger et al., 2012).  Other pro-
inflammatory genes found within this dataset, and reported to be neurotoxic, include 
matrix metalloproteinase 12 (Mmp12) (Bai et al., 2014) and prostaglandin-
endoperoxide synthase 2 (Ptgs2) (Minghetti, 2004).  The latter is known to be 
expressed in prion disease (Walsh et al., 2000, Kim et al., 2007, Minghetti and 
Pocchiari, 2007) and a target of non-steroidal anti-inflammatory drugs (NSAIDs) used 
in clinical trials to treat neurodegenerative diseases by inhibiting prostaglandin 





Figure 5-13: Genes of interest associated with immune activation and cell-to-cell signalling.  Genes have 





1700112E06Rik, 5430435G22Rik, Aggf1, Cd14, 
Cd200r4, Cd48, Cd84, Cd86, Cdc37, Clec5a, Clec7a, 
Colec12, Csf2rb2, Cxcl10, Cxcl16, Cxcr4, Fabp5, Fam20c, 
Fcgr4, Fgr, Fth1, Ftl1, Ftl2, Gadd45a, Gadd45b, Gem, 
Glipr1, Gng5, Gpr84, H28, H2-D1, H2-gs10, H2-K1, H2-
Q7, H2-T10, H2-t9, Hcst, Hscb, I830012O16Rik, Id2, 
Ifi202b, Ifi30, Ifi44, Ifih1, Ifit1, Ifit2, Ifit3, Ifitm3, Igbp1, 
Iigp1, Ikbke, Il2rg, Irf1, Irf7, Irf9, Lag3, Lrp12, Ly6a, Ly9, 
Map3k7, Map3k8, Mif, Nkap, Nmi, Ola1, Parp9, Ptger4, 
Robld3, Sdcbp, Slamf9, St5, Stat1, Tapbp, Tlr1, Tlr2, 
Tmem9b, Tnfaip2, Txndc17 
  
Synapse / Axon Function 
Alcam, Apbb2, App, Atxn10, Cadm1, Caprin1, Got1, 
Grasp, Grinl1a, Itga5, Katna1, Krtcap2, Lgals1, Neu1, 
Nrp1, Plxnb2, Sdc3, Sulf2, Syngr1,  
Cytoskeleton 
Arhgap24, Arl2, Arpc1b, Arpc5l, 
Baiap2, Bst2, Capg, Cfl1, Coro1c, 
Dctn6, Diap2, Dtnbp1, Efcab2, Ezr, 
F2r, Flna, Fmn1, Gas2l3, Gpr65, Kif3a, 
Myo1e, Myo5a, Nexn, Nuak2, 
Plekhh2, Sdc4, Tbca, Tmsb10, Tpm4, 






Adh5, Aldoa, Atox1, Cln8, Cops6, Coq7, Cox4i1, Cstb, 
Gpx4, Hif1a, Hspe1, Ifi27l2a, Mapkapk2, Myeov2, Ncf1, 
Plekha1, Ppp1r15b, Prdx1, Prdx5, S100a1, Selm, Serp1, 
Tacc3, Vac14 
  
Cell Migration & Recruitment 
Ccdc23, Ctnnb1, Hspb11, Itgb1, Lgals3, Lgals3bp, Lox, 
Lpl, Mfap1a, Ninj1, Npnt, Nptn, Plau, Plaur, Postn, 
Vcam1 
Mitosis/Proliferation 
Anapc13, Ankra2, Bola2, Ccny, Cd180, Cenpc1, Cenpo, 
Cep135, Cetn3, Cfdp1, Cks1b, Dna2, Ecd, Eid1, Gnl3, 
Hat1, Hprt, Impdh2, Mcm3, Mcm6, Mtap4, Npm1, 
Nus1, Ogfr, Ott, Ppp1cc, Ranbp1, Rcc2, Rhoc, 
Rnaseh2b, S1pr1, Slfn5, Sass6, Sssca1, Top2a  
Cytokines & Chemokines 
Ccl4, Ccl5, Ccl8, Ccl9, Ccrl2, Csf1, Cxcl11, Cxcl13, Cxcl14, 
Cxcl16, Cxcl9, Hebp1, Il12b, Il1b, Tnf 
Anti-inflammatory Signalling 
Atp6ap2, Axl, Bag1, Bcl2a1a, Bcl2a1b, Bcl2a1c, Bcl2a1d, 
Cd274, Cd300lf, Cd52, Cd72, Cd83, Cd9, Commd1, 
Csnk2b, Cst7, Fgl2, Hgf, Hint1, Ifi204, Il10rb, Itgax, 
Klf10, Lilrb4, Milr1, Naip2, Nfkbia, Nfkbib, Nfkbie, 
Rsad2, Serpine2, Slfn2, Spopl, Spp1, Tank, Timp2, 
Tnfaip3, Tpt1, Ubxn1, Usp15, Zc3h12a 
Lysosome Function 
0610031J06Rik, Arrdc4, Asah1, 
Atp6v0e, Atp6v1a, Atp6v1g1, 
Bloc1s2, Creg1, Ctbs, Ctns, Ctsa, 
Ctsb, Ctsd, Ctse, Ctsh, Ctsl, Ctsz, 
Dpp7, Dram2, Fuca1, Furin, Gaa, 
Galc, Gba, Gla, Glb1, Gm2a, Gns, 
Gsto1, Gusb, Irgm1, Lamp1, Lamp2, 
Lyst, Lyz2, Npc2, Rab12, Rilpl2, 
Rnf128, Rnf13, Rragc, Sqstm1 
Apoptosis (Pro & Anti) 
1110007C09Rik, Adar, Casp4, Ctla2a, Dusp2, Eif2ak2, 
Fam32a, Fnip2, Gabarapl1, Ghitm, Ngfrap1, Niacr1, 




The increase in levels of IL-1, Tnf-α and Csf1 strongly portray the microglia activation 
profile as pro-inflammatory and not one of atypical down-regulation or resolution of 
inflammation (Figure 5-14A). The presence of a significant increase in transcripts 
involved with proteasome activity and major-histocompatibility mediated antigen 
presentation combined with expression of CXCR3 ligand genes required for both 
direct interaction with and recruitment of INF-γ producing CD4+ T cells (Whiting et 
al., 2004) offers a microglia activation state more akin to classically activated 
macrophages.  Also of note, and crucial to the maintenance of a chronic response to 
inflammatory cytokines, was that expression of Nfκb remained stable despite an 
increase in expression of NFκB inhibitors Nfκbia, Nfκbib, Nfκbie that have been shown 
to inhibit formation of NFκB at the transcription stages (Sun et al., 1993, Arenzana-
Seisdedos et al., 1995). 
 
The marked presence of cytokines IL-1, TNF-a, but not IL-6, would suggest the 
response by microglia is lacking in the full spectrum of cytokines expected from a 
classical form of activation via the myeloid differentiation primary response 88 
(MYD88)-dependant pathway (Akira and Takeda, 2004).  Pathway analysis of this 
dataset within the Reactome database revealed many of the elements of the MYD88-
independent pathway were represented by the differentially expressed genes within 
this study.  This is supported by the lack of differential expression of Myd88 (Appendix 
8-14). 
 
Interestingly Tgfb1 was not differentially expressed by microglia during the disease 
process (Figure 5-14B).  The level of expression of Tgfb1 was nominal throughout the 
disease process and to be expected from a constitutively expressed protein 
intricately involved in microglia homeostasis (Abutbul et al., 2012).  However 
expression of Smad anchor for receptor activation (Sara) is negligible indicating no 
translocation of SMAD proteins; core intracellular complexes of the TGFb1 signalling 
pathway (Heldin et al., 1997, Tsukazaki et al., 1998).  Further indications to the lack 
of active TGFb1 signalling is demonstrated by negligible expression of suppressor-of-
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cytokine-signalling 3, 4 and 5 (Socs3-5); implying no inhibition to the JAK/STAT 
signalling pathway mediated suppression of cytokine signalling (Shuai and Liu, 2003).  
Also of note was the lack of any discernible increase in expression of the TGF-b1 
receptor with only the presence of Usp15 known to act as the TGF-b1 receptor 
stabiliser (Inui et al., 2011).  As mentioned previously the lack of significant fold-
change increase in expression of Usp15 also indicates the lack of active TGF-Β1 
mediated signalling as a significant contributor to the disease response by microglia.  
Furthermore there were no transcripts associated with either MAPK and SMAD2/3 
further downstream and directly associated with the TGF-B1 mediated signalling 
pathway (Abutbul et al., 2012). 
 
Microglia are known to interact with neurons (Tremblay et al., 2010, Siskova and 
Tremblay, 2013) and numerous genes associated with axon elongation, synapse 
regulation and neurotransmitter release were observed to increase in expression.  
Interestingly this analysis partners the expression of these genes with microglia and 
adds them to the growing body of evidence for microglia involvement in neuron 
regulation (Vukovic et al., 2012, Ji et al., 2013, Miyamoto et al., 2013, Schafer et al., 




Figure 5-14: Expression of inflammatory cytokines and transcription factors associated with the 
regulation of activation phenotype of microglia.  A:  Strong increase in expression of Tnf-a, Il-1b and 
Csf1, but not cytokines associated with recruitment and escalation toward acquired immunity imply a 
robust but self-sufficient pro-inflammatory response by microglia in mouse-adapted prion disease.  B:  
Nominal and unchanged expression of Tgf-b1 is matched by a lack of expression of downstream 
















































































































































5.4.1 Acquisition of the Microglia Transcriptome 
 
The increase in expression of Il-1β is interesting as this goes against previous 
literature using murine prion disease in which expression of the mRNA is seen at 
levels no higher than uninfected control animals (Walsh et al., 2001).  
 
Isolating microglia from adult mice required extensive modification to the procedures 
published in the literature (Fleige et al., 2001, Cardona et al., 2006a, de Haas et al., 
2007, Nikodemova and Watters, 2012, Njie et al., 2012).  The accumulation of myelin 
within the brain suspension was not successfully removed by any of the unmodified 
protocols. The viscid nature of myelin resulted in contamination to the pure microglia 
suspended in the isolation solution and difficulty in processing the sample by FACS 
analysis.  This was most likely due to the age of the mice at the time of recovery.  The 
level of myelin lipid composition increases in rodent brain with age (Norton and 
Poduslo, 1973).  The published methods utilised a discontinuous Percoll® gradient to 
allow microglia to collect within an interphase, and typically described microglia 
isolation from postnatal, weaned and young adult mice; not mice hundreds of days 
old.  The volume of myelin encountered in in this analysis, from adult mice aged over 
1 year, resulted in invariable myelin contamination to the target interphase.  The yield 
of microglia within the interphase was also very low at x104 cells.  The quantity and 
quality of total RNA isolated from this number of cells was insufficient; presumably a 
result of myelin-induced failure for microglia to separate during centrifugation.  To 
address this the Percoll® discontinuous gradient was altered to allow all cells to pellet 
rather than collect in an interphase and combining the procedure with microglia-
specific magnetic microbeads.  This substituted the Percoll® gradient from a means 
to isolate microglia to one solely of myelin removal.  Once perfected, the adopted 





The quantity of total RNA yielded from isolated microglia extracted from 
experimental animals was minimal.  Quality control checks revealed numerous 
samples to be degraded.  This necessitated rejection of half of the samples with the 
consequence that the tested population was much reduced in size with only two 
arrays per group.   Gender matching of experimental mice within the groups was also 
no longer possible, although gender difference did not appear to impact on disease-
associated gene expression and did not present with further downstream 
complications.  The RNA required amplification in order to generate sufficient cDNA.  
Amplification of RNA can induce a small level of bias following truncation of the 5’ 
transcript end by successive application rounds (Brooks et al., 1995, Baugh et al., 
2001, McClintick et al., 2003).  Bias was mitigated by utilising an amplification kit that 
incorporated random primers with the oligo-deoxythymine primers during initial 
strand synthesis.  The chosen amplification kit was also specifically designed for small 
and degraded RNA samples.  Random primers anneal throughout the sequence 
thereby mitigating premature termination at the 5’ end of longer mRNA sequences 
(Feinberg and Vogelstein, 1983, Stangegaard et al., 2006).   
 
The loss of experimental RNA samples and the use of two arrays per time point 
limited the ability to perform statistical analysis beyond determining simple fold 
change in expression.  The less the number of arrays within a tested population, the 
greater the requirement for homogeneity between arrays to overcome variance.  
Consequently it would not have been possible to determine, if conflicting results 
were yielded, which array was displaying the correct expression profile.  Many 
experiments using limited numbers of arrays have yielded convincing and publishable 
results.  These studies overcame the lack of sample repetition by either using a 
significance analysis of microarrays (SAM) approach in which a constant was applied 
to the dataset from which reference was then made for each gene in turn (Tusher et 
al., 2001), or by using an empirical Bayesian approach to determine the distribution 
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variance from the data itself (Baldi and Long, 2001).  The SAM approach has seen use 
with microarray studies of prion disease (Xiang et al., 2004, Kim et al., 2008).   
 
The use of the cluster based approach described here does present with limitations 
as the method is fully reliant on high correlation between arrays.  The overall signal 
correlation between arrays in this analysis was high as evidence by the overall low 
variance between the arrays and consequently the expression profile is one of a 
convincing disease signature.  Some notable examples of transcripts that were not 
incorporated into the clustering processes including Tnf-a.  Due to the variance in the 
increase of expression between the two 200 dpi arrays, the gene was not clustered 
within the set correlation threshold of BioLayout Express3D.  Indeed, the expression 
profile was entirety unique to Tnf-a and consequently the gene was not incorporated 
into any clusters by MCL.  Despite this, the large increase in expression of Tnf-a in 
response to disease was confirmed by both arrays and therefore the gene was 
considered disease-associated.  This also served to highlight the importance of 
familiarity with the entire dataset at the individual gene level. 
 
5.4.2 Inflammatory profile 
The inflammatory phenotype typically associated with in-vivo prion disease has been 
shown to be remarkably anti-inflammatory (Walsh et al., 2001, Baker and Manuelidis, 
2003).  The growth factor TFG-B1 has been shown to be the dominant anti-
inflammatory cytokine present in murine prion disease models (Cunningham et al., 
2002).  Via the TGF-B1 signalling pathway, the cytokine plays a key role in limiting 
microglia activation (Lodge and Sriram, 1996) and is evident throughout the disease 
process (Boche et al., 2006, Abutbul et al., 2012) providing microglia with a 
phenotype concurrent with the resolution of inflammation and wound healing (Fadok 
et al., 1998).  The lack of differential expression of Tgf-b1 within this dataset was 
therefore marked in its absence.  The cytokine is also required for the correct function 
of, and is itself unable to pass, the blood brain barrier (Kastin et al., 2003, Dohgu et 
al., 2004, Garcia et al., 2004).  This study therefore suggests that the increased 
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expression of TGF-B1 noted in other studies is not microglial in origin but is expressed 
by another group of cells from within the CNS.   Alternatively it is possible that the 
peripheral route adopted in this analysis resulted in a markedly different, and more 
pro-inflammatory phenotype to that seen when using an intracerebral route.   
 
Microglia are sensitive to inflammatory signals passed across the blood brain barrier 
into the central nervous system  (Dantzer, 2004, Lemstra et al., 2007, Quan and 
Banks, 2007).  A peripheral inflammatory signal has been observed in prion disease 
following a peripheral route of infection (Newsom et al., 2011), but not following an 
intracerebral route (Cunningham et al., 2005a).  It would also appear that following 
infection, pre-activated T-cells are found to populate the CNS (Lewicki et al., 2003, 
Iken et al., 2011) suggesting activation of these cells takes place in the periphery 
before cross over into the CNS.    Furthermore the timing and type of activation in the 
multicellular environment of the central nervous system has a marked influence on 
the overall neurotrophic or neurotoxic phenotype of the microglia response (Gomez-
Nicola et al., 2013).  Consequently the choice of a peripheral route, complete with 
the obligatory peripheral pathogenesis stages, different timing and type of response 
by microglia could result in a markedly different inflammatory phenotype. 
 
The presence of CXCR3 ligands, in addition to acting as chemo-attractants for 
activated CD4+ and CD8+ T-cells (Campanella et al., 2008) are implicated with the 
interferon response as part of a multi-cellular response within the brain parenchyma 
(Klein et al., 2005).  The presence of T-cells in the brains of mice infected with murine 
prion disease is well known, although it is not clear how full functionality is 
maintained without the presence of INF-γ (Lewicki et al., 2003).  The presence of 
increased expression for Cd274, which encodes for a membrane bound H7-protein 
receptor, is intriguing as has been implemented in co-stimulation of acquired 
immune cells.  The receptor is required for successfully myeloid cell interaction with 
activated T cells during antigen presentation (Linsley and Ledbetter, 1993).  Within 
macrophages, CD274 is inducible, enhances expression of IL-10 in the host cell and 
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plays a key role in inhibiting CD4+ T-cell activation (Loke and Allison, 2003).  CD274 is 
also a required IL-2 dependant cofactor for IL10 production (Tamura et al., 2001).  
Despite this, and as per Tgfb1, expression of the Il1r receptor was increased but not 
Il10.  The lack of evidence for T-cell co-stimulation, combined with no presence of 
anti-inflammatory cytokine transcripts, including Il-4 and Il-10, implies the chronic 
maintenance of a classical activation phenotype (Varin and Gordon, 2009).  
 
The lack of differential expression of myeloid differentiation primary response 88 
(Myd88), I-6 and the presence of many IFN-inducible genes within this dataset 
supports transcriptional regulation of cytokine cascades within microglia to be via the 
Myd88-independent pathway (Akira and Takeda, 2004).  As a key adaptor protein in 
the Toll-like and IL-1 family of receptors, the protein MYD-88 is rapidly expressed in 
myeloid cells in response to antigen and leads to NFκB mediated changes to 
transcription (Kawai et al., 1999).  Where the expression of the protein form of 
MYD88 is lacking, the response to antigen is delayed and activation of NFκB is via IFN-
inducible genes (Hoebe et al., 2003, Yamamoto et al., 2003).  The resultant cytokine 
profile of Myd88-independent activation is also marked by the absence of IL-6 
(Adachi et al., 1998).  The targeted removal of Myd88 does not interfere with prion 
disease pathogenesis (Prinz et al., 2003) indicating the innate immune response is 
not dependent upon the MYD88-dependant pathway.  Experimental evidence using 
mouse-adapted prion diseases has also uncovered the protective effects of innate 
interferon regulatory factors via toll like receptors and the Myd88-independent 
pathway (Spinner et al., 2008, Ishibashi et al., 2012).  The results in this analysis 
further confirm the importance of interferon response genes in prion disease and 
builds upon the results of the multi-cellular analysis of chapter 2 in which an entire 
cluster of interferon response genes was observed.  Therefore the possibility of 
transcriptional regulation via the MYD8-independent pathway is a core component 
of the microglia response to prion disease and offers a convincing explanation for the 




The strong translational signal, as evidenced by increased expression of genes 
encoding ribosomal subunits, supported an increased level of activity within 
microglia.  As neither mRNA nor ribosomes have a particular long half-life within the 
eukaryotic cytosol, the cell must continually produce ribosomes to function correctly 
(Retz and Steele, 1980, Warner, 1999, Tourrière et al., 2002).  There is also a close 
association between mRNA stability and ribosomal density implying an increase in 
ribosome density is beneficial to the cell when increased burdens on translation are 
imposed (Dana and Tuller, 2012, Edri and Tuller, 2014).  Consequently the increased 
level of expression of genes associated with translation was to be expected within 
activated microglia.   
 
5.4.3 Cytoskeletal Modification: Migration or Sampling? 
There is considerable debate on whether the observable regional increase in 
microglia in chronic disease is due to mitosis, migration or influx of differentiated 
peripheral monocytes.  The use of parabiosis has demonstrated a limited role for 
monocyte influx during acute injury (Mildner et al., 2007, Ajami et al., 2011), yet the 
impact of a peripheral inflammatory response as part of the overall pathology has 
not been fully explored.  Just as the peripheral priming of T-cells has been 
demonstrated as a requirement for their entry into the CNS (Lewicki et al., 2003), 
peripheral activation of monocytes would equally facilitate the contribution of 
monocytes to the resident microglia population.  By incorporating a peripheral route 
of infection in this study, the mechanisms for cell migration including adhesion 
adherence, chemokine release and matrix restructuring are intriguing as all would 
support both resident migration and peripheral influx. 
 
The increase in expression of genes involved with actin binding and restructuring 
imply microglia are undertaking changes in morphology.  Resting microglia are known 
to use protrusions to continuously sample the immediate surroundings (Nimmerjahn 
et al., 2005) and actively make and break physical contact with neighbouring cells 
(Tremblay et al., 2010).  The protrusions are guided by extracellular adenosine 
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triphosphate and adenosine diphosphate acting as chemokinetic ligands to purinergic 
receptors (Sasaki et al., 2003, Franke et al., 2007).  In the perturbed environment of 
a neurodegenerative disease it is conceivable that an increasing extracellular gradient 
of chemoattractants would explain the heightened mRNA expression for process 
motility.  Furthermore microglia recruitment in prion disease is aided by C-C 
chemokine receptor ligation and the increase in expression of the rectors was noted 
in this analysis (Marella and Chabry, 2004, Marella et al., 2005). 
 
Table 5-6:  Comparison between the identified disease-associated differential expressed gene lists of 
this analysis and that of Chapter 2.  A total of 93 genes were found to be shared.  These were highly 




5.4.4 Comparison with the Re-analysis described in Chapter 2 
In chapter 2, microglia dominated the expression profile acquired from a multi-
cellular source.  In this analysis isolated microglia present with a highly pro-
inflammatory activation phenotype.  Comparison of the gene list from this analysis 
with the genes considered myeloid in origin from the analysis in chapter 2 revealed 
29.2% of the genes were shared.  These genes were highly enriched for the innate 
immune response (Table 5-6).   It is important to point out here that the two analyses 
were not directly comparable.  The analysis in Chapter 2 was performed on data 
obtained from mouse experiments using an intracerebral route and whole brain total 
RNA and therefore differs from the peripheral route and single cell source of total 
Shared Genes Between the Two Analyses GO Enrichment 
Aif1, Anxa3, Anxa4, Arpc1b, Axl, Bcl2a1a, C3ar1, C4b, Capg, 
Ccl5, Ccl8, Ccl9, Cd14, Cd48, Cd52, Cd72, Cd84, Cd86, 
Ch25h, Clec7a, Csf1, Cst7, Cstb, Ctsa, Ctsb, Ctsd, Ctsh, Ctsl, 
Ctsz, Cxcl10, Cxcl13, Cxcl16, Cybb, Fcgr4, Ftl1, Ftl2, Fuca1, 
Fxyd5, Galnt6, Glipr1, Gns, Gpr65, Gpr84, Gusb, H2-K1, H2-
Q7, Ifi204, Ifi27l2a, Ifi30, Ifi44, Ifih1, Ifit1, Ifit2, Ifit3, Ifitm3, 
Iigp1, Il10rb, Irf7, Irf9, Irgm1, Itgax, Lag3, Lamp2, Lgals3bp, 
Lilrb4, Ly9, Mmp12, Naip2, Ncf1, Oas1g, Oasl2, Parp14, 
Parp9, Plxnb2, Psme1, Ptplad2, Rpl37a, Rsad2, Rtp4, Sgpl1, 
Slamf9, Slfn2, Spp1, Stat1, Sulf2, Tapbp, Timp2, Tlr1, Tlr2, 
Tnfaip2, Tor3a, Trim30 
Innate Immune Response: P = 4.54 x10-24 
 
Response to stress: P = 7..5 x10-13 
 
Chemokine receptor binding: P = 
7.96x10-10 
 
Lysosome: P = 2.83 x10-9 
 




RNA used here.  The use of a single cell RNA source, combined with a consistent yield 
of isolated microglia from each time point, resulted in the known concentration of 
cDNA per cell that was hybridised to the microarray.  This is not possible using a whole 
brain isolate where the number of cells is not known and neither is the proportion of 
microglia contributing to the overall signal.   Consequently the relatively low level of 
gene overlap is not surprising.  Where the two studies complement each other is in 
the overall conclusion.  Both analysis’s reveal a robust chronic inflammatory response 
confirming the importance of microglia to the disease process. 
 
5.4.5 Conclusion 
The relatively low number of microarrays utilised in this study identified a 
considerable number of differentially expressed genes associated with the microglia 
response to prion disease.  Additional microarrays would no doubt have increased 
accuracy of both the number of identified genes and the difference in expression. Yet 
the results offer a convincing signature of myeloid activation that matches the 
morphological timing of microglia activation seen in previous chapters.  Microglia in 
this analysis were shown to express a disease signature markedly more pro-
inflammatory than that currently portrayed in the literature for prion disease.  Within 
other protein-misfolding diseases, notably Alzheimer’s; microglia are observed as 
expressing a repertoire of pro-inflammatory cytokines including TNF-α (Bhaskar et 
al., 2014), IL-1β and IL-6 (Griffin et al., 1995, Tarkowski et al., 1999).  The potential of 
generating a neurotoxic microenvironment from expression of the genes within this 
inflammatory signature is high.  Despite this, the presence of genes normally shown 
to be associated with neuronal synapses, but shown here to be expressed by 
microglia, suggests ongoing intercellular interaction with other cell types residing 
within the brain.   
 
The isolation of microglia from prion infected mice has been limited to one laboratory 
and was not performed to demonstrate the in-vivo expression profile per se but to 
confirm the high level of infectivity maintained by an isolated cell population that 
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harbour negligible amounts of misfolded protein (Baker and Manuelidis, 2003).  As 
such, the microglia were rested in cell culture media for16- to 18-h post isolation to 
facilitate downstream transmission infection studies.  Consequently the 
transcriptome of incubated microglia would not be comparable to the transcriptome 
acquired immediately after isolation and the study focused on the gene expression 
differences between uninfected and infected microglia with respect to harbouring 
the disease.  This has not stopped the study being referred to repeatedly as 
confirmation of a unique down-regulated activation phenotype of microglia in prion 
disease, despite no evidence confirming the source of anti-inflammatory 
immunomodulators in whole brain studies, including TGF-B1 (Cunningham et al., 
2002, Boche et al., 2006), are indeed attributed to microglia.  Isolated microglia and 
astrocytes from murine models of Alzheimer’s Disease as part of an extensive study 
by (Orre et al., 2014) also yielded a marked increase in pro-inflammatory markers, 
yet this was also concurrent with a reduction in neuronal synapse endocytosis 
support.  The disadvantages of expensive genetic modification required to initiate 
murine Alzheimer’s Disease models were highlighted in a lack of microglia expression 
overlap between the murine dataset and a post death acquired human Alzheimer’s 
Disease dataset.  The same was not true of the differentially expressed immune genes 
found within the astrocyte dataset.  Astrocytes are able to express and act as immune 
cells in their own right and are known to phagocytise dead and dying neurons (Tashiro 
et al., 1998, Schultz et al., 2004, Chung et al., 2013) and are also implicated in 
neuronal toxicity via expressed nitric oxide and inducible nitric oxide synthase (Bal-
Price and Brown, 2001).  It was for this reason that a microglia isolation approach was 
adopted in this present study and a degree of caution should be applied where 
attribution of innate immune gene expression to microglia has been assumed in 
studies adopting a whole brain transcriptome analysis. 
 
A study by (Godbout et al., 2005) using microarray analysis of adult and aged BALB/cJ 
mouse brain noted the activation of the peripheral immune system by administration 
of LPS resulted in  activation of an innate immunological response within the central 
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nervous system.  This was characterised by compliment and classical pro-
inflammatory markers including IL-1, IL-6 and antigen presentation MHC complexes 
and was greatly inflated in aged mice.  This heightened classical innate immune 
activation was also noted in numerous other sickness behaviour studies utilising LPS 
to initiate a response (van Dam et al., 1992, Combrinck et al., 2002, Dantzer, 2004).  
The lack of expression of Inf-γ, Il-6 and Il-33 by microglia, all well-defined classical 
pro-inflammatory cytokines in this present study suggests that the pro-inflammatory 
response is unique to this model of prion disease and is not a classical stereotypic LPS 
type response and is furthermore self-sufficient and maintained by resident microglia 





Interest in the other cells that accompany neurons within the central nervous system 
has rapidly increased, indicating a shift from the neuro-centric focus which once 
dominated research into neurodegenerative diseases.  Indeed, at the 2011 Society of 
Neuroscience annual conference, held in Washington, USA, the term ‘microglia’ was 
searched on the society’s conference website with such frequency that it made 
number 6 in the list of top 10 searches made Hughes (2012).  The aim of the present 
study was set up to investigate the role of activation of microglia in chronic 
neurodegenerative disease.  Models of mouse-adapted prion disease were chosen as 
the basis for studying microglia as they demonstrate robust neuronal loss invariably 
leading to fatality, accumulation of misfolded protein and crucially, activation of glial 
cells.   
 
6.1 Determining Microglia Contribution in the Multicellular Environment of Prion 
Disease 
Endogenous PrPC is associated with cellular membrane bound lipid rafts (Naslavsky 
et al., 1997, Agostini et al., 2013) and is recycled every few minutes from the cell 
surface via pinocytic clathrin-coated pits, and then back to the surface within 
recycling endosomes (Mironov et al., 2003, Sunyach et al., 2003).  The accumulation 
of misfolded PrP protein in neuronal membranes has been blamed for dysfunction of 
neurotransmitter receptors (Kristensson et al., 1993, Diez et al., 1997) and the 
protease resistance of the misfolded form has been implicated in mitigating the 
accumulation of misfolded PrP in lysosomes following membrane recycling (Caughey 
et al., 1991, Bouzamondo-Bernstein et al., 2004).  Furthermore the N-terminal 
truncation of PrP is strongly associated with lysosomal proteases (Caughey et al., 
1991, Dron et al., 2010) with the consequence that the presence of cholesterol 
biosynthesis genes, glycosylation pathways, endosomal/lysosomal pathways and 
lysosomal catharsis have all been associated with neurons in many transcriptome 
studies of prion disease (Brown et al., 2004, Xiang et al., 2004, Brown et al., 2005, 
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Skinner et al., 2006, Xiang et al., 2007, Guillerme-Bosselut et al., 2009).  However, the 
presence of genes linked with endosome/lysosome trafficking and proteases are also 
associated with protein degradation by phagocytic immune cells.   This study initially 
made use of a comprehensive microarray dataset of prion disease in mice, made 
available in the public domain, with which to determine the contribution of microglia 
and confirm the origin of many of these pathways.  
 
The dataset was analysed using BioLayout Express3D; a novel software tool that 
supports the visualisation and clustering of correlation networks.  The dominant 
signal of differentially expressed genes was found to be associated with innate 
immunity.  By utilising an original approach of co-normalising cell-specific datasets 
from a variety of different brain cell types and macrophage activation profiles it was 
determined that the immune signal was overwhelmingly myeloid in origin and not 
just a component of the overall response suggested by other microarray studies of 
the disease  (Brown et al., 2003, Booth et al., 2004, Riemer et al., 2004, Xiang et al., 
2004, Brown et al., 2005, Skinner et al., 2006, Xiang et al., 2007, Moody et al., 2009). 
Indeed only 8.5% of the identified genes were found to be exclusively expressed by 
other brain cell types including a mere 4 genes specifically identified as neuronal in 
origin.   The very high correlation seen between nodes within BioLayout Express3D 
generated clusters further suggested the genes of interest were highly related to one 
another.  A predominantly single cell type origin would offer an explanation for this.  
This study therefore implies a degree of caution should be applied to the 
interpretation of published multicellular studies in which an assumption of cellular 
origin, particularly toward neurons, has been made for a given gene without evidence 
to validate that claim. 
 
6.2 Characterising the Morphological Response of Microglia Activation 
To further investigate the strong microglia response an in-vivo model of prion disease 
was instigated.  The microglia in this mouse model expressed EGFP under control of 
the Cfms operon.  Consequently all cells of myeloid origin expressed EGFP and the 
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confirmation that these mice were suitable for infection by mouse-adapted prion 
disease was described in chapter 3.   The quantification of the EGFP expressing 
microglia in chapter 4 confirmed activation was strong in areas of misfolded protein 
during the later stages of the disease.  Still-ramified microglia were shown to 
accumulate in areas of initial misfolded protein deposition within the medulla.  This 
suggested an independence of the initial motile response of microglia from the full 
morphological activation observed at later stages of the disease.  Although further 
evidence would be required to fully quantify this motile response, the confocal 
generated fluorescent images were very clear in qualitatively visualizing ramified 
microglia in these regions.  It has been noted in prion disease that the timing and type 
of activation in the multicellular environment of the central nervous system has a 
marked influence on the overall neurotrophic or neurotoxic phenotype of the 
microglia response (Gomez-Nicola et al., 2013).  Therefore if the initial and later 
response of microglia to misfolded protein are independent then it opens up many 
opportunities to alter the early and late behaviour of microglia and influence their 
activation at different stages of disease, with the aim of achieving a neurotrophic 
phenotype.  
 
6.3 The Transcriptomic Analysis of Microglia Activation in Prion Disease 
The overall consensus for the profile of activated microglial phenotype in protein 
misfolding diseases including  Alzheimer’s, Parkinson’s and prion disease is one of a 
down-regulated anti-inflammatory phenotype dominated by the differential 
expression of TGF-β (Fadok et al., 1998, Baker et al., 1999, Walsh et al., 2001, 
Cunningham et al., 2002, Perry et al., 2002, Baker and Manuelidis, 2003).  The data 
presented in Chapter 5, in which the transcriptome of isolated microglia was 
investigated during prion disease suggest a considerably more pro-inflammatory 
phenotype.  The recent study performed by Gomez-Nicola et al. (2013), in which an 
artificial switch to a pro-inflammatory microglia phenotype delayed disease 
progression, would imply that such a phenotype confers a degree of neuroprotection.  
The reason behind the clear difference in the overall phenotype seen in previous 
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studies to the data presented here is unclear.  The lack of inflammation within the 
control mice, run in parallel to the infected mice, rules out an artefact of isolation as 
a cause.  The obvious difference is route of infection.  The deliberate use of a 
peripheral route in this study was to ensure that microglia would respond to initial 
infection entering into the CNS environment.  Certainly the longer incubation period 
witnessed in peripheral routes, and the longer incubation period observed by Gomez-
Nicola et al. (2013) following a switch from an anti to a pro-inflammatory phenotype 
using an intracerebral route is intriguing. 
 
Despite an overwhelming microglia-centric interpretation, the results of chapters 2 
and 5 cannot completely rule out the contribution of neurons in the disease process.  
This is due to the limitations of determining cellular origin from a whole brain study.  
The use of overlaid single-cell type datasets was heavily reliant on homogeneity 
between what are effectively independent populations of arrays.  The results in 
chapter 5 were microglia cell centric and as such do not supply data on the other cells 
found in the brain.  The results do however strongly confirm the independence of 
microglia from misfolded prion protein processing.  The expression levels of Prnp in 
the dataset analysed in Chapter 5 remained negligible and unchanged throughout the 
length of the experiment both in infected and control animals. Microglia are known 
to harbour negligible quantities of PrP protein in both endogenous and misfolded 
isoforms (Baker et al., 2002, Ford et al., 2002).  Therefore it is unlikely that the 
observed differential expression of genes associated with membrane trafficking and 
protein degradation are associated with intracellular prion protein processing by 
microglia.  Furthermore microglia are known to inefficiently phagocytise extracellular 
misfolded protein in numerous neurodegenerative diseases in-vivo (Stalder et al., 
1999, Tahara et al., 2006, Bolmont et al., 2008, Hughes et al., 2010).  This study 
therefore implies it is unlikely that the presence of transcripts for membrane 
trafficking and protein degradation are involved with the processing of extracellular 
misfolded protein, and shifts the focus considerably towards an immunological 




6.4 The Response of Microglia to Disruption in the Central Nervous System: Cause 
or Consequence? 
The correlation of microglial morphology with the immunophenotype imparted by 
the cytokine and receptor repertoire imparts microglia with the ability to function in 
a highly specialised, yet plastic, manner unique to the localised microenvironment at 
that time plasticity (Streit et al., 1988, Perry et al., 2010).  Consequently is not 
sufficient to draw a conclusion on microglial function by describing the morphology 
and testing for the presence of a few selected immune-related receptors or 
cytokines.  This study adopted a transcriptomic approach in combination with 
quantifying morphology and was thereby able to identify numerous key genes and 
pathways key to determining the role of these cells within the prion diseased brain. 
 
At 200 dpi microglia in the 79A/BALBFms-EGFP/- show all the hallmarks of morphological 
activation with shortened processes and engorged soma.   A microglial response was 
also seen at 150dpi in the medulla however this was restricted to accumulation and 
these cells did not present with significant morphological changes.  The time points 
chosen in this study do not allow for determination of whether microglia are 
responding prior or after parenchymal perturbation or misfolded protein but these 
data do strongly suggest that morphological changes and initial motile response are 
separate.  The accumulation of still ramified microglia into the medulla at 150 dpi 
should not therefore be dismissed as a lack of function as clearly the act of motility 
would imply the cells are responding to a chemotactic gradient.  Previous studies 
have highlighted the dominance of an immune related signal in specific brain regions.  
A study by Riemer et al. (2004) adopted a peripheral route infecting C57bl6 mice with 
139A and performed microarray analysis on isolated cortex, medulla and Pons as a 
time course study at 100, 125, 150 and terminal stage.  A dominant innate immune 
signal was observed throughout the tested regions with greater expression fold 
change noted in the medulla and coinciding with the presence of disease-associated 
vacuolation in this region.  Others have isolated the hippocampus to allow for 
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quantifying neuronal loss in the pyramidal layers evident with this region and noted 
the increase in immune related genes to coincide with substantial neuronal loss at  
(Brown et al., 2004, Brown et al., 2005).    
 
Microglia are known to interact with neurons in both the healthy brain and migrate 
to areas of injury (Nimmerjahn et al., 2005, Tremblay et al., 2010, Chen et al., 2014).  
The involvement of localised inflammation in triggering and facilitating axonal 
regeneration has been thoroughly documented (Lu and Richardson, 1991).  More 
recent work has determined that microglial accumulation is not just an influx made 
as part of an innate immunologic response, but strongly supports the hypothesis that 
microglia are intrinsic to axonal processing.  Elegant in-vivo models utilising a 
peripheral nerve graft within the thalamus documented the accumulation of 
ramified, or at most partially activated, microglia at the site of active axonal 
regeneration with close contact documented between grafted neurons and microglia 
(Shokouhi et al., 2010).   
 
A strong gene expression signal was seen at 200dpi and a less strong signal at 150.  
The expression of cytokines is very pro-inflammatory but there is no differential 
expression of IL-6 or components of the MYD88 pathway that are typically associated 
with a classically activated phenotype.  These data therefore suggest an activation 
profile that is specific to prion disease.   If it most likely this is unique to the in-vivo 
environment as co-cultures of microglia and neurons in the presence of PrP106-126 
induces a stereotypic response with CD14 mediated detection of damaged neurons 
and increased expression of IL-6 (Bate et al., 2005), and matching the stereotypic 
neurotoxic response observed in co-cultures of neurons in the presence of LPS 
activated microglia  (Chao et al., 1992).  These data presented in this study therefore 
conclude that microglia are responding in a prion specific manner but further analysis 
of the model would be required to determine if microglia response is a cause or 
consequence of the developing pathology and if the timing of activation coincides 




6.5 Microglia Activation Phenotype 
Overall this study demonstrates that microglia present with a transcriptomic 
phenotype considerably more pro-inflammatory than the ‘down-regulated’ 
phenotype prevalent in the literature, predominately described by one laboratory 
using a very specific stereotactic intracerebral inoculation; where the immune 
response has been described as comprising low levels of pro-inflammatory cytokines 
with elevated TGF-B1 (Fadok et al., 1998, Baker et al., 1999, Walsh et al., 2001, 
Cunningham et al., 2002, Perry et al., 2002, Baker and Manuelidis, 2003, Siskova et 
al., 2009, Stanton et al., 2009, Hughes et al., 2010).  The lack of differential expression 
of TGF-B1 within the microglial isolation dataset is therefore marked in its absence.  
The lack of matrix metalloproteinase MMP3, required for TGF-B1 release, provides 
further evidence the cytokine is not produced in microglia.  The cytokine is also 
required for the correct function of, and is itself unable to pass, the blood brain 
barrier (Kastin et al., 2003, Dohgu et al., 2004, Garcia et al., 2004) ruling out any 
contribution from the periphery towards increased levels of the cytokine in the 
parenchyma.  Elements of the TGF-B1 pathway were noted in the whole brain re-
analysis.  This study therefore concludes that the increase in level of TGF-β1 is not 
microglial in origin and if the level of the cytokine does increase it must be expressed 
by another group of cells from within the CNS.  Also of note was the lack of any 
discernible increase in expression of the TGF-B1 receptor with only the presence of 
Usp15 known to act as the receptor stabiliser (Inui et al., 2011).  Furthermore there 
were no transcripts associated with either MAPK and SMAD2/3 further downstream 
and directly associated with the TGF-β1 mediated signalling pathway (Abutbul et al., 
2012).   
 
6.6 Improvements to this Study 
In chapters 3 and 4 it was suggested that microglia migrate to areas of misfolded 
protein by 150 dpi (65% of the incubation period) before undergoing morphological 
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changes indicative of activation.  Although genes associated with cellular migration 
were found at 150 dpi the fold change was not considerable.  This could be an artefact 
of signal dilution as comparatively fewer cells were observed to migrate than were 
fully activated by 200 dpi.  To address this an increase in the sample population is 
suggested and could be met by either repeating the experiment with a larger number 
of arrays or by isolating microglia in specific regions.  The latter would also serve to 
increase the sample population by virtue of increasing the number of target microglia 
per array.  Regional analysis would also further the research into the role of microglia.  
Recent research has shown that microglia activation is highly plastic and the resultant 
phenotype is dependent upon the specific insult perceived by microglia in a given 
area (Perry et al., 2010, Hanisch, 2013, Hanisch and Gertig, 2014).  Microglia in 
different regions of the brain also demonstrate phenotypic differences (Sasaki and 
Nakazato, 1992, Ong et al., 1995, Torres-Platas et al., 2014), an effect exaggerated 
during healthy aging (Sheffield and Berman, 1998, Kullberg et al., 2001). The data 
presented in this study offers a global view and the overriding similarity in co-
expression shown using clustering in BioLayout Express3D would suggest that 
activated microglia in the brain act in a homogenous population.  It is possible 
however that the differential expression of activated cells masks that of cells that are 
not morphologically activated or responding with such vigour.  Therefore a 
hypothesis can be generated that microglia in differing regions might generate a 
different activation phenotype in response to the same stimuli.  This would offer an 
explanation for the apparent regional targeting of microglia activation observed in 
many neurodegenerative diseases (Williams et al., 1994, McGeer et al., 2003, Brink 
et al., 2005).   
 
The possibility of capturing the differences between the response of microglia could 
be further extended through the use of single cell capture techniques, a technique 
that has successfully been used on both glia and neurons (Majer et al., 2012, 
Parakalan et al., 2012).  The power of these techniques has been advanced further 
with the possibility of obtaining transcriptomic data from extremely small RNA yields, 
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down to that isolated from a single cell (Tang et al., 2010, Shalek et al., 2013, Picelli 
et al., 2014).  Evidence would suggest that microglia interaction with neurons in the 
healthy brain is related to modulation of synaptic dendrites through phagocytosis 
(Tremblay et al., 2010, Tremblay and Majewska, 2011, Siskova and Tremblay, 2013).  
The use of techniques to investigate cellular interaction at a microenvironment level 
could be implemented to capture the transcriptome of individual cells interacting as 
part of a multi-partite synapse, or clustered around a specific plaque of misfiled 
protein.  This might elude to the specific mechanisms that result in the breakdown of 
homeostasis within the brain which are proposed to be key to the multicellular 
hypothesis governing neuronal loss observed in neurodegenerative diseases.   
 
6.7 Future Work 
To investigate into the cause or consequence events of microglial activation with the 
79A/BALBFms-EGFP/- model with regard to neuronal interaction would require ensuring 
the migration of microglia and their subsequent activity towards full activation are 
captured in a location where neuronal populations can either be counted or specific 
evidence for harm documented.  These data presented here would support a focus 
on the medulla where microglia and expressed markers of activation phenotype can 
both be easily visualised using immunohistochemistry, in addition to viable isolated 
at a regional level to determine specific function.  An additional time point taken 
between 150 dpi and 200 dpi should be sufficient to document the changes in 
activation phenotype following influx into the medulla and toward areas of 
perturbation as hallmarked by the presence of PrP deposition at 150 dpi.  The focus 
should however be on neuronal interaction and not whether microglia were reacting 
prior or following PrP deposition.   
 
Not documented in this study, were two further experiments run in parallel to those 
described in chapter 6.  The first involved isolating total brain RNA from half brains 
taken from the same mice as used in the experiments of chapter 4.  The second 
involved isolating total RNA and half brain fixed-tissue from mice as part of an aging 
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time course.  Uniquely the starting age of the mice in these experiments was the 
same, thereby allowing the parallels between healthy aging and neurodegenerative 
disease to be determined.  There was not sufficient time to analysis the total brain 
RNA or aging experiment.  Tissue and samples were frozen and it would be hoped are 
exploited in the near future.  A comparison of the transcriptomes of isolated microglia 
with that of whole brain would aid in determining the specific contribution made by 
microglia in the host immune response by eliminating the immunomodulators 
present in the diseased brain but expressed independently of microglia.  It is 
important to note that microglia are not the only source of immunomodulators.  
Astrocytes, as the most numerous glial cell, are also able to express many ‘classical’ 













Figure 6-1:  A series of BALB/cJFms-EGFP/- in-vivo experiments completed in parallel to document 
the role of microglia in neurodegenerative prion disease and healthy aging.  Crucially all three 
experiments use mice aged at approximately 100 days old at the point of inoculation or experimental 
start to allow for comparison.  A: Described in Chapter 4; a time course of total RNA transcriptome 
analysis from isolated microglia.  B:  Time course analysis of microglia morphology through EGFP 
quantification as described in chapter 4.  The ½ brains for total RNA isolation were processed and RNA 
frozen.  C:  Healthy ageing experiment utilising where possible already aged BALB/cJFms-EGFP/- mice 
retired from use as breeding stock.  The ½ brains for both total RNA isolation and EGFP quantification 
were processed and samples frozen.   
 
100 150 35 200 
A: 79A/ BALB/cJFms-EGFP/-: Microglial Total RNA Isolation 
Terminal 
(~220) 
100 150 35 75 125 175 200 
B: 79A/BALB/cJFms-EGFP/-: ½ Brain Whole Brain Total RNA & ½ Brain EGFP Analysis 
300 500 100 700+ 
C: Healthy Aging: ½ Brain Whole Brain Total RNA & ½ Brain EGFP Analysis 
Mouse age at 
start: 100 days 
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The impact of pro-inflammatory products on the brain is often deleterious to 
neuronal function.  Microglia are extremely sensitive to systemic inflammation and 
the increase in circulating inflammatory products seen in the elderly presents as an 
increase in delirium and depression when combined with an underlying 
neurodegenerative disease (Cerejeira et al., 2010).  Furthermore a secondary 
infection typically results in rapid worsening of the dementia.  Activated microglia in 
both an aged and neurodegenerative environment can be considered ‘pre-primed’ 
and rapidly switch to a considerably more pro-inflammatory phenotype following 
further systemic insult (Cunningham et al., 2005b, Godbout et al., 2005, Palin et al., 
2008, Field et al., 2010, Murray et al., 2012).  Crucially, upon resolution of the 
secondary infection, the severity of the dementia does not return to that seen pre-
infection (MacLullich et al., 2009, van Gool et al., 2010).   Efforts have been made to 
treat many neurodegenerative diseases through administration of nonsteroidal anti-
inflammatory drugs (Rogers et al., 1993, Lim et al., 2000, Jantzen et al., 2002).  The 
aim was to block cyclooxygenases, and stimulate peroxisome proliferator-activated 
receptors-γ mediated inhibition of inflammatory cytokine synthesis (Lehmann et al., 
1997, Combs et al., 2000).  The clinical trials saw mixed results due to the importance 
of the maintaining long term dosage combined with early administration of the drugs 
at or near onset of diagnosis for any benefit to be incurred (Stewart et al., 1997, 
Breitner et al., 2011).  There are also complications resulting from heterogeneity 
within the human population including alleles associated with increased risk of 
generating chronic neurodegenerative disease in later life (Szekely et al., 2008).   
 
The majority of the differentially expressed genes identified in this study from 
isolated microglia were associated with an increase in metabolic load and protein 
translation and included genes associated with respiratory stress and DNA repair.  
Although to be expected from an activated myeloid cell, the association of metabolic 
genes with microglia from the diseased brain could only be determined following 
successful isolation of this group of cells, and are therefore unique to this present 
study.  The use of bone marrow derived myeloid cells as the delivery vector for gene 
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therapy as a means to treat neurodegenerative diseases is rapidly gaining in 
popularity following initial successes pioneered in lysosomal storage disorders (Wynn 
et al., 2009, Langford-Smith et al., 2012, Sergijenko et al., 2013).  The potential for 
exploiting this great of genes is extensive as rather than administering anti-
inflammatory drugs to illicit a microglial response, the metabolic genes identified in 
this present study could be utilised via a gene therapy approach to limit the ability 
for microglia to response.  As per the lysosomal storage disorders trials the altered 
microglia would be induced to repopulate central nervous system following adoption 
of irradiation induced selective to reduce the number of resident microglia.   
 
6.8 Final Conclusion 
The data presented in this study is at odds with the current consensus on in-vivo 
microglia activation in chronic protein misfolding diseases and portrays a 
considerably more pro-inflammatory and phagocytic microglia activation phenotype.  
The disease associated signature in the multicellular transcriptome is dominated by 
microglia, implying these cells are crucial to the disease process.  Concurrent with the 
activation profile is a signature of heavy metabolic which contain a considerable 
number of new and potential targets to influence the response of microglia, including 
for the first time targets associated with the intracellular metabolic pathways the 
cells require in order to maintain a chronic level of activation.  Protein misfolding 
diseases typically have a very long incubation period in which there is a steady and 
progressive increase in misfolded protein deposition, neuroinflammation and 
synaptopathy as the disease progresses.  By contrast the clinical phase is relatively 
short and is the culmination of the steadily progressing pre-clinical pathological 
artefacts.  Therapeutic intervention is therefore preferable in the pre-clinical stages 
when attempts can be made to limit the pathology.  This study has revealed many 
new targets for reducing pre-clinical microglial activation that have not previously 
been associated with microglia in neurodegenerative diseases.  The considerable 
number of identified transcripts associated with translation offers many intriguing 





Abutbul, S., Shapiro, J., Szaingurten-Solodkin, I., Levy, N., Carmy, Y., Baron, R., Jung, S. & 
Monsonego, A. 2012. Tgf-Beta Signaling through Smad2/3 Induces the Quiescent 
Microglial Phenotype within the Cns Environment. Glia, 60, 1160-1171. 
 
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K. & 
Akira, S. 1998. Targeted Disruption of the Myd88 Gene Results in Loss of Il-1- and Il-
18-Mediated Function. Immunity, 9, 143-150. 
 
Adams, D. H., Caspary, E. A. & Field, E. J. 1969. The Incorporation of [3h]Thymidine, 
[14c]Orotic Acid, [14c]Uridine-Diphosphoglucose and [14c]Glucosamine into a Post-
Ribosomal Fraction of Normal and Scrapie-Affected Mouse Brain and Spleen. Journal 
of General Virology, 4, 89-100. 
 
Agostini, F., Dotti, C. G., Perez-Canamas, A., Ledesma, M. D., Benetti, F. & Legname, G. 2013. 
Prion Protein Accumulation in Lipid Rafts of Mouse Aging Brain. PloS One, 8, e74244. 
 
Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M. & Rossi, F. M. V. 2011. Infiltrating 
Monocytes Trigger Eae Progression, but Do Not Contribute to the Resident Microglia 
Pool. Nature Neuroscience, 14, 1142-1149. 
 
Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. V. 2007. Local Self-Renewal Can 
Sustain Cns Microglia Maintenance and Function Throughout Adult Life. Nature 
Neuroscience, 10, 1538-1543. 
 
Akhtar, S., Wenborn, A., Brandner, S., Collinge, J. & Lloyd, S. E. 2011. Sex Effects in Mouse 
Prion Disease Incubation Time. PloS One, 6, 13-13. 
 
Akira, S. & Takeda, K. 2004. Toll-Like Receptor Signalling. Nature Reviews: Immunology, 4, 
499-511. 
 
Alliot, F., Godin, I. & Pessac, B. 1999. Microglia Derive from Progenitors, Originating from the 
Yolk Sac, and Which Proliferate in the Brain. Brain Research. Developmental Brain 
Research, 117, 145-152. 
 
Alliot, F., Lecain, E., Grima, B. & Pessac, B. 1991. Microglial Progenitors with a High 
Proliferative Potential in the Embryonic and Adult Mouse Brain. Proceedings of the 
National Academy of Sciences of the United States of America, 88, 1541-1545. 
 
Aloia, L., Parisi, S., Fusco, L., Pastore, L. & Russo, T. 2010. Differentiation of Embryonic Stem 
Cells 1 (Dies1) Is a Component of Bone Morphogenetic Protein 4 (Bmp4) Signaling 
Pathway Required for Proper Differentiation of Mouse Embryonic Stem Cells. Journal 
of Biological Chemistry, 285, 7776-7783. 
 
Alper, T., Cramp, W. A., Haig, D. A. & Clarke, M. C. 1967. Does the Agent of Scrapie Replicate 




Alper, T., Haig, D. A. & Clarke, M. C. 1966. The Exceptionally Small Size of the Scrapie Agent. 
Biochemical and Biophysical Research Communications, 22, 278-284. 
 
Ame, J. C., Spenlehauer, C. & de Murcia, G. 2004. The Parp Superfamily. Bioessays, 26, 882-
893. 
 
Ancuta, P., Rao, R., Moses, A., Mehle, A., Shaw, S. K., Luscinskas, F. W. & Gabuzda, D. 2003. 
Fractalkine Preferentially Mediates Arrest and Migration of Cd16+ Monocytes. The 
Journal of Experimental Medicine, 197, 1701-1707. 
 
Anderson, C. F. & Mosser, D. M. 2002a. Cutting Edge: Biasing Immune Responses by Directing 
Antigen to Macrophage Fc Gamma Receptors. Journal of Immunology, 168, 3697-
3701. 
 
Anderson, C. F. & Mosser, D. M. 2002b. A Novel Phenotype for an Activated Macrophage: 
The Type 2 Activated Macrophage. Journal of Leukocyte Biology, 72, 101-106. 
 
Andersson, H., Baechi, T., Hoechl, M. & Richter, C. 1998. Autofluorescence of Living Cells. 
Journal of Microscopy, 191, 1-7. 
 
Annunziato, F., Cosmi, L., Liotta, F., Maggi, E. & Romagnani, S. 2012. Defining the Human T 
Helper 17 Cell Phenotype. Trends in Immunology, 33, 505-512. 
 
Antony, J. M., Paquin, A., Nutt, S. L., Kaplan, D. R. & Miller, F. D. 2011. Endogenous Microglia 
Regulate Development of Embryonic Cortical Precursor Cells. Journal of 
Neuroscience Research, 89, 286-298. 
 
Arakawa, Y., Bito, H., Furuyashiki, T., Tsuji, T., Takemoto-Kimura, S., Kimura, K., Nozaki, K., 
Hashimoto, N. & Narumiya, S. 2003. Control of Axon Elongation Via an Sdf-
1alpha/Rho/Mdia Pathway in Cultured Cerebellar Granule Neurons. Journal of Cell 
Biology, 161, 381-391. 
 
Araque, A., Parpura, V., Sanzgiri, R. P. & Haydon, P. G. 1998. Glutamate-Dependent Astrocyte 
Modulation of Synaptic Transmission between Cultured Hippocampal Neurons. 
European Journal of Neuroscience, 10, 2129-2142. 
 
Arenzana-Seisdedos, F., Thompson, J., Rodriguez, M. S., Bachelerie, F., Thomas, D. & Hay, R. 
T. 1995. Inducible Nuclear Expression of Newly Synthesized I Kappa B Alpha 
Negatively Regulates DNA-Binding and Transcriptional Activities of Nf-Kappa B. 
Molecular and Cellular Biology, 15, 2689-2696. 
 
Asuni, A. A., Cunningham, C., Vigneswaran, P., Perry, V. H. & O'Connor, V. 2008. Unaltered 
Snare Complex Formation in an in Vivo Model of Prion Disease. Brain Research, 1233, 
1-7. 
 
Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., Sarnacki, S., Cumano, A., 
Lauvau, G. & Geissmann, F. 2007. Monitoring of Blood Vessels and Tissues by a 




Babior, B. M., Lambeth, J. D. & Nauseef, W. 2002. The Neutrophil Nadph Oxidase. Archives of 
Biochemistry and Biophysics, 397, 342-344. 
 
Bachstetter, A. D., Morganti, J. M., Jernberg, J., Schlunk, A., Mitchell, S. H., Brewster, K. W., 
Hudson, C. E., Cole, M. J., Harrison, J. K., Bickford, P. C. & Gemma, C. 2011. Fractalkine 
and Cx3cr1 Regulate Hippocampal Neurogenesis in Adult and Aged Rats. 
Neurobiology of Aging, 32, 2030-2044. 
 
Bai, Y., Zhu, Z., Gao, Z. & Kong, Y. 2014. Tlr2 Signaling Directs No-Dependent Mmp-9 Induction 
in Mouse Microglia. Neuroscience Letters, 571, 5-10. 
 
Baker, C. A., Lu, Z. Y., Zaitsev, I. & Manuelidis, L. 1999. Microglial Activation Varies in Different 
Models of Creutzfeldt-Jakob Disease. Journal of Virology, 73, 5089-5097. 
 
Baker, C. A. & Manuelidis, L. 2003. Unique Inflammatory Rna Profiles of Microglia in 
Creutzfeldt–Jakob Disease. Proceedings of the National Academy of Sciences of the 
United States of America, 100, 675-679. 
 
Baker, C. A., Martin, D. & Manuelidis, L. 2002. Microglia from Creutzfeldt-Jakob Disease-
Infected Brains Are Infectious and Show Specific Mrna Activation Profiles. Journal of 
Virology, 76, 10905-10913. 
 
Bal-Price, A. & Brown, G. C. 2001. Inflammatory Neurodegeneration Mediated by Nitric Oxide 
from Activated Glia-Inhibiting Neuronal Respiration, Causing Glutamate Release and 
Excitotoxicity. Journal of Neuroscience, 21, 6480-6491. 
 
Baldi, P. & Long, A. D. 2001. A Bayesian Framework for the Analysis of Microarray Expression 
Data: Regularized T -Test and Statistical Inferences of Gene Changes. Bioinformatics, 
17, 509-519. 
 
Baldwin, M. A., Pan, K. M., Nguyen, J., Huang, Z., Groth, D., Serban, A., Gasset, M., Mehlhorn, 
I., Fletterick, R. J., Cohen, F. E. & et al. 1994. Spectroscopic Characterization of 
Conformational Differences between Prpc and Prpsc: An Alpha-Helix to Beta-Sheet 
Transition. Philosophical Transactions of the Royal Society of London. Series B: 
Biological Sciences, 343, 435-441. 
 
Ban, E., Haour, F. & Lenstra, R. 1992. Brain Interleukin 1 Gene Expression Induced by 
Peripheral Lipopolysaccharide Administration. Cytokine, 4, 48-54. 
 
Barrett, T. & Edgar, R. 2006. Gene Expression Omnibus: Microarray Data Storage, Submission, 
Retrieval, and Analysis. Methods in Enzymology, 411, 352-369. 
 
Barrett, T., Troup, D. B., Wilhite, S. E., Ledoux, P., Rudnev, D., Evangelista, C., Kim, I. F., 
Soboleva, A., Tomashevsky, M. & Edgar, R. 2007. Ncbi Geo: Mining Tens of Millions 
of Expression Profiles--Database and Tools Update. Nucleic Acids Research, 35, 760-
765. 
 
Basler, K., Oesch, B., Scott, M., Westaway, D., Walchli, M., Groth, D. F., McKinley, M. P., 
Prusiner, S. B. & Weissmann, C. 1986. Scrapie and Cellular Prp Isoforms Are Encoded 




Basta, G., Lazzerini, G., Massaro, M., Simoncini, T., Tanganelli, P., Fu, C., Kislinger, T., Stern, 
D. M., Schmidt, A. M. & De Caterina, R. 2002. Advanced Glycation End Products 
Activate Endothelium through Signal-Transduction Receptor Rage: A Mechanism for 
Amplification of Inflammatory Responses. Circulation, 105, 816-822. 
 
Bate, C., Boshuizen, R. & Williams, A. 2005. Microglial Cells Kill Prion-Damaged Neurons in 
Vitro by a Cd14-Dependent Process. Journal of Neuroimmunology, 170, 62-70. 
 
Bate, C., Langeveld, J. & Williams, A. 2004. Manipulation of Prpres Production in Scrapie-
Infected Neuroblastoma Cells. Journal of Neuroscience Methods, 138, 217-223. 
 
Bate, C., Reid, S. & Williams, A. 2001. Killing of Prion-Damaged Neurones by Microglia. 
Neuroreport, 12, 2589-2594. 
 
Baud, V., Chissoe, S. L., Viegas-Pequignot, E., Diriong, S., N'Guyen, V. C., Roe, B. A. & Lipinski, 
M. 1995. Emr1, an Unusual Member in the Family of Hormone Receptors with Seven 
Transmembrane Segments. Genomics, 26, 334-344. 
 
Baugh, L. R., Hill, A. A., Brown, E. L. & Hunter, C. P. 2001. Quantitative Analysis of Mrna 
Amplification by in Vitro Transcription. Nucleic Acids Research, 29, E29. 
 
Belichenko, P. V., Brown, D., Jeffrey, M. & Fraser, J. R. 2000. Dendritic and Synaptic 
Alterations of Hippocampal Pyramidal Neurones in Scrapie-Infected Mice. 
Neuropathology and Applied Neurobiology, 26, 143-149. 
 
Benzing, W. C., Wujek, J. R., Ward, E. K., Shaffer, D., Ashe, K. H., Younkin, S. G. & Brunden, K. 
R. 1999. Evidence for Glial-Mediated Inflammation in Aged App(Sw) Transgenic Mice. 
Neurobiology of Aging, 20, 581-589. 
 
Betmouni, S. & Perry, V. H. 1999. The Acute Inflammatory Response in Cns Following Injection 
of Prion Brain Homogenate or Normal Brain Homogenate. Neuropathology and 
Applied Neurobiology, 25, 20-28. 
 
Betmouni, S., Perry, V. H. & Gordon, J. L. 1996. Evidence for an Early Inflammatory Response 
in the Central Nervous System of Mice with Scrapie. Neuroscience, 74, 1-5. 
 
Bhaskar, K., Maphis, N., Xu, G., Varvel, N. H., Kokiko-Cochran, O. N., Weick, J. P., Staugaitis, 
S. M., Cardona, A., Ransohoff, R. M., Herrup, K. & Lamb, B. T. 2014. Microglial Derived 
Tumor Necrosis Factor-Alpha Drives Alzheimer's Disease-Related Neuronal Cell Cycle 
Events. Neurobiology of Disease, 62, 273-285. 
 
Bianchi, M. E. 2007. Damps, Pamps and Alarmins: All We Need to Know About Danger. 
Journal of Leukocyte Biology, 81, 1-5. 
 
Billinton, N. & Knight, A. W. 2001. Seeing the Wood through the Trees: A Review of 
Techniques for Distinguishing Green Fluorescent Protein from Endogenous 




Birkett, C. R., Hennion, R. M., Bembridge, D. A., Clarke, M. C., Chree, A., Bruce, M. E. & 
Bostock, C. J. 2001. Scrapie Strains Maintain Biological Phenotypes on Propagation in 
a Cell Line in Culture. EMBO Journal, 20, 3351-3358. 
 
Blackmore, D. G., Golmohammadi, M. G., Large, B., Waters, M. J. & Rietze, R. L. 2009. Exercise 
Increases Neural Stem Cell Number in a Growth Hormone-Dependent Manner, 
Augmenting the Regenerative Response in Aged Mice. Stem Cells, 27, 2044-2052. 
 
Blackmore, D. G., Reynolds, B. A., Golmohammadi, M. G., Large, B., Aguilar, R. M., Haro, L., 
Waters, M. J. & Rietze, R. L. 2012. Growth Hormone Responsive Neural Precursor 
Cells Reside within the Adult Mammalian Brain. Scientific Reports, 2, 250. 
 
Boche, D., Cunningham, C., Docagne, F., Scott, H. & Perry, V. H. 2006. Tgf[Beta]1 Regulates 
the Inflammatory Response During Chronic Neurodegeneration. Neurobiology of 
Disease, 22, 638-650. 
 
Boehme, S. A., Lio, F. M., Maciejewski-Lenoir, D., Bacon, K. B. & Conlon, P. J. 2000. The 
Chemokine Fractalkine Inhibits Fas-Mediated Cell Death of Brain Microglia. Journal 
of Immunology, 165, 397-403. 
 
Boellaard, J. W., Kao, M., Schlote, W. & Diringer, H. 1991. Neuronal Autophagy in 
Experimental Scrapie. Acta Neuropathologica, 82, 225-228. 
 
Boje, K. M. & Arora, P. K. 1992. Microglial-Produced Nitric Oxide and Reactive Nitrogen 
Oxides Mediate Neuronal Cell Death. Brain Research, 587, 250-256. 
 
Boldrick, J. C., Alizadeh, A. A., Diehn, M., Dudoit, S., Liu, C. L., Belcher, C. E., Botstein, D., 
Staudt, L. M., Brown, P. O. & Relman, D. A. 2002. Stereotyped and Specific Gene 
Expression Programs in Human Innate Immune Responses to Bacteria. Proceedings 
of the National Academy of Sciences of the United States of America, 99, 972-977. 
 
Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., 
Lewis, J., Hutton, M., Tolnay, M. & Jucker, M. 2007. Induction of Tau Pathology by 
Intracerebral Infusion of Amyloid-Beta -Containing Brain Extract and by Amyloid-
Beta Deposition in App X Tau Transgenic Mice. American Journal of Pathology, 171, 
2012-2020. 
 
Bolmont, T., Haiss, F., Eicke, D., Radde, R., Mathis, C. A., Klunk, W. E., Kohsaka, S., Jucker, M. 
& Calhoun, M. E. 2008. Dynamics of the Microglial/Amyloid Interaction Indicate a 
Role in Plaque Maintenance. Journal of Neuroscience, 28, 4283-4292. 
 
Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. 2003. A Comparison of Normalization 
Methods for High Density Oligonucleotide Array Data Based on Variance and Bias. 
Bioinformatics, 19, 185-193. 
 
Bolton, D. C., McKinley, M. P. & Prusiner, S. B. 1982. Identification of a Protein That Purifies 
with the Scrapie Prion. Science, 218, 1309-1311. 
 
Booth, S., Bowman, C., Baumgartner, R., Sorensen, G., Robertson, C., Coulthart, M., 
Phillipson, C. & Somorjai, R. L. 2004. Identification of Central Nervous System Genes 
232 
 
Involved in the Host Response to the Scrapie Agent During Preclinical and Clinical 
Infection. Journal of General Virology, 85, 3459-3471. 
 
Boscia, F., Esposito, C. L., Di Crisci, A., de Franciscis, V., Annunziato, L. & Cerchia, L. 2009. Gdnf 
Selectively Induces Microglial Activation and Neuronal Survival in Ca1/Ca3 
Hippocampal Regions Exposed to Nmda Insult through Ret/Erk Signalling. PloS One, 
4, e6486. 
 
Boucsein, C., Zacharias, R., Farber, K., Pavlovic, S., Hanisch, U. K. & Kettenmann, H. 2003. 
Purinergic Receptors on Microglial Cells: Functional Expression in Acute Brain Slices 
and Modulation of Microglial Activation in Vitro. European Journal of Neuroscience, 
17, 2267-2276. 
 
Boutin, H., LeFeuvre, R. A., Horai, R., Asano, M., Iwakura, Y. & Rothwell, N. J. 2001. Role of Il-
1alpha and Il-1beta in Ischemic Brain Damage. Journal of Neuroscience, 21, 5528-
5534. 
 
Bouzamondo-Bernstein, E., Hopkins, S. D., Spilman, P., Uyehara-Lock, J., Deering, C., Safar, J., 
Prusiner, S. B., Ralston, H. J., 3rd & DeArmond, S. J. 2004. The Neurodegeneration 
Sequence in Prion Diseases: Evidence from Functional, Morphological and 
Ultrastructural Studies of the Gabaergic System. Journal of Neuropathology and 
Experimental Neurology, 63, 882-899. 
 
Brandt, D. T., Marion, S., Griffiths, G., Watanabe, T., Kaibuchi, K. & Grosse, R. 2007. Dia1 and 
Iqgap1 Interact in Cell Migration and Phagocytic Cup Formation. Journal of Cell 
Biology, 178, 193-200. 
 
Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, C., Aach, J., 
Ansorge, W., Ball, C. A., Causton, H. C., Gaasterland, T., Glenisson, P., Holstege, F. C., 
Kim, I. F., Markowitz, V., Matese, J. C., Parkinson, H., Robinson, A., Sarkans, U., 
Schulze-Kremer, S., Stewart, J., Taylor, R., Vilo, J. & Vingron, M. 2001. Minimum 
Information About a Microarray Experiment (Miame)-toward Standards for 
Microarray Data. Nature Genetics, 29, 365-371. 
 
Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, 
J., Craft, S., Evans, D. E., Green, R. C., Ismail, M. S., Martin, B. K., Mullan, M. J., 
Sabbagh, M. & Tariot, P. N. 2011. Extended Results of the Alzheimer’s Disease Anti-
Inflammatory Prevention Trial. Alzheimer's & Dementia: The Journal of the 
Alzheimer's Association, 7, 402-411. 
 
Brink, B. P., Veerhuis, R., Breij, E. C., van der Valk, P., Dijkstra, C. D. & Bo, L. 2005. The 
Pathology of Multiple Sclerosis Is Location-Dependent: No Significant Complement 
Activation Is Detected in Purely Cortical Lesions. Journal of Neuropathology and 
Experimental Neurology, 64, 147-155. 
 
Brooks, E. M., Sheflin, L. G. & Spaulding, S. W. 1995. Secondary Structure in the 3' Utr of Egf 
and the Choice of Reverse Transcriptases Affect the Detection of Message Diversity 




Brooks, G. A., Dubouchaud, H., Brown, M., Sicurello, J. P. & Butz, C. E. 1999. Role of 
Mitochondrial Lactate Dehydrogenase and Lactate Oxidation in the Intracellular 
Lactate Shuttle. Proceedings of the National Academy of Sciences of the United States 
of America, 96, 1129-1134. 
 
Brotherston, J. G., Renwick, C. C., Stamp, J. T., Zlotnik, I. & Pattison, I. H. 1968. Spread of 
Scrapie by Contact to Goats and Sheep. Journal of Comparative Pathology, 78, 9-17. 
 
Brown, A. R., Rebus, S., McKimmie, C. S., Robertson, K., Williams, A. & Fazakerley, J. K. 2005. 
Gene Expression Profiling of the Preclinical Scrapie-Infected Hippocampus. 
Biochemical and Biophysical Research Communications, 334, 86-95. 
 
Brown, A. R., Webb, J., Rebus, S., Walker, R., Williams, A. & Fazakerley, J. K. 2003. Inducible 
Cytokine Gene Expression in the Brain in the Me7/Cv Mouse Model of Scrapie Is 
Highly Restricted, Is at a Strikingly Low Level Relative to the Degree of Gliosis and 
Occurs Only Late in Disease. Journal of General Virology, 84, 2605-2611. 
 
Brown, A. R., Webb, J., Rebus, S., Williams, A. & Fazakerley, J. K. 2004. Identification of up-
Regulated Genes by Array Analysis in Scrapie-Infected Mouse Brains. 
Neuropathology and Applied Neurobiology, 30, 555-567. 
 
Brown, D., Belichenko, P., Sales, J., Jeffrey, M. & Fraser, J. R. 2001. Early Loss of Dendritic 
Spines in Murine Scrapie Revealed by Confocal Analysis. Neuroreport, 12, 179-183. 
 
Brown, D. R., Schmidt, B. & Kretzschmar, H. A. 1996. Role of Microglia and Host Prion Protein 
in Neurotoxicity of a Prion Protein Fragment. Nature, 380, 345-347. 
 
Brown, D. R., Wong, B. S., Hafiz, F., Clive, C., Haswell, S. J. & Jones, I. M. 1999a. Normal Prion 
Protein Has an Activity Like That of Superoxide Dismutase. Biochemical Journal, 344 
Pt 1, 1-5. 
 
Brown, G. C. & Neher, J. J. 2012. Eaten Alive! Cell Death by Primary Phagocytosis: 
‘Phagoptosis’. Trends in Biochemical Sciences, 37, 325-332. 
 
Brown, H. C., Castano, A., Fearn, S., Townsend, M., Edwards, G., Streuli, C. & Perry, V. H. 1997. 
Adhesion Molecules Involved in Macrophage Responses to Wallerian Degeneration 
in the Murine Peripheral Nervous System. European Journal of Neuroscience, 9, 
2057-2063. 
 
Brown, K. L., Gossner, A., Mok, S. & Mabbott, N. A. 2011. The Effects of Host Age on the 
Transport of Complement-Bound Complexes to the Spleen and the Pathogenesis of 
Intravenous Scrapie Infection. Journal of Virology, 86, 25-35. 
 
Brown, K. L., Stewart, K., Ritchie, D. L., Mabbott, N. A., Williams, A., Fraser, H., Morrison, W. 
I. & Bruce, M. E. 1999b. Scrapie Replication in Lymphoid Tissues Depends on Prion 
Protein-Expressing Follicular Dendritic Cells. Nature Medicine, 5, 1308-1312. 
 
Brown, K. L., Wathne, G. J., Sales, J., Bruce, M. E. & Mabbott, N. A. 2009. The Effects of Host 
Age on Follicular Dendritic Cell Status Dramatically Impair Scrapie Agent 




Brown, S., Heinisch, I., Ross, E., Shaw, K., Buckley, C. D. & Savill, J. 2002. Apoptosis Disables 
Cd31-Mediated Cell Detachment from Phagocytes Promoting Binding and 
Engulfment. Nature, 418, 200-203. 
 
Bruce, M., Chree, A., McConnell, I., Foster, J., Pearson, G. & Fraser, H. 1994. Transmission of 
Bovine Spongiform Encephalopathy and Scrapie to Mice: Strain Variation and the 
Species Barrier. Philosophical Transactions of the Royal Society of London. Series B: 
Biological Sciences, 343, 405-411. 
 
Bruce, M. E. 1993. Scrapie Strain Variation and Mutation. British Medical Bulletin, 49, 822-
838. 
 
Bruce, M. E. 2003. Tse Strain Variation: An Investigation into Prion Disease Diversity. British 
Medical Bulletin, 66, 99-108. 
 
Bruce, M. E., Boyle, A., Cousens, S., McConnell, I., Foster, J., Goldmann, W. & Fraser, H. 2002. 
Strain Characterization of Natural Sheep Scrapie and Comparison with Bse. Journal 
of General Virology, 83, 695-704. 
 
Bruce, M. E., McConnell, I., Fraser, H. & Dickinson, A. G. 1991. The Disease Characteristics of 
Different Strains of Scrapie in Sinc Congenic Mouse Lines: Implications for the Nature 
of the Agent and Host Control of Pathogenesis. The Journal of General Virology, 72 ( 
Pt 3), 595-603. 
 
Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttie, A., McCardle, L., 
Chree, A., Hope, J., Birkett, C., Cousens, S., Fraser, H. & Bostock, C. J. 1997. 
Transmissions to Mice Indicate That 'New Variant' Cjd Is Caused by the Bse Agent. 
Nature, 389, 498-501. 
 
Büeler, H., Aguzzi, A., Sailer, A., Greiner, R. A., Autenried, P., Aguet, M. & Weissmann, C. 1993. 
Mice Devoid of Prp Are Resistant to Scrapie. Cell, 73, 1339-1347. 
 
Burgess, A. W. 1989. Epidermal Growth Factor and Transforming Growth Factor Alpha. British 
Medical Bulletin, 45, 401-424. 
 
Burrell, K., Hill, R. P. & Zadeh, G. 2012. High-Resolution in-Vivo Analysis of Normal Brain 
Response to Cranial Irradiation. PloS One, 7, e38366. 
 
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., 
Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., Fanek, Z., Liu, L., Chen, Z., 
Rothstein, J. D., Ransohoff, R. M., Gygi, S. P., Antel, J. P. & Weiner, H. L. 2014. 
Identification of a Unique Tgf-Beta-Dependent Molecular and Functional Signature 
in Microglia. Nature Neuroscience, 17, 131-143. 
 
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., 
Wu, P. M., Gali, R. R., Iyer, L. K., Lawson, R., Berry, J., Krichevsky, A. M., Cudkowicz, 
M. E. & Weiner, H. L. 2012. Modulating Inflammatory Monocytes with a Unique 





Butte, A. J. & Kohane, I. S. Mutual Information Relevance Networks: Functional Genomic 
Clustering Using Pairwise Entropy Measurements.  Pacific Symposium on 
Biocomputing, 2000. 418-429. 
 
Buttini, M. & Boddeke, H. 1995. Peripheral Lipopolysaccharide Stimulation Induces 
Interleukin-1β Messenger Rna in Rat Brain Microglial Cells. Neuroscience, 65, 523-
530. 
 
Caldeira, C., Oliveira, A. F., Cunha, C., Vaz, A. R., Falcao, A. S., Fernandes, A. & Brites, D. 2014. 
Microglia Change from a Reactive to an Age-Like Phenotype with the Time in Culture. 
Frontiers in Cellular Neuroscience, 8, 152. 
 
Campanella, G. S., Tager, A. M., El Khoury, J. K., Thomas, S. Y., Abrazinski, T. A., Manice, L. A., 
Colvin, R. A. & Luster, A. D. 2008. Chemokine Receptor Cxcr3 and Its Ligands Cxcl9 
and Cxcl10 Are Required for the Development of Murine Cerebral Malaria. 
Proceedings of the National Academy of Sciences of the United States of America, 
105, 4814-4819. 
 
Cancellotti, E., Bradford, B. M., Tuzi, N. L., Hickey, R. D., Brown, D., Brown, K. L., Barron, R. 
M., Kisielewski, D., Piccardo, P. & Manson, J. C. 2010. Glycosylation of Prpc 
Determines Timing of Neuroinvasion and Targeting in the Brain Following 
Transmissible Spongiform Encephalopathy Infection by a Peripheral Route. Journal 
of Virology, 84, 3464-3475. 
 
Capani, F., Ellisman, M. H. & Martone, M. E. 2001. Filamentous Actin Is Concentrated in 
Specific Subpopulations of Neuronal and Glial Structures in Rat Central Nervous 
System. Brain Research, 923, 1-11. 
 
Cardona, A. E., Huang, D., Sasse, M. E. & Ransohoff, R. M. 2006a. Isolation of Murine 
Microglial Cells for Rna Analysis or Flow Cytometry. Nature Protocols, 1, 1947-1951. 
 
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, 
D., Kidd, G., Dombrowski, S., Dutta, R., Lee, J. C., Cook, D. N., Jung, S., Lira, S. A., 
Littman, D. R. & Ransohoff, R. M. 2006b. Control of Microglial Neurotoxicity by the 
Fractalkine Receptor. Nature Neuroscience, 9, 917-924. 
 
Carlson, G. A., Ebeling, C., Yang, S. L., Telling, G., Torchia, M., Groth, D., Westaway, D., 
DeArmond, S. J. & Prusiner, S. B. 1994. Prion Isolate Specified Allotypic Interactions 
between the Cellular and Scrapie Prion Proteins in Congenic and Transgenic Mice. 
Proceedings of the National Academy of Sciences of the United States of America, 91, 
5690-5694. 
 
Carrillo-Vico, A., Calvo, J. R., Abreu, P., Lardone, P. J., Garcia-Maurino, S., Reiter, R. J. & 
Guerrero, J. M. 2004. Evidence of Melatonin Synthesis by Human Lymphocytes and 
Its Physiological Significance: Possible Role as Intracrine, Autocrine, and/or Paracrine 
Substance. FASEB Journal, 18, 537-539. 
 
Cattaneo, E. & McKay, R. 1990. Proliferation and Differentiation of Neuronal Stem Cells 




Caughey, B., Raymond, G. J., Ernst, D. & Race, R. E. 1991. N-Terminal Truncation of the 
Scrapie-Associated Form of Prp by Lysosomal Protease(S): Implications Regarding the 
Site of Conversion of Prp to the Protease-Resistant State. Journal of Virology, 65, 
6597-6603. 
 
Cerejeira, J., Firmino, H., Vaz-Serra, A. & Mukaetova-Ladinska, E. B. 2010. The 
Neuroinflammatory Hypothesis of Delirium. Acta Neuropathologica, 119, 737-754. 
 
Cerletti, U. 1902. Contributo Sperimentale Alla Conoscenza Dei Processi Di Fagocitosi Nelle 
Sostanza Cerebrale (Experimental Contribution to the Knowledge of the Processes of 
Phagocytosis in the Brain Substance). Annali dell'Istituto psichiatrico. della R. 
università. di Roma, 1, 65-73. 
 
Cerletti, U. 1903. Sulla Neuronofagia E Sopra Alcuni Rapporti Normali E Patologici Tra 
Elementi Nervosa Ed Elementi No-Nervosi (on Neuronophagia and Reports of Normal 
and Pathological Relationships between Elements of Nervous and Non-Nervous 
Elements). Annali dell'Istituto psichiatrico. della R. università. di Roma, 91. 
 
Cerletti, U. 1905. Sopra Alcuni Rapporti Tra Le "Cellule a Bastoncello" E Gli Elementi Nervosi 
Nella Paralisis Progressive (on Some Relationships between the "Rod Cells" and the 
Nervous Elements in the Progressive Paralysis). Rivista sperimentale di freniatria  31 
483-495. 
 
Chamak, B., Dobbertin, A. & Mallat, M. 1995. Immunohistochemical Detection of 
Thrombospondin in Microglia in the Developing Rat Brain. Neuroscience, 69, 177-
187. 
 
Chamak, B., Morandi, V. & Mallat, M. 1994. Brain Macrophages Stimulate Neurite Growth 
and Regeneration by Secreting Thrombospondin. Journal of Neuroscience Research, 
38, 221-233. 
 
Chao, C. C., Hu, S., Molitor, T. W., Shaskan, E. G. & Peterson, P. K. 1992. Activated Microglia 
Mediate Neuronal Cell Injury Via a Nitric Oxide Mechanism. Journal of Immunology, 
149, 2736-2741. 
 
Chelle, P. L. 1942. Un Cas De Tremblante Chez La Chèvre. Bulletin de l'Académie Vétérinaire 
de France, 15, 294-295. 
 
Chen, Z., Jalabi, W., Hu, W., Park, H. J., Gale, J. T., Kidd, G. J., Bernatowicz, R., Gossman, Z. C., 
Chen, J. T., Dutta, R. & Trapp, B. D. 2014. Microglial Displacement of Inhibitory 
Synapses Provides Neuroprotection in the Adult Brain. Nat Commun, 5, 4486. 
 
Chmurzyńska, A. 2006. The Multigene Family of Fatty Acid-Binding Proteins (Fabps): 
Function, Structure and Polymorphism. Journal of Applied Genetics, 47, 39-48. 
 
Cho, H. J. 1976. Is the Scrapie Agent a Virus? Nature, 262, 411-412. 
 
Cho, H. J. & Greig, A. S. 1975. Isolation of 14-Nm Virus-Like Particles from Mouse Brain 




Chung, W. S., Clarke, L. E., Wang, G. X., Stafford, B. K., Sher, A., Chakraborty, C., Joung, J., Foo, 
L. C., Thompson, A., Chen, C., Smith, S. J. & Barres, B. A. 2013. Astrocytes Mediate 
Synapse Elimination through Megf10 and Mertk Pathways. Nature, 504, 394-400. 
 
Clarkson, B. D., Heninger, E., Harris, M. G., Lee, J., Sandor, M. & Fabry, Z. 2012. Innate-
Adaptive Crosstalk: How Dendritic Cells Shape Immune Responses in the Cns. 
Advances in Experimental Medicine and Biology, 946, 309-333. 
 
Clausen, B. H., Lambertsen, K. L., Babcock, A. A., Holm, T. H., Dagnaes-Hansen, F. & Finsen, B. 
2008. Interleukin-1beta and Tumor Necrosis Factor-Alpha Are Expressed by Different 
Subsets of Microglia and Macrophages after Ischemic Stroke in Mice. Journal of 
Neuroinflammation, 5, 46. 
 
Colby, D. W., Wain, R., Baskakov, I. V., Legname, G., Palmer, C. G., Nguyen, H. O., Lemus, A., 
Cohen, F. E., DeArmond, S. J. & Prusiner, S. B. 2010. Protease-Sensitive Synthetic 
Prions. PLoS Pathogens, 6, 1000736. 
 
Colling, S. B., Khana, M., Collinge, J. & Jefferys, J. G. 1997. Mossy Fibre Reorganization in the 
Hippocampus of Prion Protein Null Mice. Brain Research, 755, 28-35. 
 
Collinge, J., Whittington, M. A., Sidle, K. C., Smith, C. J., Palmer, M. S., Clarke, A. R. & Jefferys, 
J. G. 1994. Prion Protein Is Necessary for Normal Synaptic Function. Nature, 370, 295-
297. 
 
Colton, C. A. & Gilbert, D. L. 1987. Production of Superoxide Anions by a Cns Macrophage, 
the Microglia. FEBS Letters, 223, 284-288. 
 
Comber, T. 1772. Real Improvements in Agriculture [Electronic Resource] : (on the Principles 
of A. Young, Esq;) Recommended to Accompany Improvements of Rents; in a Letter 
to Reade Peacock, ... To Which Is Added, a Letter to Dr. Hunter, ... Concerning the 
Rickets in Sheep. By T. Comber, London : Printed for W. Nicoll, 1772., Page: 73-83. 
 
Combrinck, M. I., Perry, V. H. & Cunningham, C. 2002. Peripheral Infection Evokes 
Exaggerated Sickness Behaviour in Pre-Clinical Murine Prion Disease. Neuroscience, 
112, 7-11. 
 
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B. & Landreth, G. E. 2000. Inflammatory 
Mechanisms in Alzheimer's Disease: Inhibition of Β-Amyloid-Stimulated 
Proinflammatory Responses and Neurotoxicity by Pparγ Agonists. The Journal of 
Neuroscience, 20, 558-567. 
 
Concepcion, G. P., David, M. P. & Padlan, E. A. 2005. Why Don't Humans Get Scrapie from 
Eating Sheep? A Possible Explanation Based on Secondary Structure Predictions. 
Medical Hypotheses, 64, 919-924. 
 
Conde, J. R. & Streit, W. J. 2006. Effect of Aging on the Microglial Response to Peripheral 




Cosseddu, G. M., Nonno, R., Vaccari, G., Bucalossi, C., Fernandez-Borges, N., Di Bari, M. A., 
Castilla, J. & Agrimi, U. 2011. Ultra-Efficient Prp(Sc) Amplification Highlights 
Potentialities and Pitfalls of Pmca Technology. PLoS Pathogens, 7, e1002370. 
 
Cox, G. M., Kithcart, A. P., Pitt, D., Guan, Z., Alexander, J., Williams, J. L., Shawler, T., Dagia, 
N. M., Popovich, P. G., Satoskar, A. R. & Whitacre, C. C. 2013. Macrophage Migration 
Inhibitory Factor Potentiates Autoimmune-Mediated Neuroinflammation. Journal of 
Immunology, 24, 24. 
 
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., 
Restivo, J. L., Goebel, W. D., James, M. J., Brunden, K. R., Wilson, D. A. & Landreth, G. 
E. 2012. Apoe-Directed Therapeutics Rapidly Clear Β-Amyloid and Reverse Deficits in 
Ad Mouse Models. Science, 335, 1503-1506. 
 
Cruttwell, R. 1795. Letters and Papers on Agriculture, Planting, &C.  Selected from the 
Correspondence of the Bath and West of England Society.Vol.Vii, Page: 72-73. 
 
Cunningham, C., Boche, D. & Perry, V. H. 2002. Transforming Growth Factor Β1, the Dominant 
Cytokine in Murine Prion Disease: Influence on Inflammatory Cytokine Synthesis and 
Alteration of Vascular Extracellular Matrix. Neuropathology and Applied 
Neurobiology, 28, 107-119. 
 
Cunningham, C., Campion, S., Lunnon, K., Murray, C. L., Woods, J. F., Deacon, R. M., Rawlins, 
J. N. & Perry, V. H. 2009. Systemic Inflammation Induces Acute Behavioral and 
Cognitive Changes and Accelerates Neurodegenerative Disease. Biological 
Psychiatry, 65, 304-312. 
 
Cunningham, C., Deacon, R., Wells, H., Boche, D., Waters, S., Diniz, C. P., Scott, H., Rawlins, J. 
N. P. & Perry, V. H. 2003. Synaptic Changes Characterize Early Behavioural Signs in 
the Me7 Model of Murine Prion Disease. The European Journal of Neuroscience, 17, 
2147-2155. 
 
Cunningham, C., Wilcockson, D. C., Boche, D. & Perry, V. H. 2005a. Comparison of 
Inflammatory and Acute-Phase Responses in the Brain and Peripheral Organs of the 
Me7 Model of Prion Disease. Journal of Virology, 79, 5174-5184. 
 
Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K. & Perry, V. H. 2005b. Central and 
Systemic Endotoxin Challenges Exacerbate the Local Inflammatory Response and 
Increase Neuronal Death During Chronic Neurodegeneration. Journal of 
Neuroscience, 25, 9275-9284. 
 
Cunningham, C. L., Martinez-Cerdeno, V. & Noctor, S. C. 2013. Microglia Regulate the 
Number of Neural Precursor Cells in the Developing Cerebral Cortex. Journal of 
Neuroscience, 33, 4216-4233. 
 
Dagleish, M. P., Martin, S., Steele, P., Finlayson, J., Siso, S., Hamilton, S., Chianini, F., Reid, H. 
W., Gonzalez, L. & Jeffrey, M. 2008. Experimental Transmission of Bovine Spongiform 
Encephalopathy to European Red Deer (Cervus Elaphus Elaphus). BMC Veterinary 




Dana, A. & Tuller, T. 2012. Determinants of Translation Elongation Speed and Ribosomal 
Profiling Biases in Mouse Embryonic Stem Cells. PLoS Computational Biology, 8, 
e1002755. 
 
Daneman, R., Zhou, L., Kebede, A. A. & Barres, B. A. 2010. Pericytes Are Required for Blood-
Brain Barrier Integrity During Embryogenesis. Nature, 468, 562-566. 
 
Dantzer, R. 2001. Cytokine-Induced Sickness Behavior: Mechanisms and Implications. Annals 
of the New York Academy of Sciences, 933, 222-234. 
 
Dantzer, R. 2004. Cytokine-Induced Sickness Behaviour: A Neuroimmune Response to 
Activation of Innate Immunity. European Journal of Pharmacology, 500, 399-411. 
 
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L. 
& Gan, W. B. 2005. Atp Mediates Rapid Microglial Response to Local Brain Injury in 
Vivo. Nature Neuroscience, 8, 752-758. 
 
Dawson, M., Hoinville, L. J., Hosie, B. D. & Hunter, N. 1998. Guidance on the Use of Prp 
Genotyping as an Aid to the Control of Clinical Scrapie. Scrapie Information Group. 
Veterinary Record, 142, 623-625. 
 
de Haas, A. H., Boddeke, H. W. & Biber, K. 2008. Region-Specific Expression of 
Immunoregulatory Proteins on Microglia in the Healthy Cns. Glia, 56, 888-894. 
 
de Haas, A. H., Boddeke, H. W., Brouwer, N. & Biber, K. 2007. Optimized Isolation Enables Ex 
Vivo Analysis of Microglia from Various Central Nervous System Regions. Glia, 55, 
1374-1384. 
 
DeArmond, S. J. 1993. Alzheimer's Disease and Creutzfeldt-Jakob Disease: Overlap of 
Pathogenic Mechanisms. Current Opinion in Neurology, 6, 872-881. 
 
DeArmond, S. J., Sánchez, H., Yehiely, F., Qiu, Y., Ninchak-Casey, A., Daggett, V., Camerino, A. 
P., Cayetano, J., Rogers, M., Groth, D., Torchia, M., Tremblay, P., Scott, M. R., Cohen, 
F. E. & Prusiner, S. B. 1997. Selective Neuronal Targeting in Prion Disease. Neuron, 
19, 1337-1348. 
 
DeArmond, S. J., Yang, S. L., Cayetano-Canlas, J., Groth, D. & Prusiner, S. B. 1994. The 
Neuropathological Phenotype in Transgenic Mice Expressing Different Prion Protein 
Constructs. Philosophical Transactions of the Royal Society of London. Series B: 
Biological Sciences, 343, 415-423. 
 
Deleault, N. R., Harris, B. T., Rees, J. R. & Supattapone, S. 2007. Formation of Native Prions 
from Minimal Components in Vitro. Proceedings of the National Academy of Sciences 
of the United States of America, 104, 9741-9746. 
 
Desplats, P., Lee, H. J., Bae, E. J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, 
E. & Lee, S. J. 2009. Inclusion Formation and Neuronal Cell Death through Neuron-
to-Neuron Transmission of Alpha-Synuclein. Proceedings of the National Academy of 




Dickinson, A. G. 1976. Scrapie in Sheep and Goats. Frontiers of Biology, 44, 209-241. 
 
Dickinson, A. G., Fraser, H., Meikle, V. M. & Outram, G. W. 1972. Competition between 
Different Scrapie Agents in Mice. Nature: New Biology, 237, 244-245. 
 
Dickinson, A. G. & Mackay, J. M. 1964. Genetical Control of the Incubation Period in Mice of 
the Neurological Disease, Scrapie. Heredity, 19, 279-288. 
 
Dickinson, A. G. & Meikle, V. M. 1971. Host-Genotype and Agent Effects in Scrapie Incubation: 
Change in Allelic Interaction with Different Strains of Agent. Molecular and General 
Genetics, 112, 73-79. 
 
Dickinson, A. G., Meikle, V. M. & Fraser, H. 1968. Identification of a Gene Which Controls the 
Incubation Period of Some Strains of Scrapie Agent in Mice. Journal of Comparative 
Pathology, 78, 293-299. 
 
Dickinson, A. G. & Outram, G. W. 1988. Genetic Aspects of Unconventional Virus Infections: 
The Basis of the Virino Hypothesis. Ciba Foundation Symposium, 135, 63-83. 
 
Dietrich, M. O., Andrews, Z. B. & Horvath, T. L. 2008. Exercise-Induced Synaptogenesis in the 
Hippocampus Is Dependent on Ucp2-Regulated Mitochondrial Adaptation. Journal of 
Neuroscience, 28, 10766-10771. 
 
Diez, M., Koistinaho, J., Dearmond, S. J., Groth, D., Prusiner, S. B. & Hokfelt, T. 1997. Marked 
Decrease of Neuropeptide Y Y2 Receptor Binding Sites in the Hippocampus in Murine 
Prion Disease. Proceedings of the National Academy of Sciences of the United States 
of America, 94, 13267-13272. 
 
Dilger, R. N. & Johnson, R. W. 2008. Aging, Microglial Cell Priming, and the Discordant Central 
Inflammatory Response to Signals from the Peripheral Immune System. Journal of 
Leukocyte Biology, 84, 932-939. 
 
Ding, Y., Chen, D., Tarcsafalvi, A., Su, R., Qin, L. & Bromberg, J. S. 2003. Suppressor of Cytokine 
Signaling 1 Inhibits Il-10-Mediated Immune Responses. Journal of Immunology, 170, 
1383-1391. 
 
Dohgu, S., Yamauchi, A., Takata, F., Naito, M., Tsuruo, T., Higuchi, S., Sawada, Y. & Kataoka, 
Y. 2004. Transforming Growth Factor-Beta1 Upregulates the Tight Junction and P-
Glycoprotein of Brain Microvascular Endothelial Cells. Cellular and Molecular 
Neurobiology, 24, 491-497. 
 
Dongen, V. 2000. Performance Criteria for Graph Clustering and Markov Cluster Experiments. 
CWI (Centre for Mathematics and Computer Science), INS-R0012. 
 
Donnelly, D. J., Gensel, J. C., Ankeny, D. P., van Rooijen, N. & Popovich, P. G. 2009. An Efficient 
and Reproducible Method for Quantifying Macrophages in Different Experimental 





Doyle, J. P., Dougherty, J. D., Heiman, M., Schmidt, E. F., Stevens, T. R., Ma, G., Bupp, S., 
Shrestha, P., Shah, R. D., Doughty, M. L., Gong, S., Greengard, P. & Heintz, N. 2008. 
Application of a Translational Profiling Approach for the Comparative Analysis of Cns 
Cell Types. Cell, 135, 749-762. 
 
Drake, C., Boutin, H., Jones, M. S., Denes, A., McColl, B. W., Selvarajah, J. R., Hulme, S., 
Georgiou, R. F., Hinz, R., Gerhard, A., Vail, A., Prenant, C., Julyan, P., Maroy, R., Brown, 
G., Smigova, A., Herholz, K., Kassiou, M., Crossman, D., Francis, S., Proctor, S. D., 
Russell, J. C., Hopkins, S. J., Tyrrell, P. J., Rothwell, N. J. & Allan, S. M. 2011. Brain 
Inflammation Is Induced by Co-Morbidities and Risk Factors for Stroke. Brain, 
Behavior, and Immunity, 25, 1113-1122. 
 
Drew, P. D. & Chavis, J. A. 2000. Female Sex Steroids: Effects Upon Microglial Cell Activation. 
Journal of Neuroimmunology, 111, 77-85. 
 
Dron, M., Moudjou, M., Chapuis, J., Salamat, M. K., Bernard, J., Cronier, S., Langevin, C. & 
Laude, H. 2010. Endogenous Proteolytic Cleavage of Disease-Associated Prion 
Protein to Produce C2 Fragments Is Strongly Cell- and Tissue-Dependent. Journal of 
Biological Chemistry, 285, 10252-10264. 
 
Duggan, D. J., Bittner, M., Chen, Y., Meltzer, P. & Trent, J. M. 1999. Expression Profiling Using 
Cdna Microarrays. Nature Genetics, 21, 10-14. 
 
Dujardin, S., Lecolle, K., Caillierez, R., Begard, S., Zommer, N., Lachaud, C., Carrier, S., Dufour, 
N., Auregan, G., Winderickx, J., Hantraye, P., Deglon, N., Colin, M. & Buee, L. 2014. 
Neuron-to-Neuron Wild-Type Tau Protein Transfer through a Trans-Synaptic 
Mechanism: Relevance to Sporadic Tauopathies. Acta Neuropathol Commun, 2, 14. 
 
Dunn, L. C., GrüNeberg, H. & Snell, G. D. 1940. Report of the Committee on Mouse Genetics 
Nomenclature. The Journal of Heredity, 31, 505-506. 
 
Duran-Aniotz, C., Morales, R., Moreno-Gonzalez, I., Hu, P. P. & Soto, C. 2013. Brains from 
Non-Alzheimer's Individuals Containing Amyloid Deposits Accelerate Abeta 
Deposition in Vivo. Acta Neuropathol Commun, 1, 76. 
 
Edgington, E. S. 1964. Randomization Tests. Journal of Psychology, 57, 445. 
 
Edri, S. & Tuller, T. 2014. Quantifying the Effect of Ribosomal Density on Mrna Stability. PloS 
One, 9, e102308. 
 
Eigen, M. & Schuster, P. 1977. The Hypercycle. A Principle of Natural Self-Organization. Part 
A: Emergence of the Hypercycle. Naturwissenschaften, 64, 541-565. 
 
Eitzen, U. V., Egensperger, R., Kösel, S., Grasbon-Frodl, E. M., Imai, Y., Bise, K., Kohsaka, S., 
Mehraein, P. & Graeber, M. B. 1998. Microglia and the Development of Spongiform 
Change in Creutzfeldt-Jakob Disease. Journal of Neuropathology and Experimental 




Ekdahl, C. T., Claasen, J. H., Bonde, S., Kokaia, Z. & Lindvall, O. 2003. Inflammation Is 
Detrimental for Neurogenesis in Adult Brain. Proceedings of the National Academy 
of Sciences of the United States of America, 100, 13632-13637. 
 
Eklund, C. M., Kennedy, R. C. & Hadlow, W. J. 1967. Pathogenesis of Scrapie Virus Infection 
in the Mouse. Journal of Infectious Diseases, 117, 15-22. 
 
Elishmereni, M. & Levi-Schaffer, F. 2011. Cd48: A Co-Stimulatory Receptor of Immunity. 
International Journal of Biochemistry and Cell Biology, 43, 25-28. 
 
Elkabes, S., DiCicco-Bloom, E. M. & Black, I. B. 1996. Brain Microglia/Macrophages Express 
Neurotrophins That Selectively Regulate Microglial Proliferation and Function. 
Journal of Neuroscience, 16, 2508-2521. 
 
Elmore, M. R., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., 
Kitazawa, M., Matusow, B., Nguyen, H., West, B. L. & Green, K. N. 2014. Colony-
Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, 
Unmasking a Microglia Progenitor Cell in the Adult Brain. Neuron, 82, 380-397. 
 
Espey, M. G., Chernyshev, O. N., Reinhard, J. F., Jr., Namboodiri, M. A. & Colton, C. A. 1997. 
Activated Human Microglia Produce the Excitotoxin Quinolinic Acid. Neuroreport, 8, 
431-434. 
 
European Commission 2003. Commission Regulation (Ec) No 1915/2003 of 30 October 2003 
Amending Annexes Vii, Viii and Ix to Regulation (Ec) No 999/2001 of the European 
Parliament and of the Council as Regards the Trade and Import of Ovine and Caprine 
Animals and the Measures Following the Confirmation of Transmissible Spongiform 
Encephalopathies in Bovine, Ovine and Caprine Animals (Text with Eea Relevance). 
Official Journal of the European Union, L 283, 29–33. 
 
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y. & Henson, P. M. 1998. 
Macrophages That Have Ingested Apoptotic Cells in Vitro Inhibit Proinflammatory 
Cytokine Production through Autocrine/Paracrine Mechanisms Involving Tgf-Beta, 
Pge2, and Paf. Journal of Clinical Investigation, 101, 890-898. 
 
Fallon, J., Reid, S., Kinyamu, R., Opole, I., Opole, R., Baratta, J., Korc, M., Endo, T. L., Duong, 
A., Nguyen, G., Karkehabadhi, M., Twardzik, D., Patel, S. & Loughlin, S. 2000. In Vivo 
Induction of Massive Proliferation, Directed Migration, and Differentiation of Neural 
Cells in the Adult Mammalian Brain. Proceedings of the National Academy of Sciences 
of the United States of America, 97, 14686-14691. 
 
Feinberg, A. P. & Vogelstein, B. 1983. A Technique for Radiolabeling DNA Restriction 
Endonuclease Fragments to High Specific Activity. Analytical Biochemistry, 132, 6-13. 
 
Felsenstein, J. 1985. Confidence Limits on Phylogenies: An Approach Using the Bootstrap. 
Evolution, 39, 783-791. 
 
Fernandes, A. M., Landeira-Fernandez, A. M., Souza-Santos, P., Carvalho-Alves, P. C. & 
Castilho, R. F. 2008. Quinolinate-Induced Rat Striatal Excitotoxicity Impairs 
243 
 
Endoplasmic Reticulum Ca2+-Atpase Function. Neurochemical Research, 33, 1749-
1758. 
 
Fernandez-Borja, M., Janssen, L., Verwoerd, D., Hordijk, P. & Neefjes, J. 2005. Rhob Regulates 
Endosome Transport by Promoting Actin Assembly on Endosomal Membranes 
through Dia1. Journal of Cell Science, 118, 2661-2670. 
 
Field, R., Campion, S., Warren, C., Murray, C. & Cunningham, C. 2010. Systemic Challenge 
with the Tlr3 Agonist Poly I:C Induces Amplified Ifnalpha/Beta and Il-1beta Responses 
in the Diseased Brain and Exacerbates Chronic Neurodegeneration. Brain, Behavior, 
and Immunity, 24, 996-1007. 
 
Flanary, B. E., Sammons, N. W., Nguyen, C., Walker, D. & Streit, W. J. 2007. Evidence That 
Aging and Amyloid Promote Microglial Cell Senescence. Rejuvenation Res, 10, 61-74. 
 
Flanary, B. E. & Streit, W. J. 2005. Effects of Axotomy on Telomere Length, Telomerase 
Activity, and Protein in Activated Microglia. Journal of Neuroscience Research, 82, 
160-171. 
 
Fleige, G., Nolte, C., Synowitz, M., Seeberger, F., Kettenmann, H. & Zimmer, C. 2001. 
Magnetic Labeling of Activated Microglia in Experimental Gliomas. Neoplasia, 3, 489-
499. 
 
Fodor, S. P., Read, J. L., Pirrung, M. C., Stryer, L., Lu, A. T. & Solas, D. 1991. Light-Directed, 
Spatially Addressable Parallel Chemical Synthesis. Science, 251, 767-773. 
 
Ford, M. J., Burton, L. J., Li, H., Graham, C. H., Frobert, Y., Grassi, J., Hall, S. M. & Morris, R. J. 
2002. A Marked Disparity between the Expression of Prion Protein and Its Message 
by Neurones of the Cns. Neuroscience, 111, 533-551. 
 
Franchi, L., Eigenbrod, T., Munoz-Planillo, R. & Nunez, G. 2009. The Inflammasome: A 
Caspase-1-Activation Platform That Regulates Immune Responses and Disease 
Pathogenesis. Nature Immunology, 10, 241-247. 
 
Franke, H., Schepper, C., Illes, P. & Krugel, U. 2007. Involvement of P2x and P2y Receptors in 
Microglial Activation in Vivo. Purinergic Signal, 3, 435-445. 
 
Fraser, H., Brown, K. L., Stewart, K., McConnell, I., McBride, P. & Williams, A. 1996. Replication 
of Scrapie in Spleens of Scid Mice Follows Reconstitution with Wild-Type Mouse Bone 
Marrow. Journal of General Virology, 77 1935-1940. 
 
Fraser, H. & Dickinson, A. G. 1967. Distribution of Experimentally Induced Scrapie Lesions in 
the Brain. Nature, 216, 1310-1311. 
 
Fraser, H. & Dickinson, A. G. 1968. The Sequential Development of the Brain Lesion of Scrapie 
in Three Strains of Mice. Journal of Comparative Pathology, 78, 301-311. 
 
Fraser, H. & Dickinson, A. G. 1985. Targeting of Scrapie Lesions and Spread of Agent Via the 




Freeman, T. C., Goldovsky, L., Brosch, M., van Dongen, S., Mazière, P., Grocock, R. J., Freilich, 
S., Thornton, J. & Enright, A. J. 2007. Construction, Visualisation, and Clustering of 
Transcription Networks from Microarray Expression Data. PLoS Computational 
Biology, 3, 2032-2042. 
 
Freire-de-Lima, C. G., Nascimento, D. O., Soares, M. B., Bozza, P. T., Castro-Faria-Neto, H. C., 
de Mello, F. G., DosReis, G. A. & Lopes, M. F. 2000. Uptake of Apoptotic Cells Drives 
the Growth of a Pathogenic Trypanosome in Macrophages. Nature, 403, 199-203. 
 
Fricker, M., Neher, J. J., Zhao, J. W., Thery, C., Tolkovsky, A. M. & Brown, G. C. 2012. Mfg-E8 
Mediates Primary Phagocytosis of Viable Neurons During Neuroinflammation. 
Journal of Neuroscience, 32, 2657-2666. 
 
Frigg, R., Wenzel, A., Samardzija, M., Oesch, B., Wariwoda, H., Navarini, A. A., Seeliger, M. 
W., Tanimoto, N., Reme, C. & Grimm, C. 2006. The Prion Protein Is Neuroprotective 
against Retinal Degeneration in Vivo. Experimental Eye Research, 83, 1350-1358. 
 
Fuhrmann, M., Bittner, T., Jung, C. K., Burgold, S., Page, R. M., Mitteregger, G., Haass, C., 
LaFerla, F. M., Kretzschmar, H. & Herms, J. 2010. Microglial Cx3cr1 Knockout Prevents 
Neuron Loss in a Mouse Model of Alzheimer's Disease. Nature Neuroscience, 13, 411-
413. 
 
Fukuda, S., Abematsu, M., Mori, H., Yanagisawa, M., Kagawa, T., Nakashima, K., Yoshimura, 
A. & Taga, T. 2007. Potentiation of Astrogliogenesis by Stat3-Mediated Activation of 
Bone Morphogenetic Protein-Smad Signaling in Neural Stem Cells. Molecular and 
Cellular Biology, 27, 4931-4937. 
 
Galea, I., Palin, K., Newman, T. A., Van Rooijen, N., Perry, V. H. & Boche, D. 2005. Mannose 
Receptor Expression Specifically Reveals Perivascular Macrophages in Normal, 
Injured, and Diseased Mouse Brain. Glia, 49, 375-384. 
 
Gallaher, Z. R., Ryu, V., Herzog, T., Ritter, R. C. & Czaja, K. 2012. Changes in Microglial 
Activation within the Hindbrain, Nodose Ganglia, and the Spinal Cord Following 
Subdiaphragmatic Vagotomy. Neuroscience Letters, 513, 31-36. 
 
Gao, L., Hidalgo-Figueroa, M., Escudero, L. M., Diaz-Martin, J., Lopez-Barneo, J. & Pascual, A. 
2013. Age-Mediated Transcriptomic Changes in Adult Mouse Substantia Nigra. PloS 
One, 8, e62456. 
 
Garcia, C. M., Darland, D. C., Massingham, L. J. & D'Amore, P. A. 2004. Endothelial Cell-
Astrocyte Interactions and Tgf Beta Are Required for Induction of Blood-Neural 
Barrier Properties. Brain Research: Developmental Brain Research, 152, 25-38. 
 
Gath, J., Bousset, L., Habenstein, B., Melki, R., Bockmann, A. & Meier, B. H. 2014. Unlike 
Twins: An Nmr Comparison of Two Alpha-Synuclein Polymorphs Featuring Different 
Toxicity. PloS One, 9, e90659. 
 
Gatti, S. & Bartfai, T. 1993. Induction of Tumor Necrosis Factor-Α Mrna in the Brain after 
Peripheral Endotoxin Treatment: Comparison with Interleukin-1 Family and 




Gehlenborg, N., Hwang, D., Lee, I. Y., Yoo, H., Baxter, D., Petritis, B., Pitstick, R., Marzolf, B., 
Dearmond, S. J., Carlson, G. A. & Hood, L. 2009. The Prion Disease Database: A 
Comprehensive Transcriptome Resource for Systems Biology Research in Prion 
Diseases. Database, 17, 17. 
 
Gehrmann, J., Matsumoto, Y. & Kreutzberg, G. W. 1995. Microglia: Intrinsic Immuneffector 
Cell of the Brain. Brain Research Reviews, 20, 269-287. 
 
Geissmann, F., Jung, S. & Littman, D. R. 2003. Blood Monocytes Consist of Two Principal 
Subsets with Distinct Migratory Properties. Immunity, 19, 71-82. 
 
Gerber, J. S. & Mosser, D. M. 2001. Reversing Lipopolysaccharide Toxicity by Ligating the 
Macrophage Fc Gamma Receptors. Journal of Immunology, 166, 6861-6868. 
 
Getts, D. R., Terry, R. L., Getts, M. T., Müller, M., Rana, S., Shrestha, B., Radford, J., Van 
Rooijen, N., Campbell, I. L. & King, N. J. C. 2008. Ly6c+ "Inflammatory Monocytes" 
Are Microglial Precursors Recruited in a Pathogenic Manner in West Nile Virus 
Encephalitis. The Journal of Experimental Medicine, 205, 2319-2337. 
 
Gibbons, R. A. & Hunter, G. D. 1967. Nature of the Scrapie Agent. Nature, 215, 1041-1043. 
 
Gibbs, C. J. & Gajdusek, D. C. 1972. Transmission of Scrapie to the Cynomolgus Monkey 
(Macaca Fascicularis). Nature, 236, 73-74. 
 
Gibbs, C. J., Jr., Amyx, H. L., Bacote, A., Masters, C. L. & Gajdusek, D. C. 1980. Oral 
Transmission of Kuru, Creutzfeldt-Jakob Disease, and Scrapie to Nonhuman 
Primates. Journal of Infectious Diseases, 142, 205-208. 
 
Giese, A., Brown, D. R., Groschup, M. H., Feldmann, C., Haist, I. & Kretzschmar, H. A. 1998. 
Role of Microglia in Neuronal Cell Death in Prion Disease. Brain Pathology, 8, 449-
457. 
 
Giese, A., Groschup, M. H., Hess, B. & Kretzschmar, H. A. 1995. Neuronal Cell Death in Scrapie-
Infected Mice Is Due to Apoptosis. Brain Pathology, 5, 213-221. 
 
Gil, M. P., Bohn, E., O'Guin, A. K., Ramana, C. V., Levine, B., Stark, G. R., Virgin, H. W. & 
Schreiber, R. D. 2001. Biologic Consequences of Stat1-Independent Ifn Signaling. 
Proceedings of the National Academy of Sciences of the United States of America, 98, 
6680-6685. 
 
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. 
J., Ng, L. G., Stanley, E. R., Samokhvalov, I. M. & Merad, M. 2010. Fate Mapping 
Analysis Reveals That Adult Microglia Derive from Primitive Macrophages. Science, 
330, 841-845. 
 
Gitik, M., Liraz-Zaltsman, S., Oldenborg, P. A., Reichert, F. & Rotshenker, S. 2011. Myelin 
Down-Regulates Myelin Phagocytosis by Microglia and Macrophages through 
Interactions between Cd47 on Myelin and Sirpalpha (Signal Regulatory Protein-




Godbout, J. P., Chen, J., Abraham, J., Richwine, A. F., Berg, B. M., Kelley, K. W. & Johnson, R. 
W. 2005. Exaggerated Neuroinflammation and Sickness Behavior in Aged Mice after 
Activation of the Peripheral Innate Immune System. Federation of American Societies 
for Experimental Biology Journal, 1329-1331. 
 
Godsave, S. F., Wille, H., Pierson, J., Prusiner, S. B. & Peters, P. J. 2013. Plasma Membrane 
Invaginations Containing Clusters of Full-Length Prpsc Are an Early Form of Prion-
Associated Neuropathology in Vivo. Neurobiology of Aging, 34, 1621-1631. 
 
Gomez-Nicola, D., Fransen, N. L., Suzzi, S. & Perry, V. H. 2013. Regulation of Microglial 
Proliferation During Chronic Neurodegeneration. Journal of Neuroscience, 33, 2481-
2493. 
 
Gomez-Nicola, D., Schetters, S. T. & Hugh Perry, V. 2014. Differential Role of Ccr2 in the 
Dynamics of Microglia and Perivascular Macrophages During Prion Disease. Glia, 
1041-1052. 
 
Gordon, W. S., Brownlee, A. & Wilson, D. R. 1940. Studies in Louping-Ill, Tick-Borne Fever and 
Scrapie, in Proceedings: 3rd International Congress of Microbiology, (New York). NY), 
362-363. 
 
Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T. & 
Yirmiya, R. 2007. Brain Interleukin-1 Mediates Chronic Stress-Induced Depression in 
Mice Via Adrenocortical Activation and Hippocampal Neurogenesis Suppression. 
Molecular Psychiatry, 13, 717-728. 
 
Grathwohl, S., Kälin, R., Bolmont, T., Radde, R., Odenthal, J., Mazzella, M., Käser, S., Mathews, 
P. M., Eldh, T., Wolburg, H., Kohsaka, S., Heppner, F. L. & Jucker, M. 2009. Formation 
and Maintenance of [Beta]-Amyloid Plaques in the Absence of Microglia. Alzheimer's 
and Dementia, 5, 439-440. 
 
Gray, B. C., Siskova, Z., Perry, V. H. & O'Connor, V. 2009. Selective Presynaptic Degeneration 
in the Synaptopathy Associated with Me7-Induced Hippocampal Pathology. 
Neurobiology of Disease, 35, 63-74. 
 
Green, R. P., Cohn, S. M., Sacchettini, J. C., Jackson, K. E. & Gordon, J. I. 1992. The Mouse 
Intestinal Fatty Acid Binding Protein Gene: Nucleotide Sequence, Pattern of 
Developmental and Regional Expression, and Proposed Structure of Its Protein 
Product. DNA and Cell Biology, 11, 31-41. 
 
Greenlee, J. J., Nicholson, E. M., Smith, J. D., Kunkle, R. A. & Hamir, A. N. 2012. Susceptibility 
of Cattle to the Agent of Chronic Wasting Disease from Elk after Intracranial 
Inoculation. Journal of Veterinary Diagnostic Investigation, 24, 1087-1093. 
 
Greenlee, J. J., Smith, J. D. & Kunkle, R. A. 2011. White-Tailed Deer Are Susceptible to the 
Agent of Sheep Scrapie by Intracerebral Inoculation. Veterinary Research, 42, 107. 
 
Greig, J. R. 1940. Scrapie: Observations on the Transmission of the Disease by Mediate 




Griffin, W. S., Sheng, J. G., Roberts, G. W. & Mrak, R. E. 1995. Interleukin-1 Expression in 
Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evolution. 
Journal of Neuropathology and Experimental Neurology, 54, 276-281. 
 
Griffith, J. S. 1967. Nature of the Scrapie Agent: Self-Replication and Scrapie. Nature, 215, 
1043-1044. 
 
Guillemin, G. J., Smythe, G., Takikawa, O. & Brew, B. J. 2005. Expression of Indoleamine 2,3-
Dioxygenase and Production of Quinolinic Acid by Human Microglia, Astrocytes, and 
Neurons. Glia, 49, 15-23. 
 
Guillerme-Bosselut, F., Forestier, L., Jayat-Vignoles, C., Vilotte, J. L., Popa, I., Portoukalian, J., 
Le Dur, A., Laude, H., Julien, R. & Gallet, P. F. 2009. Glycosylation-Related Gene 
Expression Profiling in the Brain and Spleen of Scrapie-Affected Mouse. Glycobiology, 
19, 879-889. 
 
Guiroy, D. C., Wakayama, I., Liberski, P. P. & Gajdusek, D. C. 1994. Relationship of Microglia 
and Scrapie Amyloid-Immunoreactive Plaques in Kuru, Creutzfeldt-Jakob Disease and 
Gerstmann-Sträussler Syndrome. Acta Neuropathologica, 87, 526-530. 
 
Guo, J. L., Covell, D. J., Daniels, J. P., Iba, M., Stieber, A., Zhang, B., Riddle, D. M., Kwong, L. K., 
Xu, Y., Trojanowski, J. Q. & Lee, V. M. 2013. Distinct Alpha-Synuclein Strains 
Differentially Promote Tau Inclusions in Neurons. Cell, 154, 103-117. 
 
Guo, J. L. & Lee, V. M. 2013. Neurofibrillary Tangle-Like Tau Pathology Induced by Synthetic 
Tau Fibrils in Primary Neurons over-Expressing Mutant Tau. FEBS Letters, 587, 717-
723. 
 
Gurtan, A. M. & D'Andrea, A. D. 2006. Dedicated to the Core: Understanding the Fanconi 
Anemia Complex. DNA Repair, 5, 1119-1125. 
 
Haig, D. A. & Clarke, M. C. 1971. Multiplication of the Scrapie Agent. Nature, 234, 106-107. 
 
Hakem, A., Sanchez-Sweatman, O., You-Ten, A., Duncan, G., Wakeham, A., Khokha, R. & Mak, 
T. W. 2005. Rhoc Is Dispensable for Embryogenesis and Tumor Initiation but Essential 
for Metastasis. Genes & Development, 19, 1974-1979. 
 
Halfmann, R., Jarosz, D. F., Jones, S. K., Chang, A., Lancaster, A. K. & Lindquist, S. 2012. Prions 
Are a Common Mechanism for Phenotypic Inheritance in Wild Yeasts. Nature, 482, 
363-368. 
 
Hamir, A. N., Kunkle, R. A., Cutlip, R. C., Miller, J. M., O'Rourke, K. I., Williams, E. S., Miller, M. 
W., Stack, M. J., Chaplin, M. J. & Richt, J. A. 2005. Experimental Transmission of 
Chronic Wasting Disease Agent from Mule Deer to Cattle by the Intracerebral Route. 
Journal of Veterinary Diagnostic Investigation, 17, 276-281. 
 
Hamir, A. N., Kunkle, R. A., Cutlip, R. C., Miller, J. M., Williams, E. S. & Richt, J. A. 2006. 
Transmission of Chronic Wasting Disease of Mule Deer to Suffolk Sheep Following 
248 
 
Intracerebral Inoculation. Journal of Veterinary Diagnostic Investigation, 18, 558-
565. 
 
Hamir, A. N., Miller, J. M., Cutlip, R. C., Kunkle, R. A., Jenny, A. L., Stack, M. J., Chaplin, M. J. & 
Richt, J. A. 2004. Transmission of Sheep Scrapie to Elk (Cervus Elaphus Nelsoni) by 
Intracerebral Inoculation: Final Outcome of the Experiment. Journal of Veterinary 
Diagnostic Investigation, 16, 316-321. 
 
Hamir, A. N., Miller, J. M., Kunkle, R. A., Hall, S. M. & Richt, J. A. 2007. Susceptibility of Cattle 
to First-Passage Intracerebral Inoculation with Chronic Wasting Disease Agent from 
White-Tailed Deer. Veterinary Pathology, 44, 487-493. 
 
Hanisch, U.-K. & Gertig, U. 2014. Microglial Diversity by Responses and Responders. Frontiers 
in Cellular Neuroscience, 8, 1-9. 
 
Hanisch, U. K. 2013. Functional Diversity of Microglia - How Heterogeneous Are They to Begin 
With? Frontiers in Cellular Neuroscience, 7, 1-18. 
 
Harrington, D. P. & Fleming, T. R. 1982. A Class of Rank Test Procedures for Censored Survival 
Data. Biometrika, 69, 553-566. 
 
Hart, A. D., Wyttenbach, A., Perry, V. H. & Teeling, J. L. 2012. Age Related Changes in 
Microglial Phenotype Vary between Cns Regions: Grey Versus White Matter 
Differences. Brain, Behavior, and Immunity, 26, 754-765. 
 
Hart, B. L. 1988. Biological Basis of the Behavior of Sick Animals. Neuroscience and 
Biobehavioral Reviews, 12, 123-137. 
 
Haynes, S. E., Hollopeter, G., Yang, G., Kurpius, D., Dailey, M. E., Gan, W. B. & Julius, D. 2006. 
The P2y12 Receptor Regulates Microglial Activation by Extracellular Nucleotides. 
Nature Neuroscience, 9, 1512-1519. 
 
Heiman, M., Schaefer, A., Gong, S., Peterson, J. D., Day, M., Ramsey, K. E., Suarez-Farinas, M., 
Schwarz, C., Stephan, D. A., Surmeier, D. J., Greengard, P. & Heintz, N. 2008. A 
Translational Profiling Approach for the Molecular Characterization of Cns Cell Types. 
Cell, 135, 738-748. 
 
Heldin, C. H., Miyazono, K. & ten Dijke, P. 1997. Tgf-Beta Signalling from Cell Membrane to 
Nucleus through Smad Proteins. Nature, 390, 465-471. 
 
Heller-Stilb, B., van Roeyen, C., Rascher, K., Hartwig, H. G., Huth, A., Seeliger, M. W., 
Warskulat, U. & Haussinger, D. 2002. Disruption of the Taurine Transporter Gene 
(Taut) Leads to Retinal Degeneration in Mice. FASEB Journal, 16, 231-233. 
 
Henry, C. J., Huang, Y., Wynne, A. M. & Godbout, J. P. 2009. Peripheral Lipopolysaccharide 
(Lps) Challenge Promotes Microglial Hyperactivity in Aged Mice That Is Associated 
with Exaggerated Induction of Both Pro-Inflammatory Il-1beta and Anti-




Heyes, M. P., Achim, C. L., Wiley, C. A., Major, E. O., Saito, K. & Markey, S. P. 1996. Human 
Microglia Convert L-Tryptophan into the Neurotoxin Quinolinic Acid. Biochemical 
Journal, 320 595-597. 
 
Hibbs, J. B. 2002. Infection and Nitric Oxide. The Journal of Infectious Diseases, 185, S9-17. 
 
Hickey, W. F. & Kimura, H. 1988. Perivascular Microglial Cells of the Cns Are Bone Marrow-
Derived and Present Antigen in Vivo. Science, 239, 290-292. 
 
Hilton, K. J., Cunningham, C., Reynolds, R. A. & Perry, V. H. 2013. Early Hippocampal Synaptic 
Loss Precedes Neuronal Loss and Associates with Early Behavioural Deficits in Three 
Distinct Strains of Prion Disease. PloS One, 8, e68062. 
 
Hines, D. J., Hines, R. M., Mulligan, S. J. & Macvicar, B. A. 2009. Microglia Processes Block the 
Spread of Damage in the Brain and Require Functional Chloride Channels. Glia, 57, 
1610-1618. 
 
Hoebe, K., Du, X., Georgel, P., Janssen, E., Tabeta, K., Kim, S. O., Goode, J., Lin, P., Mann, N., 
Mudd, S., Crozat, K., Sovath, S., Han, J. & Beutler, B. 2003. Identification of Lps2 as a 
Key Transducer of Myd88-Independent Tir Signalling. Nature, 424, 743-748. 
 
Hoeck, J. D., Jandke, A., Blake, S. M., Nye, E., Spencer-Dene, B., Brandner, S. & Behrens, A. 
2010. Fbw7 Controls Neural Stem Cell Differentiation and Progenitor Apoptosis Via 
Notch and C-Jun. Nature Neuroscience, 13, 1365-1372. 
 
Hoek, R. M., Ruuls, S. R., Murphy, C. A., Wright, G. J., Goddard, R., Zurawski, S. M., Blom, B., 
Homola, M. E., Streit, W. J., Brown, M. H., Barclay, A. N. & Sedgwick, J. D. 2000. Down-
Regulation of the Macrophage Lineage through Interaction with Ox2 (Cd200). 
Science, 290, 1768-1771. 
 
Holman, H. H. & Pattison, I. H. 1943. Further Evidence on the Significance of Vacuolated 
Nerve Cells in the Medulla Oblongata of Sheep Affected with Scrapie. Journal of 
Comparative Pathology and Therapeutics, 53, 231-236. 
 
Hsieh, C. L., Kim, C. C., Ryba, B. E., Niemi, E. C., Bando, J. K., Locksley, R. M., Liu, J., Nakamura, 
M. C. & Seaman, W. E. 2013. Traumatic Brain Injury Induces Macrophage Subsets in 
the Brain. European Journal of Immunology, 43, 2010-2022. 
 
Huang, C., Xia, P. Y. & Zhou, H. 2010. Sustained Expression of Tdp-43 and Fus in Motor 
Neurons in Rodent's Lifetime. International Journal of Biological Sciences, 6, 396-406. 
 
Hughes, M. M., Field, R. H., Perry, V. H., Murray, C. L. & Cunningham, C. 2010. Microglia in 
the Degenerating Brain Are Capable of Phagocytosis of Beads and of Apoptotic Cells, 
but Do Not Efficiently Remove Prp(Sc), Even Upon Lps Stimulation. Glia, 58, 2017-
2030. 
 
Hughes, P. M., Botham, M. S., Frentzel, S., Mir, A. & Perry, V. H. 2002. Expression of 
Fractalkine (Cx3cl1) and Its Receptor, Cx3cr1, During Acute and Chronic Inflammation 




Hughes, V. 2012. Microglia: The Constant Gardeners. Nature, 485, 570-572. 
 
Hunter, G. D., Gibbons, R. A., Kimberlin, R. H. & Millson, G. C. 1969. Further Studies of the 
Infectivity and Stability of Extracts and Homogenates Derived from Scrapie Affected 
Mouse Brains. Journal of Comparative Pathology, 79, 101-108. 
 
Hunter, G. D., Kimberlin, R. H., Millson, G. C. & Gibbons, R. A. 1971. An Experimental 
Examination of the Scrapie Agent in Cell Membrane Mixtures: I. Stability and 
Physicochemical Properties of the Scrapie Agent. Journal of Comparative Pathology, 
81, 23-32. 
 
Hunter, G. D. & Millson, G. C. 1967. Attempts to Release the Scrapie Agent from Tissue Debris. 
Journal of Comparative Pathology, 77, 301-307. 
 
Hunter, N., Goldmann, W., Foster, J. D., Cairns, D. & Smith, G. 1997a. Natural Scrapie and Prp 
Genotype: Case-Control Studies in British Sheep. Veterinary Record, 141, 137-140. 
 
Hunter, N., Moore, L., Hosie, B. D., Dingwall, W. S. & Greig, A. 1997b. Association between 
Natural Scrapie and Prp Genotype in a Flock of Suffolk Sheep in Scotland. Veterinary 
Record, 140, 59-63. 
 
Huynh, M. L., Fadok, V. A. & Henson, P. M. 2002. Phosphatidylserine-Dependent Ingestion of 
Apoptotic Cells Promotes Tgf-Beta1 Secretion and the Resolution of Inflammation. 
Journal of Clinical Investigation, 109, 41-50. 
 
Hwang, D., Lee, I. Y., Yoo, H., Gehlenborg, N., Cho, J.-H., Petritis, B., Baxter, D., Pitstick, R., 
Young, R., Spicer, D., Price, N. D., Hohmann, J. G., DeArmond, S. J., Carlson, G. A. & 
Hood, L. E. 2009. A Systems Approach to Prion Disease. Molecular Systems Biology, 
5, 252. 
 
Hynes, R. O. 1992. Integrins: Versatility, Modulation, and Signaling in Cell Adhesion. Cell, 69, 
11-25. 
 
Iken, S., Bachy, V., Gourdain, P., Lim, A., Gregoire, S., Chaigneau, T., Aucouturier, P. & 
Carnaud, C. 2011. Th2-Polarised Prp-Specific Transgenic T-Cells Confer Partial 
Protection against Murine Scrapie. PLoS Pathogens, 7, e1002216. 
 
Inoue, E., Deguchi-Tawarada, M., Togawa, A., Matsui, C., Arita, K., Katahira-Tayama, S., Sato, 
T., Yamauchi, E., Oda, Y. & Takai, Y. 2009. Synaptic Activity Prompts Gamma-
Secretase-Mediated Cleavage of Epha4 and Dendritic Spine Formation. Journal of Cell 
Biology, 185, 551-564. 
 
Inui, M., Manfrin, A., Mamidi, A., Martello, G., Morsut, L., Soligo, S., Enzo, E., Moro, S., Polo, 
S., Dupont, S., Cordenonsi, M. & Piccolo, S. 2011. Usp15 Is a Deubiquitylating Enzyme 
for Receptor-Activated Smads. Nature Cell Biology, 13, 1368-1375. 
 
Irizarry, R. A., Hobbs, B., Collin, F., Beazer-Barclay, Y. D., Antonellis, K. J., Scherf, U. & Speed, 
T. P. 2003. Exploration, Normalization, and Summaries of High Density 




Ishibashi, D., Atarashi, R., Fuse, T., Nakagaki, T., Yamaguchi, N., Satoh, K., Honda, K. & Nishida, 
N. 2012. Protective Role of Interferon Regulatory Factor 3-Mediated Signaling against 
Prion Infection. Journal of Virology, 86, 4947-4955. 
 
Ishikura, N., Clever, J. L., Bouzamondo-Bernstein, E., Samayoa, E., Prusiner, S. B., Huang, E. J. 
& DeArmond, S. J. 2005. Notch-1 Activation and Dendritic Atrophy in Prion Disease. 
Proceedings of the National Academy of Sciences of the United States of America, 
102, 886-891. 
 
Islam, R., Yang, L., Sah, M., Kannan, K., Anamani, D., Vijayan, C., Kwok, J., Cantino, M. E., Beal, 
M. F. & Fridell, Y. W. 2012. A Neuroprotective Role of the Human Uncoupling Protein 
2 (Hucp2) in a Drosophila Parkinson's Disease Model. Neurobiology of Disease, 46, 
137-146. 
 
Jamieson, E., Jeffrey, M., Ironside, J. W. & Fraser, J. R. 2001. Apoptosis and Dendritic 
Dysfunction Precede Prion Protein Accumulation in 87v Scrapie. Neuroreport, 12, 
2147-2153. 
 
Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., Coppola, D., 
Morgan, D. & Gordon, M. N. 2002. Microglial Activation and Beta -Amyloid Deposit 
Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug 
in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice. Journal of 
Neuroscience, 22, 2246-2254. 
 
Jeffrey, M., Goodsir, C. M., Bruce, M. E., McBride, P. A. & Fraser, J. R. 1997. In Vivo Toxicity 
of Prion Protein in Murine Scrapie: Ultrastructural and Immunogold Studies. 
Neuropathology and Applied Neurobiology, 23, 93-101. 
 
Jeffrey, M., Halliday, W. G., Bell, J., Johnston, A. R., MacLeod, N. K., Ingham, C., Sayers, A. R., 
Brown, D. A. & Fraser, J. R. 2000. Synapse Loss Associated with Abnormal Prp 
Precedes Neuronal Degeneration in the Scrapie-Infected Murine Hippocampus. 
Neuropathology and Applied Neurobiology, 26, 41-54. 
 
Jeffrey, M., Martin, S., Barr, J., Chong, A. & Fraser, J. R. 2001. Onset of Accumulation of 
Prpresin Murine Me7 Scrapie in Relation to Pathological and Prp 
Immunohistochemical Changes. Journal of Comparative Pathology, 124, 20-28. 
 
Jeffrey, M. & Wells, G. A. 1988. Spongiform Encephalopathy in a Nyala (Tragelaphus Angasi). 
Veterinary Pathology, 25, 398-399. 
 
Jenmalm, M. C., Cherwinski, H., Bowman, E. P., Phillips, J. H. & Sedgwick, J. D. 2006. 
Regulation of Myeloid Cell Function through the Cd200 Receptor. Journal of 
Immunology, 176, 191-199. 
 
Jensen, L. J., Kuhn, M., Stark, M., Chaffron, S., Creevey, C., Muller, J., Doerks, T., Julien, P., 
Roth, A., Simonovic, M., Bork, P. & von Mering, C. 2009. String 8--a Global View on 





Jeong, H. K., Ji, K. M., Kim, B., Kim, J., Jou, I. & Joe, E. H. 2010. Inflammatory Responses Are 
Not Sufficient to Cause Delayed Neuronal Death in Atp-Induced Acute Brain Injury. 
PloS One, 5, e13756. 
 
Ji, K., Akgul, G., Wollmuth, L. P. & Tsirka, S. E. 2013. Microglia Actively Regulate the Number 
of Functional Synapses. PloS One, 8, e56293. 
 
Johnston, A. R., Fraser, J. R., Jeffrey, M. & MacLeod, N. 1998. Synaptic Plasticity in the Ca1 
Area of the Hippocampus of Scrapie-Infected Mice. Neurobiology of Disease, 5, 188-
195. 
 
Joly, S., Francke, M., Ulbricht, E., Beck, S., Seeliger, M., Hirrlinger, P., Hirrlinger, J., Lang, K. S., 
Zinkernagel, M., Odermatt, B., Samardzija, M., Reichenbach, A., Grimm, C. & Reme, 
C. E. 2009. Cooperative Phagocytes: Resident Microglia and Bone Marrow 
Immigrants Remove Dead Photoreceptors in Retinal Lesions. American Journal of 
Pathology, 174, 2310-2323. 
 
Jucker, M. & Walker, L. C. 2013. Self-Propagation of Pathogenic Protein Aggregates in 
Neurodegenerative Diseases. Nature, 501, 45-51. 
 
Jutila, M. A., Kroese, F. G., Jutila, K. L., Stall, A. M., Fiering, S., Herzenberg, L. A., Berg, E. L. & 
Butcher, E. C. 1988. Ly-6c Is a Monocyte/Macrophage and Endothelial Cell 
Differentiation Antigen Regulated by Interferon-Gamma. European Journal of 
Immunology, 18, 1819-1826. 
 
Kakkar, R., Hei, H., Dobner, S. & Lee, R. T. 2012. Interleukin 33 as a Mechanically Responsive 
Cytokine Secreted by Living Cells. Journal of Biological Chemistry, 287, 6941-6948. 
 
Kascsak, R. J., Rubenstein, R., Merz, P. A., Carp, R. I., Wisniewski, H. M. & Diringer, H. 1985. 
Biochemical Differences among Scrapie-Associated Fibrils Support the Biological 
Diversity of Scrapie Agents. Journal of General Virology, 66 ( Pt 8), 1715-1722. 
 
Kastin, A. J., Akerstrom, V. & Pan, W. 2003. Circulating Tgf-Beta1 Does Not Cross the Intact 
Blood-Brain Barrier. Journal of Molecular Neuroscience, 21, 43-48. 
 
Kauffmann, A., Gentleman, R. & Huber, W. 2009. Arrayqualitymetrics--a Bioconductor 
Package for Quality Assessment of Microarray Data. Bioinformatics (Oxford, 
England), 25, 415-416. 
 
Kauppinen, T. M., Higashi, Y., Suh, S. W., Escartin, C., Nagasawa, K. & Swanson, R. A. 2008. 
Zinc Triggers Microglial Activation. Journal of Neuroscience, 28, 5827-5835. 
 
Kawai, T., Adachi, O., Ogawa, T., Takeda, K. & Akira, S. 1999. Unresponsiveness of Myd88-
Deficient Mice to Endotoxin. Immunity, 11, 115-122. 
 
Kayed, R., Canto, I., Breydo, L., Rasool, S., Lukacsovich, T., Wu, J., Albay, R., 3rd, Pensalfini, A., 
Yeung, S., Head, E., Marsh, J. L. & Glabe, C. 2010. Conformation Dependent 
Monoclonal Antibodies Distinguish Different Replicating Strains or Conformers of 




Kearns, A. E., Donohue, M. M., Sanyal, B. & Demay, M. B. 2001. Cloning and Characterization 
of a Novel Protein Kinase That Impairs Osteoblast Differentiation in Vitro. Journal of 
Biological Chemistry, 276, 42213-42218. 
 
Keeler, C. E. 1924. The Inheritance of a Retinal Abnormality in White Mice. Proceedings of the 
National Academy of Sciences of the United States of America, 10, 329-333. 
 
Keeler, C. E. 1931. The Laboratory Mouse; Its Origin, Heredity, and Culture, by Clyde E. Keeler, 
Cambridge, Harvard university press, Page: 32. 
 
Kennedy, D. W. & Abkowitz, J. L. 1998. Mature Monocytic Cells Enter Tissues and Engraft. 
Proceedings of the National Academy of Sciences, 95, 14944-14949. 
 
Kent, S., Bluthe, R. M., Dantzer, R., Hardwick, A. J., Kelley, K. W., Rothwell, N. J. & Vannice, J. 
L. 1992. Different Receptor Mechanisms Mediate the Pyrogenic and Behavioral 
Effects of Interleukin 1. Proceedings of the National Academy of Sciences of the 
United States of America, 89, 9117-9120. 
 
Kettenmann, H., Kirchhoff, F. & Verkhratsky, A. 2013. Microglia: New Roles for the Synaptic 
Stripper. Neuron, 77, 10-18. 
 
Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E. G., Wieghofer, P., 
Heinrich, A., Riemke, P., Holscher, C., Muller, D. N., Luckow, B., Brocker, T., Debowski, 
K., Fritz, G., Opdenakker, G., Diefenbach, A., Biber, K., Heikenwalder, M., Geissmann, 
F., Rosenbauer, F. & Prinz, M. 2013. Microglia Emerge from Erythromyeloid 
Precursors Via Pu.1- and Irf8-Dependent Pathways. Nature Neuroscience, 16, 273-
280. 
 
Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J. & Popovich, P. G. 
2009. Identification of Two Distinct Macrophage Subsets with Divergent Effects 
Causing Either Neurotoxicity or Regeneration in the Injured Mouse Spinal Cord. 
Journal of Neuroscience, 29, 13435-13444. 
 
Kim, C., Cho, E. D., Kim, H. K., You, S., Lee, H. J., Hwang, D. & Lee, S. J. 2014. Beta1-Integrin-
Dependent Migration of Microglia in Response to Neuron-Released Alpha-Synuclein. 
Experimental and Molecular Medicine, 46, e91. 
 
Kim, H. O., Snyder, G. P., Blazey, T. M., Race, R. E., Chesebro, B. & Skinner, P. J. 2008. Prion 
Disease Induced Alterations in Gene Expression in Spleen and Brain Prior to Clinical 
Symptoms. Advances and Applications in Bioinformatics and Chemistry, 1, 29-50. 
 
Kim, J. I., Cali, I., Surewicz, K., Kong, Q., Raymond, G. J., Atarashi, R., Race, B., Qing, L., 
Gambetti, P., Caughey, B. & Surewicz, W. K. 2010. Mammalian Prions Generated 
from Bacterially Expressed Prion Protein in the Absence of Any Mammalian 
Cofactors. Journal of Biological Chemistry, 285, 14083-14087. 
 
Kim, J. I., Jin, J. K., Choi, E. K., Spinner, D., Rubenstein, R., Carp, R. I. & Kim, Y. S. 2007. 
Increased Expression and Localization of Cyclooxygenase-2 in Astrocytes of Scrapie-




Kim, M. H., Choi, J., Yang, J., Chung, W., Kim, J. H., Paik, S. K., Kim, K., Han, S., Won, H., Bae, 
Y. S., Cho, S. H., Seo, J., Bae, Y. C., Choi, S. Y. & Kim, E. 2009. Enhanced Nmda 
Receptor-Mediated Synaptic Transmission, Enhanced Long-Term Potentiation, and 
Impaired Learning and Memory in Mice Lacking Irsp53. Journal of Neuroscience, 29, 
1586-1595. 
 
Kim, S., Elkon, K. B. & Ma, X. 2004. Transcriptional Suppression of Interleukin-12 Gene 
Expression Following Phagocytosis of Apoptotic Cells. Immunity, 21, 643-653. 
 
Kimberlin, R. H. 1976. The Pathogenesis of Scrapie in Mice. Slow Virus Diseases of Animals 
and Man. Amsterdam: North Holland Publishing Company, Page: 325-357. 
 
Kimberlin, R. H., Cole, S. & Walker, C. A. 1987. Pathogenesis of Scrapie Is Faster When 
Infection Is Intraspinal Instead of Intracerebral. Microbial Pathogenesis, 2, 405-415. 
 
Kimberlin, R. H., Hall, S. M. & Walker, C. A. 1983. Pathogenesis of Mouse Scrapie. Evidence 
for Direct Neural Spread of Infection to the Cns after Injection of Sciatic Nerve. 
Journal of the Neurological Sciences, 61, 315-325. 
 
Kimberlin, R. H., Millson, G. C. & Hunter, G. D. 1971a. An Experimental Examination of the 
Scrapie Agent in Cell Membrane Mixtures. 3. Studies of the Operational Size. Journal 
of Comparative Pathology, 81, 383-391. 
 
Kimberlin, R. H., Millson, G. C. & Mackenzie, A. 1971b. Biochemical and Histopathological 
Changes in the Brains of Mice Inoculated with Scrapie by the Intraperitoneal Route. 
Journal of Comparative Pathology, 81, 469-477. 
 
Kimberlin, R. H. & Walker, C. A. 1978. Pathogenesis of Mouse Scrapie: Effect of Route of 
Inoculation on Infectivity Titres and Dose-Response Curves. Journal of Comparative 
Pathology, 88, 39-47. 
 
Kimberlin, R. H. & Walker, C. A. 1979. Pathogenesis of Mouse Scrapie: Dynamics of Agent 
Replication in Spleen, Spinal Cord and Brain after Infection by Different Routes. 
Journal of Comparative Pathology, 89, 551-562. 
 
Kimberlin, R. H. & Walker, C. A. 1980. Pathogenesis of Mouse Scrapie: Evidence for Neural 
Spread of Infection to the Cns. The Journal of General Virology, 51, 183-187. 
 
Kimberlin, R. H. & Walker, C. A. 1986. Pathogenesis of Scrapie (Strain 263k) in Hamsters 
Infected Intracerebrally, Intraperitoneally or Intraocularly. Journal of General 
Virology, 67 255-263. 
 
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N. & LaFerla, F. M. 2005. 
Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-
Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's 
Disease. Journal of Neuroscience, 25, 8843-8853. 
 
Kitzing, T. M., Wang, Y., Pertz, O., Copeland, J. W. & Grosse, R. 2010. Formin-Like 2 Drives 




Kiyota, T., Ingraham, K. L., Swan, R. J., Jacobsen, M. T., Andrews, S. J. & Ikezu, T. 2012. Aav 
Serotype 2/1-Mediated Gene Delivery of Anti-Inflammatory Interleukin-10 Enhances 
Neurogenesis and Cognitive Function in App+Ps1 Mice. Gene Therapy, 19, 724-733. 
 
Kiyota, T., Okuyama, S., Swan, R. J., Jacobsen, M. T., Gendelman, H. E. & Ikezu, T. 2010. Cns 
Expression of Anti-Inflammatory Cytokine Interleukin-4 Attenuates Alzheimer’s 
Disease-Like Pathogenesis in App+Ps1 Bigenic Mice. The FASEB Journal, 24, 3093-
3102. 
 
Klein, R. S., Lin, E., Zhang, B., Luster, A. D., Tollett, J., Samuel, M. A., Engle, M. & Diamond, M. 
S. 2005. Neuronal Cxcl10 Directs Cd8+ T-Cell Recruitment and Control of West Nile 
Virus Encephalitis. Journal of Virology, 79, 11457-11466. 
 
Kluger, M. J. 1979. Temperature Regulation, Fever, and Disease. International Review of 
Physiology, 20, 209-251. 
 
Kocisko, D. A., Come, J. H., Priola, S. A., Chesebro, B., Raymond, G. J., Lansbury, P. T. & 
Caughey, B. 1994. Cell-Free Formation of Protease-Resistant Prion Protein. Nature, 
370, 471-474. 
 
Kohman, R. A., Bhattacharya, T. K., Kilby, C., Bucko, P. & Rhodes, J. S. 2013. Effects of 
Minocycline on Spatial Learning, Hippocampal Neurogenesis and Microglia in Aged 
and Adult Mice. Behavioural Brain Research, 242, 17-24. 
 
Kong, Q., Huang, S., Zou, W., Vanegas, D., Wang, M., Wu, D., Yuan, J., Zheng, M., Bai, H., Deng, 
H., Chen, K., Jenny, A. L., O'Rourke, K., Belay, E. D., Schonberger, L. B., Petersen, R. 
B., Sy, M. S., Chen, S. G. & Gambetti, P. 2005. Chronic Wasting Disease of Elk: 
Transmissibility to Humans Examined by Transgenic Mouse Models. Journal of 
Neuroscience, 25, 7944-7949. 
 
Konold, T., Spiropoulos, J., Chaplin, M. J., Stack, M. J., Hawkins, S. A. C., Wilesmith, J. W. & 
Wells, G. A. H. 2013. Unsuccessful Oral Transmission of Scrapie from British Sheep to 
Cattle. Veterinary Record, 118. 
 
Konsman, J. P., Kelley, K. & Dantzer, R. 1999. Temporal and Spatial Relationships between 
Lipopolysaccharide-Induced Expression of Fos, Interleukin-1 Β and Inducible Nitric 
Oxide Synthase in Rat Brain. Neuroscience, 89, 535-548. 
 
Kovac, A., Erickson, M. A. & Banks, W. A. 2011. Brain Microvascular Pericytes Are 
Immunoactive in Culture: Cytokine, Chemokine, Nitric Oxide, and Lrp-1 Expression in 
Response to Lipopolysaccharide. Journal of Neuroinflammation, 8, 139. 
 
Kozai, T. D., Vazquez, A. L., Weaver, C. L., Kim, S. G. & Cui, X. T. 2012. In Vivo Two-Photon 
Microscopy Reveals Immediate Microglial Reaction to Implantation of 
Microelectrode through Extension of Processes. J Neural Eng, 9, 066001. 
 
Kreutzberg, G. W., Graeber, M. B. & Streit, W. J. 1989. Neuron-Glial Relationship During 




Krieglstein, K., Henheik, P., Farkas, L., Jaszai, J., Galter, D., Krohn, K. & Unsicker, K. 1998. Glial 
Cell Line-Derived Neurotrophic Factor Requires Transforming Growth Factor-Beta for 
Exerting Its Full Neurotrophic Potential on Peripheral and Cns Neurons. Journal of 
Neuroscience, 18, 9822-9834. 
 
Kristensson, K., Feuerstein, B., Taraboulos, A., Hyun, W. C., Prusiner, S. B. & DeArmond, S. J. 
1993. Scrapie Prions Alter Receptor-Mediated Calcium Responses in Cultured Cells. 
Neurology, 43, 2335-2341. 
 
Krupenko, S. A. & Oleinik, N. V. 2002. 10-Formyltetrahydrofolate Dehydrogenase, One of the 
Major Folate Enzymes, Is Down-Regulated in Tumor Tissues and Possesses 
Suppressor Effects on Cancer Cells. Cell Growth and Differentiation, 13, 227-236. 
 
Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., Saya, H. & Suda, T. 2009. 
M-Csf Inhibition Selectively Targets Pathological Angiogenesis and 
Lymphangiogenesis. Journal of Experimental Medicine, 206, 1089-1102. 
 
Kullberg, S., Aldskogius, H. & Ulfhake, B. 2001. Microglial Activation, Emergence of Ed1-
Expressing Cells and Clusterin Upregulation in the Aging Rat Cns, with Special 
Reference to the Spinal Cord. Brain Research, 899, 169-186. 
 
Kutzbach, C. & Stokstad, E. L. R. 1971. [199] 10-Formyl Tetrahydrofolate: Nadp 
Oxidoreductase. In: Donald, B. M. & Lemuel, D. W. (eds.) Methods in Enzymology. 
Academic Press, Page: 793-798. 
 
Ladeby, R., Wirenfeldt, M., Garcia-Ovejero, D., Fenger, C., Dissing-Olesen, L., Dalmau, I. & 
Finsen, B. 2005. Microglial Cell Population Dynamics in the Injured Adult Central 
Nervous System. Brain Research: Brain Research Reviews, 48, 196-206. 
 
Lai, A. Y., Dhami, K. S., Dibal, C. D. & Todd, K. G. 2011. Neonatal Rat Microglia Derived from 
Different Brain Regions Have Distinct Activation Responses. Neuron Glia Biology, 7, 
5-16. 
 
Lai, A. Y., Dibal, C. D., Armitage, G. A., Winship, I. R. & Todd, K. G. 2013. Distinct Activation 
Profiles in Microglia of Different Ages: A Systematic Study in Isolated Embryonic to 
Aged Microglial Cultures. Neuroscience, 254, 185-195. 
 
Lancet, T. 1926. Obituary (Sir Stewart Stockman, M.R.C.V.S.). The Lancet, 207, 1171-1174. 
 
Lander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A. & Schmidt, A. M. 1997. 
Activation of the Receptor for Advanced Glycation End Products Triggers a P21(Ras)-
Dependent Mitogen-Activated Protein Kinase Pathway Regulated by Oxidant Stress. 
Journal of Biological Chemistry, 272, 17810-17814. 
 
Landriscina, M., Bagala, C., Mandinova, A., Soldi, R., Micucci, I., Bellum, S., Prudovsky, I. & 
Maciag, T. 2001. Copper Induces the Assembly of a Multiprotein Aggregate 
Implicated in the Release of Fibroblast Growth Factor 1 in Response to Stress. Journal 




Langevin, C., Andreoletti, O., Le Dur, A., Laude, H. & Beringue, V. 2011. Marked Influence of 
the Route of Infection on Prion Strain Apparent Phenotype in a Scrapie Transgenic 
Mouse Model. Neurobiology of Disease, 41, 219-225. 
 
Langford-Smith, A., Wilkinson, F. L., Langford-Smith, K. J., Holley, R. J., Sergijenko, A., Howe, 
S. J., Bennett, W. R., Jones, S. A., Wraith, J., Merry, C. L., Wynn, R. F. & Bigger, B. W. 
2012. Hematopoietic Stem Cell and Gene Therapy Corrects Primary Neuropathology 
and Behavior in Mucopolysaccharidosis Iiia Mice. Molecular Therapy, 20, 1610-1621. 
 
Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. 1983. Chronic Parkinsonism in Humans 
Due to a Product of Meperidine-Analog Synthesis. Science, 219, 979-980. 
 
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A. & Karluk, D. 1999. Evidence 
of Active Nerve Cell Degeneration in the Substantia Nigra of Humans Years after 1-
Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Exposure. Annals of Neurology, 46, 
598-605. 
 
Lashkari, D. A., DeRisi, J. L., McCusker, J. H., Namath, A. F., Gentile, C., Hwang, S. Y., Brown, 
P. O. & Davis, R. W. 1997. Yeast Microarrays for Genome Wide Parallel Genetic and 
Gene Expression Analysis. Proceedings of the National Academy of Sciences of the 
United States of America, 94, 13057-13062. 
 
Lassmann, H., Zimprich, F., Vass, K. & Hickey, W. F. 1991. Microglial Cells Are a Component 
of the Perivascular Glia Limitans. Journal of Neuroscience Research, 28, 236-243. 
 
Latarjet, R., Muel, B., Haig, D. A., Clarke, M. C. & Alper, T. 1970. Inactivation of the Scrapie 
Agent by near Monochromatic Ultraviolet Light. Nature, 227, 1341-1343. 
 
Lattin, J. E., Schroder, K., Su, A. I., Walker, J. R., Zhang, J., Wiltshire, T., Saijo, K., Glass, C. K., 
Hume, D. A., Kellie, S. & Sweet, M. J. 2008. Expression Analysis of G Protein-Coupled 
Receptors in Mouse Macrophages. Immunome Research, 4, 1745-7580. 
 
Lawson, L. J., Frost, L., Risbridger, J., Fearn, S. & Perry, V. H. 1994. Quantification of the 
Mononuclear Phagocyte Response to Wallerian Degeneration of the Optic Nerve. 
Journal of Neurocytology, 23, 729-744. 
 
Lawson, L. J., Perry, V. H., Dri, P. & Gordon, S. 1990. Heterogeneity in the Distribution and 
Morphology of Microglia in the Normal Adult Mouse Brain. Neuroscience, 39, 151-
170. 
 
Lawson, L. J., Perry, V. H. & Gordon, S. 1992. Turnover of Resident Microglia in the Normal 
Adult Mouse Brain. Neuroscience, 48, 405-415. 
 
Laye, S., Parnet, P., Goujon, E. & Dantzer, R. 1994. Peripheral Administration of 
Lipopolysaccharide Induces the Expression of Cytokine Transcripts in the Brain and 
Pituitary of Mice. Brain Research: Molecular Brain Research, 27, 157-162. 
 
Lee, C. K., Weindruch, R. & Prolla, T. A. 2000. Gene-Expression Profile of the Ageing Brain in 




Lee, Y. J., Jin, J. K., Jeong, B. H., Carp, R. I. & Kim, Y. S. 2006. Increased Expression of Glial Cell 
Line-Derived Neurotrophic Factor (Gdnf) in the Brains of Scrapie-Infected Mice. 
Neuroscience Letters, 410, 178-182. 
 
Legname, G., Baskakov, I. V., Nguyen, H. O., Riesner, D., Cohen, F. E., DeArmond, S. J. & 
Prusiner, S. B. 2004. Synthetic Mammalian Prions. Science, 305, 673-676. 
 
Legname, G., Nguyen, H. O., Baskakov, I. V., Cohen, F. E., Dearmond, S. J. & Prusiner, S. B. 
2005. Strain-Specified Characteristics of Mouse Synthetic Prions. Proceedings of the 
National Academy of Sciences of the United States of America, 102, 2168-2173. 
 
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. & Kliewer, S. A. 1997. Peroxisome 
Proliferator-Activated Receptors Α and Γ Are Activated by Indomethacin and Other 
Non-Steroidal Anti-Inflammatory Drugs. Journal of Biological Chemistry, 272, 3406-
3410. 
 
Lemstra, A. W., Groen in't Woud, J. C. M., Hoozemans, J. J. M., van Haastert, E. S., Rozemuller, 
A. J. M., Eikelenboom, P. & van Gool, W. A. 2007. Microglia Activation in Sepsis: A 
Case-Control Study. Journal of Neuroinflammation, 4, 4-4. 
 
Lenz, K. M., Nugent, B. M., Haliyur, R. & McCarthy, M. M. 2013. Microglia Are Essential to 
Masculinization of Brain and Behavior. Journal of Neuroscience, 33, 2761-2772. 
 
Leopold, J. G. 1759. Nützliche Und Auf Die Erfahrung Gegründete Einleitung Zu Der 
Landwirthschaft: Fünf Theile. Mit Kupfer Und Baurissen, Günther, Page: 348. 
 
Levi, G., Minghetti, L. & Aloisi, F. 1998. Regulation of Prostanoid Synthesis in Microglial Cells 
and Effects of Prostaglandin E2 on Microglial Functions. Biochimie, 80, 899-904. 
 
Lewicki, H., Tishon, A., Homann, D., Mazarguil, H., Laval, F., Asensio, V. C., Campbell, I. L., 
DeArmond, S., Coon, B., Teng, C., Gairin, J. E. & Oldstone, M. B. A. 2003. T Cells 
Infiltrate the Brain in Murine and Human Transmissible Spongiform 
Encephalopathies. Journal of Virology, 77, 3799-3808. 
 
Lewin, P. 1972. Scrapie : An Infective Peptide ? The Lancet, 299, 748. 
 
Leymarie, F. & Levine, M. D. 1992. Fast Raster Scan Distance Propagation on the Discrete 
Rectangular Lattice. CVGIP: Image Underst., 55, 84-94. 
 
Li, J., Wang, J. J., Peng, Q., Chen, C., Humphrey, M. B., Heinecke, J. & Zhang, S. X. 2012. 
Macrophage Metalloelastase (Mmp-12) Deficiency Mitigates Retinal Inflammation 
and Pathological Angiogenesis in Ischemic Retinopathy. PloS One, 7, e52699. 
 
Liang, K. J., Lee, J. E., Wang, Y. D., Ma, W., Fontainhas, A. M., Fariss, R. N. & Wong, W. T. 2009. 
Regulation of Dynamic Behavior of Retinal Microglia by Cx3cr1 Signaling. 
Investigative Ophthalmology and Visual Science, 50, 4444-4451. 
 
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., 
Frautschy, S. A. & Cole, G. M. 2000. Ibuprofen Suppresses Plaque Pathology and 
259 
 
Inflammation in a Mouse Model for Alzheimer's Disease. Journal of Neuroscience, 20, 
5709-5714. 
 
Lim, S. H., Park, E., You, B., Jung, Y., Park, A. R., Park, S. G. & Lee, J. R. 2013. Neuronal Synapse 
Formation Induced by Microglia and Interleukin 10. PloS One, 8, e81218. 
 
Linsley, P. S. & Ledbetter, J. A. 1993. The Role of the Cd28 Receptor During T Cell Responses 
to Antigen. Annual Review of Immunology, 11, 191-212. 
 
Liu, B., Chen, H., Johns, T. G. & Neufeld, A. H. 2006. Epidermal Growth Factor Receptor 
Activation: An Upstream Signal for Transition of Quiescent Astrocytes into Reactive 
Astrocytes after Neural Injury. Journal of Neuroscience, 26, 7532-7540. 
 
Liu, B. S., Janssen, H. L. & Boonstra, A. 2012. Type I and Iii Interferons Enhance Il-10r 
Expression on Human Monocytes and Macrophages, Resulting in Il-10-Mediated 
Suppression of Tlr-Induced Il-12. European Journal of Immunology, 11, 201142360. 
 
Liu, Y., Wong, T. P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T. W., Wu, D. C., Lu, J., Tymianski, 
M., Craig, A. M. & Wang, Y. T. 2007. Nmda Receptor Subunits Have Differential Roles 
in Mediating Excitotoxic Neuronal Death Both in Vitro and in Vivo. Journal of 
Neuroscience, 27, 2846-2857. 
 
Lodge, P. A. & Sriram, S. 1996. Regulation of Microglial Activation by Tgf-Beta, Il-10, and Csf-
1. Journal of Leukocyte Biology, 60, 502-508. 
 
Loeuillet, C., Boelle, P. Y., Lemaire-Vieille, C., Baldazza, M., Naquet, P., Chambon, P., Cesbron-
Delauw, M. F., Valleron, A. J., Gagnon, J. & Cesbron, J. Y. 2010. Sex Effect in Mouse 
and Human Prion Disease. Journal of Infectious Diseases, 202, 648-654. 
 
Loke, P. n. & Allison, J. P. 2003. Pd-L1 and Pd-L2 Are Differentially Regulated by Th1 and Th2 
Cells. Proceedings of the National Academy of Sciences of the United States of 
America, 100, 5336-5341. 
 
London, A., Itskovich, E., Benhar, I., Kalchenko, V., Mack, M., Jung, S. & Schwartz, M. 2011. 
Neuroprotection and Progenitor Cell Renewal in the Injured Adult Murine Retina 
Requires Healing Monocyte-Derived Macrophages. Journal of Experimental 
Medicine, 208, 23-39. 
 
Lu, X. & Richardson, P. M. 1991. Inflammation near the Nerve Cell Body Enhances Axonal 
Regeneration. Journal of Neuroscience, 11, 972-978. 
 
Lucassen, P. J., Williams, A., Chung, W. C. & Fraser, H. 1995. Detection of Apoptosis in Murine 
Scrapie. Neuroscience Letters, 198, 185-188. 
 
M'Fadyean, J. 1918. Scrapie. Journal of Comparative Pathology and Therapeutics, 31, 102-
131. 
 





Macdowell, E. C., Allen, E. & Macdowell, C. G. 1927. The Prenatal Growth of the Mouse. 
Journal of General Physiology, 11, 57-70. 
 
MacLullich, A. M. J., Beaglehole, A., Hall, R. J. & Meagher, D. J. 2009. Delirium and Long-Term 
Cognitive Impairment. International Review of Psychiatry, 21, 30-42. 
 
Mahal, S. P., Browning, S., Li, J., Suponitsky-Kroyter, I. & Weissmann, C. 2010. Transfer of a 
Prion Strain to Different Hosts Leads to Emergence of Strain Variants. Proceedings of 
the National Academy of Sciences of the United States of America, 107, 22653-22658. 
 
Majer, A., Medina, S. J., Niu, Y., Abrenica, B., Manguiat, K. J., Frost, K. L., Philipson, C. S., 
Sorensen, D. L. & Booth, S. A. 2012. Early Mechanisms of Pathobiology Are Revealed 
by Transcriptional Temporal Dynamics in Hippocampal Ca1 Neurons of Prion Infected 
Mice. PLoS Pathogens, 8, e1003002. 
 
Makarava, N., Kovacs, G. G., Bocharova, O., Savtchenko, R., Alexeeva, I., Budka, H., Rohwer, 
R. G. & Baskakov, I. V. 2010. Recombinant Prion Protein Induces a New Transmissible 
Prion Disease in Wild-Type Animals. Acta Neuropathologica, 119, 177-187. 
 
Manson, J. C., Clarke, A. R., Hooper, M. L., Aitchison, L., McConnell, I. & Hope, J. 1994a. 
129/Ola Mice Carrying a Null Mutation in Prp That Abolishes Mrna Production Are 
Developmentally Normal. Molecular Neurobiology, 8, 121-127. 
 
Manson, J. C., Clarke, A. R., McBride, P. A., McConnell, I. & Hope, J. 1994b. Prp Gene Dosage 
Determines the Timing but Not the Final Intensity or Distribution of Lesions in Scrapie 
Pathology. Neurodegeneration: A Journal for Neurodegenerative Disorders, 
Neuroprotection, and Neuroregeneration, 3, 331-340. 
 
Mantovani, A., Sica, A. & Locati, M. 2007. New Vistas on Macrophage Differentiation and 
Activation. European Journal of Immunology, 37, 14-16. 
 
Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A. & Locati, M. 2004. The Chemokine 
System in Diverse Forms of Macrophage Activation and Polarization. Trends in 
Immunology, 25, 677-686. 
 
Manuelidis, L., Fritch, W. & Xi, Y.-G. 1997. Evolution of a Strain of Cjd That Induces Bse-Like 
Plaques. Science, 277, 94-98. 
 
Marella, M. & Chabry, J. 2004. Neurons and Astrocytes Respond to Prion Infection by 
Inducing Microglia Recruitment. Journal of Neuroscience, 24, 620-627. 
 
Marella, M., Gaggioli, C., Batoz, M., Deckert, M., Tartare-Deckert, S. & Chabry, J. 2005. 
Pathological Prion Protein Exposure Switches on Neuronal Mitogen-Activated 
Protein Kinase Pathway Resulting in Microglia Recruitment. Journal of Biological 
Chemistry, 280, 1529-1534. 
 
Marín-Teva, J. L., Dusart, I., Colin, C., Gervais, A., Van Rooijen, N. & Mallat, M. 2004. Microglia 




Martin, D. P., Schmidt, R. E., DiStefano, P. S., Lowry, O. H., Carter, J. G. & Johnson, E. M., Jr. 
1988. Inhibitors of Protein Synthesis and Rna Synthesis Prevent Neuronal Death 
Caused by Nerve Growth Factor Deprivation. Journal of Cell Biology, 106, 829-844. 
 
Martinez, F. O., Helming, L. & Gordon, S. 2009. Alternative Activation of Macrophages: An 
Immunologic Functional Perspective. Annual Review of Immunology, 27, 451-483. 
 
Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. 2008. Macrophage Activation and 
Polarization. Frontiers in Bioscience, 13, 453-461. 
 
Martinon, F. & Tschopp, J. 2007. Inflammatory Caspases and Inflammasomes: Master 
Switches of Inflammation. Cell Death and Differentiation, 14, 10-22. 
 
Massengale, M., Wagers, A. J., Vogel, H. & Weissman, I. L. 2005. Hematopoietic Cells Maintain 
Hematopoietic Fates Upon Entering the Brain. Journal of Experimental Medicine, 
201, 1579-1589. 
 
McClintick, J. N., Jerome, R. E., Nicholson, C. R., Crabb, D. W. & Edenberg, H. J. 2003. 
Reproducibility of Oligonucleotide Arrays Using Small Samples. BMC Genomics, 4, 4-
4. 
 
McGeer, E. G. & McGeer, P. L. 1999. Brain Inflammation in Alzheimer Disease and the 
Therapeutic Implications. Current Pharmaceutical Design, 5, 821-836. 
 
McGeer, P. L., Kawamata, T., Walker, D. G., Akiyama, H., Tooyama, I. & McGeer, E. G. 1993. 
Microglia in Degenerative Neurological Disease. Glia, 7, 84-92. 
 
McGeer, P. L. & McGeer, E. G. 2008. Glial Reactions in Parkinson's Disease. Movement 
Disorders, 23, 474-483. 
 
McGeer, P. L., Schwab, C., Parent, A. & Doudet, D. 2003. Presence of Reactive Microglia in 
Monkey Substantia Nigra Years after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine 
Administration. Annals of Neurology, 54, 599-604. 
 
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., 
Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J. & Maki, R. A. 1996. Targeted 
Disruption of the Pu.1 Gene Results in Multiple Hematopoietic Abnormalities. EMBO 
Journal, 15, 5647-5658. 
 
McKinley, M. P., Bolton, D. C. & Prusiner, S. B. 1983. A Protease-Resistant Protein Is a 
Structural Component of the Scrapie Prion. Cell, 35, 57-62. 
 
McLean, A. R. & Bostock, C. J. 2000. Scrapie Infections Initiated at Varying Doses: An Analysis 
of 117 Titration Experiments. Philosophical Transactions of the Royal Society of 
London. Series B: Biological Sciences, 355, 1043-1050. 
 
Mechnikov, I. 1908. Nobel Lecture: On the Present State of the Question of Immunity in 





lecture.html [Accessed Web. 25 Feb 2014. 
 
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Jr., Baron, P., Villalba, M., Ferrari, D. & 
Rossi, F. 1995. Activation of Microglial Cells by Beta-Amyloid Protein and Interferon-
Gamma. Nature, 374, 647-650. 
 
Mehrotra, P., Riley, J. P., Patel, R., Li, F., Voss, L. & Goenka, S. 2011. Parp-14 Functions as a 
Transcriptional Switch for Stat6-Dependent Gene Activation. Journal of Biological 
Chemistry, 286, 1767-1776. 
 
Miele, G., Jeffrey, M., Turnbull, D., Manson, J. & Clinton, M. 2002. Ablation of Cellular Prion 
Protein Expression Affects Mitochondrial Numbers and Morphology. Biochemical 
and Biophysical Research Communications, 291, 372-377. 
 
Mildner, A., Schmidt, H., Nitsche, M., Merkler, D., Hanisch, U.-K., Mack, M., Heikenwalder, 
M., Bruck, W., Priller, J. & Prinz, M. 2007. Microglia in the Adult Brain Arise from Ly-
6chiccr2+ Monocytes Only under Defined Host Conditions. Nature Neuroscience, 10, 
1544-1553. 
 
Miller, M. W., Williams, E. S., Hobbs, N. T. & Wolfe, L. L. 2004. Environmental Sources of Prion 
Transmission in Mule Deer. Emerging Infectious Diseases, 10, 1003-1006. 
 
Miller, N. E. 1964. Some Psychophysiological Studies of Motivation and of the Behavioral-
Effects of Illness. Bulletin of the British Psychological Society, 17, 1-20. 
 
Millson, G. C., Hunter, G. D. & Kimberlin, R. H. 1971. An Experimental Examination of the 
Scrapie Agent in Cell Membrane Mixtures: Ii. The Associations of Scrapie Activity with 
Membrane Fractions. Journal of Comparative Pathology, 81, 255-265. 
 
Millson, G. C., Kimberlin, R. H., Jane Manning, E. & Collis, S. C. 1979. Early Distribution of 
Radioactive Liposomes and Scrapie Infectivity in Mouse Tissues Following 
Administration by Different Routes. Veterinary Microbiology, 4, 89-99. 
 
Minghetti, l. 2004. Cyclooxygenase‐2 (Cox‐2) in Inflammatory and Degenerative Brain 
Diseases. Journal of Neuropathology & Experimental Neurology, 63, 901-910. 
 
Minghetti, L. & Levi, G. 1998. Microglia as Effector Cells in Brain Damage and Repair: Focus 
on Prostanoids and Nitric Oxide. Progress in Neurobiology, 54, 99-125. 
 
Minghetti, L. & Pocchiari, M. 2007. Cyclooxygenase-2, Prostaglandin E2, and Microglial 
Activation in Prion Diseases. International Review of Neurobiology, 82, 265-275. 
 
Minin, A. A., Kulik, A. V., Gyoeva, F. K., Li, Y., Goshima, G. & Gelfand, V. I. 2006. Regulation of 
Mitochondria Distribution by Rhoa and Formins. Journal of Cell Science, 119, 659-
670. 
 
Mironov, A., Jr., Latawiec, D., Wille, H., Bouzamondo-Bernstein, E., Legname, G., Williamson, 
R. A., Burton, D., DeArmond, S. J., Prusiner, S. B. & Peters, P. J. 2003. Cytosolic Prion 




Miyamoto, A., Wake, H., Moorhouse, A. J. & Nabekura, J. 2013. Microglia and Synapse 
Interactions: Fine Tuning Neural Circuits and Candidate Molecules. Frontiers in 
Cellular Neuroscience, 7, 1-6. 
 
Moller, J. C., Klein, M. A., Haas, S., Jones, L. L., Kreutzberg, G. W. & Raivich, G. 1996. 
Regulation of Thrombospondin in the Regenerating Mouse Facial Motor Nucleus. 
Glia, 17, 121-132. 
 
Monje, M. L., Toda, H. & Palmer, T. D. 2003. Inflammatory Blockade Restores Adult 
Hippocampal Neurogenesis. Science, 302, 1760-1765. 
 
Moody, L. R., Herbst, A. J., Yoo, H. S., Vanderloo, J. P. & Aiken, J. M. 2009. Comparative Prion 
Disease Gene Expression Profiling Using the Prion Disease Mimetic, Cuprizone. Prion, 
3, 99-109. 
 
Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O'Garra, A. 2001. Interleukin-10 and the 
Interleukin-10 Receptor. Annual Review of Immunology, 19, 683-765. 
 
Moore, R. C., Hope, J., McBride, P. A., McConnell, I., Selfridge, J., Melton, D. W. & Manson, J. 
C. 1998. Mice with Gene Targetted Prion Protein Alterations Show That Prnp, Sinc 
and Prni Are Congruent. Nature Genetics, 18, 118-125. 
 
Mosmann, T. R. & Coffman, R. L. 1989. Th1 and Th2 Cells: Different Patterns of Lymphokine 
Secretion Lead to Different Functional Properties. Annual Review of Immunology, 7, 
145-173. 
 
Mosser, D. M. 2003. The Many Faces of Macrophage Activation. Journal of Leukocyte Biology, 
73, 209-212. 
 
Mosser, D. M. & Edwards, J. P. 2008. Exploring the Full Spectrum of Macrophage Activation. 
Nature Reviews: Immunology, 8, 958-969. 
 
Mouihate, A. 2014. Tlr4-Mediated Brain Inflammation Halts Neurogenesis: Impact of 
Hormonal Replacement Therapy. Frontiers in Cellular Neuroscience, 8, 146. 
 
Mould, D. L., Smith, W. & Dawson, A. M. 1965. Centrifugation Studies on the Infectivities of 
Cellular Fractions Derived from Mouse Brain Infected with Scrapie (Suffolk Strain). 
Journal of General Microbiology, 40, 71-79. 
 
Mouta Carreira, C., LaVallee, T. M., Tarantini, F., Jackson, A., Lathrop, J. T., Hampton, B., 
Burgess, W. H. & Maciag, T. 1998. S100a13 Is Involved in the Regulation of Fibroblast 
Growth Factor-1 and P40 Synaptotagmin-1 Release in Vitro. Journal of Biological 
Chemistry, 273, 22224-22231. 
 
Mouton, P. R., Long, J. M., Lei, D. L., Howard, V., Jucker, M., Calhoun, M. E. & Ingram, D. K. 
2002. Age and Gender Effects on Microglia and Astrocyte Numbers in Brains of Mice. 




Mowen, K. A., Tang, J., Zhu, W., Schurter, B. T., Shuai, K., Herschman, H. R. & David, M. 2001. 
Arginine Methylation of Stat1 Modulates Ifnalpha/Beta-Induced Transcription. Cell, 
104, 731-741. 
 
Murray, C., Sanderson, D. J., Barkus, C., Deacon, R. M., Rawlins, J. N., Bannerman, D. M. & 
Cunningham, C. 2012. Systemic Inflammation Induces Acute Working Memory 
Deficits in the Primed Brain: Relevance for Delirium. Neurobiology of Aging, 33, 603-
616. e603. 
 
Murray, C. L., Skelly, D. T. & Cunningham, C. 2011. Exacerbation of Cns Inflammation and 
Neurodegeneration by Systemic Lps Treatment Is Independent of Circulating Il-1beta 
and Il-6. Journal of Neuroinflammation, 8, 50. 
 
Nahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J. L., 
Libby, P., Weissleder, R. & Pittet, M. J. 2007. The Healing Myocardium Sequentially 
Mobilizes Two Monocyte Subsets with Divergent and Complementary Functions. 
Journal of Experimental Medicine, 204, 3037-3047. 
 
Nakagawa, T., Guichard, A., Castro, C. P., Xiao, Y., Rizen, M., Zhang, H. Z., Hu, D., Bang, A., 
Helms, J., Bier, E. & Derynck, R. 2005. Characterization of a Human Rhomboid 
Homolog, P100hrho/Rhbdf1, Which Interacts with Tgf-Alpha Family Ligands. 
Developmental Dynamics, 233, 1315-1331. 
 
Naslavsky, N., Stein, R., Yanai, A., Friedlander, G. & Taraboulos, A. 1997. Characterization of 
Detergent-Insoluble Complexes Containing the Cellular Prion Protein and Its Scrapie 
Isoform. Journal of Biological Chemistry, 272, 6324-6331. 
 
Neumann, H., Kotter, M. R. & Franklin, R. J. M. 2009. Debris Clearance by Microglia: An 
Essential Link between Degeneration and Regeneration. Brain, 132, 288-295. 
 
Neumann, H. & Wekerle, H. 2013. Brain Microglia: Watchdogs with Pedigree. Nature 
Neuroscience, 16, 253-255. 
 
Neumann, J., Sauerzweig, S., Ronicke, R., Gunzer, F., Dinkel, K., Ullrich, O., Gunzer, M. & 
Reymann, K. G. 2008. Microglia Cells Protect Neurons by Direct Engulfment of 
Invading Neutrophil Granulocytes: A New Mechanism of Cns Immune Privilege. 
Journal of Neuroscience, 28, 5965-5975. 
 
Newsom, D. M., Liggitt, H. D., O'Rourke, K., Zhuang, D., Schneider, D. A. & Harrington, R. D. 
2011. Cytokine Antibody Array Analysis in Brain and Periphery of Scrapie-Infected 
Tg338 Mice. Comparative Immunology, Microbiology and Infectious Diseases, 34, 
387-397. 
 
Ng, E. L., Ng, J. J., Liang, F. & Tang, B. L. 2009. Rab22b Is Expressed in the Cns Astroglia Lineage 
and Plays a Role in Epidermal Growth Factor Receptor Trafficking in A431 Cells. 
Journal of Cellular Physiology, 221, 716-728. 
 
Nguyen, C., Rocha, D., Granjeaud, S., Baldit, M., Bernard, K., Naquet, P. & Jordan, B. R. 1995a. 
Differential Gene Expression in the Murine Thymus Assayed by Quantitative 




Nguyen, J., Baldwin, M. A., Cohen, F. E. & Prusiner, S. B. 1995b. Prion Protein Peptides Induce 
.Alpha.-Helix To .Beta.-Sheet Conformational Transitions. Biochemistry, 34, 4186-
4192. 
 
Nikodemova, M. & Watters, J. J. 2012. Efficient Isolation of Live Microglia with Preserved 
Phenotypes from Adult Mouse Brain. Journal of Neuroinflammation, 9, 1742-2094. 
 
Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. 2005. Resting Microglial Cells Are Highly 
Dynamic Surveillants of Brain Parenchyma in Vivo. Science, 308, 1314-1318. 
 
Nissl, F. 1899. Ueber Einige Beziehungen Zwishcen Nerven Zellerkrankungen Und Gliosen 
Erscheinnungen Bei Verschiedenen Psychosen.  In: 24. Wanderversammlung Der 
Südwestdeutschen Neurologen Und Irrenärzte in Baden-Baden. Archiv für 
Psychiatrie und Nervenkrankheiten, 32, 657-676. 
 
Njie, E. G., Boelen, E., Stassen, F. R., Steinbusch, H. W., Borchelt, D. R. & Streit, W. J. 2012. Ex 
Vivo Cultures of Microglia from Young and Aged Rodent Brain Reveal Age-Related 
Changes in Microglial Function. Neurobiology of Aging, 33, 195-195, e191-112. 
 
Noda, U. 1921. A Study of Nissl's Staebchenzellen in the Cerebral Cortex of General Paresis, 
Senile Dementia, Epilepsy. Glioma, Tuberculous, Meningitis and Delirium Tremens. 
The Journal of Nervous and Mental Disease, 53, 161-216. 
 
Norden, D. M., Fenn, A. M., Dugan, A. & Godbout, J. P. 2014. Tgfbeta Produced by Il-10 
Redirected Astrocytes Attenuates Microglial Activation. Glia, 62, 881-895. 
 
Norton, W. T. & Poduslo, S. E. 1973. Myelination in Rat Brain: Changes in Myelin Composition 
During Brain Maturation. Journal of Neurochemistry, 21, 759-773. 
 
O'Connor, J. C., André, C., Wang, Y., Lawson, M. A., Szegedi, S. S., Lestage, J., Castanon, N., 
Kelley, K. W. & Dantzer, R. 2009. Interferon-Γ and Tumor Necrosis Factor-Α Mediate 
the Upregulation of Indoleamine 2,3-Dioxygenase and the Induction of Depressive-
Like Behavior in Mice in Response to Bacillus Calmette-Guérin. The Journal of 
Neuroscience, 29, 4200-4209. 
 
Oesch, B., Westaway, D., Walchli, M., McKinley, M. P., Kent, S. B., Aebersold, R., Barry, R. A., 
Tempst, P., Teplow, D. B., Hood, L. E. & et al. 1985. A Cellular Gene Encodes Scrapie 
Prp 27-30 Protein. Cell, 40, 735-746. 
 
Ohtsuji, M., Katsuoka, F., Kobayashi, A., Aburatani, H., Hayes, J. D. & Yamamoto, M. 2008. 
Nrf1 and Nrf2 Play Distinct Roles in Activation of Antioxidant Response Element-
Dependent Genes. Journal of Biological Chemistry, 283, 33554-33562. 
 
Ong, W. Y., Leong, S. K., Garey, L. J., Tan, K. K. & Zhang, H. F. 1995. A Light and Electron 
Microscopic Study of Hla-Dr Positive Cells in the Human Cerebral Cortex and 




Orre, M., Kamphuis, W., Osborn, L. M., Jansen, A. H., Kooijman, L., Bossers, K. & Hol, E. M. 
2014. Isolation of Glia from Alzheimer's Mice Reveals Inflammation and Dysfunction. 
Neurobiology of Aging, 35, 2746-2760. 
 
Outram, G. W. 1976. The Pathogenesis of Scrapie in Mice. Frontiers of Biology, 44, 325-357. 
 
Outram, G. W., Dickinson, A. G. & Fraser, H. 1973. Developmental Maturation of 
Susceptibility to Scrapie in Mice. Nature, 241, 536-537. 
 
Pahl, H. L. 1999. Activators and Target Genes of Rel/Nf-Kappab Transcription Factors. 
Oncogene, 18, 6853-6866. 
 
Palin, K., Cunningham, C., Forse, P., Perry, V. H. & Platt, N. 2008. Systemic Inflammation 
Switches the Inflammatory Cytokine Profile in Cns Wallerian Degeneration. 
Neurobiology of Disease, 30, 19-29. 
 
Pandi-Perumal, S. R., Srinivasan, V., Maestroni, G. J., Cardinali, D. P., Poeggeler, B. & 
Hardeland, R. 2006. Melatonin: Nature's Most Versatile Biological Signal? FEBS 
Journal, 273, 2813-2838. 
 
Pandi-Perumal, S. R., Trakht, I., Srinivasan, V., Spence, D. W., Maestroni, G. J., Zisapel, N. & 
Cardinali, D. P. 2008. Physiological Effects of Melatonin: Role of Melatonin Receptors 
and Signal Transduction Pathways. Progress in Neurobiology, 85, 335-353. 
 
Paolicelli, R. C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., 
Ferreira, T. A., Guiducci, E., Dumas, L., Ragozzino, D. & Gross, C. T. 2011. Synaptic 
Pruning by Microglia Is Necessary for Normal Brain Development. Science (New York, 
N.Y.), 333, 1456-1458. 
 
Papadopoulos, V., Lecanu, L., Brown, R. C., Han, Z. & Yao, Z. X. 2006. Peripheral-Type 
Benzodiazepine Receptor in Neurosteroid Biosynthesis, Neuropathology and 
Neurological Disorders. Neuroscience, 138, 749-756. 
 
Pappano, W. N., Scott, I. C., Clark, T. G., Eddy, R. L., Shows, T. B. & Greenspan, D. S. 1998. 
Coding Sequence and Expression Patterns of Mouse Chordin and Mapping of the 
Cognate Mouse Chrd and Human Chrd Genes. Genomics, 52, 236-239. 
 
Paradis, E., Clavel, S., Bouillaud, F., Ricquier, D. & Richard, D. 2003. Uncoupling Protein 2: A 
Novel Player in Neuroprotection. Trends in Molecular Medicine, 9, 522-525. 
 
Parakalan, R., Jiang, B., Nimmi, B., Janani, M., Jayapal, M., Lu, J., Tay, S. S., Ling, E. A. & Dheen, 
S. T. 2012. Transcriptome Analysis of Amoeboid and Ramified Microglia Isolated from 
the Corpus Callosum of Rat Brain. BMC Neuroscience, 13, 64. 
 
Parkhurst, C. N., Yang, G., Ninan, I., Savas, J. N., Yates, J. R., 3rd, Lafaille, J. J., Hempstead, B. 
L., Littman, D. R. & Gan, W. B. 2013. Microglia Promote Learning-Dependent Synapse 
Formation through Brain-Derived Neurotrophic Factor. Cell, 155, 1596-1609. 
 
Parkinson, H., Kapushesky, M., Shojatalab, M., Abeygunawardena, N., Coulson, R., Farne, A., 
Holloway, E., Kolesnykov, N., Lilja, P., Lukk, M., Mani, R., Rayner, T., Sharma, A., 
267 
 
William, E., Sarkans, U. & Brazma, A. 2007. Arrayexpress--a Public Database of 
Microarray Experiments and Gene Expression Profiles. Nucleic Acids Research, 35, 
747-750. 
 
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J. Y., Takano, H., Moss, 
S. J., McCarthy, K. & Haydon, P. G. 2005. Astrocytic Purinergic Signaling Coordinates 
Synaptic Networks. Science, 310, 113-116. 
 
Passlick, B., Flieger, D. & Ziegler-Heitbrock, H. W. 1989. Identification and Characterization of 
a Novel Monocyte Subpopulation in Human Peripheral Blood. Blood, 74, 2527-2534. 
 
Patel, N. K., Pavese, N., Javed, S., Hotton, G. R., Brooks, D. J. & Gill, S. S. 2013. Benefits of 
Putaminal Gdnf Infusion in Parkinson Disease Are Maintained after Gdnf Cessation. 
Neurology, 81, 1176-1178. 
 
Patino, M. M., Liu, J. J., Glover, J. R. & Lindquist, S. 1996. Support for the Prion Hypothesis for 
Inheritance of a Phenotypic Trait in Yeast. Science, 273, 622-626. 
 
Pattison, I. H. 1957. Myopathy in Sheep. The Lancet, 269, 104-105. 
 
Pattison, I. H. 1966. The Relative Susceptibility of Sheep, Goats and Mice to Two Types of the 
Goat Scrapie Agent. Research in Veterinary Science, 7, 207-212. 
 
Pattison, I. H., Gordon, W. S. & Millson, G. C. 1959. Experimental Production of Scrapie in 
Goats. Journal of Comparative Pathology and Therapeutics, 69, 300-IN320. 
 
Pattison, I. H. & Jones, K. M. 1967. The Possible Nature of the Transmissible Agent of Scrapie. 
Veterinary Record, 80, 2-9. 
 
Pattison, I. H. & Millson, G. C. 1961. Scrapie Produced Experimentally in Goats with Special 
Reference to the Clinical Syndrome. Journal of Comparative Pathology, 71, 101-109. 
 
Pekny, M., Leveen, P., Pekna, M., Eliasson, C., Berthold, C. H., Westermark, B. & Betsholtz, C. 
1995. Mice Lacking Glial Fibrillary Acidic Protein Display Astrocytes Devoid of 
Intermediate Filaments but Develop and Reproduce Normally. EMBO Journal, 14, 
1590-1598. 
 
Penfield, W. 1925. Microglia and the Process of Phagocytosis in Gliomas. American Journal of 
Pathology, 1, 77-U21. 
 
Perez-Asensio, F. J., Perpina, U., Planas, A. M. & Pozas, E. 2013. Interleukin-10 Regulates 
Progenitor Differentiation and Modulates Neurogenesis in Adult Brain. Journal of Cell 
Science, 126, 4208-4219. 
 
Perry, V. H., Cunningham, C. & Boche, D. 2002. Atypical Inflammation in the Central Nervous 
System in Prion Disease. Current Opinion in Neurology, 15, 349-354. 
 
Perry, V. H., Matyszak, M. K. & Fearn, S. 1993. Altered Antigen Expression of Microglia in the 




Perry, V. H., Nicoll, J. A. R. & Holmes, C. 2010. Microglia in Neurodegenerative Disease. Nature 
Reviews Neurology, 6, 193-201. 
 
Pestka, S., Krause, C. D., Sarkar, D., Walter, M. R., Shi, Y. & Fisher, P. B. 2004. Interleukin-10 
and Related Cytokines and Receptors. Annual Review of Immunology, 22, 929-979. 
 
Peterziel, H., Unsicker, K. & Krieglstein, K. 2002. Tgfβ Induces Gdnf Responsiveness in 
Neurons by Recruitment of Gfrα1 to the Plasma Membrane. The Journal of Cell 
Biology, 159, 157-167. 
 
Peyrin, J. M., Lasmezas, C. I., Haik, S., Tagliavini, F., Salmona, M., Williams, A., Richie, D., 
Deslys, J. P. & Dormont, D. 1999. Microglial Cells Respond to Amyloidogenic Prp 
Peptide by the Production of Inflammatory Cytokines. Neuroreport, 10, 723-729. 
 
Piccio, L., Rossi, B., Scarpini, E., Laudanna, C., Giagulli, C., Issekutz, A. C., Vestweber, D., 
Butcher, E. C. & Constantin, G. 2002. Molecular Mechanisms Involved in Lymphocyte 
Recruitment in Inflamed Brain Microvessels: Critical Roles for P-Selectin Glycoprotein 
Ligand-1 and Heterotrimeric G(I)-Linked Receptors. Journal of Immunology, 168, 
1940-1949. 
 
Picelli, S., Faridani, O. R., Björklund, Å. K., Winberg, G., Sagasser, S. & Sandberg, R. 2014. Full-
Length Rna-Seq from Single Cells Using Smart-Seq2. Nat. Protocols, 9, 171-181. 
 
Pinotsi, D., Buell, A. K., Galvagnion, C., Dobson, C. M., Kaminski Schierle, G. S. & Kaminski, C. 
F. 2014. Direct Observation of Heterogeneous Amyloid Fibril Growth Kinetics Via 
Two-Color Super-Resolution Microscopy. Nano Letters, 14, 339-345. 
 
Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I. & Pitossi, F. J. 2008. Central and 
Systemic Il-1 Exacerbates Neurodegeneration and Motor Symptoms in a Model of 
Parkinson's Disease. Brain, 131, 1880-1894. 
 
Potter, M. 1985. History of the Balb/C Family. Current Topics in Microbiology and 
Immunology, 122, 1-5. 
 
Priller, J., Prinz, M., Heikenwalder, M., Zeller, N., Schwarz, P., Heppner, F. L. & Aguzzi, A. 2006. 
Early and Rapid Engraftment of Bone Marrow-Derived Microglia in Scrapie. Journal 
of Neuroscience, 26, 11753-11762. 
 
Prinz, M., Heikenwalder, M., Schwarz, P., Takeda, K., Akira, S. & Aguzzi, A. 2003. Prion 
Pathogenesis in the Absence of Toll-Like Receptor Signalling. EMBO Rep, 4, 195-199. 
 
Prusiner, S. B. 1982. Novel Proteinaceous Infectious Particles Cause Scrapie. Science (New 
York, N.Y.), 216, 136-144. 
 
Prusiner, S. B. 1998. Prions. Proceedings of the National Academy of Sciences of the United 
States of America, 95, 13363-13383. 
 
Quan, N. & Banks, W. A. 2007. Brain-Immune Communication Pathways. Brain, Behavior, and 




Quan, N., Stern, E. L., Whiteside, M. B. & Herkenham, M. 1999. Induction of Pro-Inflammatory 
Cytokine Mrnas in the Brain after Peripheral Injection of Subseptic Doses of 
Lipopolysaccharide in the Rat. Journal of Neuroimmunology, 93, 72-80. 
 
Race, R. E., Priola, S. A., Bessen, R. A., Ernst, D., Dockter, J., Rall, G. F., Mucke, L., Chesebro, 
B. & Oldstone, M. B. 1995. Neuron-Specific Expression of a Hamster Prion Protein 
Minigene in Transgenic Mice Induces Susceptibility to Hamster Scrapie Agent. 
Neuron, 15, 1183-1191. 
 
Radogna, F., Nuccitelli, S., Mengoni, F. & Ghibelli, L. 2009. Neuroprotection by Melatonin on 
Astrocytoma Cell Death. Annals of the New York Academy of Sciences, 1171, 509-513. 
 
Rafice, S. A., Chauhan, N., Efimov, I., Basran, J. & Raven, E. L. 2009. Oxidation of L-Tryptophan 
in Biology: A Comparison between Tryptophan 2,3-Dioxygenase and Indoleamine 
2,3-Dioxygenase. Biochemical Society Transactions, 37, 408-412. 
 
Raivich, G., Bohatschek, M., Kloss, C. U., Werner, A., Jones, L. L. & Kreutzberg, G. W. 1999. 
Neuroglial Activation Repertoire in the Injured Brain: Graded Response, Molecular 
Mechanisms and Cues to Physiological Function. Brain Research: Brain Research 
Reviews, 30, 77-105. 
 
Ramaswamy, S., Soderstrom, K. E. & Kordower, J. H. 2009. Trophic Factors Therapy in 
Parkinson's Disease. In: Joost Verhaagen, E. M. H. I. H. J. W. A. B. B. G. J. B. & Dick, F. 
S. (eds.) Progress in Brain Research. Elsevier, Page: 201-216. 
 
Ransohoff, R. M. 2007. Microgliosis: The Questions Shape the Answers. Nature Neuroscience, 
10, 1507-1509. 
 
Ransohoff, R. M. 2011. Microglia and Monocytes: 'Tis Plain the Twain Meet in the Brain. 
Nature Neuroscience, 14, 1098-1100. 
 
Raymond, G. J., Bossers, A., Raymond, L. D., O'Rourke, K. I., McHolland, L. E., Bryant, P. K., 
3rd, Miller, M. W., Williams, E. S., Smits, M. & Caughey, B. 2000. Evidence of a 
Molecular Barrier Limiting Susceptibility of Humans, Cattle and Sheep to Chronic 
Wasting Disease. EMBO Journal, 19, 4425-4430. 
 
Retz, K. C. & Steele, W. J. 1980. Ribosome Turnover in Rat Brain and Liver. Life Sciences, 27, 
2601-2604. 
 
Rezaie, P. & Lantos, P. L. 2001. Microglia and the Pathogenesis of Spongiform 
Encephalopathies. Brain Research Reviews, 35, 55-72. 
 
Ridley, A. J. 2006. Rho Gtpases and Actin Dynamics in Membrane Protrusions and Vesicle 
Trafficking. Trends in Cell Biology, 16, 522-529. 
 
Riemer, C., Neidhold, S., Burwinkel, M., Schwarz, A., Schultz, J., Kratzschmar, J., Monning, U. 
& Baier, M. 2004. Gene Expression Profiling of Scrapie-Infected Brain Tissue. 




Riemer, C., Schultz, J., Burwinkel, M., Schwarz, A., Mok, S. W., Gultner, S., Bamme, T., Norley, 
S., van Landeghem, F., Lu, B., Gerard, C. & Baier, M. 2008. Accelerated Prion 
Replication in, but Prolonged Survival Times of, Prion-Infected Cxcr3-/- Mice. Journal 
of Virology, 82, 12464-12471. 
 
Rio-Hortega, P. 1932. Microglia In: Cytology & Cellular Pathology of the Nervous System, P.B. 
Hoeber, Inc., Page: 482-534. 
 
Río-Hortega, P. d. 1920. La Microglia Y Su Transformación En Celulas En Bastoncito Y Cuerpos 
Granulo-Adiposos. trabajo del lab de investigacion biologia, xviii (18), 37-82. 
 
Río-Hortega, P. d. 1921. El Tercer Elemento De Los Centros Nerviosos: Histogénesis Y 
Evolución Normal; Éxodo Y Distribución Regional De La Microglía, Madrid, : Sociedad 
Española de Historia Natural, Page: 213-268. 
 
Robertson, F. 1900. A Microscopic Demonstration of the Normal and Pathological Histology 
of Mesoglia Cells. The British Journal of Psychiatry, 46, 724-724. 
 
Robinson, C. M., Hale, P. T. & Carlin, J. M. 2006. Nf-Kappa B Activation Contributes to 
Indoleamine Dioxygenase Transcriptional Synergy Induced by Ifn-Gamma and Tumor 
Necrosis Factor-Alpha. Cytokine, 35, 53-61. 
 
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, 
J., Cofield, M., Mansukhani, L., Willson, P. & et al. 1993. Clinical Trial of Indomethacin 
in Alzheimer's Disease. Neurology, 43, 1609-1611. 
 
Rogers, J. T., Morganti, J. M., Bachstetter, A. D., Hudson, C. E., Peters, M. M., Grimmig, B. A., 
Weeber, E. J., Bickford, P. C. & Gemma, C. 2011. Cx3cr1 Deficiency Leads to 
Impairment of Hippocampal Cognitive Function and Synaptic Plasticity. Journal of 
Neuroscience, 31, 16241-16250. 
 
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., 
Luini, W., van Hinsbergh, V., Sozzani, S., Bussolino, F., Poli, V., Ciliberto, G. & 
Mantovani, A. 1997. Role of Il-6 and Its Soluble Receptor in Induction of Chemokines 
and Leukocyte Recruitment. Immunity, 6, 315-325. 
 
Russell, E. S. 1978. Origins and History of Mouse Inbred Strains: Contributions of Clarence 
Cook Little. In: Herbert, C. M., III (ed.) Origins of Inbred Mice. Academic Press, Page: 
33-44. 
 
Russell, W. M. S. B. R. L. 1959. The Principles of Humane Experimental Technique, London, 
Methuen, Page: 238. 
 
Saba, R., Gushue, S., Huzarewich, R. L., Manguiat, K., Medina, S., Robertson, C. & Booth, S. A. 
2012. Microrna 146a (Mir-146a) Is over-Expressed During Prion Disease and 
Modulates the Innate Immune Response and the Microglial Activation State. PloS 
One, 7, 17. 
 
Saborio, G. P., Permanne, B. & Soto, C. 2001. Sensitive Detection of Pathological Prion Protein 




Saederup, N., Cardona, A. E., Croft, K., Mizutani, M., Cotleur, A. C., Tsou, C. L., Ransohoff, R. 
M. & Charo, I. F. 2010. Selective Chemokine Receptor Usage by Central Nervous 
System Myeloid Cells in Ccr2-Red Fluorescent Protein Knock-in Mice. PloS One, 5, 
0013693. 
 
Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F. E. & Prusiner, S. B. 
1998. Eight Prion Strains Have Prp(Sc) Molecules with Different Conformations. 
Nature Medicine, 4, 1157-1165. 
 
Sakai, K., Hasebe, R., Takahashi, Y., Song, C. H., Suzuki, A., Yamasaki, T. & Horiuchi, M. 2013. 
Absence of Cd14 Delays Progression of Prion Diseases Accompanied by Increased 
Microglial Activation. Journal of Virology, 87, 13433-13445. 
 
Sallusto, F. & Lanzavecchia, A. 2009. Heterogeneity of Cd4 Memory T Cells: Functional 
Modules for Tailored Immunity. European Journal of Immunology, 39, 2076-2082. 
 
Samuel, D. & Kroner, A. 2011. Repertoire of Microglial and Macrophage Responses after 
Spinal Cord Injury. Nature Reviews: Neuroscience, 12, 388-399. 
 
Saravia, F., Beauquis, J., Pietranera, L. & De Nicola, A. F. 2007. Neuroprotective Effects of 
Estradiol in Hippocampal Neurons and Glia of Middle Age Mice. 
Psychoneuroendocrinology, 32, 480-492. 
 
Sasaki, A. & Nakazato, Y. 1992. The Identity of Cells Expressing Mhc Class Ii Antigens in Normal 
and Pathological Human Brain. Neuropathology and Applied Neurobiology, 18, 13-
26. 
 
Sasaki, Y., Hoshi, M., Akazawa, C., Nakamura, Y., Tsuzuki, H., Inoue, K. & Kohsaka, S. 2003. 
Selective Expression of Gi/O-Coupled Atp Receptor P2y12 in Microglia in Rat Brain. 
Glia, 44, 242-250. 
 
Sasmono, R. T., Ehrnsperger, A., Cronau, S. L., Ravasi, T., Kandane, R., Hickey, M. J., Cook, A. 
D., Himes, S. R., Hamilton, J. A. & Hume, D. A. 2007. Mouse Neutrophilic Granulocytes 
Express Mrna Encoding the Macrophage Colony-Stimulating Factor Receptor (Csf-1r) 
as Well as Many Other Macrophage-Specific Transcripts and Can Transdifferentiate 
into Macrophages in Vitro in Response to Csf-1. Journal of Leukocyte Biology, 82, 111-
123. 
 
Sasmono, R. T., Oceandy, D., Pollard, J. W., Tong, W., Pavli, P., Wainwright, B. J., Ostrowski, 
M. C., Himes, S. R. & Hume, D. A. 2003. A Macrophage Colony-Stimulating Factor 
Receptor-Green Fluorescent Protein Transgene Is Expressed Throughout the 
Mononuclear Phagocyte System of the Mouse. Blood, 101, 1155-1163. 
 
Savill, J. S., Wyllie, A. H., Henson, J. E., Walport, M. J., Henson, P. M. & Haslett, C. 1989. 
Macrophage Phagocytosis of Aging Neutrophils in Inflammation. Programmed Cell 
Death in the Neutrophil Leads to Its Recognition by Macrophages. Journal of Clinical 




Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., 
Ransohoff, R. M., Greenberg, M. E., Barres, B. A. & Stevens, B. 2012. Microglia Sculpt 
Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. 
Neuron, 74, 691-705. 
 
Schafer, D. P., Lehrman, E. K. & Stevens, B. 2013. The "Quad-Partite" Synapse: Microglia-
Synapse Interactions in the Developing and Mature Cns. Glia, 61, 24-36. 
 
Schebesch, C., Kodelja, V., Muller, C., Hakij, N., Bisson, S., Orfanos, C. E. & Goerdt, S. 1997. 
Alternatively Activated Macrophages Actively Inhibit Proliferation of Peripheral 
Blood Lymphocytes and Cd4+ T Cells in Vitro. Immunology, 92, 478-486. 
 
Schena, M., Shalon, D., Davis, R. W. & Brown, P. O. 1995. Quantitative Monitoring of Gene 
Expression Patterns with a Complementary DNA Microarray. Science, 270, 467-470. 
 
Schena, M., Shalon, D., Heller, R., Chai, A., Brown, P. O. & Davis, R. W. 1996. Parallel Human 
Genome Analysis: Microarray-Based Expression Monitoring of 1000 Genes. 
Proceedings of the National Academy of Sciences of the United States of America, 93, 
10614-10619. 
 
Schenkel, A. R., Mamdouh, Z. & Muller, W. A. 2004. Locomotion of Monocytes on 
Endothelium Is a Critical Step During Extravasation. Nature Immunology, 5, 393-400. 
 
Schiefer, J., Kampe, K., Dodt, H. U., Zieglgansberger, W. & Kreutzberg, G. W. 1999. Microglial 
Motility in the Rat Facial Nucleus Following Peripheral Axotomy. Journal of 
Neurocytology, 28, 439-453. 
 
Schilling, E., El Chartouni, C. & Rehli, M. 2009. Allele-Specific DNA Methylation in Mouse 
Strains Is Mainly Determined by Cis-Acting Sequences. Genome Research, 19, 2028-
2035. 
 
Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., 
Moshrefi, M., Qin, J., Li, X., Gorman, D. M., Bazan, J. F. & Kastelein, R. A. 2005. Il-33, 
an Interleukin-1-Like Cytokine That Signals Via the Il-1 Receptor-Related Protein St2 
and Induces T Helper Type 2-Associated Cytokines. Immunity, 23, 479-490. 
 
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. 2012. Nih Image to Imagej: 25 Years of Image 
Analysis. Nat Meth, 9, 671-675. 
 
Schober, A., Hertel, R., Arumäe, U., Farkas, L., Jaszai, J., Krieglstein, K., Saarma, M. & Unsicker, 
K. 1999. Glial Cell Line-Derived Neurotrophic Factor Rescues Target-Deprived 
Sympathetic Spinal Cord Neurons but Requires Transforming Growth Factor-Β as 
Cofactor in Vivo. Journal of Neuroscience, 19, 2008-2015. 
 
Schuitemaker, A., van der Doef, T. F., Boellaard, R., van der Flier, W. M., Yaqub, M., 
Windhorst, A. D., Barkhof, F., Jonker, C., Kloet, R. W., Lammertsma, A. A., Scheltens, 
P. & van Berckel, B. N. 2012. Microglial Activation in Healthy Aging. Neurobiology of 




Schultz, J., Schwarz, A., Neidhold, S., Burwinkel, M., Riemer, C., Simon, D., Kopf, M., Otto, M. 
& Baier, M. 2004. Role of Interleukin-1 in Prion Disease-Associated Astrocyte 
Activation. American Journal of Pathology, 165, 671-678. 
 
Scott, E. W., Simon, M. C., Anastasi, J. & Singh, H. 1994. Requirement of Transcription Factor 
Pu.1 in the Development of Multiple Hematopoietic Lineages. Science, 265, 1573-
1577. 
 
Scott, J. R., Davies, D. & Fraser, H. 1992. Scrapie in the Central Nervous System: 
Neuroanatomical Spread of Infection and Sinc Control of Pathogenesis. Journal of 
General Virology, 73, 1637-1644. 
 
Scott, M., Groth, D., Foster, D., Torchia, M., Yang, S.-L., DeArmond, S. J. & Prusiner, S. B. 1993. 
Propagation of Prions with Artificial Properties in Transgenic Mice Expressing 
Chimeric Prp Genes. Cell, 73, 979-988. 
 
Sergijenko, A., Langford-Smith, A., Liao, A. Y., Pickford, C. E., McDermott, J., Nowinski, G., 
Langford-Smith, K. J., Merry, C. L., Jones, S. A., Wraith, J. E., Wynn, R. F., Wilkinson, 
F. L. & Bigger, B. W. 2013. Myeloid/Microglial Driven Autologous Hematopoietic 
Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal Disease. Molecular 
Therapy, 21, 1938-1949. 
 
Serrats, J., Schiltz, J. C., Garcia-Bueno, B., van Rooijen, N., Reyes, T. M. & Sawchenko, P. E. 
2010. Dual Roles for Perivascular Macrophages in Immune-to-Brain Signaling. 
Neuron, 65, 94-106. 
 
Shalek, A. K., Satija, R., Adiconis, X., Gertner, R. S., Gaublomme, J. T., Raychowdhury, R., 
Schwartz, S., Yosef, N., Malboeuf, C., Lu, D., Trombetta, J. J., Gennert, D., Gnirke, A., 
Goren, A., Hacohen, N., Levin, J. Z., Park, H. & Regev, A. 2013. Single-Cell 
Transcriptomics Reveals Bimodality in Expression and Splicing in Immune Cells. 
Nature, 498, 236-240. 
 
Shechter, R., London, A., Varol, C., Raposo, C., Cusimano, M., Yovel, G., Rolls, A., Mack, M., 
Pluchino, S., Martino, G., Jung, S. & Schwartz, M. 2009. Infiltrating Blood-Derived 
Macrophages Are Vital Cells Playing an Anti-Inflammatory Role in Recovery from 
Spinal Cord Injury in Mice. PLoS Medicine, 6, e1000113. 
 
Sheffield, L. G. & Berman, N. E. 1998. Microglial Expression of Mhc Class Ii Increases in Normal 
Aging of Nonhuman Primates. Neurobiology of Aging, 19, 47-55. 
 
Sheng, J. G., Mrak, R. E. & Griffin, W. S. 1997. Glial-Neuronal Interactions in Alzheimer 
Disease: Progressive Association of Il-1alpha+ Microglia and S100beta+ Astrocytes 
with Neurofibrillary Tangle Stages. Journal of Neuropathology and Experimental 
Neurology, 56, 285-290. 
 
Shi, L., Campbell, G., Jones, W. D., Campagne, F., Wen, Z., Walker, S. J., Su, Z., Chu, T. M., 
Goodsaid, F. M., Pusztai, L., Shaughnessy, J. D., Jr., Oberthuer, A., Thomas, R. S., 
Paules, R. S., Fielden, M., Barlogie, B., Chen, W., Du, P., Fischer, M., Furlanello, C., 
Gallas, B. D., Ge, X., Megherbi, D. B., Symmans, W. F., Wang, M. D., Zhang, J., Bitter, 
H., Brors, B., Bushel, P. R., Bylesjo, M., Chen, M., Cheng, J., Cheng, J., Chou, J., 
274 
 
Davison, T. S., Delorenzi, M., Deng, Y., Devanarayan, V., Dix, D. J., Dopazo, J., Dorff, 
K. C., Elloumi, F., Fan, J., Fan, S., Fan, X., Fang, H., Gonzaludo, N., Hess, K. R., Hong, 
H., Huan, J., Irizarry, R. A., Judson, R., Juraeva, D., Lababidi, S., Lambert, C. G., Li, L., 
Li, Y., Li, Z., Lin, S. M., Liu, G., Lobenhofer, E. K., Luo, J., Luo, W., McCall, M. N., 
Nikolsky, Y., Pennello, G. A., Perkins, R. G., Philip, R., Popovici, V., Price, N. D., Qian, 
F., Scherer, A., Shi, T., Shi, W., Sung, J., Thierry-Mieg, D., Thierry-Mieg, J., Thodima, 
V., Trygg, J., Vishnuvajjala, L., Wang, S. J., Wu, J., Wu, Y., Xie, Q., Yousef, W. A., Zhang, 
L., Zhang, X., Zhong, S., Zhou, Y., Zhu, S., Arasappan, D., Bao, W., Lucas, A. B., 
Berthold, F., Brennan, R. J., Buness, A., Catalano, J. G., Chang, C., Chen, R., Cheng, Y., 
et al. 2010. The Microarray Quality Control (Maqc)-Ii Study of Common Practices for 
the Development and Validation of Microarray-Based Predictive Models. Nature 
Biotechnology, 28, 827-838. 
 
Shi, L., Jones, W., Jensen, R., Harris, S., Perkins, R., Goodsaid, F., Guo, L., Croner, L., Boysen, 
C., Fang, H., Qian, F., Amur, S., Bao, W., Barbacioru, C., Bertholet, V., Cao, X., Chu, T.-
M., Collins, P., Fan, X.-h. & Frueh, F. 2008. The Balance of Reproducibility, Sensitivity, 
and Specificity of Lists of Differentially Expressed Genes in Microarray Studies. BMC 
Bioinformatics, 9, S10. 
 
Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de 
Longueville, F., Kawasaki, E. S., Lee, K. Y., Luo, Y., Sun, Y. A., Willey, J. C., Setterquist, 
R. A., Fischer, G. M., Tong, W., Dragan, Y. P., Dix, D. J., Frueh, F. W., Goodsaid, F. M., 
Herman, D., Jensen, R. V., Johnson, C. D., Lobenhofer, E. K., Puri, R. K., Schrf, U., 
Thierry-Mieg, J., Wang, C., Wilson, M., Wolber, P. K., Zhang, L., Amur, S., Bao, W., 
Barbacioru, C. C., Lucas, A. B., Bertholet, V., Boysen, C., Bromley, B., Brown, D., 
Brunner, A., Canales, R., Cao, X. M., Cebula, T. A., Chen, J. J., Cheng, J., Chu, T. M., 
Chudin, E., Corson, J., Corton, J. C., Croner, L. J., Davies, C., Davison, T. S., Delenstarr, 
G., Deng, X., Dorris, D., Eklund, A. C., Fan, X. H., Fang, H., Fulmer-Smentek, S., Fuscoe, 
J. C., Gallagher, K., Ge, W., Guo, L., Guo, X., Hager, J., Haje, P. K., Han, J., Han, T., 
Harbottle, H. C., Harris, S. C., Hatchwell, E., Hauser, C. A., Hester, S., Hong, H., Hurban, 
P., Jackson, S. A., Ji, H., Knight, C. R., Kuo, W. P., LeClerc, J. E., Levy, S., Li, Q. Z., Liu, 
C., Liu, Y., Lombardi, M. J., Ma, Y., Magnuson, S. R., Maqsodi, B., McDaniel, T., Mei, 
N., Myklebost, O., Ning, B., Novoradovskaya, N., Orr, M. S., Osborn, T. W., Papallo, 
A., Patterson, T. A., Perkins, R. G., Peters, E. H., Peterson, R., et al. 2006. The 
Microarray Quality Control (Maqc) Project Shows Inter- and Intraplatform 
Reproducibility of Gene Expression Measurements. Nature Biotechnology, 24, 1151-
1161. 
 
Shigemoto-Mogami, Y., Hoshikawa, K., Goldman, J. E., Sekino, Y. & Sato, K. 2014. Microglia 
Enhance Neurogenesis and Oligodendrogenesis in the Early Postnatal Subventricular 
Zone. Journal of Neuroscience, 34, 2231-2243. 
 
Shimoda, K., van Deursen, J., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., Chu, 
C., Quelle, F. W., Nosaka, T., Vignali, D. A., Doherty, P. C., Grosveld, G., Paul, W. E. & 
Ihle, J. N. 1996. Lack of Il-4-Induced Th2 Response and Ige Class Switching in Mice 
with Disrupted Stat6 Gene. Nature, 380, 630-633. 
 
Shokouhi, B. N., Wong, B. Z., Siddiqui, S., Lieberman, A. R., Campbell, G., Tohyama, K. & 
Anderson, P. N. 2010. Microglial Responses around Intrinsic Cns Neurons Are 




Shuai, K. & Liu, B. 2003. Regulation of Jak-Stat Signalling in the Immune System. Nature 
Reviews: Immunology, 3, 900-911. 
 
Sierra, A., Encinas, J. M., Deudero, J. J., Chancey, J. H., Enikolopov, G., Overstreet-Wadiche, 
L. S., Tsirka, S. E. & Maletic-Savatic, M. 2010. Microglia Shape Adult Hippocampal 
Neurogenesis through Apoptosis-Coupled Phagocytosis. Cell Stem Cell, 7, 483-495. 
 
Sierra, A., Gottfried-Blackmore, A. C., McEwen, B. S. & Bulloch, K. 2007. Microglia Derived 
from Aging Mice Exhibit an Altered Inflammatory Profile. Glia, 55, 412-424. 
 
Sigurdsson, B., Palsson, P. & Grimsson, H. 1957. Visna, a Demyelinating Transmissible Disease 
of Sheep. Journal of Neuropathology and Experimental Neurology, 16, 389-403. 
 
Sigurdsson, B. & Palsson, P. A. 1958. Visna of Sheep; a Slow, Demyelinating Infection. British 
Journal of Experimental Pathology, 39, 519-528. 
 
Sikorska, B., Liberski, P. P., Giraud, P., Kopp, N. & Brown, P. 2004. Autophagy Is a Part of 
Ultrastructural Synaptic Pathology in Creutzfeldt-Jakob Disease: A Brain Biopsy 
Study. International Journal of Biochemistry and Cell Biology, 36, 2563-2573. 
 
Sironi, M., Martinez, F. O., D'Ambrosio, D., Gattorno, M., Polentarutti, N., Locati, M., 
Gregorio, A., Iellem, A., Cassatella, M. A., Van Damme, J., Sozzani, S., Martini, A., 
Sinigaglia, F., Vecchi, A. & Mantovani, A. 2006. Differential Regulation of Chemokine 
Production by Fcgamma Receptor Engagement in Human Monocytes: Association of 
Ccl1 with a Distinct Form of M2 Monocyte Activation (M2b, Type 2). Journal of 
Leukocyte Biology, 80, 342-349. 
 
Siskova, Z., Page, A., O'Connor, V. & Perry, V. H. 2009. Degenerating Synaptic Boutons in Prion 
Disease: Microglia Activation without Synaptic Stripping. American Journal of 
Pathology, 175, 1610-1621. 
 
Siskova, Z., Reynolds, R. A., O'Connor, V. & Perry, V. H. 2013. Brain Region Specific Pre-
Synaptic and Post-Synaptic Degeneration Are Early Components of Neuropathology 
in Prion Disease. PloS One, 8, 30. 
 
Siskova, Z. & Tremblay, M. E. 2013. Microglia and Synapse: Interactions in Health and 
Neurodegeneration. Neural Plasticity, 2013, 425845. 
 
Sisó, S., Chianini, F., Eaton, S. L., Witz, J., Hamilton, S., Martin, S., Finlayson, J., Pang, Y., 
Stewart, P., Steele, P., Dagleish, M. P., Goldmann, W., Reid, H. W., Jeffrey, M. & 
Gonzalez, L. 2012. Disease Phenotype in Sheep after Infection with Cloned Murine 
Scrapie Strains. Prion, 6, 174-183. 
 
Siso, S., Puig, B., Varea, R., Vidal, E., Acin, C., Prinz, M., Montrasio, F., Badiola, J., Aguzzi, A., 
Pumarola, M. & Ferrer, I. 2002. Abnormal Synaptic Protein Expression and Cell Death 




Skinner, P. J., Abbassi, H., Chesebro, B., Race, R. E., Reilly, C. & Haase, A. T. 2006. Gene 
Expression Alterations in Brains of Mice Infected with Three Strains of Scrapie. BMC 
Genomics, 7, 114-114. 
 
Sly, L. M., Krzesicki, R. F., Brashler, J. R., Buhl, A. E., McKinley, D. D., Carter, D. B. & Chin, J. E. 
2001. Endogenous Brain Cytokine Mrna and Inflammatory Responses to 
Lipopolysaccharide Are Elevated in the Tg2576 Transgenic Mouse Model of 
Alzheimer's Disease. Brain Research Bulletin, 56, 581-588. 
 
Snell, G. D. 1941. Biology of the Laboratory Mouse, York U.S.A., Maple Press Company, Page: 
242-243. 
 
Snell, G. D. 1978. Congenic Resistant Strains of Mice. In: Herbert, C. M., III (ed.) Origins of 
Inbred Mice. Academic Press, Page: 119-156. 
 
Sofroniew, M. V. & Vinters, H. V. 2010. Astrocytes: Biology and Pathology. Acta 
Neuropathologica, 119, 7-35. 
 
Sogn, C., Puchades, M. & Gundersen, V. 2013. Rare Contacts between Synapses and 
Microglial Processes Containing High Levels of Iba1 and Actin - a Postembedding 
Immunogold Study in the Healthy Rat Brain. European Journal of Neuroscience, 2030-
2040. 
 
Sollberger, G., Strittmatter, G. E., Kistowska, M., French, L. E. & Beer, H. D. 2012. Caspase-4 
Is Required for Activation of Inflammasomes. Journal of Immunology, 188, 1992-
2000. 
 
Somerville, R. A., Chong, A., Mulqueen, O. U., Birkett, C. R., Wood, S. C. & Hope, J. 1997. 
Biochemical Typing of Scrapie Strains. Nature, 386, 564. 
 
Song, D. Y., Yu, H. N., Park, C. R., Lee, J. S., Lee, J. Y., Park, B. G., Woo, R. S., Han, J. T., Cho, B. 
P. & Baik, T. K. 2013. Down-Regulation of Microglial Activity Attenuates Axotomized 
Nigral Dopaminergic Neuronal Cell Loss. BMC Neuroscience, 14, 112. 
 
Sparkes, R. S., Simon, M., Cohn, V. H., Fournier, R. E., Lem, J., Klisak, I., Heinzmann, C., Blatt, 
C., Lucero, M., Mohandas, T. & et al. 1986. Assignment of the Human and Mouse 
Prion Protein Genes to Homologous Chromosomes. Proceedings of the National 
Academy of Sciences of the United States of America, 83, 7358-7362. 
 
Spinner, D. S., Cho, I. S., Park, S. Y., Kim, J. I., Meeker, H. C., Ye, X., Lafauci, G., Kerr, D. J., Flory, 
M. J., Kim, B. S., Kascsak, R. B., Wisniewski, T., Levis, W. R., Schuller-Levis, G. B., Carp, 
R. I., Park, E. & Kascsak, R. J. 2008. Accelerated Prion Disease Pathogenesis in Toll-
Like Receptor 4 Signaling-Mutant Mice. Journal of Virology, 82, 10701-10708. 
 
Spudich, A., Frigg, R., Kilic, E., Kilic, U., Oesch, B., Raeber, A., Bassetti, C. L. & Hermann, D. M. 
2005. Aggravation of Ischemic Brain Injury by Prion Protein Deficiency: Role of Erk-




Stahl, N., Baldwin, M. A., Teplow, D. B., Hood, L., Gibson, B. W., Burlingame, A. L. & Prusiner, 
S. B. 1993. Structural Studies of the Scrapie Prion Protein Using Mass Spectrometry 
and Amino Acid Sequencing. Biochemistry, 32, 1991-2002. 
 
Stalder, M., Deller, T., Staufenbiel, M. & Jucker, M. 2001. 3d-Reconstruction of Microglia and 
Amyloid in App23 Transgenic Mice: No Evidence of Intracellular Amyloid. 
Neurobiology of Aging, 22, 427-434. 
 
Stalder, M., Phinney, A., Probst, A., Sommer, B., Staufenbiel, M. & Jucker, M. 1999. 
Association of Microglia with Amyloid Plaques in Brains of App23 Transgenic Mice. 
American Journal of Pathology, 154, 1673-1684. 
 
Stangegaard, M., Dufva, I. H. & Dufva, M. 2006. Reverse Transcription Using Random 
Pentadecamer Primers Increases Yield and Quality of Resulting Cdna. BioTechniques, 
40, 649-657. 
 
Stanley, E. R., Berg, K. L., Einstein, D. B., Lee, P. S., Pixley, F. J., Wang, Y. & Yeung, Y. G. 1997. 
Biology and Action of Colony--Stimulating Factor-1. Molecular Reproduction and 
Development, 46, 4-10. 
 
Stanton, J. B., Knowles, D. P., Call, D. R., Mathison, B. A. & Baszler, T. V. 2009. Limited 
Transcriptional Response of Ovine Microglia to Prion Accumulation. Biochemical and 
Biophysical Research Communications, 386, 345-350. 
 
Stefater, J. A., 3rd, Lewkowich, I., Rao, S., Mariggi, G., Carpenter, A. C., Burr, A. R., Fan, J., 
Ajima, R., Molkentin, J. D., Williams, B. O., Wills-Karp, M., Pollard, J. W., Yamaguchi, 
T., Ferrara, N., Gerhardt, H. & Lang, R. A. 2011. Regulation of Angiogenesis by a Non-
Canonical Wnt-Flt1 Pathway in Myeloid Cells. Nature, 474, 511-515. 
 
Stein, M., Keshav, S., Harris, N. & Gordon, S. 1992. Interleukin 4 Potently Enhances Murine 
Macrophage Mannose Receptor Activity: A Marker of Alternative Immunologic 
Macrophage Activation. Journal of Experimental Medicine, 176, 287-292. 
 
Stewart, W. F., Kawas, C., Corrada, M. & Metter, E. J. 1997. Risk of Alzheimer's Disease and 
Duration of Nsaid Use. Neurology, 48, 626-632. 
 
Stockman, S. 1913. Scrapie: An Obscure Disease of Sheep. Journal of Comparative Pathology 
and Therapeutics, 26, 317-327. 
 
Stockman, S. 1926. Contribution to the Study of the Disease Known as Scrapie. Journal of 
Comparative Pathology and Therapeutics, 39, 42-71. 
 
Stohr, J., Condello, C., Watts, J. C., Bloch, L., Oehler, A., Nick, M., DeArmond, S. J., Giles, K., 
DeGrado, W. F. & Prusiner, S. B. 2014. Distinct Synthetic Abeta Prion Strains 
Producing Different Amyloid Deposits in Bigenic Mice. Proceedings of the National 
Academy of Sciences of the United States of America, 111, 10329-10334. 
 
Stohr, J., Watts, J. C., Mensinger, Z. L., Oehler, A., Grillo, S. K., DeArmond, S. J., Prusiner, S. B. 
& Giles, K. 2012. Purified and Synthetic Alzheimer's Amyloid Beta (Abeta) Prions. 
278 
 
Proceedings of the National Academy of Sciences of the United States of America, 
109, 11025-11030. 
 
Stone, T. W. 2001. Endogenous Neurotoxins from Tryptophan. Toxicon, 39, 61-73. 
 
Stone, T. W. & Perkins, M. N. 1981. Quinolinic Acid: A Potent Endogenous Excitant at Amino 
Acid Receptors in Cns. European Journal of Pharmacology, 72, 411-412. 
 
Stoner, G. D., Adam-Rodwell, G. & Morse, M. A. 1993. Lung Tumors in Strain a Mice: 
Application for Studies in Cancer Chemoprevention. Journal of Cellular Biochemistry. 
Supplement, 95-103. 
 
Streit, W. J. 2002. Microglia as Neuroprotective, Immunocompetent Cells of the Cns. Glia, 40, 
133-139. 
 
Streit, W. J., Graeber, M. B. & Kreutzberg, G. W. 1988. Functional Plasticity of Microglia: A 
Review. Glia, 1, 301-307. 
 
Streit, W. J., Graeber, M. B. & Kreutzberg, G. W. 1989a. Expression of Ia Antigen on 
Perivascular and Microglial Cells after Sublethal and Lethal Motor Neuron Injury. 
Experimental Neurology, 105, 115-126. 
 
Streit, W. J., Graeber, M. B. & Kreutzberg, G. W. 1989b. Expression of Ia Antigen on 
Perivascular and Microglial Cells after Sublethal and Lethal Motor Neuron Injury. 
Experimental Neurology, 105, 115-126. 
 
Streit, W. J., Graeber, M. B. & Kreutzberg, G. W. 1989c. Peripheral Nerve Lesion Produces 
Increased Levels of Major Histocompatibility Complex Antigens in the Central 
Nervous System. Journal of Neuroimmunology, 21, 117-123. 
 
Streit, W. J., Sammons, N. W., Kuhns, A. J. & Sparks, D. L. 2004. Dystrophic Microglia in the 
Aging Human Brain. Glia, 45, 208-212. 
 
Strong, L. C. 1936. The Establishment of the “a” Strain of Inbred Mice. Journal of Heredity, 
27, 21-24. 
 
Su, A. I., Cooke, M. P., Ching, K. A., Hakak, Y., Walker, J. R., Wiltshire, T., Orth, A. P., Vega, R. 
G., Sapinoso, L. M., Moqrich, A., Patapoutian, A., Hampton, G. M., Schultz, P. G. & 
Hogenesch, J. B. 2002. Large-Scale Analysis of the Human and Mouse 
Transcriptomes. Proceedings of the National Academy of Sciences of the United 
States of America, 99, 4465-4470. 
 
Sun, S. C., Ganchi, P. A., Ballard, D. W. & Greene, W. C. 1993. Nf-Kappa B Controls Expression 
of Inhibitor I Kappa B Alpha: Evidence for an Inducible Autoregulatory Pathway. 
Science, 259, 1912-1915. 
 
Sunderkötter, C., Nikolic, T., Dillon, M. J., Van Rooijen, N., Stehling, M., Drevets, D. A. & 
Leenen, P. J. M. 2004. Subpopulations of Mouse Blood Monocytes Differ in 
Maturation Stage and Inflammatory Response. Journal of Immunology (Baltimore, 




Sunyach, C., Jen, A., Deng, J., Fitzgerald, K. T., Frobert, Y., Grassi, J., McCaffrey, M. W. & 
Morris, R. 2003. The Mechanism of Internalization of Glycosylphosphatidylinositol-
Anchored Prion Protein. EMBO Journal, 22, 3591-3601. 
 
Sykova, E. 2004. Extrasynaptic Volume Transmission and Diffusion Parameters of the 
Extracellular Space. Neuroscience, 129, 861-876. 
 
Szekely, C. A., Breitner, J. C., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H. & Zandi, P. 
P. 2008. Nsaid Use and Dementia Risk in the Cardiovascular Health Study: Role of 
Apoe and Nsaid Type. Neurology, 70, 17-24. 
 
Tahara, K., Kim, H.-D., Jin, J.-J., Maxwell, J. A., Li, L. & Fukuchi, K.-i. 2006. Role of Toll-Like 
Receptor Signalling in a{Beta} Uptake and Clearance. Brain, 129, 3006-3019. 
 
Takahashi, K., Rochford, C. D. & Neumann, H. 2005. Clearance of Apoptotic Neurons without 
Inflammation by Microglial Triggering Receptor Expressed on Myeloid Cells-2. 
Journal of Experimental Medicine, 201, 647-657. 
 
Tamura, H., Dong, H., Zhu, G., Sica, G. L., Flies, D. B., Tamada, K. & Chen, L. 2001. B7-H1 
Costimulation Preferentially Enhances Cd28-Independent T-Helper Cell Function. 
Blood, 97, 1809-1816. 
 
Tanaka, M., Kishi, K., McCarron, R. M. & Miyatake, T. 1993. The Generation of Macrophages 
from Precursor Cells Incubated with Brain Endothelial Cells--a Release of Csf-1 Like 
Factor from Endothelial Cells. Tohoku Journal of Experimental Medicine, 171, 211-
220. 
 
Tang, F., Barbacioru, C., Nordman, E., Li, B., Xu, N., Bashkirov, V. I., Lao, K. & Surani, M. A. 
2010. Rna-Seq Analysis to Capture the Transcriptome Landscape of a Single Cell. 
Nature Protocols, 5, 516-535. 
 
Tarkowski, E., Blennow, K., Wallin, A. & Tarkowski, A. 1999. Intracerebral Production of 
Tumor Necrosis Factor-Alpha, a Local Neuroprotective Agent, in Alzheimer Disease 
and Vascular Dementia. Journal of Clinical Immunology, 19, 223-230. 
 
Tashiro, H., Dohura, K. & Iwaki, T. 1998. Differential Expression of Transforming Growth 
Factor-Beta Isoforms in Human Prion Diseases. Neuropathology and Applied 
Neurobiology, 24, 284-292. 
 
Tasker, J. G., Oliet, S. H., Bains, J. S., Brown, C. H. & Stern, J. E. 2012. Glial Regulation of 
Neuronal Function: From Synapse to Systems Physiology. Journal of 
Neuroendocrinology, 24, 566-576. 
 
Taylor, D. M., Brown, J. M., Fernie, K. & McConnell, I. 1997. The Effect of Formic Acid on Bse 





Taylor, P. R., Martinez-Pomares, L., Stacey, M., Lin, H. H., Brown, G. D. & Gordon, S. 2005. 
Macrophage Receptors and Immune Recognition. Annual Review of Immunology, 23, 
901-944. 
 
Tereshchenko, J., Maddalena, A., Bahr, M. & Kugler, S. 2014. Pharmacologically Controlled, 
Discontinuous Gdnf Gene Therapy Restores Motor Function in a Rat Model of 
Parkinson's Disease. Neurobiology of Disease, 65, 35-42. 
 
Thackray, A. M., McKenzie, A. N., Klein, M. A., Lauder, A. & Bujdoso, R. 2004. Accelerated 
Prion Disease in the Absence of Interleukin-10. Journal of Virology, 78, 13697-13707. 
 
Thaler, J. P., Yi, C. X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, 
D. A., Izgur, V., Maravilla, K. R., Nguyen, H. T., Fischer, J. D., Matsen, M. E., Wisse, B. 
E., Morton, G. J., Horvath, T. L., Baskin, D. G., Tschop, M. H. & Schwartz, M. W. 2012. 
Obesity Is Associated with Hypothalamic Injury in Rodents and Humans. Journal of 
Clinical Investigation, 122, 153-162. 
 
Theocharidis, A., van Dongen, S., Enright, A. J. & Freeman, T. C. 2009. Network Visualization 
and Analysis of Gene Expression Data Using Biolayout Express3d. Nat. Protocols, 4, 
1535-1550. 
 
Thomson, C. A., McColl, A., Cavanagh, J. & Graham, G. J. 2014. Peripheral Inflammation Is 
Associated with Remote Global Gene Expression Changes in the Brain. Journal of 
Neuroinflammation, 11, 73. 
 
Timmes, A. G., Moore, R. A., Fischer, E. R. & Priola, S. A. 2013. Recombinant Prion Protein 
Refolded with Lipid and Rna Has the Biochemical Hallmarks of a Prion but Lacks in 
Vivo Infectivity. PloS One, 8, e71081. 
 
Tobler, I., Gaus, S. E., Deboer, T., Achermann, P., Fischer, M., Rulicke, T., Moser, M., Oesch, 
B., McBride, P. A. & Manson, J. C. 1996. Altered Circadian Activity Rhythms and Sleep 
in Mice Devoid of Prion Protein. Nature, 380, 639-642. 
 
Torres-Platas, S. G., Comeau, S., Rachalski, A., Bo, G. D., Cruceanu, C., Turecki, G., Giros, B. & 
Mechawar, N. 2014. Morphometric Characterization of Microglial Phenotypes in 
Human Cerebral Cortex. Journal of Neuroinflammation, 11, 12. 
 
Tourrière, H., Chebli, K. & Tazi, J. 2002. Mrna Degradation Machines in Eukaryotic Cells. 
Biochimie, 84, 821-837. 
 
Trapp, B. D., Wujek, J. R., Criste, G. A., Jalabi, W., Yin, X., Kidd, G. J., Stohlman, S. & Ransohoff, 
R. 2007. Evidence for Synaptic Stripping by Cortical Microglia. Glia, 55, 360-368. 
 
Tremblay, M.-È., Lowery, R. L. & Majewska, A. K. 2010. Microglial Interactions with Synapses 
Are Modulated by Visual Experience. PLoS Biology, 8, e1000527. 
 
Tremblay, M.-È. & Majewska, A. K. 2011. A Role for Microglia in Synaptic Plasticity? 




Tremblay, P., Ball, H. L., Kaneko, K., Groth, D., Hegde, R. S., Cohen, F. E., DeArmond, S. J., 
Prusiner, S. B. & Safar, J. G. 2004. Mutant Prpsc Conformers Induced by a Synthetic 
Peptide and Several Prion Strains. Journal of Virology, 78, 2088-2099. 
 
True, H. L. & Lindquist, S. L. 2000. A Yeast Prion Provides a Mechanism for Genetic Variation 
and Phenotypic Diversity. Nature, 407, 477-483. 
 
Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L. & Wrana, J. L. 1998. Sara, a Fyve Domain 
Protein That Recruits Smad2 to the Tgfbeta Receptor. Cell, 95, 779-791. 
 
Turtzo, L. C., Lescher, J., Janes, L., Dean, D. D., Budde, M. D. & Frank, J. A. 2014. Macrophagic 
and Microglial Responses after Focal Traumatic Brain Injury in the Female Rat. 
Journal of Neuroinflammation, 11, 82. 
 
Tusher, V. G., Tibshirani, R. & Chu, G. 2001. Significance Analysis of Microarrays Applied to 
the Ionizing Radiation Response. Proceedings of the National Academy of Sciences of 
the United States of America, 98, 5116-5121. 
 
Ulevitch, R. J. & Tobias, P. S. 1995. Receptor-Dependent Mechanisms of Cell Stimulation by 
Bacterial Endotoxin. Annual Review of Immunology, 13, 437-457. 
 
van Dam, A.-M., Brouns, M., Louisse, S. & Berkenbosch, F. 1992. Appearance of Interleukin-
1 in Macrophages and in Ramified Microglia in the Brain of Endotoxin-Treated Rats: 
A Pathway for the Induction of Non-Specific Symptoms of Sickness? Brain Research, 
588, 291-296. 
 
Van Dam, A. M., Bauer, J., Tilders, F. J. & Berkenbosch, F. 1995. Endotoxin-Induced 
Appearance of Immunoreactive Interleukin-1 Beta in Ramified Microglia in Rat Brain: 
A Light and Electron Microscopic Study. Neuroscience, 65, 815-826. 
 
van Gool, W. A., van de Beek, D. & Eikelenboom, P. 2010. Systemic Infection and Delirium: 
When Cytokines and Acetylcholine Collide. Lancet, 375, 773-775. 
 
Vane, J. R. 1971. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-
Like Drugs. Nature: New Biology, 231, 232-235. 
 
Vargas, L. M., Leal, N., Estrada, L. D., Gonzalez, A., Serrano, F., Araya, K., Gysling, K., Inestrosa, 
N. C., Pasquale, E. B. & Alvarez, A. R. 2014. Epha4 Activation of C-Abl Mediates 
Synaptic Loss and Ltp Blockade Caused by Amyloid-Beta Oligomers. PloS One, 9, 
e92309. 
 
Varin, A. & Gordon, S. 2009. Alternative Activation of Macrophages: Immune Function and 
Cellular Biology. Immunobiology, 214, 630-641. 
 
Varvel, N. H., Grathwohl, S. A., Baumann, F., Liebig, C., Bosch, A., Brawek, B., Thal, D. R., 
Charo, I. F., Heppner, F. L., Aguzzi, A., Garaschuk, O., Ransohoff, R. M. & Jucker, M. 
2012. Microglial Repopulation Model Reveals a Robust Homeostatic Process for 
Replacing Cns Myeloid Cells. Proceedings of the National Academy of Sciences of the 




Vass, K. & Lassmann, H. 1990. Intrathecal Application of Interferon Gamma. Progressive 
Appearance of Mhc Antigens within the Rat Nervous System. American Journal of 
Pathology, 137, 789-800. 
 
Vastrik, I., D'Eustachio, P., Schmidt, E., Gopinath, G., Croft, D., de Bono, B., Gillespie, M., 
Jassal, B., Lewis, S., Matthews, L., Wu, G., Birney, E. & Stein, L. 2007. Reactome: A 
Knowledge Base of Biologic Pathways and Processes. Genome Biology, 8, R39. 
 
Vasudevan, A., Long, J. E., Crandall, J. E., Rubenstein, J. L. & Bhide, P. G. 2008. Compartment-
Specific Transcription Factors Orchestrate Angiogenesis Gradients in the Embryonic 
Brain. Nature Neuroscience, 11, 429-439. 
 
Ventura, G., Moinard, C., Segaud, F., Le Plenier, S., Cynober, L. & De Bandt, J. P. 2010. 
Adaptative Response of Nitrogen Metabolism in Early Endotoxemia: Role of 
Ornithine Aminotransferase. Amino Acids, 39, 1417-1426. 
 
Vinet, J., Weering, H. R., Heinrich, A., Kalin, R. E., Wegner, A., Brouwer, N., Heppner, F. L., 
Rooijen, N., Boddeke, H. W. & Biber, K. 2012. Neuroprotective Function for Ramified 
Microglia in Hippocampal Excitotoxicity. Journal of Neuroinflammation, 9, 27. 
 
Virchow, R. 1846. Über Das Granulierte Aussehen Der Wandungen Des Gehirnvenrtikels. 
Zeitschrift für Psychiatrie, 242-250. 
 
Virchow, R. 1858. Das Nervensystem, In: Die Cellularpathologie in Ihrer Begründung Auf 
Physiologische Und Pathologische Gewebelchre (the Cellular Pathology in Its 
Reasoning on Physiological and Pathological Histology), Frankfurt, Page: 218-237. 
 
Viselli, S. M., Stanziale, S., Shults, K., Kovacs, W. J. & Olsen, N. J. 1995. Castration Alters 
Peripheral Immune Function in Normal Male Mice. Immunology, 84, 337-342. 
 
Voll, R. E., Herrmann, M., Roth, E. A., Stach, C., Kalden, J. R. & Girkontaite, I. 1997. 
Immunosuppressive Effects of Apoptotic Cells. Nature, 390, 350-351. 
 
Vukovic, J., Colditz, M. J., Blackmore, D. G., Ruitenberg, M. J. & Bartlett, P. F. 2012. Microglia 
Modulate Hippocampal Neural Precursor Activity in Response to Exercise and Aging. 
Journal of Neuroscience, 32, 6435-6443. 
 
Wake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S. & Nabekura, J. 2009. Resting Microglia 
Directly Monitor the Functional State of Synapses in Vivo and Determine the Fate of 
Ischemic Terminals. The Journal of Neuroscience: The Official Journal of the Society 
for Neuroscience, 29, 3974-3980. 
 
Walsh, D. T., Perry, V. H. & Minghetti, L. 2000. Cyclooxygenase-2 Is Highly Expressed in 
Microglial-Like Cells in a Murine Model of Prion Disease. Glia, 29, 392-396. 
 
Walsh, D. T. P., Betmouni, S. D. & Perry, V. H. D. 2001. Absence of Detectable Il-1[Beta] 
Production in Murine Prion Disease: A Model of Chronic Neurodegeneration. 





Wang, F., Wang, X., Yuan, C. G. & Ma, J. 2010. Generating a Prion with Bacterially Expressed 
Recombinant Prion Protein. Science, 327, 1132-1135. 
 
Wang, F., Zhang, Z., Wang, X., Li, J., Zha, L., Yuan, C. G., Weissmann, C. & Ma, J. 2012. Genetic 
Informational Rna Is Not Required for Recombinant Prion Infectivity. Journal of 
Virology, 86, 1874-1876. 
 
Wang, J., Yang, Z., Liu, C., Zhao, Y. & Chen, Y. 2013. Activated Microglia Provide a 
Neuroprotective Role by Balancing Glial Cell-Line Derived Neurotrophic Factor and 
Tumor Necrosis Factor-Alpha Secretion after Subacute Cerebral Ischemia. 
International Journal of Molecular Medicine, 31, 172-178. 
 
Warner, J. R. 1999. The Economics of Ribosome Biosynthesis in Yeast. Trends in Biochemical 
Sciences, 24, 437-440. 
 
Watts, J. C., Condello, C., Stohr, J., Oehler, A., Lee, J., DeArmond, S. J., Lannfelt, L., Ingelsson, 
M., Giles, K. & Prusiner, S. B. 2014. Serial Propagation of Distinct Strains of Abeta 
Prions from Alzheimer's Disease Patients. Proceedings of the National Academy of 
Sciences of the United States of America, 111, 10323-10328. 
 
Wehinger, J., Gouilleux, F., Groner, B., Finke, J., Mertelsmann, R. & Weber-Nordt, R. M. 1996. 
Il-10 Induces DNA Binding Activity of Three Stat Proteins (Stat1, Stat3, and Stat5) and 
Their Distinct Combinatorial Assembly in the Promoters of Selected Genes. FEBS 
Letters, 394, 365-370. 
 
Weissmann, C., Li, J., Mahal, S. P. & Browning, S. 2011. Prions on the Move. EMBO Rep, 12, 
1109-1117. 
 
Wells, G. A., Scott, A. C., Johnson, C. T., Gunning, R. F., Hancock, R. D., Jeffrey, M., Dawson, 
M. & Bradley, R. 1987. A Novel Progressive Spongiform Encephalopathy in Cattle. 
Veterinary Record, 121, 419-420. 
 
Westfall, P. H. 1993. Resampling-Based Multiple Testing: Examples and Methods for P-Value 
Adjustment, Hoboken U.S.A., John Wiley & Sons, Page: 1359-64. 
 
Whiting, D., Hsieh, G., Yun, J. J., Banerji, A., Yao, W., Fishbein, M. C., Belperio, J., Strieter, R. 
M., Bonavida, B. & Ardehali, A. 2004. Chemokine Monokine Induced by Ifn-
Gamma/Cxc Chemokine Ligand 9 Stimulates T Lymphocyte Proliferation and Effector 
Cytokine Production. Journal of Immunology, 172, 7417-7424. 
 
Wilesmith, J. W., Ryan, J. B. & Atkinson, M. J. 1991. Bovine Spongiform Encephalopathy: 
Epidemiological Studies on the Origin. Veterinary Record, 128, 199-203. 
 
Wilesmith, J. W., Wells, G. A., Cranwell, M. P. & Ryan, J. B. 1988. Bovine Spongiform 
Encephalopathy: Epidemiological Studies. Veterinary Record, 123, 638-644. 
 
Williams, A., Lucassen, P. J., Ritchie, D. & Bruce, M. 1997. Prp Deposition, Microglial 





Williams, A. E., Lawson, L. J., Perry, V. H. & Fraser, H. 1994. Characterization of the Microglial 
Response in Murine Scrapie. Neuropathology and Applied Neurobiology, 20, 47-55. 
 
Williams, A. E., Ryder, S. & Blakemore, W. F. 1995. Monocyte Recruitment into the Scrapie-
Affected Brain. Acta Neuropathologica, 90, 164-169. 
 
Williams, E. S. & Young, S. 1980. Chronic Wasting Disease of Captive Mule Deer: A Spongiform 
Encephalopathy. Journal of Wildlife Diseases, 16, 89-98. 
 
Wong, C. H., Abeynaike, L. D., Crack, P. J. & Hickey, M. J. 2011. Divergent Roles of Glutathione 
Peroxidase-1 (Gpx1) in Regulation of Leukocyte-Endothelial Cell Interactions in the 
Inflamed Cerebral Microvasculature. Microcirculation, 18, 12-23. 
 
Wu, C., Orozco, C., Boyer, J., Leglise, M., Goodale, J., Batalov, S., Hodge, C. L., Haase, J., Janes, 
J., Huss, J. W., 3rd & Su, A. I. 2009. Biogps: An Extensible and Customizable Portal for 
Querying and Organizing Gene Annotation Resources. Genome Biology, 10, 2009-
2010. 
 
Wu, D. C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H. & Przedborski, 
S. 2003. Nadph Oxidase Mediates Oxidative Stress in the 1-Methyl-4-Phenyl-1,2,3,6-
Tetrahydropyridine Model of Parkinson's Disease. Proceedings of the National 
Academy of Sciences of the United States of America, 100, 6145-6150. 
 
Wu, J., Yang, S., Luo, H., Zeng, L., Ye, L. & Lu, Y. 2006. Quantitative Evaluation of Monocyte 
Transmigration into the Brain Following Chemical Opening of the Blood-Brain Barrier 
in Mice. Brain Research, 1098, 79-85. 
 
Wynn, R. F., Wraith, J. E., Mercer, J., O'Meara, A., Tylee, K., Thornley, M., Church, H. J. & 
Bigger, B. W. 2009. Improved Metabolic Correction in Patients with Lysosomal 
Storage Disease Treated with Hematopoietic Stem Cell Transplant Compared with 
Enzyme Replacement Therapy. Journal of Pediatrics, 154, 609-611. 
 
Wynne, A. M., Henry, C. J., Huang, Y., Cleland, A. & Godbout, J. P. 2010. Protracted 
Downregulation of Cx3cr1 on Microglia of Aged Mice after Lipopolysaccharide 
Challenge. Brain, Behavior, and Immunity, 24, 1190-1201. 
 
Xiang, W., Hummel, M., Mitteregger, G., Pace, C., Windl, O., Mansmann, U. & Kretzschmar, 
H. A. 2007. Transcriptome Analysis Reveals Altered Cholesterol Metabolism During 
the Neurodegeneration in Mouse Scrapie Model. Journal of Neurochemistry, 102, 
834-847. 
 
Xiang, W., Windl, O., Wunsch, G., Dugas, M., Kohlmann, A., Dierkes, N., Westner, I. M. & 
Kretzschmar, H. A. 2004. Identification of Differentially Expressed Genes in Scrapie-
Infected Mouse Brains by Using Global Gene Expression Technology. Journal of 
Virology, 78, 11051-11060. 
 
Xie, W. L., Shi, Q., Zhang, J., Zhang, B. Y., Gong, H. S., Guo, Y., Wang, S. B., Xu, Y., Wang, K., 
Chen, C., Liu, Y. & Dong, X. P. 2013. Abnormal Activation of Microglia Accompanied 
with Disrupted Cx3cr1/Cx3cl1 Pathway in the Brains of the Hamsters Infected with 




Xu, Y., Tian, C., Wang, S. B., Xie, W. L., Guo, Y., Zhang, J., Shi, Q., Chen, C. & Dong, X. P. 2012. 
Activation of the Macroautophagic System in Scrapie-Infected Experimental Animals 
and Human Genetic Prion Diseases. Autophagy, 8, 1604-1620. 
 
Xue, L., Fletcher, G. C. & Tolkovsky, A. M. 1999. Autophagy Is Activated by Apoptotic Signalling 
in Sympathetic Neurons: An Alternative Mechanism of Death Execution. Molecular 
and Cellular Neurosciences, 14, 180-198. 
 
Yamada, A., Akimoto, H., Kagawa, S., Guillemin, G. J. & Takikawa, O. 2009. Proinflammatory 
Cytokine Interferon-Gamma Increases Induction of Indoleamine 2,3-Dioxygenase in 
Monocytic Cells Primed with Amyloid Beta Peptide 1-42: Implications for the 
Pathogenesis of Alzheimer's Disease. Journal of Neurochemistry, 110, 791-800. 
 
Yamada, J. & Jinno, S. 2013. Novel Objective Classification of Reactive Microglia Following 
Hypoglossal Axotomy Using Hierarchical Cluster Analysis. Journal of Comparative 
Neurology, 521, 1184-1201. 
 
Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Takeuchi, O., Sugiyama, 
M., Okabe, M., Takeda, K. & Akira, S. 2003. Role of Adaptor Trif in the Myd88-
Independent Toll-Like Receptor Signaling Pathway. Science, 301, 640-643. 
 
Zhang, B. & Horvath, S. 2005. A General Framework for Weighted Gene Co-Expression 
Network Analysis. Statistical Applications in Genetics and Molecular Biology, 4, 
Article17. 
 
Zhang, G., Bogdanova, N., Gao, T., Song, J. J., Cragg, M. S., Glennie, M. J. & Sheikh, K. A. 2014. 
Fcgamma Receptor-Mediated Inflammation Inhibits Axon Regeneration. PloS One, 9, 
e88703. 
 
Zhang, Y., McCartney, A. J., Zolov, S. N., Ferguson, C. J., Meisler, M. H., Sutton, M. A. & 
Weisman, L. S. 2012. Modulation of Synaptic Function by Vac14, a Protein That 
Regulates the Phosphoinositides Pi(3,5)P(2) and Pi(5)P. EMBO Journal, 31, 3442-
3456. 
 
Zharkikh, A. & Li, W. H. 1995. Estimation of Confidence in Phylogeny: The Complete-and-
Partial Bootstrap Technique. Molecular Phylogenetics and Evolution, 4, 44-63. 
 
Zhou, X. M., Xu, G. X. & Zhao, D. M. 2008. In Vitro Effect of Prion Peptide Prp 106-126 on 
Mouse Macrophages: Possible Role of Macrophages in Transport and Proliferation 
for Prion Protein. Microbial Pathogenesis, 44, 129-134. 
 
Zhu, P., Hata, R., Cao, F., Gu, F., Hanakawa, Y., Hashimoto, K. & Sakanaka, M. 2008. Ramified 
Microglial Cells Promote Astrogliogenesis and Maintenance of Neural Stem Cells 
through Activation of Stat3 Function. FASEB Journal, 22, 3866-3877. 
 
Zlotnik, A. & Spittau, B. 2014. Gdnf Fails to Inhibit Lps-Mediated Activation of Mouse 




Zlotnik, I. & Rennie, J. C. 1962. The Pathology of the Brain of Mice Inoculated with Tissues 
from Scrapie Sheep. Journal of Comparative Pathology, 72, 360-365. 
 
Zlotnik, I. & Rennie, J. C. 1963. Further Observations on the Experimental Transmission of 
Scrapie from Sheep and Goats to Laboratory Mice. Journal of Comparative Pathology, 
73, 150-162. 
 
Zlotnik, I. & Rennie, J. C. 1965. Experimental Transmission of Mouse Passaged Scrapie to 








Appendix 8-1: Origins of Scrapie.  Scrapie is a notifiable disease and requires the 
Animal and Plant Health Agency to be made aware of any animal suspected of being 
infected.  As the disease is infectious and there is no cure a positive identification of 
Scrapie invariably leads to euthanasia of the infected animal.  Genetic screening of 
sheep made it possible to identify the genotypes most susceptible to infection.   
European schemes were put in place from 2001 with the aim of significantly reducing 
the presence of the disease within the national flocks (European Commission, 2003).   
 
Prior to the application of breeding programs, action to disease was taken post-hoc 
in an effort to identify patterns in susceptibility.  The result was a considerable period 
of time in which the disease was considered as nothing more than a singular event.  
The infection of sheep with the deceptive ‘itching’ disease, in which sheep rub 
themselves raw against their enclosure, had been documented in Europe for many 
centuries.  The name ‘Scrapie’, an adaptation of the Scottish word for scratching, was 
first attributed to a flock of cross-bred Cheviot and Leicester sheep in a  farm near 
Yetholm within the Scottish Borders in 1853 (Stockman, 1913).  This also led to the 
hypothesis that transmission was vertical from ewe to progeny.  The symptoms of 
sheep with Scrapie-like nervous disorders are claimed to have been recorded even 
earlier circa 1732 (M'Gowan, 1918) however the descriptions were vague and there 
were many other diseases of sheep present in Eighteenth century Britain for which 
the visual symptoms were similar.  Indeed the disease, then more widely known in 
the field as ‘Goggles’ or ‘Rickets’ was so little regarded by the British authorities that 
flock owners could only respond to and not influence the literature of the time 
(Comber, 1772, Cruttwell, 1795).  By contrast the disease was well characterised by 
the German authorities during the mid-Eighteenth century as ‘Trot’ and accepted as 




























Ideas were consolidated in the early twentieth century when it was realised that little 
experimental evidence had been accumulated, incorrect conclusions had been drawn 
from narrow-minded (sic) laboratory observations and there was little regard for the 
reports made by farmers (M'Fadyean, 1918).  A new set of veterinary scientists 
reviewed the field and realised the disease had an exceptionally long incubation 
Figure 8-1: The first true characterisation of Scrapie can be found in German agricultural literature 
from 1759 (Leopold, 1759). This extract from the section on diseases of sheep describes both topical 
and nervous symptoms and recognises the dangers of the transmissible nature of the disease to healthy 
members of the flock.  The volume in which the extract is found is a highly comprehensive guideline 
for agriculture in the country including land sustainability and the effects of economy.  The complete 
translation for the extract is: 
 
“Of the various Diseases of Sheep, Scrapie* is a disease of sheep and is contagious. Scrapie in sheep 
is a disease that can be recognised when the animal that gets the diseases lays down, bites with its 
mouth on the feet and the legs, rubs with the crossbars on the enclosure, will lose prosperity, also 
does not eat right, and finally; they drag themselves along, gradually lose weight, and at last they 
invariably die. When an animal gets this distemper, there is no cure.  Therefore it is best for the 
shepherd who sees one of his sheep has fallen to Scrapie, to carry it away for slaughter by non-stately 
servants.  The shepherd must take steps to separate such a case from the healthy, because it is 
contagious and can cause much harm to the flock”  
 




period and was past-down from the mother; as exemplified by lambs from an 
infected ewe which would still develop Scrapie even when moved to a new 
environment days after birth (Stockman, 1926).  Post-mortem analysis, principally led 
by Sir Stewart Stockman (Lancet, 1926) began to piece together the association 
between Scrapie and nervous tissue damage (Stockman, 1926, Holman and Pattison, 
1943).  Beginning in the late 1930s, flock analysis studies in Britain finally caught up 
with what was already known in Germany and documented the horizontal 
transmissibility of Scrapie infection between unrelated sheep (Gordon et al., 1940, 
Greig, 1940) and from sheep to goats (Chelle, 1942, Pattison et al., 1959, Pattison and 




Appendix 8-2: Robust prion disease associated signal in all strains encoded PrPC.  The mean expression 
profile from the 492 disease associated genes identified in this study is very similar in all strains despite 
pronounced differences in incubation period.  A lack of disease in FVB
PrnP00
 null mice serves as 





























Appendix 8-3: Clusters demonstrate a high level of inter-correlation.  The secondary cluster (purple) 
contains a significant number of interferon response genes.  The considerable number of co-expressed 
(edge linked) genes both within the same cluster and residing in the opposite cluster are evidence of a 
complex tightly regulated mechanism.  Increasing the matrix threshold within BioLayout Express did 
not allow for further separation of the graph into components indicating the dataset is inseparable using 
this type of whole brain analysis.  





Appendix 8-4: Ontological data for the 492 disease associated genes found in this experiment organised 
into cell types.  Those identified in the original study are highlighted in red.  Note that the majority of 
the red highlighted genes were not associated in the original study with the cell types portrayed here. 
 
Cell Type Number Genes 
Macrophage Only 315 4632428N05Rik, A830007P12Rik, AA467197, Abi3, Adcy7, Adfp, 
AF251705, Aif1, Alox5ap, Anxa2, Anxa3, Anxa4, Arhgdib, Arpc1b, 
Aspg, Axl, B2m, Bcl2a1a, Bcl3, Brd4, C1qa, C1qb, C1qc, C3, C3ar1, 
C4b, Capg, Casp1, Casp8, Ccl12, Ccl2, Ccl3, Ccl5, Ccl6, Ccl8, Ccl9, 
Ccr5, Cd14, Cd37, Cd44, Cd48, Cd52, Cd53, Cd68, Cd72, Cd74, 
Cd84, Cd86, Cebpa, Cebpb, Ch25h, Clec4a3, Clec7a, Clic1, Cln3, 
Cmtm3, Cmtm6, Cmtm7, Cp, Crispld2, Csf1, Csf1r, Csf2rb, Csf3r, 
Cst7, Cstb, Ctsa, Ctsb, Ctsc, Ctsd, Ctsh, Ctsl, Ctss, Ctsz, Cxcl10, 
Cxcl13, Cxcl16, Cyba, Cybb, Ddx58, Ddx60, Dock2, Dtx3l, Ebi3, 
Edem1, EG667823 (Trim5), Emr1, Epsti1, Fas, Fcer1g, Fcgr1, 
Fcgr2b, Fcgr3, Fcgr4, Fcrls, Fermt3, Fgd2, Ftl1, Ftl2, Fuca1, Fxyd5, 
Fyb, Galnt6, Gbp2, Gbp3, Ggta1, Glipr1, Gmfg, Gngt2, Gns, 
Gpnmb, Gpr183, Gpr34, Gpr65, Gpr84, Gpsm3, Grn, Gusb, H2-
Ab1, H2-DMb2, H2-K1, H2-M3, H2-Q7, Havcr2, Hck, Hcls1, Hexa, 
Hexb, Hfe, Hmox1, Hpgd, Hsd3b7, Hvcn1, Icam1, Ifi204, Ifi205, 
Ifi27l2a, Ifi30, Ifi35, Ifi44, Ifi47, Ifih1, Ifit1, Ifit2, Ifit3, Ifitm3, Igtp, 
Iigp1, Ikzf1, Il10rb, Il13ra1, Inpp5d, Irf5, Irf7, Irf8, Irf9, Irgm1, 
Irgm2, Itgam, Itgax, Itgb2, Itpripl2, Kcnk6, Lag3, Lair1, Lamp2, 
Laptm5, Lat2, Lcp1, Lcp2, Lgals3bp, Lgals9, Lgmn, Lilrb4, Lpcat2, 
Lpxn, Lrrc33, Lst1, Ltbr, Ly9, Lyn, Mafb, Man2b1, Man2b2, Mdfic, 
Mmp12, Mpa2l, Mpeg1, Ms4a6b, Ms4a6d, Ms4a7, Msn, Myd88, 
Myo1f, Naglu, Naip2, Naip5, Ncf1, Ncf2, Ncf4, Nckap1l, Nek6, 
Nfe2l2, Nlrc5, Oas1g, Oasl2, OTTMUSG00000000971, P2ry13, 
P2ry6, Parp12, Parp14, Parp3, Parp9, Phf20l1, Pld4, Plec1, Plek, 
Plp2, Plxnb2, Pon3, Pros1, Psmb8, Psmb9, Psme1, Psme2, 
Ptgds2, Ptplad2, Ptpn18, Ptpn6, Ptprc, Pycard, Pyhin1, Rab32, 
Rab3il1, Renbp, Rmcs5, Rnase4, Rnaset2a, Rnf213, Rrad, Rsad2, 
Rtp4, S100a11, S100a4, S100a6, S1pr3, Samd9l, Samsn1, Sash3, 
Scpep1, Selplg, Sema4d, Sepx1, Sfpi1, Sgpl1, Sh3bp2, Shisa5, 
Siglec5, Siglech, Skap2, Slamf9, Slc11a1, Slc15a3, Slc29a3, 
Slc39a14, Slc43a3, Slc5a3, Slc7a7, Slfn2, Slfn8, Socs3, Spp1, Sqrdl, 
Srgn, Stat1, Stat3, Sulf2, Syngr2, Tagln2, Tap2, Tapbp, Tbxas1, 
Tcn2, Tgfb1, Tgfbr1, Tgfbr2, Tgif1, Tgm2, Thbs2, Tifa, Timp1, 
Timp2, Tln1, Tlr1, Tlr13, Tlr2, Tm4sf1, Tmem119, Tmem173, 
Tmem86a, Tnfaip2, Tnfaip8l2, Tnfrsf1a, Tor3a, Trem2, Trim25, 
Trim30, Trim34, Trim47, Trpt1, Tspo, Tyrobp, Ube1l, Unc93b1, 
Usp18, Vwa5a, Xaf1 
Macrophage & 
Neuron 
7 A2m, Cyb5r3, Glipr2, Gpx1, Lgals1, Lgals3, Olfml3 
Astrocyte Only 19 Abhd4, Aldh1l1, Aqp4, Casp12, Chi3l1, Cyp4f14, Decr1, Fgfrl1, 
Gal3st4, Gm967, Id3, Naprt1, Plcd4, Plscr2, Prelp, Prrx2, Rbp1, 
Slc25a18, Sox9 





11 Ccdc122, Fxyd1, Kcne1l, Lgi4, Lmcd1, Mlc1, S100a16, Slc14a1, 




27 Cd81, Cotl1, Cyp4v3, Dbi, Ifi27l1, Igfbp2, Itgb5, Ltc4s, Mt1, Mt2, 
Necap2, Npc2, Oat, Pdlim4, Rab31, Rab7l1, Rhbdf1, Rhoc, 
S100a13, Sh3glb1, Tmbim1, Tmem176a, Tmem176b, Tspan4, 
Ucp2, Vamp8, Vim 
Macrophage & 
Astrocyte 
28 Cd151, Clec5a, Cybrd1, Dhrs1, Efemp2, Eya4, Galnt4, Gfap, 
Gstm1, Klk8, Lpcat3, Ly86, Mtmr11, Npl, Nupr1, Pbxip1, Pdpn, 
Pnpla7, Prdx6, Retsat, S100a1, Sat1, Sh3pxd2b, Tlr3, Trf, Upp1, 
Vcam1, Zfp91 
Oligodendrocyte 8 Tppp3, Tmem98, Pdlim2, Klk6, Galntl2, Dbndd2, Apod, Adamtsl4,  
Genric (All CNS 
cell types) 
73 Znrf2, Tax1bp3, Srebf1, Spsb1, Spata13, Slco2b1, Scrg1, Scamp2, 
Rgs10, Pik3ap1, Phyhd1, Palld, P2rx7, Osmr, Nat2, Mrps6, Lyz2, 
Lyz1, Lrrfip1, Litaf, Klhl6, Itpkb, Il33, Igsf6, Igf1, Ifitm2, Idh2, 
Hspb6, H2-DMb1, H2-Aa, Gpr37l1, Golm1, Gbp6, Gba, Fzd9, 
Fkbp7, Fes, Farp1, Fam129b, Fam102a, F13a1, Ephx1, Entpd1, 
Emp3, Emp1, Ecm1, E230029C05Rik, Dok1, Ddr1, Dap, 
D4Ertd22e, Cyth4, Cyp7b1, Cst3, Col16a1, Cnn3, Clu, Cklf, Cebpd, 
Cd9, Ccdc80, Capn3, Bmp2k, Bdh2, BC026585, Avp, Atp6v0e, 
Angpt1, Ampd3, Aga, Afp, 5430427O19Rik, 1700112E06Rik 








Appendix 8-5: Cross reference of the 333 genes identified in the original study by Hwang et al., (2009) 
with co-normalised GNFv3, Trap and M0/LPS data within the expression viewer of BioLayout 
Express3D.  Although an immune response was described in the original publication, the majority of 
differentially expressed genes were attributed to neurons.  This figure illustrates clearly the dominant 







































































































































































































































































































































































































































































































































































































































































































































Appendix 8-6:  The BALB/cJ strain of mouse was first developed in 1912 at The Memorial Hospital, 
New York by Dr. Halsey J. Bagg using albino fancy mouse stock obtained from a mouse dealer in Ohio.    
Control was transferred in 1920 to Dr. C. Little and Dr. E.C. MacDowell at the Carnegie Institution of 
Washington in Cold Spring Harbor, New York.  Inbred status was achieved in 1923 reaching filial 
generation (F) 12 in 1927 (Macdowell et al., 1927).  The newly inbred strain was characterised by Dr. 
Little and Clyde E. Keeler and found to have albino linked retinal degeneration (Keeler, 1924, Keeler, 
1931).  It was at Cold Spring Harbor that the Bagg strain also led to the development of the “A” (or A/J) 
strain of mice widely used in cancer and immunology research following a cross with the Cold Spring 
Harbor albino line in 1921 (Strong, 1936, Stoner et al., 1993). 
 
A breeding sample of the Bagg albino was acquired by Dr. Hermann Joseph Muller at the University of 
Texas and cared for by Dr George Davis Snell who subsequently maintained the line (Russell, 1978, 
Potter, 1985).  A breeding sample of mice at F26 was taken by Dr George Davis Snell to the Jackson’s 
laboratory in 1935 (Russell, 1978, Snell, 1978).  At this point the line was named “Balb” derived from 
a shortening of Bagg Albino and given the /c substrain designation by Dr Snell to indicate that the 
genotype at the "colour" locus was c/c (Potter, 1985).  The name was formally capitalized in 1940 to 
“BALB/c” as required by the Committee on ‘Standardized Nomenclature for Inbred Strain of Mice’ to 
distinguish between name and mutation characters (Dunn et al., 1940, Snell, 1941).  
 
Dr. Snell gave a breeding colony to Dr. John Paul Scott in 1945 who maintained these mice in The 
Jackson Laboratory behavioural unit in Hamilton Station, New Jersey.  It was this group of mice, at 
F41, that were used to continue the line following the 1947 Bar Harbor fire which devastated The 
Jackson Laboratory’s main buildings.  In 1974 at F136, The Jackson Laboratory attached the /cJ 
designation to indicate both substrain and laboratory code and supplied the mice to Charles River where 







Appendix 8-7:  The Origin of the mouse-adapted prion strains used in this project.  79A is a Scrapie 
strain purified by limiting dilutions (cloned) from an SSBP/1 infected goat source into C57BL mice at 
Compton in 1961.  From the same source were derived 139A, 79V and RML.  The latter is not a cloned 
strain but an isolate comprising 79A which can, dependent upon the host, mutate into 139A (Dickinson, 
1976).  ME7 is derived from a naturally occurring Scrapie case of Suffolk sheep transmitted into C57BL 
and VM mice at Moredon in 1963.  ME7 is not isolated from sources derived from SSBP/1 (Zlotnik and 







 Drowsy Goat Scrapie   
 Isolated from goats infected with SSBP/1 at Compton (Holman and Pattison, 
1943, Pattison, 1957). 
 Gave rise to Chandler Strain in mice/rat/hamster (Pattison and Millson, 1961) 
 3rd pass donated to Rocky Mountain Laboratories as the RML isolate 
 21-25th pass transmitted into C57BL – 139A 
 Drowsy goat source into C57BL gave 79A.  VM gave 79V 
 4th Chandler hamster pass gave 263K 
ME7  Suffolk Sheep Scrapie.  
 Can be extracted directly. 
 Transmission made to mice: Mouse Experiment 7 at Moredun (Zlotnik and 




Appendix 8-8: Cultured microglia-like cell lines display variance in persistence of infection dependent 
upon prion strain.  A series of in-vitro experiments, performed within the Neurobiology Division, The 
Roslin Institute, suggested killing of neurons is increased in the presence of a prion infected “Scrapie 
Mouse Brain” (SMB) microglia-like cell line; first isolated and characterised by Haig and Clarke (1971).  
The in-vitro concept of increased neuronal death in the presence of microglia was first published by 
Bate et al. (2004).  The unpublished experiments performed in The Roslin Institute were performed in 
an attempt to further this in-vitro work using neurons able and unable to express PrPC, thereby 
confirming that neurotoxicity is neuronal PrPC independent and cell death is instead mediated through 
a pro-inflammatory cytokine bystander effect.  As part of this work SMB cells were infected with a 















Variability in capacity of differing prion strains to persistently infect cultured SMB microglia-like cell 
line across multiple passages.  Data from 22F passages are from Birkett et al. (2001) the remaining 
from unpublished work by Dr E Cancellotti, The Roslin Institute & R(D)SVS.  Confirmation of 





Appendix 8-9: Incubation periods from historic records of wild type mouse strains.  Data published by 
Outram (1976) comprising infection studies of over 4000 mice both i.c. or i.p. with 0.02ml of 10-2 w/v 
infected brain material reveals the incubation periods for 79A into BALB/cJ mice have remained 
unchanged as per the data sourced (Appendix 8-12) from the Neurobiology Division archives (The 
Roslin Institute & R(D)SVS, The University of Edinburgh).  It is unclear if the sourced archive 
experimental data was included by Outram who at the time was working in Edinburgh.  BALB/cJ mice 
i.p. infected with ME7 revealed a mixed gender average of 261 days.  Incubation periods for 
BALB/cJFms-EGFP/- and BALB/cJ challenged i.p. with ME7 succumbed in an unexpected average of 






Appendix 8-10: Source of Prion Infected Brain Material used in the BALB/cJFms-EGFP/- and BALB/cJ 
infections. Brain homogenates (10-2 w/v) used in these experiments were produced from the pooling of 
two frozen brains dissected from C57Bl/6J mice previously infected by intracerebral challenge and 















Appendix 8-11:  Intense auto fluorescence from blood artefacts severely limited EGFP detection in 
mouse brain tissue of mice not subjected to saline perfusion.   A: Auto-fluorescence was detectable in 
brain as vascular structures containing B:  non-Fms-EGFP expressing (no nuclei) erythrocytes.  Scale 















79A-13Z C57Bl/6J 79A B53873 ♂ i.c. 176 816A-1A1 
79A-13Z C57Bl/6J 79A B53874 ♂ i.c. 176 816A-1A1 
135X-10Z C57Bl/6J ME7 B54120 ♀ i.c. 166 816B-1A1 
135X-10Z C57Bl/6J ME7 B54104 ♀ i.c. 171 816B-1A1 
79A-13Z C57Bl/6J 79A B53813 ♂ i.c. 162 816D-1A1/1B1 












107A-1T (*21-168 days) 107C-1E (*35-42 days
110A-1A (*28-98 days) 816A-1A (*100 days)
Appendix 8-12 
Appendix 8-12: Historic 79A experiments documented in the Neurobiology Division archives (The 
Roslin Institute & R(D)SVS, The University of Edinburgh) utilising BALB/cJ mice infected i.p. with 
79A mouse-adapted Scrapie at 0.02ml of 10-2 w/v.  Experiments 816A-1A1 and 816B-1A1 are those 
documented in this chapter.  521Z-1G is a recently performed aging study using CB20+/+ (congenic 
BALB/cJ) with a comparable starting age.  The remaining 8 experiments were all completed prior to 
1975 and show only the control mice infected with 79A alongside further groups with an additional 
tested variable that rules out their inclusion here.  Lesion profiles were constructed using grey matter 
data from experiments in which lesion scoring information was available.  Incubation periods and 
regional targeting of lesions were similar in all experiments although the superior colliculus does present 
with some variability.  These data show the considerable lack of variation in both the BALB/cJ and 79A 









Group Size Mouse Strain Incubation Period (days) SE Age at Infection (days) 
816A-1A1† 9 BALB/cJFms-EGFP/- 225 6.3 100 
816B-1A1† 8 BALB/cJ 227.9 6.5 100 
110A-1A 5 BALB/cJ 235.6 1 28-98 
99K-1C 3 BALB/cJ 235 0 21-252 
134A-1F 6 BALB/cJ 234.5 4.3 91 
134A-1F 6 BALB/cJ 240.7 5.9 51-70 
107B-1G 2 BALB/cJ 235 3 49-56 
107A-1T 9 BALB/cJ 217.3 1.1 21-168 
107A-1D 2 BALB/cJ 236.5 11.5 28-70 
107C-1E 5 BALB/cJ 223 5.9 32-42 














































Appendix 8-13:  Mean Euclidean distance of thalamic microglia from healthy normal brain inoculated 
BALB/cJFms-EGFP/- mice.  No statistical difference was gained between any tested combinations for these 
data.  Consequently the adoption of a mean value is not a cause of the significant difference observed 
between the mean value of these data and that gained from 100 and 150 dpi thalamic microglia in 79A 





























































































Array Group Avg. Expression
Appendix 8-14: Expression profile of Myd88. Rapidly induced during an innate immune response to 
antigen, the expression levels of Myd88 in this study remain nominal and unchanged in response to 
disease. 
Appendix 8-14 
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